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Economic Evaluation of Prophylactic Antiemetic Regimens for Prevention of 
Chemotherapy-Induced Nausea and Vomiting (CINV) 
 
 
Reema R Mody 
 
New antiemetic agents, aprepitant and palonosetron have been approved for prevention of 
chemotherapy-induced nausea and vomiting (CINV).  The objectives of the two phases of the 
study were: 1) to conduct cost-effectiveness analysis of antiemetic regimens for prevention of 
CINV in patients receiving highly emetogenic chemotherapy (HEC) and in patients receiving 
moderately emetogenic chemotherapy (MEC) using decision models, and 2) to determine the 
monetary value of improved emesis control and conduct cost-benefit analysis of the new 
antiemetic regimens.  Regimen A, one of the four antiemetic strategies included in the HEC 
decision model was a combination of aprepitant and the standard regimen of 
ondansetron+dexamethasone. The other three regimens had standard regimen in the acute phase 
but differed in the delayed phase regimens: regimen B - dexamethasone only, regimen C - 
dexamethasone+metoclopramide and regimen D - dexamethasone+ondansetron.  The four 
antiemetic strategies for prevention of CINV due to MEC were:  regimen 1) IV palonosetron, 2) 
IV ondansetron, 3) ondansetron+dexamethasone in acute phase, only dexamethasone in delayed 
phase, 4) ondansetron+dexamethasone in acute and delayed phase.  The outcome measure was 
the incremental cost-effectiveness ratios (ICER) measured as cost/patient with complete control 
of emesis.  For the HEC model, the ICER of regimen A compared to C was $3,363.18 and 
$2,881.61 per patient with complete control of emesis, from payer and societal perspectives 
respectively.  One-way and probabilistic sensitivity analyses indicated that the conclusions were 
relatively stable to variations in multiple parameters.  For MEC model, regimen 1 was found to 
be most cost-effective with ICER of $3,582.48 and $3,549.02, from payer and societal 
perspectives respectively.  Overall, the ICER results showed that the regimen A and regimen 1 
could be considered cost-effective therapies for prevention of CINV.  In phase II, a contingent 
valuation survey was developed and administered to 120 cancer patients who were either 
receiving or had received chemotherapy.  The results showed that respondents were willing-to-
pay on average $83.50 for a single dose of palonosetron and $89.90 for a three-day regimen of 
aprepitant.  Phase II qualitative results also emphasized that cancer patients receiving 
chemotherapy placed a high importance on receiving even a modest improvement in the control 
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1.1: Epidemiology of Chemotherapy-Induced Nausea and Vomiting (CINV) 
 
Chemotherapy, one of the mainstays in the treatment of cancer has two main goals: 1) to 
control the progression of tumors and increase survival and 2) to improve health-related quality 
of life (HRQOL).  In 2001, approximately 1.4 million cancer patients in the United States (US) 
received chemotherapy.  It is also estimated that almost 600,000 of the approximately 1.4 million 
newly diagnosed cancer patients per year are candidates for cancer chemotherapy (Plosker & 
Benfield, 1996).  However, chemotherapy drugs are associated with a number of adverse effects 
such as nausea, vomiting, anemia, neutropenia, alopecia, constipation, diarrhea and stomatitis 
(DeVita, Hellman, & Rosenberg, 2001).  
 
Chemotherapy-induced nausea and vomiting (CINV) are perceived among the most 
distressing side effects of chemotherapy by patients with cancer (Boer-Dennert et al., 1997; 
Griffin et al., 1996).  A study conducted in 1983, assessing patients’ perceptions of side effects of 
cancer chemotherapy, before the introduction of 5-HT3 receptor antagonists (5-HT3 RAs), showed 
that nausea and vomiting were ranked as the most distressing side effects (Coates, et al., 1983).  
More recent studies showed that CINV is still ranked among the top five distressing side effects 
of chemotherapy, despite the development of efficacious antiemetic agents (Boer-Dennert et al., 
1997; Griffin et al., 1996).  However, a study conducted (Carelle et al., 2002) in French patients 
showed that patients’ perceptions of the side effects of cancer chemotherapy had changed, with 
fatigue and psychosocial concerns predominating compared to emesis and nausea.  
 
The actual incidence and severity of nausea and vomiting is difficult to determine due to: 
type of chemotherapy given, dose, schedule, individual patient characteristics, health condition of 
patients who receive the chemotherapy drugs, underassessment by clinicians and underreporting 
by patients (Doherty, 1999; Osoba, et al., 1997a).  Irrespective of various factors, approximately 
60% to 80% of all cancer patients receiving chemotherapy experience some degree of nausea and 
vomiting (King, 1997).  Based on the time of its occurrence, CINV can be classified into acute, 
delayed and anticipatory CINV (Refer Chapter 2 for definitions).  Among patients treated with 
1 
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highly emetogenic (HE) chemotherapy (such as cisplatin) and not receiving any prophylaxis for 
CINV, the incidence of acute and delayed emesis is more than 90% and between 60-90%, 
respectively.  Similarly, in patients receiving moderately emetogenic (ME) chemotherapy agents 
(such as carboplatin, cyclophosphamide or doxorubicin), the incidence of acute and delayed 
emesis is between 30-90% and 20-33% respectively (Gralla, 1997; Gralla et al., 1999; Hesketh, 
1999).  
 
1.2: Impact of CINV on Clinical, Humanistic and Economic Outcomes 
 
Impact on clinical outcomes  
Uncontrolled and suboptimally controlled CINV may lead to physiological consequences 
such as fluid and electrolyte disturbances, dehydration, esophageal tears, weight loss, aspiration 
pneumonia and liver function abnormalities (Bender et al., 2002).  The goal for chemotherapy 
patients is to maintain adequate nutritional intake to prevent weight loss and to maintain protein 
stores and muscle mass.  However, prolonged or delayed nausea and vomiting may lead to 
inadequate nutritional intake leading to weight loss and muscle wasting (Brown et al., 2001).  
Poor emesis control can also lead to anticipatory nausea and vomiting in 10-30% of the patients 
(Boakes, Tarrier, Barnes, & Tattersall, 1993).  It can also lead to psychological effects that may 
lead to depression and anxiety.  Though hospitalizations for complications of emesis are rare 
(Feldman & Dixon, 2000), failure to control treatment-related nausea and vomiting can lead to 
20-50% of patients delaying or refusing possible lifesaving chemotherapy (Herrstedt, 2002; 
Schnell, 2003).  
 
Impact on humanistic outcomes  
Health-related quality of life (HRQOL) is a subjective, multidimensional perspective of 
well-being that is influenced by disease and treatment (Grant, 1997).  It is an important outcome 
measure of patient response to cancer and cancer treatment.  CINV affects the physical, 
psychological, spiritual and social well-being of the patient (Grant, 1997).  A review article of 
various observational studies showed that, after adjusting for HRQOL before chemotherapy, 
CINV was associated with a decrease in HRQOL of patients with emesis compared to patients 
without emesis (Ballatori & Roila, 2003).  
 
Osoba et al.(Osoba et al., 1997b) studied the effect of post-chemotherapy nausea and 
vomiting on HRQOL among 802 cancer patients receiving HE and ME chemotherapy.  The 
2 
INTRODUCTION  Reema Mody 
patients completed the European Organization for Research and Treatment of Cancer (EORTC) 
core Quality of Life Questionnaire before and 7 days after the first chemotherapy dose, and on 
the first day of the second cycle of chemotherapy.  It was found that the group with nausea and 
vomiting showed significantly worse physical, cognitive and social functioning as compared to 
the group that did not experience nausea or vomiting.  The group with nausea and vomiting also 
had worse scores on global quality of life, fatigue, anorexia, insomnia and dyspnea.  Patients with 
only nausea tended to have less worsening in functioning and symptoms than those having both 
nausea and vomiting.  Increased severity of vomiting (> 2 episodes) was associated with 
worsening of global quality of life and anorexia compared with one to two episodes of vomiting.  
 
Lindley et al. (Lindley et al., 1992) conducted a study among 122 patients with various 
cancers, receiving different chemotherapy and antiemetic regimens to evaluate the impact of 
CINV on quality of life (QOL).  The Functional Living Index – Emesis (FLIE), a validated 
instrument was administered at baseline and three days after chemotherapy to study the impact of 
CINV on physical activities, social and emotional function and ability to enjoy meals.  There was 
a significant decrease in the mean QOL score of patients who experienced emesis compared to 
the non-emesis patient group.  CINV also has an impact on daily life such as maintaining 
hobbies, preparing a meal or carrying out minor tasks around the house etc.  A cross-sectional 
multinational study conducted to assess the impact of CINV on daily life showed that 77% of 
patients who suffered from nausea and 53% of those suffering from vomiting reported a negative 
impact on their daily life (Glaus et al., 2004).  
 
Though studies have shown that CINV has a significant impact on patients’ HRQOL, it is 
difficult to quantify the impact of uncontrolled CINV on intangible effects such as HRQOL, 
patient distress and suffering.  These intangible effects can be valued either by using monetary 
values or by using economic and psychometric scaling techniques.  
 
Impact on economic outcomes 
In addition to its clinical impact, uncontrolled nausea and vomiting also have significant 
economic burden.  Uncontrolled CINV and subsequent medical complications can lead to 
increase in the direct, indirect and intangible costs associated with CINV.  Direct costs associated 
with CINV include cost of prophylactic and rescue medications, health care personnel costs, 
extended hospitalizations and material costs, whereas indirect costs include lost or reduced 
patient/caregiver productivity and lost income (Miller & Kearney, 2004; Pendergrass, 1998).  
3 
INTRODUCTION  Reema Mody 
The intangible costs associated with uncontrolled CINV include decreased QOL, patient distress 
and patient suffering.  
 
The information on costs of CINV is limited due to very few published studies. Before 
the introduction of costlier and more effective 5-HT3RAs to prevent CINV, the direct and indirect 
costs associated with CINV in Canadian cancer centers were approximately US $127 per patient 
(O'Brien et al., 1993).  The direct costs associated with CINV included cost of prophylactic and 
rescue medications, nurse time, physician time, hospital admissions, and material costs.  Indirect 
costs which accounted for two-thirds of the total costs included the out-of-pocket expenses for 
the purchase of nonprescription medicines, travel costs, and patient or caregiver time away from 
work.  The study also reported a total loss of 198 hours of paid employment and 409 hours of 
unpaid employment, among 72 patients who experienced emesis.  An additional loss of 186 
hours was found among caregivers.   
 
A more recent, prospective, cross-sectional, cost-of-illness study conducted in German 
cancer centers showed that the most frequently used resources due to delayed emesis were rescue 
medications, outpatient hospital and physician office visits (Ihbe-Heffinger et al., 2004).  In 
2002, the mean direct and indirect costs per treatment cycle with CINV per patient was 
€77.30±146.59 (US $93.37±177.06).  In this study, one patient required hospitalization and three 
patients lost workdays due to delayed CINV.  However, this study did not consider cost 
associated with lost personal time from daily activities and lost unpaid work due to CINV.  In 
another study, Roila and colleagues (2000) showed that of patients who experienced CINV, 23% 
were unable to go to work, 22% reported they were unable to prepare meals, and 12% were 
unable to take prescribed medications.  The impact of CINV on work productivity and daily life 
activities were not quantified in this study. Thus, uncontrolled CINV poses a significant 
economic burden on the patient in the form of direct medical and indirect costs.  The intangible 
costs associated with uncontrolled or suboptimally controlled CINV have not been assessed 
satisfactorily.  Though there are only a few cost-of-burden studies in the area of CINV, it is 
difficult to compare the results due to variation in methodology employed, study setting, study 
country and availability of various antiemetic agents.  
 
1.3: Prevention Strategies for CINV 
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The most important point about managing CINV is that preventing CINV is more 
effective than treating it (Markman, 2002).  Antiemetic agents administered before chemotherapy 
are effective in reducing the incidence of acute emesis, but it is difficult to completely control 
CINV once it has begun.  Thus, prophylaxis with appropriate antiemetic agents is very critical in 
preventing acute, delayed and anticipatory emesis during the first and subsequent cycles of 
chemotherapy.  One of the goals of antiemetic therapy is to achieve complete control in all 
settings, beginning with the initial cycle of chemotherapy, thus improving patient compliance, 
quality of life, and preventing development of anticipatory and refractory nausea and vomiting 
during subsequent cycles of chemotherapy. 
 
Various classes of drugs such as phenothiazines, butryophenones, substituted 
benzamides, cannabinoids, steroids and 5-HT3 receptor antagonists  (5-HT3 RA) are available to 
control the incidence of CINV (Gralla, 1997).  Due to the side effect profile of older antiemetic 
agents such as phenothiazines, butyrophenones and substituted benzamides, these are primarily 
used as rescue medications for breakthrough emesis.  
 
5-HT3 Receptor Antagonists (5-HT3 RAs) 
Due to its high efficacy and favorable toxicity profile compared to other antiemetic 
agents, 5-HT3 RAs are currently the first-line agents and the gold standard for prevention of 
CINV in patients receiving HE or ME chemotherapy (Gralla et al., 1999; Schnell, 2003).  These 
agents exert their antiemetic activity by antagonism of 5-HT3 receptors.  As monotherapy, the 5-
HT3 RAs provide complete acute antiemetic protection, i.e. no nausea, no vomiting and no use of 
rescue medications, in 40-60% of patients receiving cisplatin based chemotherapy and 60-80% of 
patients receiving ME chemotherapy (Schnell, 2003).  In patients receiving high-dose cisplatin-
based chemotherapy regimens, 5-HT3 RAs provides complete antiemetic protection in the acute 
phase in 25-60% of patients (Audhuy et al., 1996; Beck et al., 1992; P. Hesketh et al., 1996; 
Marty et al., 1995; Navari et al., 1995).  Three 5-HT3 RAs are currently available in the US for 
prevention of emesis: dolasetron (Anzemet), granisetron (Kytril) and ondansetron (Zofran).  
Several randomized, controlled studies have shown that ondansetron, granisetron and dolasetron 
have equivalent complete control rates, defined as complete absence of nausea or vomiting, 
among patients receiving HE or ME chemotherapy (Berger & Clark-Snow, 2001; Gralla et al., 
1998; Hesketh, 2000).  
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Though the existing antiemetic regimens provide reasonably good protection against 
acute emesis, they do not provide adequate protection against delayed emesis, with 
approximately 50% of patients experiencing delayed emesis (Olver et al., 1996).  In addition, 5-
HT3 RAs have not demonstrated sustainable efficacy in controlling CINV over repeated cycles of 
chemotherapy (de Wit et al., 1996; de Wit et al., 1998).  Due to the shortcomings of the existing 
antiemetic agents, newer agents with better efficacy were needed and have been recently 
introduced in the market.  Two such antiemetic agents are aprepitant (Emend®) and palonosteron 
(Aloxi®).  
 
New Antiemetic Agents 
 
Aprepitant (Emend®) 
Aprepitant is the first oral selective nonpeptide NK-1 receptor antagonist indicated for 
use in combination with a 5-HT3RA and a corticosteroid for prevention of acute and delayed 
emesis due to HE chemotherapy regimens (Emend® Monograph).  Aprepitant, in a dose of 125 
mg, is recommended as a part of combination antiemetic regimen with a corticosteroid and a 5-
HT3 RA prior to chemotherapy (day one) and a dose of 80 mg on day two and three.  The results 
of two large phase III clinical trials showed that the aprepitant based regimen had superior 
antiemetic efficacy as compared to the standard regimen in patients receiving high-dose cisplatin 
(≥70mg/m2) (Hesketh et al., 2003; Poli-Bigelli et al., 2003).  
 
Studies also showed that the antiemetic efficacy of aprepitant is maintained over multiple 
cycles of chemotherapy (de Wit et al., 2003; de Wit et al., 2004).  But aprepitant has not been 
shown to mitigate ongoing emetic symptoms and has not been tested for continuous use for 
duration greater than five days in patients receiving emetogenic chemotherapy.  Although 
addition of aprepitant improved overall antiemetic protection, the 2005 average wholesale price 
(AWP) of $309.00 for a three-day regimen (Red Book, 2005) makes it expensive compared to the 
other antiemetic agents used for prevention of acute and delayed emesis following administration 
of HE chemotherapy. 
 
Palonosetron (Aloxi®) 
Palonosetron, a 5-HT3 RA, is an injectable antiemetic agent with a higher binding affinity 
to the 5-HT3 receptors, a higher potency and a longer half-life compared to the older 5-HT3 RAs.  
It is indicated for prevention of acute emesis due to HE regimens and prevention of acute and 
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delayed emesis due to ME regimens (Aloxi® Monograph).  In patients receiving HE 
chemotherapy, including cisplatin, a single 0.25 mg intravenous (IV) dose of palonosetron was at 
least as effective as a 32 mg IV dose of ondansetron for acute and delayed emesis.  In patients 
receiving ME chemotherapy, a 0.25 mg IV dose of palonosetron is at least as effective as a 100 
mg IV dose of dolasetron, but the former regimen provides superior antiemetic protection in the 
delayed phase (Eisenberg et al., 2003; Gralla et al., 2003).  Compared to the older 5-HT3 RAs, 
palonosetron provides the convenience of a single dose schedule for prevention of emesis.  More 
clinical trials of combination antiemetic regimens with palonosetron need to be carried out to 
establish whether it is more efficacious than the combination of a corticosteroid with either 
metoclopramide or a 5-HT3 RA for protection of delayed emesis due to HE chemotherapy.  With 
the 2005 AWP of a 0.25mg 5 ml single dose vial at $340.20 (Red Book, 2005), palonosetron is 
expensive as compared to the older 5-HT3 RAs.  
 
1.4: Combination antiemetic regimens and Recommendations for Antiemetic Use 
 
Combination of two or more antiemetic agents provides better efficacy than a single 
antiemetic agent in prevention of CINV following the administration of HE and ME 
chemotherapy.  Several professional organizations such as the Multinational Association of 
Supportive Cancer Care (MASCC), the American Society of Clinical Oncology (ASCO), the 
American Society of Health-System Pharmacists (ASHP), the National Comprehensive Cancer 
Network (NCCN), and the Canadian Medical Association have published guidelines and 
evidence-based recommendations for the use of antiemetics in management of CINV (ASHP, 
1999; ESMO, 2001; Gralla et al., 1999; MASCC, 1998; NCCN, 1997).  
 
The 1999 ASCO and ASHP guidelines recommended a combination of dexamethasone 
and a 5-HT3 RA (standard regimen) for prevention of acute emesis in patients receiving HE 
chemotherapy (ASHP, 1999; Gralla et al., 1999).   A combination regimen of dexamethasone 
with either metoclopramide or a 5-HT3 RA was recommended for prevention of delayed CINV 
following HE chemotherapy.  With the introduction of aprepitant, new guidelines have been 
proposed by the NCCN and the MASCC for management of CINV.  In patients receiving HE 
chemotherapy, a three-drug combination of aprepitant, dexamethasone and a 5-HT3 RA is 
recommended for control of acute emesis.  A combination of aprepitant and a corticosteroid, such 
as dexamethasone is now recommended for delayed emesis following HE chemotherapy.   
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In patients receiving ME chemotherapy regimens, combination of a corticosteroid and a 
5-HT3 RA is recommended for prevention of acute emesis (ASHP, 1999; Gralla et al., 1999).  
Previous guidelines have recommended the use of either dexamethasone alone or combination of 
dexamethasone with a 5-HT3 RA or metoclopramide for prevention of delayed emesis due to ME 
chemotherapy (ASHP, 1999; Gralla et al., 1999).  The 2005 NCCN and 2004 MASCC guidelines 
recommend using palonosetron as the 5-HT3 RA for prevention of acute emesis and either 
dexamethasone alone or a 5-HT3 RA alone for prevention of delayed emesis.  If aprepitant was 
included in the antiemetic regimen during the acute phase, a combination of aprepitant and 
dexamethasone is recommended for prevention of delayed emesis (MASCC, 2004; NCCN, 
2005).  
1.5: Utilization of Prophylactic Antiemetics in Clinical Practice  
 
As discussed earlier, various guidelines for appropriate prevention and management of 
CINV have been published.  Results from observational studies showed that guideline 
recommendations were not transferred completely into clinical practice (DURTO, 2003).  Studies 
have shown that despite evidence from randomized clinical trials and publication of various 
guidelines and recommendations, there is underutilization of antiemetic drugs to prevent delayed 
emesis (Mertens et al., 2003; Roila, 2004; Roila, Donati, Tamberi, & Margutti, 2002).   
 
A drug utilization study was undertaken to determine if the 1999 MASCC antiemetic 
guidelines for prevention of CINV were followed in clinical practice.  The study was conducted 
among 87 Italian oncological centers in breast cancer patients undergoing chemotherapy with 
moderate to high emetic potential (DURTO, 2003).  The study results showed that all 
chemotherapy patients received prophylactic antiemetics for acute emesis whereas only about 
60% received prophylactic antiemetics for the delayed phase.  Fifty six percent of patients 
received a combination of 5-HT3RA and corticosteroid, the MASCC-recommended prophylaxis 
for acute emesis.  The MASCC-recommended prophylaxis for delayed phase, a 5-HT3RA, a 
corticosteroid or their combination was prescribed to 46% of patients.   However, only 19.2% of 
patients received the ASCO and ESMO recommended prophylaxis for delayed emesis, such as, a 
corticosteroid alone or combined with either 5-HT3RA or metoclopramide (ESMO, 2001; Gralla 
et al., 1999).  Thus, the study results show that there are discrepancies between the 
recommendations for utilization of antiemetic regimens and their actual utilization in daily 
clinical practice.  
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Fabi and colleagues conducted a prospective, observational, longitudinal study to 
determine the appropriate prevention of delayed emesis in clinical practice (Fabi et al., 2003).  
The study results indicated that the clinical practice did not conform to the MASCC-
recommended guidelines for prevention of nausea and vomiting.  There were reports of 
underutilization of prophylaxis for prevention of delayed emesis and overtreatment with 5-
HT3RA in patients receiving chemotherapy with low emetic potential (Fabi et al., 2003; IGAR, 
1998b).  This inappropriate use of costly agents such as 5-HT3RAs leads to increased costs to the 
health care system without a proportionate increase in the health benefits to patients.  The present 
study makes an attempt to compare the regimen commonly employed in clinical practice as one 
of the strategies in the decision model designed to assess the cost-effectiveness of the new 
regimen.  
 
1.6: Economics of Prevention of CINV  
 
The introduction of serotonin receptor antagonists in the early 1990’s made a significant 
impact on the prophylaxis and management of CINV.  Compared to the older antiemetic agents, 
regimens with 5-HT3RAs have resulted in better emesis control in patients receiving HE and ME 
chemotherapy.  However, at the same time, these agents were costly compared to the older 
antiemetic agents.  Rising health care expenditures coupled with limited resources have led to an 
increased interest in conducting economic evaluations of healthcare interventions, a method in 
which both costs and benefits of interventions are evaluated to make resource allocation 
decisions.  In addition to using effectiveness information, it has become necessary to incorporate 
the economic aspects to determine the appropriateness of using new healthcare interventions in 
an increasingly cost-conscious environment.  An important question that needs to be addressed is 
whether there are increased clinical, economic and humanistic benefits that will offset the 
increased cost of preventing CINV.  Cost effectiveness analysis (CEA) is a technique applied 
when a choice must be made between two or more competing alternatives for which the expected 
health gain can be measured as one outcome measure, such as complete control of emesis.  
 
A recent review of economic evaluations of antiemetic agents showed that the majority of 
the studies were conducted after the introduction of 5-HT3RAs (Lachaine & Crott, 2003).  A 
large proportion of these studies have been carried out in patients receiving HE chemotherapy 
(Ballatori et al., 1994; Becker et al., 1996; Buxton & O'Brien, 1992; Cunningham et al., 1993; 
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Sands, Roberts, Marsh, & Gill, 1992; Stewart, Dahrouge, Coyle, & Evans, 1999; Tejedor, Idoate, 
Jimenez, Sierrasesumaga, & Giraldez, 1999; Zbrozek, Cantor, Cardenas, & Hill, 1994), with 
some conducted in patients receiving ME chemotherapy (Cox & Hirsch, 1993; Johnson & 
Bosanquet, 1995; Johnson, Nash, Carpenter, & Sistek, 1993; Kwong & Parasuraman, 1999).  
Also, most of these studies have only evaluated the costs and benefits of antiemetic therapy 
during the acute phase of CINV.  The economics of using combination antiemetic regimens for 
the delayed phase have not been adequately studied.  Most of the economic evaluations 
conducted in the past compared 5-HT3RAs to traditional agents such as metoclopramide or one 
5-HT3RA against another.  The results from these studies showed that the additional cost due to 
use of 5-HT3RAs is offset by a favorable side effect profile, lower personnel and administration 
costs and improved efficacy.  These studies are explained in detail in Chapter 2.  
 
Recently, three studies evaluating the cost effectiveness of aprepitant given with the 
standard regimen have been presented at international symposiums and published in abstract 
format (Deuson, 2004; Ehlken et al., 2004; Moore, Tumeh, Wojtanowski, & Flowers, 2005).  
Ehlken and colleagues conducted a cost-effectiveness evaluation of the three-drug regimen of 
aprepitant, dexamethasone and 5-HT3 RA during the acute phase and combination of aprepitant 
and dexamethasone for the delayed phase (Deuson, 2004; Ehlken et al., 2004; Moore et al., 
2005).  The comparator for the economic evaluation was the standard regimen for the acute phase 
and dexamethasone for the delayed phase.  In addition to the alternative used in the above 
economic evaluation, a comprehensive economic evaluation of antiemetics for prevention of 
CINV following HE chemotherapy comparing the new MASCC recommended regimen, old 
ASCO regimens and clinical practice is needed.   
 
To our knowledge, there is only one published pharmacoeconomic analysis of 
palonosetron in patients receiving ME chemotherapy.  The study was conducted from the payer’s 
perspective and concluded that palonsetron is a cost-effective treatment strategy compared to the 
older 5-HT3RAs (Vanscoy, Rubenstein, Smith, Weber, & Rihn, 2004).  Notable also, the study 
did not compare the new regimen to previous ASCO-recommended guidelines and clinical 







INTRODUCTION  Reema Mody 
1.7: Need for the Study 
 
CINV is a significant problem among cancer patients especially those receiving HE and 
ME chemotherapy.  With the advent of new cytotoxic agents and colony stimulating factors, both 
of which facilitate more aggressive, and therefore potentially more emetogenic drug therapy, 
effective management of CINV by health professionals is imperative.  As discussed earlier, 
uncontrolled or suboptimally controlled emesis has a considerable impact on clinical, economic 
and QOL outcomes.  Though hospitalization due to severe emesis is rare, cost of prophylactic 
and rescue antiemetic medications pose a significant economic burden for third-party payers, 
hospitals and patients.  With the advent of managed care, it is estimated that more than 70% of 
chemotherapy is administered in the outpatient setting in freestanding cancer centers, community 
oncology offices, comprehensive cancer centers, and ambulatory infusion suites (Average 
Wholesale Price, 2003). 
 
Antiemetic agents used for prevention of CINV also form a substantial portion of the 
pharmacy budgets of managed care organizations, hospitals and cancer centers.  The growing US 
market for the 5-HT3 RAs is approximately $1.4 billion and includes the more than $800 million 
market for CINV prevention and treatment.  With the entry of new agents such as aprepitant and 
palonosetron, new antiemetic guidelines and recommendations have been proposed by 
organizations such as the MASCC and the NCCN.  These new guidelines recommend 
combination regimens, which include the new antiemetic drugs in addition to the old standard 
regimen.  Though the new antiemetic regimens are more effective in controlling emesis, they 
increase the financial burden on managed care, hospital formulary budgets and patients.  
Oncology practitioners now have a number of new antiemetic regimens for use in preventing 
acute and delayed CINV.  Since supportive care, which includes prevention of emesis is not 
perceived to directly affect cure, they are often targets for cost containment policies (Rubenstein, 
1995a, 1995b).  While, these policies focus on the high immediate drug procurement costs, they 
fail to incorporate the economic impact of therapies over the full course of the treatment in their 
reimbursement decisions (Rubenstein, 1995a, 1995b).  An economic evaluation of supportive 
care therapies that incorporates a comprehensive assessment of direct, indirect and intangible 
costs and benefits of treatment will help demonstrate the value of the product.  
 
Though cisplatin is no longer a widely used chemotherapy agent, economic evaluation of 
regimens for prevention of CINV following cisplatin administration is necessary because 
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practically all patients receiving it experience emesis if prophylactic treatment is not given.  On 
the other hand, though the incidence and severity of emesis is lower in patients receiving ME 
chemotherapy, it represents the largest group of cancer patients who experience nausea and 
vomiting.  Earlier economic evaluations compared different 5-HT3 RAs with one another (five 
studies), or compared 5-HT3 RA containing regimens with regimens containing older antiemetic 
agents (15 studies) such as metoclopramide, diphenhydramine, dexamethasone, 
methylprednisolone, and prochlorperazine.  In addition, almost half of the economic evaluations 
were limited to acute nausea and vomiting following administration of chemotherapy (Lachaine 
& Laurier, 2002).  A majority of the economic evaluations have compared treatment regimens 
that are no longer relevant and do not reflect the actual clinical practice of CINV management.  
Thus, an economic evaluation comparing new antiemetic guidelines to guidelines recommended 
prior to the introduction of new antiemetic agents, and also to widely used regimens in clinical 
practice for prevention of both acute and delayed emesis is required.  
 
Cost-effectiveness analysis (CEA), cost-utility analysis (CUA), and cost-benefit analysis 
(CBA) which combines information on the health benefits, health risks and costs of health care 
services, are approaches that can incorporate and complement evidence on effectiveness for 
informed policy decision making.  CINV has a significant impact on the QOL but has no known 
impact on survival of cancer patients.  Thus antiemetic regimens that control acute and delayed 
CINV may lead to a significant qualitative improvement in survival but no quantitative change at 
all.  Since HRQOL is now recognized as a primary outcome for the evaluation of supportive care 
therapies (Uyl-de Groot, Wait, & Buijt, 2000), it is necessary to incorporate the impact of CINV 
and its treatment on intangible outcomes such as HRQOL, patient suffering and distress in the 
form of preferences or utilities.  Due to this, traditional cost-effectiveness analysis using life 
years gained may not be the most appropriate outcome measure in antiemetic economic 
evaluations.  Cost per completely controlled patient is important from the payer and hospital 
perspective but outcome measures such as quality-adjusted life years (QALYS) or willingness-to-
pay (WTP) that incorporate the effect of disease and treatment on QOL are more appropriate for 
use in antiemetic economic evaluations from a societal and patient perspective.  
 
Zbrozek et al. (1995) performed a cost utility analysis comparing ondansetron with 
metoclopramide using efficacy data from published clinical trials.  To calculate the incremental 
cost per QALY, a relative difference of 0.00014 QALY between two antiemetic agents was 
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arbitrarily estimated.  The incremental cost per QALY in patients receiving high-dose cisplatin 
was US$407,667 and in patients receiving moderate-dose cisplatin was US$372,255.  CINV lasts 
for about 5-7 days following chemotherapy administration and can be classified as an acute 
health condition.  The use of QALYs to value morbidity for short-term condition such as CINV 
has both measurement and evaluation problems (Bala & Zarkin, 2000) which are explained in 
Chapter 2. The evaluation problem arises because the multiplicative product of the utility weights 
and life-years gained is extremely small leading to high cost per QALY estimates.  Thus, CUA 
also may not be an appropriate economic evaluation method for determining the value of 
antiemetic regimens for prevention of CINV.  Therefore, CBA where costs and benefits of the 
health care interventions are compared in monetary values is being proposed to be the most 
appropriate method for valuing antiemetic regimens for prevention of CINV, an acute health 
condition with significant impact on HRQOL.  
 
In a CBA, benefits are measured in monetary values by determining the willingness-to-
pay (WTP) for the outcomes due to the new health care intervention. Dranitsaris et al (2001b) 
conducted a multinational study to determine the WTP for improved emesis control due to NK-1 
receptor antagonists, following cisplatin-based chemotherapy.  The study showed that there were 
considerable differences in cancer patients’ valuation of improved emetic control between 
countries. Thus it is necessary to evaluate the WTP for improved emetic control, specifically 
among patients in the United States.  The study was conducted before the benefits of NK-1 
receptor antagonists were established in randomized clinical trials.  Now, WTP amounts can be 
determined for the actual benefit provided by the new antiemetic agents as results from phase III 
randomized clinical trials of NK-1 receptor antagonists are available. Though this study 
determined the WTP for improved emesis control, it was not used for further economic 
evaluation of the antiemetic regimens.  Thus, it is necessary to determine the value of improved 
emesis control in the US and use those values in a cost-benefit study of new antiemetic regimens. 
 
The current study is a comprehensive economic evaluation of antiemetic regimens for 
prevention of CINV following highly and moderately emetogenic chemotherapy.  The current 
study conducted cost-effectiveness evaluations of new antiemetic regimens compared to the 
previous guidelines and clinical practice for prevention of CINV following chemotherapy.  Cost-
benefit analysis using the contingent valuation method was done to compare the new regimen to 
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the standard regimen for prevention of CINV following highly and moderately emetogenic 
chemotherapy.  
 
1.8: Research Objectives 
 
1) What are the incremental costs and consequences of introducing the three-drug regimen 
(aprepitant in addition to the standard regimen) for prevention of CINV following HE regimen 
from the payer and societal perspective? 
2) What are the incremental costs and consequences of introducing palonosetron for prevention 
of CINV following ME chemotherapy regimen from the payer and societal perspective?  
3)  What is the monetary value that patients place on improved emesis control due to the new 
antiemetic regimen for prevention of CINV due to HE chemotherapy?  
4) What is the monetary value that patients place on improved emesis control due to the 
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1.9: Conceptual Framework of the Study 
 
The purpose of this study is to conduct a comprehensive economic evaluation of 
antiemetic agents for prevention of CINV.  The study will be conducted in two phases.  Figure 1-
1 shows a schematic representation of the conceptual framework of the study.  Phase I involves 
construction of a decision analytic model to compare the incremental costs and benefits 
associated with prophylactic antiemetic regimens for prevention of CINV.   The incremental 
cost-effectiveness ratios (ICER) for the antiemetic regimens will also be determined in Phase I.  
Phase II will determine the monetary value that patients place on the improved emesis control 
due to the new antiemetic regimens for prevention of CINV following highly emetogenic and 
moderately emetogenic chemotherapy.  Phase II also involves conducting cost-benefit analyses 
of the new antiemetic regimens using the monetary value of benefits determined by using the 
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Figure 1-1: Conceptual Framework for Economic Evaluation of Prophylactic Antiemetic Regimens for  
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Phase I 
 
CINV can be managed by different prophylactic antiemetic regimens and the challenge is 
to quantify the effects and identify the regimens that deliver maximum benefit in the most 
efficient manner.  Phase I involves constructing two decision analytical models to systematically 
compare the different prophylactic antiemetic regimens for prevention of CINV due to HE and 
ME chemotherapy.  The alternative antiemetic regimens are discussed in the section titled 
“Economics of Prevention of CINV” and later in Chapter 3, Methods. The CEA will be 
conducted from the payer and societal perspective. 
 
A hypothetical cohort of patients with cancer who are receiving their first cycle of 
cisplatin-based HE chemotherapy will be considered for the HE model.  Another hypothetical 
cohort of patients with cancer who are receiving their first cycle of ME chemotherapy such as 
cyclophosphamide, plus an anthracyclines such as doxorubicin, epirubicin etc. will be considered 
for the ME model.  The cohorts will be tracked for a period of 5 days to coincide with the time 
period for which patients usually experience CINV during a cycle of chemotherapy and for 
which relevant clinical data from studies are available.  For both HE and ME models, the primary 
outcomes of Phase I are 1) number of patients with complete control defined as no emesis and no 
rescue medications over the 5-day period and 2) costs.   
 
The effectiveness of the various antiemetic regimens included in the models will be 
obtained from the published literature.  The resource costs include cost of prophylactic antiemetic 
regimens, drug administration costs, cost of managing breakthrough emesis and indirect costs.  
The costs included for calculation of cost-effectiveness ratios will be based on the perspective of 
the analysis.  The incremental cost per completely controlled patient will be calculated for each 
strategy relative to the next most costly strategy as the difference in the total costs of the two 
regimens divided by the difference in the effectiveness of the two regimens 
Incremental cost-effectiveness ratios (ICER) =     ∆ Total Costs   
∆ Effectiveness  
   
 
The incremental analysis helps in determining if the additional benefit offered by the new 
regimen is worth the additional cost of delivering the intervention.  To test the impact of 
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uncertainties in the effectiveness and cost parameters on the results, one way sensitivity analysis 




Phase II of the study involves using the contingent valuation (CV) method to determine 
the monetary value that patients place on improved emesis control due to the new regimens.  The 
CV method is a direct measurement of WTP using a survey based measure to elicit monetary 
values by presenting hypothetical scenarios about the healthcare intervention under evaluation.  
The maximum WTP for improved emesis control is determined for two scenarios: improved 
emesis control due to addition of aprepitant to the standard regimen for prevention of CINV 
following HE chemotherapy and improved emesis control due to palonosetron for prevention of 
CINV due to ME chemotherapy.  An ex-post/user-based perspective will be used to construct the 
CV survey.  A payment card method will be used to determine the maximum WTP for the two 
scenarios.  The study population will include patients above 18 years of age who are currently 
receiving their first or subsequent cycles of chemotherapy, or have received it within the past 
three months are and are able to understand and speak English.  
 
Face to face interviews will be conducted with the patients who agree to participate in the 
study.  In addition to the maximum WTP, information on age, gender, education, annual 
household income, number of members in the household, type of insurance, marital status, and 
employment status will be collected.  The survey also elicits information about the level of 
importance placed on improved emesis control, preference of new versus the old regimens, 
reasons for the preference and level of difficulty in understanding and answering the WTP 
questions.  The amount indicated by the respondents on the payment card was taken as the 
monetary value placed by the patients on improved emesis control.  Multivariate semi-
logarithmic regression models were used to assess the association between WTP amount and 
annual household income, which is also the method used to establish construct validity of the 
WTP survey.  
The WTP amounts obtained using the CV method will be used to conduct CBA for the 
new regimens for prevention of CINV following HE and ME chemotherapy.  The net benefit of 
the new regimens will be calculated as the difference between the incremental costs and 
incremental benefits of the new regimens compared to the standard regimens used for prevention 
of CINV.  
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1.10: Study Goals and Objectives 
 
The overall goal of the study was to conduct a comprehensive economic evaluation of 
prophylactic antiemetic regimens for prevention of CINV following administration of HE and 
ME chemotherapy.  The aim of the study was to determine the cost-effectiveness of new 
antiemetic regimens compared to the regimens recommended by previous guidelines and used in 
clinical practice.  The study also involved determining the monetary value of improved emesis 
control offered by the new antiemetic regimens.  
 
Objectives for Phase I 
 
Objective 1.1:
To develop a decision analytical model that identifies the costs and effectiveness of 
alternative regimens for prevention of CINV in cancer patients receiving HE chemotherapy. 
Objective 1.2: 
To develop a decision analytical model that identifies the costs and effectiveness of 
alternative regimens for prevention of CINV in cancer patients receiving ME chemotherapy. 
Objective 1.3:
To determine the incremental costs and benefits of using the new antiemetic regimen 
(aprepitant with standard regimen) versus the older regimens for prevention of CINV in cancer 
patients receiving HE chemotherapy. 
Objective 1.4: 
To determine the incremental costs and benefits of using the new antiemetic regimen 




Objectives for Phase II 
 
Objective 2.1: 
To determine the monetary value that cancer patients place on improved emesis control 
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To determine the monetary value that cancer patients place on improved emesis control 
with the introduction of palonosetron instead of the standard regimen following ME 
chemotherapy using the CV method. 
Objective 2.3: 
To determine the association between maximum WTP for improved emesis control 
following HE chemotherapy and respondents’ demographic and clinical characteristics (age, 
gender, martial status, education, annual household income, number of members in the 
household, employment status, insurance status, type of cancer, previous experience of 
chemotherapy and previous experience of emesis due to chemotherapy). 
Objective 2.4: 
To determine the association between maximum WTP for improved emesis control 
following ME chemotherapy and respondents’ demographic and clinical characteristics (age, 
gender, martial status, education, annual household income, number of members in the 
household, employment status, insurance status, type of cancer, previous experience of 
chemotherapy and previous experience of emesis due to chemotherapy). 
Objective 2.5: 
To conduct a CBA to estimate the net benefit of adding aprepitant to the standard 
regimen for prevention of CINV following HE chemotherapy.   
Objective 2.6: 
To conduct a CBA to estimate the net benefit of using palonosetron instead of the 
standard regimen for prevention of CINV following ME chemotherapy.   
 
1.11: Significance of Study 
 
The economics of prevention of CINV using antiemetic agents needs to be studied in the 
light of higher costs of the antiemetic drugs.  Introduction of newer interventions in addition to 
the existing ones can threaten drug formulary budgets of third-party payers, hospitals and cancer 
centers.  Consequently, there is a growing pressure to evaluate all new interventions before 
implementation.  Clinical practice guidelines recommend the use of treatment strategies based on 
effectiveness of the intervention, which should be the primary requirement for its acceptance in 
health care.  However, effectiveness alone is not a sufficient criterion to initiate services in most 
practical health care contexts, emphasizing the important role of the cost-effectiveness approach 
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in policy decisions.  Thus, the study results will have relevance to different players in the health 
care sector, namely patients, physicians, hospitals, third party payers and society as a whole.  
Society/policy makers 
The results of the CEA and CBA analysis which combines information on health 
benefits, health risks and costs of health care services will assist informed policy decision 
making.  The WTP estimates will provide important information about the value placed on CINV 
and improved emesis control due to new antiemetic agents.  Willingness-to-pay can be used to 
calculate the benefit to cost ratio for comparing treatment of CINV with other health care 
interventions for resource allocation decisions.  
Payers 
Many policy decisions are made at the local levels namely the health plan, hospital or 
health maintenance organization (HMO) level.  These policy decisions include inclusion of drugs 
on the local or regional formulary of the HMO or health plan.  HMOs and managed care 
organizations (MCOs) can utilize the ICER to aid formulary decision making.  The decision 
analytical models developed in this study can be applied to provide ICER for different 
subpopulations of specific managed card plans.  
Health care professionals 
The results will also have relevance to clinical decision-making.  In clinical practice, 
physicians and other decision-makers can use the study results to determine whether costs 
associated with each antiemetic regimen are worth the benefits provided by the therapies. The 
study can also help physicians, other health care professionals and researchers in developing 
clinical practice guidelines, which incorporate not only benefits and risk but also costs of 
antiemetic therapy.  
Hospitals 
CEA/CBA results will have relevance to the hospital policy makers to determine the 
impact of new interventions on their formulary budgets.  The study results will provide the 
incremental cost per successfully treated patient on new antiemetic regimen compared to 
standard regimen. Net benefit (WTP – Cost) is a more relevant outcome measure to the hospital 
policy makers to create a monetary rank order based on user value as new products are 
introduced into clinical practice.  
Scientific literature 
Finally, the study will be a valuable addition to the scientific literature in the field of 
supportive cancer care, pharmacoeconomics, and economic evaluation methodologies.  In the 
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recent years, researchers have developed a renewed interest in CBA as a method for assessing the 














2.1: Pathophysiology of Chemotherapy-Induced Nausea and Vomiting (CINV) 
 
Chemotherapy-induced nausea and vomiting (CINV) are perceived among the most 
distressing and feared side effects of chemotherapy by patients with cancer (Boer-Dennert et al., 
1997; Griffin et al., 1996).  It is estimated that between 60-80% of cancer patients receiving 
chemotherapy experience nausea and/or vomiting if prophylactic antiemetic drugs are not used 
(DeVita et al., 2001; King, 1997).   
 
The exact mechanism by which chemotherapy induces nausea and vomiting is not clearly 
understood.  Different chemotherapy agents act on various sites and cause nausea and vomiting 
by diverse mechanisms of action (Stewart, 1991).  Chemotherapy agents cause nausea and 
vomiting by direct or indirect activation of the chemoreceptor trigger zone (CTZ), peripheral 
stimulation of the gastrointestinal tract, direct cerebral activation, vestibular mechanisms and 
alterations of taste and smell.  It is suggested that the most common mechanism is through the 
activation of the CTZ.  The interaction between chemotherapy and the CTZ releases various 
neurotransmitters that activate the vomiting center (Berger & Clark-Snow, 2001).  Some of the 
neurotransmitters released are dopamine, serotonin, histamine, and substance P (Bender et al., 
2002).  Though a single neurotransmitter is not responsible for all CINV, serotonin and 5-
hydroxytryptamine (5-HT) play an important role in the pathophysiology of acute CINV.  
Substance P, another neurotransmitter found in the gastrointestinal tract and the CTZ of the area 
postrema, exerts its emetic effects by binding to a specific neuroreceptor, NK1 (Olver, 2004).  
Antiemetic agent, aprepitant exert its antiemetic effect by antagonism of the NK1 receptors and is 
found to have better antiemetic control during delayed CINV, compared to previous regimens.  
 
Some terms associated with CINV and their definitions are presented in Table 2-1.  
CINV can be classified into five distinct syndromes based on the time of occurrence during a 
chemotherapy cycle (Bender et al., 2002; Navari, 2003).  These five syndromes are described in 
Table 2-2. 
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Nausea is a subjective, unobservable phenomenon of an unpleasant sensation 
experienced in the back of the throat and the epigastrium that may or may not 
culminate in vomiting. 
Vomiting Vomiting is the forceful expulsion of the contents of the stomach, duodenum, or 
jejunum through the oral/nasal cavity. 
Retching Retching is an associated phenomenon that is described as an attempt to vomit 
without bringing anything up. 
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Table 2-2: Chemotherapy-Induced Nausea and Vomiting Related Syndromes and Their 
Definitions 
 
CINV Syndromes Definitions 
Acute CINV Occurs within the first 24 hours after administration of chemotherapy. 
Delayed CINV 
Defined as nausea and vomiting occurring more than 24 hours (days two 
to seven of chemotherapy cycle) after the administration of emetogenic 
chemotherapy (Kris et al., 1985; Tavorath & Hesketh, 1996). 
Anticipatory CINV 
Occurs within one week prior to the actual administration of 
chemotherapy and is linked to repeated associations with chemotherapy 
side effects and environmental stimuli. For example, certain tastes, 
sensations, smells, or even thoughts experienced by patients who receive 
chemotherapy may evoke nausea and/or vomiting.  
Breakthrough CINV 
Occurs either in the acute or delayed phases of emesis, in spite of patients 
being treated with prophylactic antiemetic therapy. Rescue therapy is 
usually administered to control breakthrough CINV.  
Refractory CINV Occurs during subsequent cycles of chemotherapy when antiemetic prophylaxis or rescue therapy has failed in earlier cycles.  
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2.2: Factors Associated with Increased Risk of CINV 
 
A number of patient, disease and treatment-related characteristics have been identified as 
potential factors associated with increased risk of nausea and vomiting following chemotherapy.  
These factors are important for developing antiemetic treatment guidelines and tailoring 
antiemetic regimens to achieve the maximum emetic control in patients receiving chemotherapy.  
 
Disease and Treatment-related Factors 
 
Emetogenicity of the Chemotherapy Agents 
The emetogenic potential of the chemotherapy agent, defined, as the intrinsic capacity of 
a chemotherapy agent to produce an emetic episode in a patient who is receiving the agent, is the 
most important predictor of CINV (Lindley, Bernard, & Fields, 1989; Osoba et al., 1997a; Pater 
et al., 1994).  Hesketh et al. (Hesketh, 1999; Hesketh et al., 1997) and the expert consensus by the 
American Society of Health-System Pharmacists (ASHP) (ASHP, 1999) have classified the 
available chemotherapy agents into five levels of emetogenicity based on the proportion of 
patients who experience acute emesis in absence of effective antiemetic prophylaxis.  Table 2-3 
shows the classification of single chemotherapy agents into the various levels based on their 
emetogenicity.  Chemotherapy agents in level 5 are termed as highly emetogenic (HE) 
chemotherapy and regimens with cisplatin are specifically termed as cisplatin-based HE 
chemotherapy.  Chemotherapy agents classified under levels 3 and 4 are termed as moderately 
emetogenic (ME) chemotherapy.  The chemotherapy agents that fall under levels 1 and 2 have 
low potential of causing CINV.  
 
For combination chemotherapy regimens, the level of emetogenicity is determined based 
on an algorithm which combines the emetogenicity of the single agents (DeVita et al., 2001; 
Hesketh et al., 1997).  Table 2-4 describes the algorithm used to calculate the emetogenicity of 
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Table 2-3: Classification of Emetogenicity of Single Chemotherapy Agents 
   
Level Frequency of Acute Emesis  
(%)*
Chemotherapy Agents 
5 > 90 % Carmustine > 250 mg/m2
  Cisplatin ≥ 50 mg/m2
  Cyclophosphamide > 1,500 mg/m2
  Dacarbazine 
  Mechlorethamine 
  Streptozotocin 
4 60-90 % Amifostine > 500 mg/m2
  Busulfan > 4mg/d 
  Carboplatin 
  Carmustine < 250 mg/m2
  Cisplatin < 50mg/m2
  Cyclophosphamide >750 ≤ 1,500 mg/m2
  Cytarabine ≥ 1g/m2
  Doxorubicin > 60 mg/m2
  Epirubicin > 90 mg/m2
  Melphalan > 50 mg/m2
  Methotrexate > 1,000 mg/m2
  Procarbazine (oral) 
3 30-60 % Cyclophosphamide ≤ 750 mg/m2
  Cyclophosphamide (oral) 
  Doxorubicin 20-60 mg/m2
  Epirubicin ≤ 90 mg/m2
  Hexamethylmelamine (oral) 
  Idarubicin  
  Ifosfamide  
  Irinotecan  
  Methotrexate 250-1000 mg/m2
  Mitoxantrone < 15 mg/m2
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Table 2-3 (Continued): Classification of Emetogenicity of Single Chemotherapy Agents 
   
Level Frequency of Acute Emesis  
(%)*
Chemotherapy Agents 
2 10-30% Capecitabine  
  Cytarabine 100-200 mg/m2
  Docetaxel 
  Etoposide 
  5-Fluorouracil < 1000 mg/m2
  Gemcitabine 
  Methotrexate > 50 mg/m2 < 250 mg/m2
  Mitomycin 
  Paclitaxel 
  Topotecan 
1 < 10% Alpha Interferon 
  Bleomycin 
  Chlorambucil (oral) 
  Dexrazoxane 
  Fludarabine 
  Gemtuzumab 
  Hydroxyurea 
  Imatinib 
  Methotrexate ≤ 50 mg/m2
  Rituximab 
  Vinblastine 
  Vincristine 
  Vinorelbine 
 
* Proportion of patients who experience emesis in the absence of effective antiemetic prophylaxis 
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Table 2-4: Algorithm for Determining Emetogenicity of Combination Chemotherapy 
Regimens 
 
TO DETERMINE THE LEVEL OF EMETOGENICITY OF THE COMBINATION REGIMEN: 
First identify the drug in the combination regimen with the highest emetic potential based on the 
Hesketh classification. To this level add the emetogenic potential of other drugs in the regimen based 
on the following:  
 
1. Level 1 agent does not add to the emetogenic potential of the combination regimen.  
2. One or more agents of level 2 in the combination regimen will increase the emetic potential 
by 1 level.  
3. Each agent of level 3 or 4 in the combination regimen will increase the emetic potential by 1 
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For a classification schema to be more relevant and serve as a basis for treatment 
recommendations, it must also account for the ability of certain chemotherapy agents to produce 
delayed emesis.  The potential for a chemotherapy agent to cause delayed emesis is proportionate 
to its ability to cause acute emesis.  In the absence of prophylaxis for delayed emesis, the 
incidence of delayed emesis is 60-90% in patients treated with cisplatin and 20-33% in those 
receiving carboplatin, cyclophosphamide or doxorubicin (Gralla, 1997; Gralla et al., 1999; 
Hesketh, 1999).  Though emesis in the acute phase is a strong predictor for incidence of delayed 
emesis, 40% of patients suffer from delayed emesis despite complete protection in the acute 
phase (de Wit, 2003).  Individual risk assessment is imperative and because chemotherapy is 
most commonly administered in cycles over a period of time, it is also important that assessment 
be maintained throughout the treatment period.  
 
Previous Exposure to Emetogenic Chemotherapy 
Patients with uncontrolled emesis in earlier cycles of chemotherapy are more likely to 
experience emesis in subsequent cycles in spite of prophylactic antiemetic administration.  Poorly 
controlled nausea and vomiting in previous cycles also increases the likelihood of anticipatory 
nausea and vomiting. 
 
Other Possible Disease-related Factors 
Performance status (as measured by the European Cooperative Oncology Group (ECOG) 
Performance Status Scale), tumor burden and stage of disease may be associated with incidence 
of CINV.  The ECOG performance status scale is used to assess how a cancer patient’s disease is 
progressing, assess how the disease affects the daily living abilities of the patient, and determine 
appropriate treatment and prognosis (Oken et al., 1982).  The assessment is conducted on a scale 
of 0-5 where 0 indicates that the patient is fully active, and able to carry on all activities without 
restriction.  A score of 5 on the scale indicated death.  Osoba et al. (Osoba et al., 1997a) found 
that 57% of patients with a ECOG performance status of either 1 or 2 experienced CINV 
compared to 49% of patients with ECOG performance status of 0 or normal.  A large tumor 
burden especially in patients with ovarian cancer or abdominal malignancies also may increase 
the likelihood of experiencing emesis (Doherty, 1999).  A prospective longitudinal study 
designed to study factors predicting development of CINV in Chinese breast cancer patients 
receiving moderately emetogenic chemotherapy found that later stage of disease increased the 
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risk of longer duration of acute nausea and greater frequency of acute nausea and vomiting 




Patient-related factors such as age, gender, history of alcohol use, motion sickness, 
previous exposure to chemotherapy, and prior experience of emesis may increase or decrease the 
risk of developing CINV (Doherty, 1999; Osoba et al., 1997a).  Elderly patients tend to tolerate 
chemotherapy better than younger patients.  Women, younger than 50 years of age require 
aggressive antiemetic regimens since they are more likely to experience nausea and vomiting 
compared to men.  Patients with prior history of emesis during pregnancy or due to motion 
sickness are also at an increased risk of experiencing CINV.  In patients receiving cisplatin, those 
who have a history of chronic alcohol ingestion, greater than 100g/day (approximately five 
alcoholic beverages per day) appear to experience less intense nausea and vomiting (Goodman, 
1997).  
 
Certain psychosocial and behavioral factors such as stress, negative attitude towards 
chemotherapy (Tsavaris et al., 2000), anxiety (Molassiotis et al., 2002) and pretreatment 
expectations of nausea and vomiting (Andrykowski et al., 1988; Jacobsen et al., 1988; Roscoe, 
Hickok, & Morrow, 2000) may also lead to increased risk of emesis.  
 
Factors Specifically Associated with Increased Risk of Delayed CINV 
 
The level of protection achieved in the acute phase of the first chemotherapy cycle is a 
very important prognostic factor for incidence of delayed emesis in the same and subsequent 
chemotherapy cycles (IGAR, 1994).  Independent of the type of antiemetic treatment received for 
acute or delayed emesis, complete protection from nausea and vomiting in the acute phase 
significantly reduces the risk of developing emesis in the delayed phase (Schnell, 2003).  
Delayed CINV is more frequently seen in patients receiving HE chemotherapy.  Some other 
possible factors associated with increased risk of delayed emesis include cisplatin > 90mg/m2, 
younger age, female gender, and larger tumor burden (Roila et al., 2002). 
 
It is important to identify the prognostic or risk factors that predict the likelihood of 
cancer patients developing acute, delayed and anticipatory CINV.  These factors will aid in 
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developing a risk profile for the patients at the greatest risk of CINV and tailor antiemetic 
regimens for prevention of CINV based on individual risk profile.  
 
2.3: Prevention Strategies for CINV 
 
The most important point about managing CINV is that preventing CINV is more 
effective than treating it (Markman, 2002).  Antiemetic agents administered before chemotherapy 
are effective in reducing the incidence of acute emesis, but it is difficult to completely control 
CINV once it has begun.  One of the goals of antiemetic therapy is to achieve complete control in 
all settings, beginning with the initial cycle of chemotherapy, thus improving patient compliance, 
quality of life, and preventing development of anticipatory and refractory nausea and vomiting 
during subsequent cycles of chemotherapy.  The other goals of antiemetic therapy are to provide 
maximum convenience for patients and staff, to eliminate potential side effects of the agents, and 
to minimize the cost of treatment of CINV (Berger & Clark-Snow, 2001).  Inappropriate control 
of acute emesis leads to breakthrough, delayed, refractory and anticipatory emesis in the same 
and subsequent chemotherapy cycles.  
 
The currently available antiemetic agents have not been adequately tested for 
breakthrough, refractory and anticipatory emesis (King, 1997).  In addition to pharmacological 
interventions, nonpharmacologic interventions can be used to prevent anticipatory nausea and 
vomiting or control CINV.  Nonpharmacologic interventions are “techniques that unite the mind 
and body by using psychologic interventions to control physiologic responses” (Bender et al., 
2002; King, 1997).  These include behavioral interventions, such as relaxation, self-hypnosis, 
cognitive distraction, acupuncture, acupressure and music therapy (Bender et al., 2002; King, 
1997). Since the focus of the study is the use of pharmacological interventions, 
nonpharmacological interventions will not be discussed.  
 
Assessment of Efficacy of Antiemetic Agents 
 
Vomiting or emesis can be assessed by calculating the number of emetic episodes 
experienced by patients each day during the period of interest, usually 5-7 days.  The percentage 
of patients with no emetic episode (with or without nausea) during the acute, delayed and overall 
phase is the primary outcome measure for control of emesis (Kris et al., 2005).  The gold 
standard for determining the efficacy of antiemetic agents is the complete prevention of all 
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emesis and nausea (Hesketh, Gralla, du, & Tonato, 1998).  It is suggested that control of emesis 
and nausea should be reported separately due to the subjective nature of nausea.  The assessment 
of intensity of nausea is measured using visual analog scales (VAS) or descriptive ordinal scales.  
A four-point descriptive ordinal scale measuring intensity of nausea as none, mild, moderate, and 
severe has been found to have a high correlation with a VAS (Hesketh et al., 1998).  
 
A more stringent criterion for determining the efficacy of antiemetic agents is total 
control – complete control of both emesis and nausea.  In clinical trials, complete control of 
nausea was approximately 10% lower compared to complete control of emesis (Hesketh et al., 
1998).  Thus, when ‘total control’ is used as an outcome measure, the total control rates are 
reported to be very similar to the complete control rates of nausea.  Also, nausea and vomiting 
depend on different pathophysiological mechanisms and thus they should be separately evaluated 
in clinical trials.  Other secondary measures include complete protection, defined as proportion of 
patients with minimal or no nausea, no vomiting or retching and no use of rescue medication in 
the post-chemotherapy period.  Outcome measures based on the number of emetic episodes: 
major control (< 3 emetic episode), minor control (3-5 emetic episodes) and failure (> 5 emetic 
episodes), are also sometimes reported in clinical trials.   
 
Pharmacotherapy for Prevention of CINV 
 
Various classes of drugs such as phenothiazines, butryophenones, substituted 
benzamides, cannabinoids, steroids and 5-HT3 receptor antagonists (5-HT3 RA) are available to 
control the incidence of CINV (Gralla, 1997).  Some older classes of drugs such as 
phenothiazines, benzodiazepines and butyrophenones are used as rescue medications for 
breakthrough emesis.  Newer antiemetic agents such as aprepitant and palonosetron have been 
introduced recently.  
 
Older Antiemetic Agents 
 
A) Phenothiazines (Phenergan®, Compazine®)  
Phenothiazines such as prochlorperazine, promethazine and thiethylperazine block the 
vomiting impulses by antagonizing the dopamine receptors (Flake, Scalley, & Bailey, 2004). 
These agents have tranquilizing and antiemetic effects and are used in combination antiemetic 
regimens for prevention of nausea and vomiting due to mildly emetogenic chemotherapy 
(Goodman, 1997).  Phenothiazines are also given as rescue medications for breakthrough nausea 
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and vomiting.  Phenothiazines may increase risk of extrapyramidal symptoms, especially in 
patients aged 30 years or younger (Goodman, 1997).  Some other common side effects include 
sedation, lethargy and skin sensitization (ASHP, 1999).  
 
B) Butyrophenones (Haldol®) 
Butyrophenones are major tranquilizers but are less effective in preventing nausea and 
vomiting compared to other antiemetics such as 5-HT3 RA.  But these agents are particularly 
useful when anxiety and anticipatory symptoms aggravate the degree and intensity of nausea and 
vomiting.  Butyrophenones such as haloperidol and droperidol may be used in combination with 
5-HT3 RA.  However, adverse effects such as extrapyramidal symptoms, and dystonic reactions 
can be severe with butyrophenones (Goodman, 1997).  
 
C) Substituted Benzamides  
Substituted benzamides such as metoclopramide in high dosages were found to 
effectively block 5-HT3 receptors and were widely used for preventing CINV. But high doses of 
metoclopramide can cause extrapyramidal symptoms in up to 5% of patients (Schnell, 2003).  
With the advent of 5-HT3 RA which are more effective and less toxic in prevention of cisplatin-
induced emesis, metoclopramide is now used only in combination with other antiemetic agents or 
as rescue medication for breakthrough emesis (Goodman, 1997; NCCN, 2005).  Some guidelines 
recommend oral metoclopramide in combination with corticosteroids for prevention of delayed 
emesis due to HE and ME chemotherapy (Gralla et al., 1999; NCCN, 2005).  The dose of 
metoclopramide ranges from 20mg and 40mg to be given two to four times a day for three or 
four days for control of delayed CINV.  
 
D) Benzodiazepines  
Benzodiazepines such as lorazepam and diazepam may have an antiemetic effect due to 
their anxiolytic and amnesic effects.  The temporary amnesic effects of benzodiazepines make it 
useful in patients who suffer anticipatory nausea and vomiting and the anxiolytic effects make it 
useful in patients awaiting their first chemotherapy.  It was found that lorazepam reduced the 
incidence of anticipatory nausea and vomiting and acute emesis induced by cisplatin (Malik et 
al., 1995).  These agents have little antiemetic efficacy as single agents and are recommended as 
adjuncts to other antiemetics (DeVita et al., 2001).  
 
E) Cannabinoids  
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Cannabinoids such as dronabinol can be used as an option in patients with CINV which is 
refractory to conventional antiemetic treatment and as an adjuvant to other antiemetics.  This 
class of drugs may be useful in younger patients without cardiac or psychiatric illness and/or in 
patients who are sensitive to phenothiazines (Goodman, 1997). Some common side effects of 
dronabinol include drowsiness, euphoria and vision difficulties (ASHP, 1999).  
 
F) Corticosteroids  
Corticosteroids are effective as single agents or in combination for prevention of CINV.  
Dexamethasone is the most widely studied corticosteroid and is an effective, convenient and 
inexpensive anti-emetic useful in both acute and delayed emesis with chemotherapy of mild, 
moderate and severe emetic potential.  A meta-analysis of randomized clinical trials showed that 
single agent dexamethasone was significantly superior to placebo or no treatment in complete 
control of acute and delayed CINV among patients receiving different types of chemotherapy 
regimens (Ioannidis, Hesketh, & Lau, 2000).  The pooled results of three studies comparing 
dexamethasone to metoclopramide showed that the former provided better control of acute CINV 
(Ioannidis et al., 2000).  In patients receiving cyclophosphamide or anthracycline-based 
chemotherapy, dexamethasone has been shown to be equal or superior to metoclopramide or 
equal to 5-HT3 RAs (Herrstedt et al., 2005) in providing acute antiemetic control.  
 
As an antiemetic, dexamethasone has been administered in doses ranging from 4 mg to 
20 mg for a period of one to five days for prevention of acute and delayed CINV following 
highly emetogenic and moderately emetogenic chemotherapy.  A comparison study of 
intravenous (IV) dexamethasone in dosages ranging from 4 mg to 20 mg to control acute emesis 
was conducted among patients receiving cisplatin-based chemotherapy (IGAR, 1998a).  The 
study results showed that a single 20 mg IV dose before chemotherapy was considered as the 
most efficacious dose for prevention of acute cisplatin-induced acute emesis.  In another 
randomized, double-blind clinical trial to determine optimum dose of IV dexamethasone in 
patients receiving ME chemotherapy such as anthracyclines, carboplatin or cyclophosphamide, a 
single dose of 8 mg was recommended as sufficient for acute control of emesis (IGAR, 2004).  
 
Though single agent dexamethasone is effective in controlling emesis in patients 
receiving ME chemotherapy and low doses of cisplatin, it is ineffective for patients receiving 
higher doses of cisplatin (Herrstedt, 2004).  Since corticosteroids improve the antiemetic effects 
of other antiemetics, they are ideal drugs for use in combination chemotherapy.  Dexamethasone, 
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in combination with 5-HT3RAs showed increased effectiveness in prevention of acute CINV 
following administration of both HE and ME chemotherapy (Joss et al., 1994).  Continuous use 
of corticosteroids for a period of four to five days may cause adverse effects such as insomnia, 
anxiety, or euphoria (Goodman, 1997).  
 
G) 5-HT3 receptor antagonists (5-HT3 RAs)  
Due to its high efficacy and favorable toxicity profile compared to other antiemetic 
agents, 5-HT3RAs are currently the first-line agents and the gold standard for prevention of 
CINV in patients receiving HE or ME chemotherapy (Gralla et al., 1999; Schnell, 2003).  The 5-
HT3RAs specifically prevent the binding of the neurotransmitter, serotonin to the 5- HT3 
receptors on the vagal nerves that trigger the emetic response.  Due to the specific nature of its 
binding, it precludes the severe and distressing side effects associated with conventional 
antiemetics such as metoclopramide.  The 5-HT3RAs provide complete acute antiemetic 
protection, i.e. no nausea, no vomiting and no use of rescue medications in 40-60% of patients 
receiving cisplatin based chemotherapy and 60-80% of patients receiving ME chemotherapy 
(Schnell, 2003).  In patients receiving high-dose cisplatin-based chemotherapy regimens, 5-
HT3RAs provide complete antiemetic protection in the acute phase in 25-60% of patients 
(Audhuy et al., 1996; Beck et al., 1992; Hesketh et al., 1996; Marty et al., 1995; Navari et al., 
1995).  
 
Three 5-HT3 RAs are currently available in the United States for prevention of emesis: 
dolasetron (Anzemet®), granisetron (Kytril®) and ondansetron (Zofran®).  All three agents are 
available in both injectable and oral formulations.  The injectable formulations of all three agents 
are indicated for use with highly and moderately emetogenic chemotherapy, whereas only the 
oral route of granisetron and ondansetron are indicated for use with highly emetogenic 
chemotherapy.  Oral administration of a 5-HT3RA and dexamethasone provide similar clinical 
outcomes as IV administration.  The administration of 5-HT3 RAs by the oral route is 
recommended whenever appropriate if the gastrointestinal tract is intact and compliance is 
assured.  Studies have also shown that the oral dosage form of 5-HT3 RA have equivalent 
efficacy to its intravenous form (Berger & Clark-Snow, 2001).  Several randomized, controlled 
studies have shown that ondansetron, granisetron and dolasetron have equivalent complete 
control rates, defined as complete absence of nausea or vomiting, among patients on HE or ME 
chemotherapy (Berger & Clark-Snow, 2001; Gralla et al., 1998; Hesketh, 2000).  For the purpose 
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of this study, ondansetron is used as representative of the 5-HT3RA class of antiemetics and is 




a) For Highly Emetogenic Chemotherapy 
Ondansetron was the first 5-HT3RA to be approved in the US for prevention of nausea 
and vomiting in patients receiving chemotherapy.  There is conflicting data regarding the single 
optimal dose of ondansetron for prevention of acute emesis from cisplatin.  A study by Beck and 
colleagues, comparing various doses of ondansetron for prevention of acute CINV showed that 
32 mg dose was superior to 8 mg, particularly in patients receiving high dose cisplatin (> 
100mg/m2) (Beck et al., 1992).  However, in another study, Seynaeve and colleagues showed that 
a single dose of 8 mg was equally effective to a 32 mg dose for prevention of acute emesis from 
cisplatin (Seynaeve et al., 1992).  A number of other studies show results that support the 
equivalent efficacy of 8 mg dose to 32 mg dose of ondansetron (IGAR, 1995b).  There are also 
controversies regarding the single vs. multiple administration of ondansetron for prevention of 
acute emesis following cisplatin.  Clinical trial results suggest that increasing the number of 
doses does not improve efficacy and multiple-dose administration does not improve outcomes 
(Hesketh et al., 1996; Seynaeve et al., 1992).  The study by Beck and colleagues also showed that 
a single IV dose of ondansetron was as effective as multiple dosing regimen of ondansetron 
(Beck et al., 1992).  
 
Based on the results of a recent systematic literature review, the dosing recommendations 
of ondansetron for prevention of acute nausea and vomiting due to high emetic risk 
chemotherapy is a single oral dose of 24mg of ondansetron or single IV dose of 8mg (Jordan, 
Kasper, & Schmoll, 2005; M. G. Kris et al., 2005). 
 
b) For Moderately Emetogenic Chemotherapy 
For ME chemotherapy, the recommended adult oral dose of ondansetron is a single dose 
of 8 mg.  For delayed emesis following ME chemotherapy, one 8 mg ondansetron tablet can be 
administered twice a day for 1-2 days following chemotherapy (ZOFRAN Prescribing 
Information Monograph).  But dosing recommendations are not without controversy, and based 
on literature search, Herrstedt and colleagues have recommended 8 mg tablets twice daily for 
acute emesis or one single 8 mg IV dose of ondansetron (Herrstedt et al., 2005).  There are no 
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randomized controlled studies to compare a single oral dose of ondansetron to a multiple dosing 
regimen for prevention of CINV following administration of ME chemotherapy.   
For Prevention of Delayed CINV 
 
The dosing regimen of ondansetron for prevention of delayed CINV due to HE and ME 
chemotherapy is not clearly outlined.  It is seen from various randomized clinical trials with 
uniform antiemetic prophylaxis of the acute phase, that the control of cisplatin-induced delayed 
emesis with single agent 5-HT3RAs is not significantly different than placebo (Gandara, Harvey, 
Monaghan, Perez, & Hesketh, 1993; Pater et al., 1997; Smyth, 1992).  The efficacy of single 
agent granisetron compared to placebo for delayed emesis due to HE chemotherapy has been 
studied in 533 patients receiving cisplatin.  In the delayed phase, the patients were randomized to 
receive either placebo or one of three doses (2.5mg, 5mg or 10mg) of oral granisetron twice a day 
until day seven after chemotherapy.  The study results reported no significant differences in the 
efficacy of delayed emetic control among the various groups (Smyth, 1992).  Thus, this suggests 
that as single agents, 5-HT3RAs have minimal to modest activity against cisplatin-induced 
delayed emesis (Gandara et al., 1993; Kris et al., 2005).  
 
Antiemetic Efficacy for Multiple Cycles of Chemotherapy  
 
The emesis protection provided by the combination regimen of 5-HT3RAs and 
dexamethasone decreases with each subsequent cycles of chemotherapy (de Wit et al., 1996; de 
Wit et al., 1998).   A study conducted among 125 patients receiving six cycles of cisplatin-based 
chemotherapy reported that the antiemetic efficacy provided by combination of granisetron and 
dexamethasone decreased over subsequent cycles of chemotherapy.  The initial complete acute 
emesis protection decreased from 66% to 39% in the sixth cycle and initial delayed emesis 
protection decreased from 52% to 43% in the sixth cycle (de Wit et al., 1996; de Wit et al., 
1998).   
 
Side Effects of 5-HT3RA  
 
Reports of clinical trial results and practical clinical experience showed that 5-HT3 RAs 
are well-tolerated (Hesketh, 2000).  There are no significant differences in the side effect profile 
of ondansetron, granisetron and dolasetron (Anastasia, 2000).  The most common adverse events 
reported for all three 5-HT3 RAs are headache, constipation and diarrhea (Audhuy et al., 1996; 
Bleiberg, Spielmann, Falkson, & Romain, 1995; Ettinger et al., 1996; Gralla et al., 1998).  They 
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do not produce the extrapyramidal symptoms associated with dopaminergic antagonists such as 
metoclopramide.  Other adverse events include transient changes in the blood pressure and 
clinically asymptomatic changes in the electrocardiographic parameters (Audhuy et al., 1996; 
Hesketh et al., 1996; Plosker & Goa, 1991).  Transient changes in blood pressure resolve without 
treatment and are considered clinically insignificant.  
 
New Antiemetic Agents 
 
H) Aprepitant (Brand Name: Emend®)  
Aprepitant is the first oral selective nonpeptide neurokinin (NK-1) receptor antagonist 
indicated for use in combination with a 5-HT3 RA and corticosteroid for prevention of acute and 
delayed emesis due to HE chemotherapy regimens.  Aprepitant prevents substance P from 
binding to the NK-1 receptors in the brain stem and thus resulting in inhibition of emesis 
(Bountra et al., 1996; Dando & Perry, 2004).  Although aprepitant is more efficacious, the 2005 
average wholesale price (AWP) of $309.00 for a three-day regimen makes it expensive compared 
to the other antiemetic agents used for prevention of acute and delayed emesis following 
administration of HE chemotherapy. 
 
a) For Highly Emetogenic Chemotherapy
Two large phase III clinical trials have been conducted to determine the antiemetic 
efficacy of aprepitant in patients receiving high-dose cisplatin (≥70mg/m2) (Hesketh et al., 2003; 
Poli-Bigelli et al., 2003).  One group of patients received standard antiemetic therapy consisting 
of IV ondansetron 32 mg and oral dexamethasone 20 mg on day one and oral dexamethasone 8 
mg twice daily on day two to four.  The other group received oral aprepitant 125 mg in addition 
to the standard therapy on day one and aprepitant 80 mg and oral dexamethasone 8 mg on days 
two and three and oral dexamethasone 8 mg on day four.  The overall complete response (no 
emesis and no use of rescue therapy) rates reported in the two clinical trials were 62.7% and 
72.7% for the aprepitant group compared to 43.3% and 52.3% of the standard regimen group.  
Complete response rates in the delayed phase were achieved in 67.7% and 75.4% of patients in 
the aprepitant group compared to 46.8% and 55.8% in the standard regimen group.  These results 
show the superior efficacy of the aprepitant-based regimen in control of acute and delayed CINV 
compared to the standard regimen.  
 
b) For Moderately Emetogenic Chemotherapy
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Randomized clinical trials assessing efficacy of aprepitant in prevention of CINV 
following moderately emetogenic chemotherapy have been recently published.  Warr and 
colleagues conducted a study among 857 chemotherapy naïve breast cancer patients receiving 
cyclophosphamide and either doxorubicin or epirubicin (Warr et al., 2005).  The standard 
regimen group received two doses of 8 mg oral ondansetron on days one to three and 20 mg oral 
dexamethasone on day one.  The aprepitant group received 125 mg of oral aprepitant, 8 mg of 
oral ondansetron twice daily, and 12 mg oral dexamethasone on day one.  The aprepitant group 
also received 80 mg oral aprepitant on days two and three.  The study results showed that 
compared to the standard regimen, more patients in the aprepitant group reported complete 
response during the acute phase, delayed phase and the overall study period.  Thus, aprepitant 
added to the standard regimen has demonstrated better control of CINV compared to the standard 
regimen in patients receiving ME chemotherapy.  
 
c) For Multiple Cycles of Chemotherapy  
The antiemetic efficacy of aprepitant in addition to the standard regimen for prevention 
of CINV due to HE chemotherapy has been found to be sustained over multiple cycles of 
chemotherapy (de Wit et al., 2003; de Wit et al., 2004).  De Wit and colleagues reported results 
from pooled analysis of multiple-cycle extensions of two large phase III aprepitant clinical trials 
(de Wit et al., 2003; de Wit et al., 2004).  Chemotherapy naïve cancer patients receiving their 
first cycle of cisplatin were randomized to either the standard regimen group: IV ondansetron 32 
mg and dexamethasone 20 mg on day one, dexamethasone 8 mg twice daily on days two to four, 
or aprepitant group: aprepitant 125 mg, IV ondansetron 32 mg, dexamethasone 12 mg on day 
one, aprepitant 80 mg on day two and three and dexamethasone 8 mg on days two to four.  The 
patients received these regimens for six cycles and the end point of no emesis and no significant 
nausea was assessed for each cycle.  A cumulative probabilities approach incorporating a model 
for transitional probabilities was used to analyze the data.  The results showed that the estimated 
rates of no emesis and no significant nausea was higher for the aprepitant group compared to the 
standard group for all cycles of chemotherapy.  
 
d) For Breakthrough CINV  
Aprepitant has not been shown to mitigate ongoing emetic symptoms and has not been 
tested for continuous use for duration greater than five days in patients receiving emetogenic 
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chemotherapy.  It should not be used to treat established nausea and vomiting regardless of its 
etiology and should not be prescribed on a PRN basis (Kohler & Hughes, 2003). 
 
e) Adverse effects  
The most common adverse events that occurred more frequently in the aprepitant group 
compared to the standard group include: asthenia/fatigue, dizziness, diarrhea, cough and hiccups 
(Hesketh et al., 2003; Poli-Bigelli et al., 2003).  
 
I) Palonosetron (Brand Name: Aloxi®)  
Palonosetron is a 5-HT3 RA available as an injectable antiemetic agent. Palonosetron 
differs from older 5-HT3 RAs since it has a higher binding affinity to the 5-HT3 receptors, higher 
potency and a longer half-life.  It is indicated for prevention of acute emesis due to HE regimens 
and prevention of acute and delayed emesis due to ME regimens.  In the US, the recommended 
dose of palonosetron for the prevention of CINV is a single IV infusion of 0.25 mg 
approximately 30 minutes before the start of chemotherapy.  Compared to other 5-HT3RAs, 
palonosetron provides convenience for prevention of emesis due to its single dose schedule.  The 
2005 AWP of a 0.25mg 5 ml single dose vial is $340.20.  
 
a) For Highly Emetogenic Chemotherapy 
Currently for patients receiving HE chemotherapy, palonosetron has only been indicated 
for prevention of acute CINV.   In a study of 650 patients receiving HE chemotherapy, two doses 
(0.25 mg or 0.75 mg) of palonosetron were compared to a single 32 mg dose of ondansetron.  
The study results showed no differences in the acute or delayed complete response rates between 
the three study groups.  Thus, it can be concluded that a single 0.25 mg IV dose of palonosetron 
was at least as effective as a 32 mg IV dose of ondansetron for acute and delayed emesis 
following HE chemotherapy (Aapro, Bertoli, Lordick, Bogdanova, & Macciocchi, 2003).  
Studies comparing palonosetron to other regimens for prevention of acute and delayed CINV due 
to HE chemotherapy are currently lacking.  More clinical trials of combination antiemetic 
regimens with palonosetron need to be carried out to establish whether it is more efficacious than 
the combination of corticosteroid with either metoclopramide or a 5-HT3 RA for protection of 
delayed emesis due to HE chemotherapy. 
 
b) For Moderately Emetogenic Chemotherapy 
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The efficacy of palonosetron as part of various different regimens has been extensively 
studied in patients receiving ME chemotherapy.  The results from a study conducted among 569 
patients receiving ME chemotherapy showed that a 0.25 mg IV dose of palonosetron provided 
significantly higher antiemetic control compared to a single 100 mg IV dose of dolasetron 
(Eisenberg et al., 2003).  The study results showed that the single dose of palonosetron is as 
effective as a single dose of dolasetron in preventing acute CINV but the former regimen 
provides better emetic control in the delayed phase.  In the delayed phase, approximately 57% of 
patients who received palonosetron reported achieving complete response as compared to 39% of 
patients who received dolasetron.   
 
Gralla and colleagues conducted a multicenter, randomized, double blind study to 
compare two doses (0.25 mg or 0.75 mg) of IV palonosetron and a single IV dose of 32 mg 
ondansetron among 570 patients receiving ME chemotherapy (Gralla et al., 2003).  The results 
indicated that a single IV dose of palonosetron provided significantly higher acute and delayed 
emetic control compared to a single IV dose of ondansetron.  A phase II open label study was 
conducted to determine the efficacy of a single dose of palonosetron combined with a three-day 
regimen of aprepitant to prevent CINV in patients receiving moderately to moderately-high 
emetogenic chemotherapy.  The preliminary results of the study showed that the combination 
was safe and may improve the overall prevention of CINV (Grote et al., 2004).  
 
c) For Multiple Cycles of Chemotherapy
To date, only one noncomparative trial has been conducted to evaluate the efficacy of 
palonosetron in preventing CINV over repeated cycles of moderately to highly emetogenic 
chemotherapy (Cartmell et al., 2003).  A single 0.75 mg IV dose of palonosetron with or without 
corticosteroids was given to the participants.  The results showed that the efficacy of 
palonosetron was maintained during acute, delayed and overall phases during four cycles of 
chemotherapy (Cartmell et al., 2003).  
 
d) Adverse Effects
The side effect profile of palonosetron is similar to that of the other 5-HT3RAs with 
headache and constipation being among the most frequently reported side effects in clinical trials 
(Eisenberg et al., 2003; Gralla et al., 2003). Other serious side effects occur with a very low 
frequency and were similar in the palonosetron and the comparator group.  
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Combination antiemetic regimens and Recommendations for Antiemetic Use 
 
Combination of two or more antiemetic agents provides better efficacy in prevention of 
CINV following administration of HE and ME chemotherapy than use of a single antiemetic 
agent.  Several professional organizations such as the Multinational Association of Supportive 
Cancer Care (MASCC), the American Society of Clinical Oncology (ASCO), the American 
Society of Health-System Pharmacists (ASHP), the National Comprehensive Cancer Network 
(NCCN), and the Canadian Medical Association have published guidelines and evidence-based 
recommendations for the use of antiemetics in management of CINV (ASHP, 1999; ESMO, 
2001; Gralla et al., 1999; MASCC, 1998; NCCN, 1997). 
 
Highly Emetogenic Chemotherapy  
 
Acute Phase 
Several randomized double-blind clinical trials have been conducted to compare single 
agent 5-HT3RA with a combination of 5-HT3 RA and dexamethasone for prevention of CINV in 
patients receiving HE chemotherapy (Heron, Goedhals, Jordaan, Cunningham, & Cedar, 1994; 
IGAR, 1995a; Latreille et al., 1995; Olver et al., 1996).  The results from these studies have 
unequivocally shown that the combination of a 5-HT3 RA and dexamethasone provides superior 
antiemetic efficacy in the acute phase compared to 5-HT3 RA alone.  Thus, previous guidelines 
have recommended a combination of 5-HT3 RA and corticosteroids before chemotherapy for 
control of acute emesis in patients receiving HE chemotherapy regimens (ASHP, 1999; Gralla et 
al., 1999).  
 
Based on the results of randomized clinical trials (Chawla et al., 2003; Hesketh et al., 
2003; Poli-Bigelli et al., 2003), new guidelines from the MASCC and the NCCN now 
recommend a triple combination of aprepitant, a 5-HT3RA and dexamethasone for prevention of 
acute emesis due to HE chemotherapy (MASCC, 2004; NCCN, 2005).  The use of palonosetron 
as a part of the triple combination regimen with aprepitant and dexamethasone has been 
recommended for prevention of acute emesis by the NCCN 2005 guidelines (NCCN, 2005).  
Though this regimen is a part of the new recommendations, randomized, double blind clinical 
trials determining its efficacy as compared to the triple combination regimen containing other 5-
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The recommendations for prevention of delayed emesis following HE chemotherapy are 
not as clear cut as those for the acute phase.  The incidence of delayed emesis in patients 
receiving cisplatin-based chemotherapy is reduced from 90% to 40-50% by the use of 
corticosteroids alone, or combined with metoclopramide or a 5-HT3RA (IGAR, 1997; Kris et al., 
1989; Latreille et al., 1998b; Navari, 2003).  The 1999 American Society of Clinical Oncology 
(ASCO) and the American Society of Health-System Pharmacists (ASHP) guidelines 
recommended a combination of corticosteroid and either metoclopramide or 5-HT3 RA for 
prevention of delayed emesis in patients receiving HE chemotherapy (ASHP, 1999; Gralla et al., 
1999).  
 
Early clinical trial results showed that the combination of dexamethasone and 
metoclopramide had higher antiemetic efficacy during the delayed phase as compared to 
dexamethasone alone (Kris et al., 1989).  Several other studies have reported that the 
combination of a 5-HT3RA and dexamethasone has similar efficacy as dexamethasone alone 
(Goedhals, Heron, Kleisbauer, Pagani, & Sessa, 1998; Latreille et al., 1998a; Tsukada, Hirose, 
Yokoyama, & Kurita, 2001).  Thus based on the evidence, it can be concluded that the 
combination of dexamethasone and metoclopramide has better efficacy than dexamethasone 
alone and similar efficacy to dexamethasone and 5-HT3 RA combination.  Also, dexamethasone 
and 5-HT3 RA combination does not provide any additional antiemetic benefit compared to 
dexamethasone alone.  
 
The introduction of aprepitant led to the development of new guidelines and 
recommendations for prevention of delayed CINV following HE chemotherapy.  The MASCC 
and NCCN recommends (MASCC, 2004; NCCN, 2005) using a combination of dexamethasone 
and aprepitant to prevent delayed emesis based on its superiority to dexamethasone alone 
(Hesketh et al., 2003; Poli-Bigelli et al., 2003).  This combination has not been compared for its 
antiemetic efficacy to other combination regimens previously recommended.  Since head-to-head 
clinical trials are not available, decision analytical models can be used to combine data from 
diverse sources to compare various antiemetic regimens to determine their cost-effectiveness 
(CE) compared to the new regimen.  The dexamethasone and 5-HT3RA combination needs to be 
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Moderately Emetogenic Chemotherapy 
 
Acute Phase 
A study was conducted among 428 patients receiving ME chemotherapy to compare three 
antiemetic regimens: dexamethasone alone, granisetron alone, and combination of 
dexamethasone and granisetron for prevention of acute emesis (IGAR, 1995a).  The results 
showed that patients who received the combination regimen were found to have complete 
protection from both nausea and vomiting (70%) more frequently compared to patients receiving 
dexamethasone (49%) and granisetron (43%) alone.  Thus, a combination of a 5-HT3RA and 
dexamethasone was recommended by previous guidelines (ASHP, 1999; Gralla et al., 1999).  
The 2005 NCCN guidelines (NCCN, 2005) reiterate the recommendations of the previous 
guidelines and gives preference to palonosetron based on the results of the recent clinical trials 




In the absence of prophylactic antiemetic agents, the incidence of delayed emesis was 20-
25% among patients receiving ME chemotherapy, such as cyclophosphamide plus either 
doxorubicin or epirubicin.  But other studies have placed the incidence of delayed emesis in 
patients receiving ME chemotherapy without prophylactic antiemetic regimens as high as 70%. 
(IGAR, 2000b; Navari, 2003).  Previous guidelines have recommended the use of either 
dexamethasone alone or combination of dexamethasone with a 5-HT3RA or metoclopramide for 
prevention of delayed emesis due to ME chemotherapy (ASHP, 1999; Gralla et al., 1999).  With 
the introduction of new antiemetic agents, aprepitant and palonosetron, new guidelines have been 
published.  The 2005 NCCN and 2004 MASCC guidelines recommend either dexamethasone 
alone or a 5-HT3 RA alone or combination of aprepitant and dexamethasone if aprepitant was 
given during the acute phase (MASCC, 2004; NCCN, 2005).  
 
2.4: Economic Evaluation of Antiemetics for Prevention of CINV  
 
The introduction of serotonin receptor antagonists in the early 1990’s made a significant 
impact on the prophylaxis and management of CINV.  Antiemetic regimens with 5-HT3RAs have 
resulted in better antiemetic control in patients receiving HE and ME chemotherapy compared to 
the older antiemetic agents.  But these agents are costly compared to the older antiemetic agents.  
The introduction of the new antiemetic agents, which provide better antiemetic control for 
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prevention of delayed emesis compared to only 5-HT3RAs, has further increased the cost of 
prophylactic combination antiemetic regimens.  Rising health care expenditure coupled with 
limited resources have led to an increased interest in conducting economic evaluations of 
healthcare interventions, a method in which both costs and benefits of interventions are evaluated 
to make resource allocation decisions.  The next two sections outline some of the previous 
economic evaluations conducted to compare various antiemetic regimens for prevention of CINV 
following HE and ME chemotherapy. 
 
A recent review of cost-effectiveness studies of antiemetics for CINV included 20 studies 
(Lachaine & Crott, 2003).  Out of these 20 studies, 15 studies conducted cost-effectiveness 
analysis (CEA) comparing 5-HT3RAs to traditional antiemetics such as metoclopramide and 5 
studies compared 5-HT3RAs against one another.  A large number of these were limited to the 
acute phase of nausea and vomiting following administration of chemotherapy (Ballatori et al., 
1994; Buxton & O'Brien, 1992; Cunningham et al., 1993; Sands et al., 1992).  
 
For Highly Emetogenic Chemotherapy 
 
A majority (14 studies) of the previous economic evaluations have been conducted for 
patients receiving HE chemotherapy.  Ballatori and colleagues conducted a retrospective CEA 
using data from a study in cancer patients receiving cisplatin (Ballatori et al., 1994).  The trial 
compared the antiemetic efficacy of an intravenous regimen of dexamethasone with either 
ondansetron or metoclopramide for prevention of acute emesis for three cycles of chemotherapy 
(IGAR, 1992).  A hospital perspective was adopted for the study and the incremental cost-
effectiveness ratio (ICER) was US$369 (1991 costs) for each additional patient with complete 
emesis control obtained by the ondansetron group.  The impact of delayed emesis was not 
considered in the study.  Also, the study was conducted based on multi-dosing regimens of 
antiemetics and studies since then have shown the equivalent efficacy of multi-dosing regimens 
to single-dose regimens of 5-HT3RAs (Beck et al., 1992; Ettinger et al., 1996).  Cost-
effectiveness analysis based on single-dose regimens may lead to decreased personnel and drug 
administration costs and alter the ICER of the comparators.  Thus, there is a need to conduct 
economic evaluations of new antiemetic regimens to the previous standard regimens using the 
optimal dosing regimens. 
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Economic evaluations comparing 5-HT3RAs against one another have been conducted 
(Barrajon & de las, 2000; Becker et al., 1996).  Two of those studies can be considered as cost 
minimization analyses since the efficacy of the comparators were considered to be equivalent and 
there were only cost differences (Barrajon & de las, 2000; Becker et al., 1996).  Economic 
evaluations comparing 5-HT3RAs to traditional antiemetics such as metoclopramide for 
prevention of acute CINV following HE chemotherapy showed that the higher costs of 5-
HT3RAs are compensated for by superior efficacy, less side effects and lower personnel and 
administration costs (Ballatori et al., 1994; Buxton & O'Brien, 1992; Cunningham et al., 1993; 
Sands et al., 1992).  However, to our knowledge, none of the prior economic evaluations of 
antiemetics for prevention of CINV following highly emetogenic chemotherapy were conducted 
for delayed emesis or for the overall period of emesis.  
 
Recently, three studies evaluating the cost-effectiveness of aprepitant given with standard 
regimen have been presented at international symposiums and published in abstract format 
(Deuson, 2004; Ehlken et al., 2004; Moore et al., 2005).  Ehlken and colleagues conducted a 
CEA of adding aprepitant to the standard regimen of ondansetron and dexamethasone in patients 
undergoing highly emetogenic chemotherapy in office-based settings in Germany.  The study 
was conducted from the payer’s perspective.  A decision analytic model was constructed to 
determine the costs and benefits associated with the two alternative strategies.  The outcome 
measures were patients with complete control of emesis, i.e. no emesis and no rescue 
medications, and quality-adjusted life years (QALY).  The effectiveness of the antiemetic 
regimens were obtained from phase III trials of aprepitant and the German tariffs and prices were 
used to value the health care resources associated with CINV.  The results showed that 43% of 
the higher cost of aprepitant was offset by lower resource use.  The incremental cost per QALY 
of aprepitant compared to the standard regimen was calculated to be €21,764.  The results of 
sensitivity analyses showed that the results were sensitive to costs of hospitalizations and rescue 
medications.  The authors concluded that the use of aprepitant in office-based settings in 
Germany was cost-effective.  
 
Due to the inability to access the entire study, it is difficult to determine the source of 
utilities used in the estimation of QALYs.  As discussed earlier, there is no consensus about the 
best method to generate utilities for short-term health states.  The cost per QALY estimates 
obtained from the above study may be sensitive to the method used for utility elicitation.  The 
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CEA in the study was based on the regimens used during the clinical trial, aprepitant and 
dexamethasone compared to dexamethasone alone for the delayed phase. But this does not reflect 
clinical practice where a combination of dexamethasone with a 5-HT3RA is most commonly 
employed.   
 
Another study was conducted to determine the cost-effectiveness of three regimens from 
the payer’s perspective: standard therapy, adding aprepitant to the standard regimen (strategy 1) 
and adding aprepitant when CINV occurs (strategy 2) (Moore et al., 2005).  The study used a 
Markov model to compare the two alternative strategies for a hypothetical cohort of patients 
receiving four cycles of HE chemotherapy. The outcomes measures used were healthy-days 
equivalent and QALYs.  The probabilities and utilities for the model were obtained from the 
published clinical trials. The costs were based on resource use for CINV management using 
Medicare reimbursement rates for hospital and physician services and the average wholesale 
price (AWP) for medications.  Compared to the standard regimen, the ICERs were 
$172,789/QALY for strategy 1 and $160,236/QALY for strategy 2.  The probabilistic Monte 
Carlo trials showed that using the $50,000/QALY threshold, strategy 1 was not cost-effective in 
89.7% of the trials.  The authors concluded that aprepitant should be used after CINV occurs or 
should be used in high-risk populations for it to be cost effective.   
 
For Moderately Emetogenic Chemotherapy 
 
Several cost-effectiveness analyses of different antiemetic regimens for prevention of 
CINV due to ME chemotherapy have been conducted (Cox & Hirsch, 1993; Kwong & 
Parasuraman, 1999; Lachaine & Laurier, 2002; Lachaine, Laurier, Langleben, & Vaillant, 1999).  
Kwong and Parasuraman conducted a retrospective CEA of oral ondansetron and 
prochlorperazine for prevention of CINV in patients receiving ME chemotherapy.  The outcome 
measure was defined as the number of patients who had no emetic episodes and no adverse 
events during the three day study period.  The study was conducted from a third-party payer 
perspective.  A decision analytic model was constructed to outline the outcomes of the treatment 
alternatives.  The data on the probabilities of complete relief during the study period, of adverse 
effects, of requiring rescue medications, and hospitalizations were obtained from published 
clinical trials.  The medication costs were based on the 1996 average wholesale price, and the 
hospitalization costs were based on expenses per inpatient day reported in the American Hospital 
Association’s 1994 annual survey of hospitals.  The incremental CEA showed that the cost of one 
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additional effectively treated patient with ondansetron was $258.  The cost-effectiveness results 
were sensitive to variations in the duration of antiemetic therapy, total cost of antiemetic rescue 
medications and percentage of patients using ondansetron as rescue medication.  
 
Recently, Vanscoy and colleagues conducted a pharmacoeconomic analysis of 
palonosetron in patients receiving ME chemotherapy from the payer perspective and concluded 
that palonosetron is a cost-effective treatment strategy compared to the older 5-HT3RAs 
(Vanscoy et al., 2004).  
 
2.5: Willingness-To-Pay (WTP) 
 
Valuation of health gains produced by new interventions can be conducted by quality-
adjusted life year (QALY) or willingness-to-pay (WTP) methodology.  The QALY is a measure 
of health outcome which simultaneously captures improvement in HRQOL and gains in survival 
(Drummond, O'Brien, Stoddart, & Torrance, 1997).  QALYs are calculated as the product of the 
change in utility value induced by the treatment and duration of the treatment effect.  The utilities 
assigned to a specific state of health can be estimated using techniques such as Standard Gamble 
(SG), Time Trade-Off (TTO) or Rating Scale, or by means of pre-scored health state sorting 
systems (i.e. Health Utilities Index).  The standard gamble (SG) method asks the respondent the 
probability of death that they are willing to accept to move from the diseased state to perfect 
health.  The time trade-off (TTO) method requires the respondent to specify the number of years 
of life in perfect health that would be equivalent to the given number of years in the given health 
state.  
 
CINV is an acute condition lasting for a period of 5-7 days.  The impact of CINV on 
survival has not been established in clinical trials but it has a significant impact on morbidity 
which is reflected in HRQOL.  The use of QALYs to value morbidity for short-term condition 
such as CINV has both measurement and evaluation problems (Bala & Zarkin, 2000).  The 
measurement problems correspond to problems associated with eliciting the utility value for the 
health state in question in a valid and reliable fashion.  In the SG method, the patients’ preference 
for either maintaining a fixed intermediate health state or taking a gamble with perfect health and 
death as possible outcomes is determined.  But for acute conditions like CINV, it is difficult for 
respondents to consider and evaluate the probability of immediate death that would be acceptable 
to them to move from a disease state that lasts for 5-7 days to perfect health.  A study by Franic 
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and colleagues found that respondents were extremely risk averse with acute conditions such as 
CINV and the primary factor contributing to the refusal to gamble was the focus on death in the 
SG method (Franic & Pathak, 2003).   
 
Two methods to overcome the problem of using death as a negative anchor for utility 
elicitation for CINV-related health states is to use the cascading or chained SG method or 
chained TTO method (Furlong, Feeney, & Torrance, 1990; Jansen, Kievit, Nooij, & Stiggelbout, 
2001; Jansen et al., 1998).  In these methods, a surrogate negative anchor health state is used 
instead of death.  The surrogate negative anchor is a health state severe enough for the patient to 
be able to visualize this state in relation to the gamble of perfect health and immediate death.  
The other health states are then evaluated in comparison with perfect health vs. surrogate 
negative anchor state.  The scores thus obtained are then adjusted in proportion to the utility of 
the surrogate negative anchor health state which has been determined using the traditional utility 
elicitation methods (Grunberg, Srivastava, Grunberg, & Weeks, 2002; Jansen et al., 1998).  One 
of the drawbacks of this approach is that patients who are presented with an anchor health state 
find it irrelevant to the situation of interest.  The results of chained TTO or SG methods may also 
be affected by the anchor state used in the chaining procedure (Bala & Zarkin, 2000).  
 
In addition to measurement problems, the use of QALYs for acute health conditions has 
evaluation issues which correspond to problems in using the elicited health utility value to make 
optimal health care coverage decisions.  Zbrozek et al. (1995) performed a cost utility analysis 
comparing ondansetron with metoclopramide using efficacy data from published clinical trials.  
To calculate the incremental cost per QALY, a relative difference of 0.00014 QALY between 
two antiemetic agents was arbitrarily estimated.  The incremental cost per QALY in patients 
receiving high-dose cisplatin was US$407,667 and in patients receiving moderate-dose cisplatin 
was US$372,255.  One of the reasons for such a high incremental cost-effectiveness ratio (ICER) 
is that the multiplicative product of the utility weights and life-years gained, which in the case of 
CINV is small due to the acute nature of the health condition, leads to high cost per QALY 
estimates.  Thus, an alternative technique to valuing health benefits produced by new 
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Monetary Valuation of Health Outcomes 
 
The WTP methodology directly estimates the value of health gains in monetary terms 
which can be then used to conduct cost-benefit analysis (CBA).  CBA is a method of economic 
evaluation in which health benefits are valued in monetary terms.  There are three methods to the 
monetary valuation of health outcomes or benefits: a) human capital approach, b) revealed 
preferences and c) contingent valuation (CV) (Drummond et al., 1997).  The human capital 
approach is not recommended to measure health outcomes in monetary terms since it is 
production-based and is not consistent with the principles of welfare economics.  The revealed 
preference method is an indirect measurement method, which has been used in wage-risk trade 
off studies (Gafni, 1991).  These studies are undertaken to understand the association between 
health risk associated with particular jobs and the wages that individuals require to accept the job.  
Though this method is based on actual consumer behavior, it is context and job-specific and 
cannot be applied widely (Drummond et al., 1997).  
 
The contingent valuation (CV) method is based on stated preferences where the 
respondents are asked to value goods in a contingent or hypothetical market using survey 
measures (O'Brien & Gafni, 1996).  Contingent valuation involves direct measurement in which 
respondents are asked to provide either their maximum WTP to maintain the current level of 
utility or minimum willingness to accept (WTA) to make the utility equal to what it would have 
been after the change.  WTP is a method to determine the monetary value that patients place on 
health improvements, for example, improved emetic control. WTP estimates for improved emetic 
control can provide important evidence to managed care and hospital formulary committees to 
justify budgetary increases for new antiemetic agents such as aprepitant and palonosetron.  The 
individual can be assumed to take into account all the attributes of the commodity while 
considering their maximum WTP. 
 
2.6: Methodological Issues in WTP 
 
Willingness-to-pay using the CV method is based on the premise that the maximum 
amount of money an individual is willing to pay for a commodity is an indicator of the utility or 
satisfaction to them of that commodity.  In implementing the CV method to determine WTP for 
improved emesis control, the following methodological issues need discussion: global versus 
restricted measurement of benefits, perspective of analysis (ex-ante and ex-post user), payment 
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vehicle (out-of-pocket, or increases in insurance premiums or increases in tax payments), and 
format of the WTP question (single open-ended, or multiple close-ended questions) (O'Brien & 
Viramontes, 1994; Smith, Olsen, & Harris, 1999a)  
 
Global vs. restricted approach  
The three broad categories of benefits that arise from any health care program include: 1) 
intangible benefits which are the value of the improved health to the consumer of the program, 
for example: prevention of nausea and vomiting, impact of intervention on improving HRQOL; 
2) future health care costs avoided, for example: cost of breakthrough emesis, additional 
physician visits, hospitalization, any cost to patient and/or health care sector associated with 
suboptimal control of emesis; 3) increased productive output due to improved health status, for 
example: work productivity.  
 
In the restricted approach to WTP, the respondents are asked to value only the intangible 
health benefits for which market values do not exist.  The future health care savings and 
increased productive outputs are valued using market prices (Drummond et al., 1997).  One of 
the problems with the restricted approach is development of valuation scenarios that can isolate 
the health effects of the intervention from other effects such as out-of-pocket costs, income lost 
due to time off work etc. (Currie et al., 2002).  On the other hand, the global approach to WTP 
asks the respondents to take into account all the potential benefits of the commodity while 
considering their maximum WTP.  While using the global approach to assessing WTP, 
respondents should be told explicitly to consider income effects due to work absence due to 
disease (emesis) or its treatment (side effects of antiemetics), cost offsets due to improved emesis 
control etc.  Depending upon the complexity and amount of information presented, there may be 
substantial cognitive burden placed on the study respondents.  
 
Perspective of the WTP analysis 
 
WTP can be measured using either the ex-post/user-based perspective or the ex-
ante/insurance-based perspective.  In the ex-post or user-based approach, respondents know that 
they are consumers of the treatment, i.e. either patients who already have the disease in question 
(cancer and receiving chemotherapy) or individuals presented with hypothetical scenarios with a 
certainty of having the disease in question and only the treatment outcomes are uncertain 
(probability of complete control of emesis).  This method captures only the user values since the 
52 
LITERATURE REVIEW   Reema Mody 
valuation involves certain use of the program and only uncertainty in the outcomes of the health 
program.  Respondents for WTP surveys based on user perspective can include patients or 
caregivers, random sample of general population and convenient samples.  General population 
and convenient samples are provided with scenarios where they are asked to assume to have the 
disease in question and state their WTP for uncertain health outcomes.  
 
In the ex-ante perspective, along with the uncertain treatment outcomes, the valuation 
needs to incorporate the probability of contracting the disease and needing the service in question 
in the future.  Thus, in this perspective the respondents are provided with the probabilities of 
being diagnosed with cancer in the future, requiring chemotherapy and complete control of 
emesis due to the antiemetic interventions.  WTP surveys with ex-ante perspective are conducted 
in random samples of the general population or convenient samples to include currently diseased 
individuals, currently non-diseased who are at future risk of disease, and currently non-diseased 
who are not themselves at personal risk of the disease.  The respondents are asked their WTP as 
increase in insurance premiums to ensure coverage for the health intervention for a specified 
disease.  In countries with national health care system funded by tax monies, respondents are 
asked their WTP as increase in tax payment amounts over their lifetime.  
 
It is thought that the WTP questions in the context of health care should be framed in the 
form of hypothetical insurance purchasing since users typically do not pay for medical services at 
the point of consumption and due to its ability to capture user, option and externalities values 
(Gafni, 1991).  But respondents may have difficulty understanding the multiple uncertainties 
involved in the hypothetical scenario for determining WTP for improved emesis control based on 
ex-ante perspective.  These could include: incidence of cancer in a specified period of time, 
probability of receiving HE or ME chemotherapy, probability of emesis with chemotherapy and 
uncertainty associated with antiemetic regimen outcomes.  These compound probabilities can 
pose substantial cognitive burden for the respondents.  It can also be argued that the patients who 
are experiencing the condition are the best candidates to provide the value of the benefits 
provided by the related health interventions.  Thus, for the purpose of this study, we will use the 
user-based perspective for determination of WTP.  
 
Payment vehicle (Out-of-pocket, tax, insurance) 
The most common payment vehicles are direct out-of-pocket (OOP) payments, additional 
tax payments, and private insurance premiums.  The user-based perspective usually employs 
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OOP payments whereas; the ex-ante perspective employs additional tax payments or increase in 
insurance premiums as payment vehicle (Smith, Olsen, & Harris, 1999b). There is a lack of 
consensus regarding the appropriate payment vehicle.  Some argue (Birch, 1993) that insurance 
premiums should be used whereas others argue (Donaldson et al, 1995) for different vehicles 
(Smith et al., 1999b).  It is likely that appropriateness of payment vehicle for a particular 
commodity will depend on the type of product, and different health care systems.  For example, 
insurance premiums may be appropriate for the USA but not for the United Kingdom where 
increased taxation would be more appropriate.  Similarly, insurance premiums may be the 
appropriate vehicle for high technology items or expensive low probability items and OOP in the 
form of increased co-payments for pharmaceuticals (Drummond et al, 1997).  Smith, Olsen and 
Harris (1999) (Smith et al., 1999b) recommend that OOP payment is most relevant if users are 
asked, whereas taxation is most relevant if the general population is asked in ex-ante perspective.  
For the purpose of our study, OOP payments will be the payment vehicle, as it is an appropriate 
approach for WTP for pharmaceuticals using user-based perspective.  We will not ask WTP as 
OOP payments in increased co-payments since respondents may base their responses on their 
current co-payment structure.  
 
Questionnaire format/Survey method 
The WTP questions can be presented in five formats: 1) open-ended; 2) bidding game; 3) 
payment card; 4) discrete-choice and 5) discrete choice with follow-up (Smith, 2000).  
1) Open-ended questions  
The respondents are simply asked to report their maximum willingness-to-pay. This 
format may produce unbiased estimates of WTP since the respondents are not prompted.  Though 
easy to construct, open-ended questions are too hypothetical, do not reflect the way people 
behave in the market and may be cognitively challenging for respondents, as they are not used to 
answering such questions (Donaldson, Shackley, & Abdalla, 1997).  The WTP estimates may be 
imprecise due to wide variance and many non-responses or protest responses (Johannesson, 
1996).  
2) Bidding game method  
In the bidding game method, the respondents are provided with an initial WTP amount, 
which they can either accept or reject.  Depending on whether they accept or reject the amount, a 
higher or lower bid, respectively is presented and the process is continued until the maximum 
WTP is reached.  The bidding game method has improved precision but it may introduce a 
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starting point bias, in which the respondents’ answers may be biased by the initial amounts 
presented in the bidding game.  There is no consistency in the published health care literature 
about the presence of starting point bias in the bidding game method of eliciting WTP.  Health 
care studies specifically conducted to test for starting point bias did not show evidence of its 
presence (O'Brien & Viramontes, 1994; O'Brien et al., 1998).  
3) Payment card method  
Payment cards have a specified range of values and the respondents are asked to indicate 
which amounts they will definitely not pay, which amounts they will definitely pay and what is 
the maximum amount they would pay for the health intervention.  The payment card approach 
was developed by Mitchell and Carson (Mitchell & Carson, 1981) and is believed to simulate 
real-life situations by allowing the individuals to “shop around” for a value that they would most 
pay (Donaldson, Thomas, & Torgerson, 1997).  Donaldson and colleagues (Donaldson et al., 
1997) showed that compared to the open-ended format, the payment card method yields higher 
response rates to WTP questions, more consistent mean and median values, and a stronger 
association between WTP and ability to pay.  
 
The payment card method may be susceptible to range bias i.e. the range of amounts 
presented may influence the WTP responses (Neumann & Johannesson, 1994; Ryan, Scott, & 
Donaldson, 2004).  Midpoint or centering bias may also be a potential bias in WTP estimates 
using payment card method. Midpoint bias is said to occur when the respondents have a tendency 
to state the midpoint of the range as their WTP (Ryan, 2004).  Studies have shown conflicting 
results about the presence of range and centering bias with Neumann and colleagues (1994) 
reporting its presence whereas a study by Ryan and colleagues (2004) did not find significant 
range or centering bias in their study.  Another study conducted to test for range and centering 
bias used four versions of payment card with different ranges and center values and did not find 
the existence of these biases (Rowe, Schulze, & Brefle, 1996).   
4) Discrete choice (DC) method  
The DC method also referred to as the referendum method is the recommended format by 
the US National Oceanic and Atmospheric Administration Panel on contingent evaluation 
(NOAA) (National Oceanic and Atmostpheric Administration, 1993).  Each respondent is 
provided with a single WTP amount, which they either accept or reject. Thus, each respondent 
provides limited information about his or her WTP, which may be either equal, or above or 
below the presented amounts.  Different bids are presented to different subsamples, and then 
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statistical methods are used to determine the societal WTP.  The DC method can be modified by 
introducing single bid-up or double bid-up following the initial amount.  In the single bid-up 
method, based on the acceptance or rejection of the initial WTP amount, the respondent is 
provided with a higher or a lower bid amount.  In the double bid-up method, the iterations are 
truncated after providing two follow-up bids.  Though the DC method avoids starting point and 
range bias, the single-bid up and double-up versions of the method are susceptible to these biases.  
This is because the single bid-up amount and the double bid-up amounts will be based on the 
starting value used in the method.  Also, the DC method is highly inefficient as large sample size 
is required to identify the distribution of values with a degree of accuracy.  
 
2.7: Willingness-To-Pay (WTP) Studies in CINV Literature 
 
To date, only one study measuring the monetary value of improved emesis control has 
been published.  Following phase II randomized clinical trials establishing efficacy of NK-1 
receptor antagonists, Dranitsaris et al (2001) undertook a multinational study (countries included 
were Canada, Italy, Greece and Spain) to measure the maximum amount that cancer patients 
would be willing to pay for reducing their risk of CINV following cisplatin-based chemotherapy.  
Willingness-to-pay for various scenarios of absolute risk reduction of acute and delayed emesis 
was assessed using the CV approach and the user-based perspective.  The respondents were 
presented with background information on CINV and the current treatments for emesis followed 
by the various clinical scenarios for eliciting WTP.  A payment card method was used to avoid 
starting point bias and the first value given by the respondent was recorded as the WTP estimate.  
Sociodemographic information such as age, marital status, education, family income, religious 
affiliation and clinical characteristics such as diagnosis, history of previous chemotherapy, 
previous emesis and treatment location were collected.  
 
Results showed that cancer patients from Canada, Italy and Spain were willing to pay 
$US46, $US34, and $US63 per day compared to $US8 for patients from Greece for 20% risk 
reduction in acute emesis (baseline risk was 30%).  For 30% risk reduction in delayed emesis 
(baseline risk was 40%), Canadian, Italian and Spanish cancer patients were willing to pay 
$US41, $US31, and $US50 daily for four days compared to US$9 for Greek patients. 
Multivariate analyses adjusting for sociodemographic variables and previous history of emesis 
showed that significant differences in patient value between countries still remained. For acute 
and delayed emesis, family income was the only other significant variable predicting maximum 
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WTP.  The results also bring to light the cultural or geographical differences in the mean WTP 
for improved control of emesis.  
 
WTP for improved emesis control due to the addition of aprepitant to the standard 
regimen for prevention of CINV due to highly emetogenic chemotherapy and use of palonosetron 
instead of the other 5-HT3RA for prevention of CINV due to ME chemotherapy has not been 
conducted in the United States.  The NK-1 receptor antagonist, aprepitant is recommended for a 
period of 3 days whereas the study provided a scenario with hypothetical antiemetic benefit and 
duration of regimen.   
 
To our knowledge, there are no studies that have conducted comprehensive economic 
evaluation of the new antiemetic regimens for prevention of CINV following HE and ME 
chemotherapy.  No study has evaluated the cost-effectiveness of an antiemetic regimen with 
aprepitant compared to the standard regimen of 5-HT3RA and dexamethasone, and regimen 
recommended by ASCO and clinical practice.  Lastly, due to the acute nature of CINV, a cost-
benefit analysis using monetary value of improved emetic control would be appropriate for 
resource allocation decisions.  The next chapter provides the objectives for the two phases of the 











The study was conducted in two phases.  Phase I involved constructing two decision 
analytic models to determine the incremental costs and benefits of alternative antiemetic 
regimens for prevention of chemotherapy-induced nausea and vomiting (CINV) following 1) 
highly emetogenic (HE) and 2) moderately emetogenic (ME) chemotherapy.  Phase II involved 
conducting face to face interviews to determine the maximum amount that patients with cancer 
were willing to pay for improved emesis control provided by new antiemetic regimens.  The 
monetary value of the benefits of the new antiemetic regimens were used in cost-benefit analyses 
(CBA) to estimate the net benefits provided by the new regimens. 
  
3.1: Phase I - Development of Decision Analytical Model  
 
It is expensive and time consuming to conduct clinical trials to compare an intervention 
to all its relevant alternatives.  In spite of that, the critical data obtained from clinical trials along 
with other evidence is required to optimize the use of healthcare interventions.  Thus, there is a 
tradeoff between obtaining evidence of effects of alternative healthcare interventions and the cost 
of obtaining such evidence.  Decision models represent the sequence of chance events and 
decisions over time.  These models are one of the ways to synthesize evidence from different 
sources in an attempt to form decisions about optimal health care interventions (Mandelblatt et 
al., 1996). 
 
Two decision analytical models were constructed to identify the relevant costs and 
consequences of alternative antiemetic regimens for prevention of CINV following 
administration of HE and ME chemotherapy.  For the purpose of this study, HE chemotherapy 
includes only cisplatin-based chemotherapy, which causes acute emesis in 99% of cancer patients 
receiving it.  The ME chemotherapy includes agents, which results in acute emesis in 30-90% of 
patients and are listed in Table 2-3.  
 
The cost-effectiveness analyses (CEA) were conducted from two different perspectives, 
namely societal and third-party payer.  The use of multiple perspectives is to make the study 
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results relevant to different groups of stakeholders.  The societal perspective is the broadest 
perspective and includes the costs and benefits of the health care intervention, irrespective of who 
incurs it.  The CEA conducted from societal perspective includes both direct and indirect costs 
associated with the intervention.  It is also the recommended approach for CEA by the Panel on 
Cost-effectiveness in Health and Medicine, U.S. Public Health Service (Gold, Siegel, Russell, & 
Weinstein, 1996).  CEA conducted from the societal perspective also helps in decision making 
for allocation of resources from a public policy framework. Conducting CEA from the societal 
perspective does not preclude us from conducting analyses from other perspectives of interest to 
specific groups.  Groups such as hospitals and payers are interested in making decisions about 
coverage of effective but costly health care interventions by taking into account the costs and 
benefits that are relevant to their setting.  Thus, CEA conducted from the narrower third-party 
payer perspective will assist the relevant groups in formulary decision-making for alternative 
antiemetic regimens.  The CEA conducted from the payer’s perspective include only the direct 
costs related to the intervention incurred by the payer.  
 
Intervention and Alternative Strategies  
 
The rationale for choosing the alternatives for the decision models were explained in 
Chapter 1.  The choice of the antiemetic intervention strategies was based on recommendations 
following the introduction of new antiemetic agents, regimens employed in clinical trials of the 
new antiemetics, previous guidelines and commonly used regimens in clinical practice.  
 
Alternative Strategies for Prevention of CINV Following HE Chemotherapy 
 
Table 3-1 describes the prophylactic antiemetic strategies in terms of dosage, 
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Table 3-1: Antiemetic Strategies for Prevention of Chemotherapy-Induced Nausea and 
Vomiting following Highly Emetogenic Chemotherapy 
 
Strategies Acute Phase (Day 1) Delayed Phase (Days 2-4) 
Regimen A 
(Aprepitant) 
Oral Aprepitant 125 mg  
Oral Dexamethasone 12 mg      
IV Ondansetron 32 mg  
Oral Aprepitant  80 mg (Days 2-3) 
Oral Dexamethasone 8 mg (Days 2-4) 
Regimen B (Only 
dexamethasone) 
Oral Dexamethasone 20 mg  
IV Ondansetron 32 mg 




IV Dexamethasone 20 mg  
IV Ondansetron 8 mg 
IM   Dexamethasone  8 mg BID (Days 2-3) and 
4 mg BID (Day 4) 




IV Dexamethasone 20 mg  
IV Ondansetron 8 mg 
IM Dexamethasone  8 mg BID (Days 2-3) and 
4mg BID (Day 4) 
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Addition of aprepitant to the standard regimen, regimen A in Table 3-1, has been 
recommended by the Multinational Association of Supportive Cancer Care (MASCC) as the 
regimen of choice for prevention of acute and delayed emesis following cisplatin-based HE 
chemotherapy (MASCC, 2004).  Regimen B has been employed as the comparator antiemetic 
strategy in clinical trials of aprepitant (Hesketh et al., 2003; Poli-Bigelli et al., 2003).  The other 
comparators, regimens C and D are based on previous guidelines published by the American 
Society of Clinical Oncology (ASCO), which recommended the use of combination therapy of 
dexamethasone with either metoclopramide or a 5-HT3RA for prevention of delayed emesis 
(Gralla et al., 1999).   
 
The combination therapy of dexamethasone and a 5-HT3RA has been extensively used in 
clinical practice for management of delayed emesis (DURTO, 2003), even though there is not 
sufficient evidence to suggest that it has higher efficacy as compared to the dexamethasone and 
metoclopramide combination.  Thus, it is important to compare the two combination strategies 
for prevention of delayed emesis since metoclopramide, in large doses is associated with side 
effects in large doses whereas 5-HT3RAs are more expensive compared to metoclopramide.  
Thus, based on published guidelines and clinical practice, we will compare the MASCC 
recommended regimen to the standard regimen used in clinical trials, the regimen recommended 
by ASCO, and a widely used regimen in clinical practice.  
 
Alternative Strategies for Prevention of CINV Following ME Chemotherapy  
 
Table 3-2 describes the prophylactic antiemetic strategies in terms of dosages, 
formulations and duration of therapy for prevention of CINV following administration of ME 
chemotherapy.  Regimen 1 is IV administration of a single dose of palonosetron before 
chemotherapy and regimen 2 is a single IV dose of an older 5-HT3RA which has been employed 
as the comparator in clinical trials of palonosetron.  The NCCN recommendations include a 5-
HT3RA and dexamethasone combination for prevention of acute emesis due to ME 
chemotherapy and either dexamethasone or a 5-HT3RA for prevention of delayed emesis. The 
antiemetic strategy regimen 3 reflects the NCCN 2005 guidelines. The 1999 ASCO guidelines 
recommend a combination of a 5-HT3RA and dexamethasone for prevention of delayed emesis 
and this is included as regimen 4 in the model.    
Randomized controlled clinical trials have shown that the older 5-HT3RAs (ondansetron, 
dolasetron and granisetron) are equivalent in their efficacy, and their oral dosage forms are also 
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equivalent to their intravenous forms.  A majority of the randomized clinical trials conducted for 
establishing the efficacy of aprepitant and palonosetron have used ondansetron as the comparator.  
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Table 3-2: Antiemetic Strategies for Prevention of Chemotherapy-Induced Nausea and 
Vomiting following Moderately Emetogenic Chemotherapy 
 
Strategies Acute Phase (Day 1) Delayed Phase (Days 2-5) 
Regimen 1 
(Only Palonosetron) 
IV   Palonosetron 0.25 mg  -  
Regimen 2  IV Ondansetron 32 mg -  
Regimen 3 
(2005 NCCN) 
IV Ondansetron 8 mg  
IV Dexamethasone 8 mg 
Oral Dexamethasone 8mg 
BID (Days 2-5) 
Regimen 4  
(1999 ASCO) 
IV Ondansetron 8 mg  
IV Dexamethasone 8 mg 
Oral Dexamethasone 8mg 
BID (Days 2-5) 
Oral Ondansetron 8mg BID 
(Days 2-5) 
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Model Structure and Simulation 
 
The decision analytical models for antiemetic regimens for prevention of CINV 
following HE and ME chemotherapy for a single cycle are described in Figure 3-1.  The models 
were developed using TreeAge Pro software (TreeAge Software, Inc., 2005).  The first branch 
point on the decision tree is a decision node indicating a choice of prophylactic antiemetic 
regimens for prevention of CINV.  Subsequently, the decision model is identical for all the 
treatment alternatives.  After receiving chemotherapy and a prophylactic regimen for the acute 
phase, patients can either experience acute emesis or no acute emesis.   
 
No Acute Emesis Arm: 
For patients who do not experience acute emesis, these patients may or may not receive 
rescue medications for control of nausea in the acute phase.  In both cases, patients could 
experience delayed emesis or no delayed emesis.  The incidence of delayed emesis is assumed to 
be dependent on the prophylactic antiemetic regimen received in the acute phase and the CINV 
control obtained in the acute phase.  The control of delayed CINV is assumed to be independent 
of the receipt of rescue medications in the acute phase.  Patients who do not experience any 
delayed emesis may or may not receive rescue medications to control for delayed nausea.  
Following this, patients may or may not experience the side effects due to the antiemetic 
regimens.  For the base-case analysis of both decision models, it was assumed that the proportion 
of adverse events is the same for all the alternative antiemetic regimens.  If patients experience 
delayed emesis they may or may not receive rescue medications.  In both instances, patients 
could either receive outpatient care for uncontrolled emesis or may not require further care.   
 
Acute Emesis Arm: 
For patients who do experience acute emesis, they can either receive or not receive rescue 
medications.  Subsequently, these patients may or may not require outpatient care for 
uncontrolled emesis.  Following this, patients may or may not experience delayed emesis and 
subsequently, the model is identical to those who had no acute emesis.  
 
Most clinical studies conducted to determine the efficacy of antiemetic agents for 
prevention of CINV following HE chemotherapy pertain to cisplatin-naïve adult patients 
receiving their first cycle of single day cisplatin-based HE chemotherapy.  Therefore, a 
hypothetical cohort of 10,000 cisplatin-naïve cancer patients over the age of 18 who are 
64 
METHODOLOGY   Reema Mody 
scheduled to receive their first cycle of single day, outpatient, cisplatin-based chemotherapy 
regimen was considered for the HE decision analytical model.  Based on the mean age of the 
population in the aprepitant clinical trials the mean age of the hypothetical cohort was assumed to 
be 55 years.  Similarly for the ME decision model the hypothetical cohort was chosen such that 
its underlying characteristics were similar to the population in the clinical trials conducted for 
determining the efficacy of antiemetic agents following ME chemotherapy.  Therefore, for the 
ME decision model, a hypothetical cohort of 10,000 chemotherapy-naïve patients over the age of 
18 who are scheduled to receive their first cycle of single day, outpatient, ME chemotherapy such 
as, any dose of carboplatin, epirubcin, cyclophosphamide < 1,500mg/m2, doxorubicin > 25 
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Figure 3-1: Structure of the Decision Analytical Model for Determining Cost-Effectiveness 
of Prophylactic Antiemetic Regimens 
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Time Horizon of Analysis  
ancer patients for four to six cycles. Economic 
evaluation of antiemetic regimens for prevention of CINV should be conducted for multiple 
cycles o







re or expert opinion.  A 




Chemotherapy is usually administered to c
f chemotherapy to capture all the relevant costs and benefits.  Thus, ideally, the model 
should represent four to six cycles of chemotherapy to capture the costs and outcomes 
comprehensively.  However, randomized controlled clinical trials for multiple cycles of 
chemotherapy have only been conducted for the new regimen and the standard antiemetic 
regimen.  D
n analytical model was constructed to represent only one cycle of chemotherapy.  The 
time horizon of the model was five days to coincide with the actual time for which patients 
experience CINV during one cycle of chemotherapy.  
 
For both HE and ME chemotherapy models, the primary outcome measures are the co
per completely controlled patient at the end of the five-day period.  Completely controlled is 
defined as no episodes of emesis and no use of rescue medications in both acute and delay
phases.  For the societal perspective, the total costs included the direct costs associated with 
prevention and treatment of CINV and indirect costs due to lost work productivity due to 
uncontrolled CINV.  The CEA conducted from the third-party payer’s perspective included
the direct costs associated with prevention and treatment of CINV.  
 
Data for the Decision Models  
 
The following section describes in detail data that were used to populate the model.  The 
probabilities of various events and associated treatment costs were the two types of data requ
to populate the models.  Probabilities of various events in the decision models can be obtain
through direct observation, review of the published literatu
in the decision model.  For probabilities not available from published literature, expert 
opinion was used.  The expert opinion was obtained by conducting structured interviews with
panel of oncologists and oncology nurses.  
 
Probabilities for HE Decision Model  
  
Efficacy of Alternative Prophylactic Regimens 
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The efficacy data represents the probability of achieving complete control of acute and 
delayed emesis following the administration of the four prophylactic antiemetic regimens.  The 
base ca ble 
et al., 2003).  In both trials, patients were randomized to receive either the standard 
regimen or the three-drug combination containing aprepitant.  The studies were conducted in 
duled to receive their first cycle of 




iven acute emesis were based on the 
individ
and D.  
se estimates for acute and delayed efficacy of the alternative regimens are shown in Ta
3-3.  The table also includes the ranges of estimates that were used to conduct sensitivity 
analyses.  
 
The efficacy data for regimens A and B were based on the published results of two multi-
center, randomized, double blind placebo controlled phase III trials (Hesketh et al., 2003; Poli-
Bigelli 
cisplatin-naïve patients above 18 years of age who were sche
lity of no acute emesis, no delayed emesis among those with no acute emesis and no 
delayed emesis among those with acute emesis.  Since the distribution of the study population 
based on demographic characteristics was different for the two studies, the averages of the 
probabilities obtained were used as base case estimates.  For conducting sensitivity analyses, the 
higher of the two estimates obtained from the two studies was used as the upper limit of the ran
for the probability of no acute emesis.  The lower limit of the range was set at the efficacy of the 
standard regimen (74.2%) which includes the lower estimate obtained from the clinical trials a
also enable us to determine the robustness of the results if the benefit of the aprepitant regimen is 
same as the standard regimen in the acute phase.  The ranges for probabilities of no delayed 
emesis given no acute emesis and no delayed emesis g
ual estimates obtained from the two clinical trials.  
 
The antiemetic drugs used for prophylaxis of acute emesis are same in regimens C 
The efficacy of the regimen for control of acute emesis was obtained from three randomized 
controlled clinical trials (IGAR, 1995b, 1997, 1998a) and one observational study (IGAR, 
2000a).  The base case estimate of no acute emesis for regimens C and D was estimated to be 
79.9%, calculated as the average of the individual estimates obtained from the four studies.  
Similar to the range for regimen A, the upper limit was the highest estimate obtained from the 
studies and the lower limit was set to be equal to the base case estimate of regimen B.  
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The efficacy of regimen C in controlling delayed emesis was based on the publishe
results of two studies, one observational study and one multi-center, randomized double-blind 
trial (IGAR, 1997, 2000a).  The proportion of patients who do not have delayed emesis given tha
they have control of acute emesis was calculated to be 73.55% and given that they have acute 
emesis was 14.40%.  The efficacy of regimen D in controlling delayed em
d 
t 
esis was based on a 
random ed, double blind trial conducted by the Italian Group for Antiemetic Research (IGAR, 
1997). 
d 
 rescue medications following no acute emesis, acute emesis, no delayed 
mesis and delayed emesis were obtained from calculations conducted using published data from 
two randomized clinical trials of aprepitant (Hesketh et al., 2003; Poli-Bigelli et al., 2003).  In 
these two clinical trials, rescue medications were given for any degree of nausea or vomiting due 
to chemotherapy.  The receipt of rescue medications in the delayed phase was assumed to be 
dependent on the prophylactic antiemetic regimen received for the delayed phase.  The receipt of 
rescue medications was assumed to be independent of the level of control of acute emesis or on 
the receipt of rescue medications in the acute phase.  
 
The clinical trials conducted to study the efficacy of regimens C and D (IGAR, 1995b, 
1997, 1998a) stipulated the use of rescue medications only for patients with three or more 
episodes of emesis whereas, the protocol of clinical trials for aprepitant and the standard regimen 
stipulated that patients with any degree of nausea or vomiting could receive rescue medications 
(Hesketh et al., 2003; Poli-Bigelli et al., 2003).  Thus, for regimens C and D, the probability of 
receiving rescue medications in the acute phase following no acute emesis and acute emesis is 
assumed to be equal to that for regimen B.  This assumption was made since the antiemetic drugs 
for the acute phase are the same for the three regimens except for the difference in the dose of 
ondansetron.  The difference in the dose of ondansetron will not have an impact on the incidence 
of emesis or use of rescue mediation since studies have shown that IV 8 mg offers similar acute 
antiemetic efficacy as compared to IV 32 mg.  In a randomized, double-blind clinical trial 
conducted to determine the efficacy of regimens C and D for delayed emesis, rescue medications 
were given for patients experiencing three or more emetic episodes in the delayed phase (IGAR 
iz
 
Receiving Rescue Medications for Breakthrough Emesis 
 
The base case probabilities for receiving rescue medications for breakthrough emesis an
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70 
1997).  Due to lack of relevant and appropriate information in the included clinical trials, the 
e corresponding estimates for regimens A and B were used.  
 
For those who experience acute or delayed emesis, the probability of receiving rescue 
tio as ranged e lower limits obtained from the individual study estim s and 
its %, ents in  who experien
edications.  The lower limit of the range for sensitivity analyses for the 
eters: probability of receiving rescue medications given no acute emes ayed 














esis will were se  i.e. all pati  the cohort ce em
is and no del
ates obtained fromre se t zero and the her limit was s t the higher of
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Table 3-3: Base-Case Estimates and Sensitivity Analysis Ranges of Efficacy of Prophylactic Antiemetic Regimens for Acute and 
Delayed Phase – For HE Model 
 
Parameter Baseli Estine mate Lower limit Upper limit References 
No Acute Emesis     
Regimen A 0 0
0 0
0 0




0.7 0.5 0.8 8 




0.2 0.2 0.343 
.870 .742 0.900 1, 2 
Regimen B .742 .690 0.793 1, 2 
Regimen C .799 .742 0.832 3, 4, 5, 6 
Regimen D 0.799 0.742 0.832 3, 4, 5, 6 
ayed Emesis 
Regimen A .830 .793 0.866 1, 2 
Regimen B .670 .646 0.694 1, 2 
Regimen C .736 .733 0.738 4, 5 
Regimen D 15 72 5 5 
ayed Emesis 
Regimen A .317 .308 0.326 1, 2 
Regimen B .154 .122 0.185 1, 2 
Regimen C .144 .088 0.200 4, 5 
Regimen D 86 28 5 
 
References: . (Poli-Bigelli et al., 2003); 3. (IGAR, 1995b); 4. (IGAR, 2000a)
5. (IGAR, 1997); 6. (IGA
 
Regimen A:  Oral Aprep  Oral Dexamethasone 12 mg + IV Onda mg (Day repitant 80 s 2-3) + O ethasone 8 mg 
Days 2- ays 2-4) 
Regimen M Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
QID (Day  (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral 
ndansetron 8 mg BID (Days 2-4) 
1. (P. J. Hesketh et al., 2003); 2  
R, 1998a) 
itant 125 mg + nsetron 32  1), Oral Ap mg (Day ral Dexam
( 4); Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (D
 C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), I
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Table 3-4: Base-Case Estimates and Sensitivity Analysis Ranges for Receiving Rescue Medications for Uncontrolled CINV – For HE
Model  
 
Parameter Baseline Estimate  Lower limit Upper limit References 
In the acute phase given no acute emesis     
Regimen A 0.012 0.000 0.015 1, 2 
Regimen B 0.012 0.000 0.015 1, 2 
Regimen C 0.012 0.000 0.015 Assumed*
Regimen D 0.012 0.000 0.015 Assumed*
In the acute phase given acute emesis     
Regimen A 0.338 0.175 1.000 1, 2 
Regimen B 0.394 0.304 1.000 1, 2 
Regimen C 0.394 0.304 1.000 Assumed*
Regimen D 0.394 0.304 1.000 Assumed*
In the delayed phase given no delayed emesis     
Regimen A 0.050 0.000 0.055 1, 2 
Regimen B 0.028 0.000 0.035 1, 2 
Regimen C 0.039 0.000 0.045 Assumed**
Regimen D 0.039 0.000 0.045 Assumed**
In the delayed phase given delayed emesis     
Regimen A 0.576 0.454 1.000 1, 2 
Regimen B 0.531 0.477 1.000 1, 2 
Regimen C 0.553 0.465 1.000 Assumed**
Regimen D 0.553 0.465 1.000 Assumed**
 * Assumed based on the estimates for Regimen B as the acute phase antiemetics are same for the two regimens  
** Assumed to be the average of estimates of regimen A and B.   
 References: 1. (P. J. Hesketh et al., 2003); 2. (Poli-Bigelli et al., 2003) 
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4); Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
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73 
y m mide 20 
nsetron  (D Oral 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Da
QID (Days 2-4); Regimen D:  IV Dexamethasone 20 mg + IV Onda
Ondansetron 8 mg BID (Days 2-4) 
 1), IM Dexa
 8 mg
ethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopra
ay 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + 
mg 
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Adverse Events due to Prophylactic Antiemetic Regimens  
 
For the base-case model, it was assumed that the probability of experiencing adverse 
ens.  The probability of adverse effects due to regimen C 
 for scenario analysis, only the adverse events 





 CINV.  The probability of requiring an outpatient visit for receiving intravenous 
saline infusion and rescue medications was based on a structured interview conducted among an 
expert panel consisting of three oncologists and three oncology nurses. The survey used for the 
interview is included as Appendix I.  Based on the responses obtained from the survey, the 
probability of outpatient visits in the acute phase is extremely rare and 0.01 was used as the base 
case probability.  For sensitivity analysis, the probability was ranged from zero to 3% based on 
the survey responses.  Ihbe-Heffinger and colleagues (Ihbe-Heffinger et al., 2004) conducted a 
study among German cancer centers and reported that 2.5% were hospitalized for dehydration 
due to uncontrolled severe nausea and vomiting.  Our survey respondents reported that 
approximately 5% of patients may require additional care due to severe nausea and vomiting in 
the delayed phase.  Based on these estimates, the baseline probability of requiring outpatient 
events is similar between the four regim
was modeled to conduct a scenario analysis.  Thus
d
s were assumed to be similar.  The serious adverse reactions associated with the use of 
metoclopramide are parkinsonism and/or other extrapyramidal reactions.  These consist often of a
feeling of restlessness, facial spasms, involuntary movements and in some cases, muscular 
twitching.  Schnell and colleagues reported that five percent of patients receiving 
pramide will experience extrapyramidal symptoms (EPS) (Schnell, 2003).  Based on th
database, Bleiberg and colleagues reported that 2.6% of patients had EPS due to metoclopramide 
(Bleiberg, Autier, & Michaux, 1994).  The average of the two estimates was used as the 
probability of experiencing EPS in patients receiving regimen C.  Extrapyramidal reactions have 
been successfully controlled by antiparkinson and antihistamine/anticholinergic agents such as 
25-50 mg of diphenhydramine hydrochloride.  It was assumed that all patients experiencing EPS
will require treatment with diphenhydramine hydrochloride.   
 
Probability of Outpatient Physician Visit due to Uncontrolled Emesis  
 
The probability of uncontrolled emesis resulting in an outpatient physician visit or 
inpatient hospitalization is very low.  But since it involves a substantial amount of healthcare 
resource utilization, the costs need to be modeled to provide an accurate representation of 
management of
74 
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75 
physician visit for uncontrolled delayed emesis was estimated to be 3.5% and was ranged from 




Probabilities for ME Deci  
lternative ylactic Regimens 
The efficacy data represents the probability of achieving complete control of acute and 
ed emesis following administration of the four prophylactic antiemetic regim
s for acute and delayed efficacy of the alternative regimens are shown in Table 3-5.  
 analyses.  
 
The efficacy data for regimens 1 and 2 were based on the published results of a multi-
mized, double blind, phase III trial conducted to study the antiemetic efficacy of 
 (Gralla et al., 2003).  In 
 clinic ial, patients were randomized to receive either the stan  regim
ndansetron 32 mg or a single IV dose of palonosetron 0.25 m s were 
ine the probabilities of no acute emesis, no delayed em ong those with no 
 an me e w sensitivity 
sis of probabilities of no acute em o d cute 
sis w et at ±20% of the baseline probability estimates.  If the probability 1.00, 
upper limit was reduced. The sensitivity analysis range for the probability of no delayed 
ong those with acute emesis was ranged from 0.0 to 0.30.  The upper limit of 0.30 was 
sults if the probability was as high as the base case estimate 







The table also includes the ranges that 
center, rando
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Table 3-5: Base-Ca stimate actic A








d Sensitvity Analysis Ranges of Efficacy of Prophyl
 Baseline Estimate Lower limit 
ntiemetic Regimens for Acute and 
pper limit References 





























0.850 0.680  
0.720 0.576  
0.892 0.714  
0.892 0.714  
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References: 1. (R. Gralla 3); 2. (IGAR, 20 2005) 
 
Regimen 1: IV Palonoset g;  
Regimen 2: IV Ondans  
Regimen 3: IV Ondanset IV Dexamethaso
Regimen 4: IV Ondanset IV Dexamethaso ansetron
 et al., 200
ron 0.25m
etron 32mg, 
ron 8mg + 
ron 8mg + 
04); 3. (Kaizer et al., 1994); 4. (IGAR, 2000c); 5. (Warr et al., 
ne 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
ne 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ond  4mg BID (Days 2-5) 
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The antiemetic drugs used for prophylaxis of acute emesis are the same in gimens 3 
onducted a dexamethasone dose-finding study among patients receiving 
 emetogenic chemotherapy (IGAR, 2004).  One of the study arms em  
bin  of 8mg IV ondans g IV dexam one as the prop lactic acute 
me gim
esis f ens 3 and 4.  T e for sen were 
of the baseline probability estimates. This range included the individual 
ates obtained from the results of three randomized controlled clinical trials that employ 
en ul 0c  1 arr et 
 of regimen 3 in controlling delayed emesis was based on the publ
ni R,   T
y arm f a lini G R, w ed
 of no delayed emesis given no acute emesis and probability of no delay esis 
esis for regimen 3.  The range for sensitivity analysis was set at
no  of 
mesis given acute emesis the lower limit was set at 0.00 and the baseline 
ate of regimen 4 was set as the upper limit. This range included the individual estimates 
 the two randomized clinical trials.  The efficacy of regimen 4 in controlling 
ed emesis was based on a randomized, double blind trial conducted by the Italian Group 
e  for the sensitivity analyses was 
ations for Breakthrough Emesis 
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Table 3-6: Base-Case Estimates and Sensitivity Analyses Ranges for Receiving Rescue Medications for Uncontrolled CINV – For 
ME Model 
 
Parameter Baseline Estimate  Lower limit Upper limit References 
In the acute phase given no acute emesis     
Regimen 1 0.047  
   
  
   
    




    
   
   
  
  






Regimen 2 0.047 0.000 0.104 1
Regimen 3 0.104 0.000 0.125 2 
Regimen 4 0.104 0.000 0.125 2
In the acute phase given acute emesis 
Regimen 1 0.300 0.240 1.000 Assumed
Regimen 2 0.300 0.240 1.000 Assumed 
Regimen 3 0.523 0.300 1.000 2 
Regimen 4 0.523 0.300 1.000 2 
In the delayed phase given no delayed emesis 
Regimen 1 0.074 0.000 0.100 1
Regimen 2 0.097 0.000 0.120 1
Regimen 3 0.085 0.000 0.120 Assumed*
Regimen 4 0.085 0.000 0.120 Assumed*
In the delayed phase given delayed emesis 
Regimen 1 0.500 0.400 1.000 1 
Regimen 2 0.472 0.378 1.000 1 
Regimen 3 0.486 0.389 1.000 Assumed*
Regimen 4 0.486 0.389 1.000 Assumed*
 
* Assumed to be the average of estimates of regimen 1 and 2.  References: 1. (R. Gralla et al., 2003); 2. (Warr et al., 2005) 
Regimen 1: IV Palonosetron 0.25mg; Regimen 2: IV Ondansetron 32mg; Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID 
(Days 2-5); Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5) 
78 
METHODOLOGY   Reema Mody 
For regimens 1 and 2, the probability of receiving rescue medications following no 
emesis, no delayed emesis, and delayed emesis were obtained from calculations conducted u
published data from a randomized clinical trial of palonosetron (Gralla et al., 2003).  The receipt 
of rescue medications following acute emesis was assumed to be 0.30 for regimens 1 and 
 
For regimens 3 and 4, the probability of receiving rescue medications in the acute ph
following no acute emesis and following acute emesis, was assumed to be equal because it was 






ial (Warr et al., 2005).  Due to lack of relevant data in the published literature, the 
verage of the probability estimates of regimens 1 and 2 were used as baseline estimates for 
ed phase following no delayed emesis and delayed 
mesis. 
 
emesis will receive 
scue meds.  The lower limit of the range for sensitivity analyses for the parameters: probability 
te emesis and no delayed emesis were set at zero 
and the
ble-blind controlled clinical trial conducted to determine the efficacy and safety 
of palonosetron compared to ondansetron, found no significant differences in the proportion of 
treatme t-related adverse events in the two groups (Gralla et al., 2003).  The prophylactic 
antieme c regimens used for prevention of CINV in the ME model were comprised of similar 
individual antiemetics and thus it was assumed that the probability of experiencing adverse 
events is similar between the four regimens.  Thus, adverse events were not modeled for the ME 
model.  
 
Probability of Outpatient Physician Visit due to Uncontrolled Emesis  
a
receiving rescue medications in the delay
e
 
For those patients who experience acute or delayed emesis, the probability of receiving
rescue medications was ranged from the lower limits calculated as -20% of baseline and the 
upper limits were set at 1.00, i.e. all patients in the cohort who experience 
re
of receiving rescue medications given no acu
 higher limit was set at +20% of the baseline estimates.  
 
Adverse Events due to Prophylactic Antiemetic Regimens  
 
The 5HT3RAs including palonosetron have been found to have a favorable side effect 
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The probability of uncontrolled emesis resulting in an outpatient physician visit or 
patient hospitalization is very low.  However, because it involves a substantial amount of 
are resource utilization, the costs nee deled n ac ntation 
re is no reason to believe that the probability of outpatient 
physician visits due to uncontrolled emesis will be dependent on the type of ch py 
received.  The probability is more likely to d ly on the f uncontr sis 
experie hus, for this stu assumed probabil eiving 
outpatient physician visits is similar to those E model and also similar for all treatment 
strategi
 
Cost Es odels 
in
healthc d to be mo  to provide a curate represe
of management of CINV.  The
emothera
epend on  level o olled eme
nced by the patients. T dy, it is  that the ity of rec
for the H
es.  
timates for the Decision M  
 
Direct 
model includ sts of pr ic antiem ens, 
, rescue medications for managing breakthrough emesis, outpatient care for 
uncontr verse even tiemetic ns.   
 
Costs o etic Regimens
Costs 
The direct costs for the ed the co ophylact etic regim
drug administration
olled emesis and treating ad ts of an regime
f Prophylactic Antiem  
 
The drug costs for prophylactic antiemetic regimens, rescue medications and medications 
to treat side effects were obtained from the Drug Topics Red Book (Red Book, 2005).  The Red 
Book lists the average wholesale price (AWP) for virtually every medicine prescribed.  For drugs 
which are available in generic forms, the average of the highest and lowest prices was used as the 
drug cost.  The unit costs for the various antiemetic agents and rescue medications are provided 
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Table 3
it 
-7: Unit Costs for Individual Antiemetic Drugs Used in the Decision Models 
 
Drug  Base case 
cost 
Upper limit Lower Lim
Prophylactic Antiemetic Drugs     
Aprepitant 125 mg  $108.77 $87.02 $130.52 
Aprepitant 80 mg  $100.12 $80.10 $120.14 
IV Ondansetron 32 mg $206.41 $165.13 $247.69 
IV Ondansetron 8 mg $51.28 $41.02 $61.54 
Oral Ondansetron 8 mg $36.72 $29.38 $44.06 
IV Dexamethasone 20 mg $4.04 $1.31 $6.60 
Oral Dexamethasone 4 mg $1.57 $0.67 $2.33 
IM/IV Dexamethasone 8 mg $4.15 $1.34 $4.66 
Oral Metoclopramide 20 mg $1.43 $0.55 $3.22 
IV Palonosetron 0.25mg $340.20 $272.16 $408.24 
Rescue Medications    
Oral Prochlorperazine 10 mg $0.82 $0.58 $1.07 
Oral Promethazine 25 mg $0.52 $0.45 $0.59 
Oral Lorazepam 1mg $1.01 $0.57 $1.32 
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For antiemetic drugs that were administered as infusion, administration costs were added 
o the treatment ct osts.  The administration costs were based on the G codes published by 
Medicare for reimbursement (Department of Health and Human Services, 2004).  The 
ted from
ve but tal r th ecti
costs incurred for administering the antiemetic drugs should be used for the analysis. However, in 
ctual co icly e re es a
commonly employed.  Thus, the Medicare reimbursement values have been used in this study for 
 from t ect se etw
onduct sensitivity analyses.  The cost of prophylactic antiemetic regimens, administration costs 
nd the total treatment costs for the various strategies are shown in Tables 3-8 and 3-9.  
reimbursement values for drug administration are appropriate for CEA conduc  the 
payer’s perspecti  not for the socie  perspective.  Fo e societal persp ve, the actual 
most cases the a sts are not publ  available and th imbursed charg re most 
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Table 3-8: Cost of Prophylactic Antiemetic Regimens Used in the Decision Analysis Model - 
For HE Model 
 
Costs Regimen A Regimen B Regimen C Regimen D 
Prophylactic 
antiemetic drugs $530.00 (±20%) $233.10 (±20%) $93.23 (±20%) $296.39(±20%) 
Administration $5 $5
$5 $2 $1
8.95 (±20%) 8.95 (±20%) $86.67 (±20%) $86.67 (±20%) 
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Table 3-9: Cost of Prophylactic Antiemetic Regimens Used in the Decision Analysis Model - 
For ME Model 
 
Costs Regimen 1 Regimen 2 Regimen 3 Regimen 4 
Prophylactic 
antiemetic drugs $340.20 (±20%) $206.41 (±20%) $67.99 (±20%) $361.75 (±20%) 
Administration  $58.95 (±20%) $58.95 (±20%) $86.67 (±20%) $86.67 (±20%) 
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Costs of Managing Breakthrough Emesis 
 
The rescue medications prescribed for breakthrough emesis were based on the 2005 
NCCN guidelines.  In previous economic evaluations it was assumed that patients will 
experience on average two emetic episodes during a 24-hour time period and thus two doses of 
rescue medications will be provided each day (Johnson & Bosanquet, 1995; Kwong & 
Parasuraman, 1999).  The base case analysis in this study was conducted assuming that patients 
are pres
cause the 
rophylactic regimen for delayed phase does not include a 5-HT3RA and it may be preferred 
instead of prochlorperazine for managing breakthrough emesis.   
ased on unstructured interviews with oncology nurses at the cancer center it was found 
that nurses conduct follow-up phone calls with patients to inquire about side effects of 
chemotherapy.  It was assumed that all patients who received rescue medications during the 
delayed phase would spend a minimum of 15 minutes on the phone with the nurse to relate CINV 
events.  The hourly wage rate for registered nurses was multiplied with the time taken on the 
phone to calculate the personnel costs associated with managing breakthrough emesis.  The costs 
for managing breakthrough emesis are presented in Table 3-10. 
 
For patients that require additional care for extreme CINV event, it was assumed that the 
patient will come for an outpatient visit and will require intravenous infusion of saline and rescue 
antiemetic medications. It was assumed that the probability of requiring additional outpatient care 
does not differ based on the prophylactic antiemetic regimen received.  
 
Indirect Costs Associated with Management of CINV
cribed prochlorperazine (Compazine) twice a day for one day for breakthrough emesis 
during the acute phase and four times a day for two days during the delayed phase.  The costs and 
benefits were calculated for two scenarios where the drugs used for managing breakthrough 






Indirect costs associated with CINV were included to capture the impact of potential 
savings associated with control of CINV with each treatment. O’Brien and colleagues (O'Brien et 
al., 1993) conducted a study in five Canadian cancer centers to determine the costs associated 
with CINV.  The study reported a total loss of 198 hours of paid employment, 409 hours of 
unpaid employment, and 186 hours of caregiver time among 72 patients who experienced emesis. 
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Based on this study, we assumed that the patient’s average time away from paid or unpaid work 
as 11.00 hours (the total of time away from employment – 793 divided by 72 patients).  The 
time away from wo ncontrolled CINV wa ing ge 
ureau of Labor Statistics (US Department of Labor, 2 05).  The base case 
estimate was varied between 2.75 hours (estimated using only loss of p ployment)  
nducting sensiti ity analyses.   
ed from the payer perspective, direct total cost included the cost of 
the tota ted with managing breakthrough emesis, cost of outpatient care for 
uncontrolled em ents of antiemetic agents.  The indirect costs 




rk due to u s valued us the adult avera wage rate 
obtained from the B 0
aid em and 24
hours (3 days) of lost employment for co v
 
For the CEA conduct
l regimen, cost associa
esis and cost of treating adverse ev
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Table 3-10: Costs of Managing Breakthrough Emesis  
er Limit 
 
Resources Unit Costs Upper Limit Low
Rescue Medications    
Oral Prochlorperazine 10 mg $0.82 $0.58 $1.07 
l Personnel costs (For delayed phase)    
Average Salary – Registered Nurse 
Tota
$26.61/hour $21.29/hour $31.93/hour 




Saline Infusion 1000cc $0.99 $0.79 $1.
Physician Outpatient Visit  $48.98 $39.18 
Administration cost for saline (1st hr) $64.8 $51.84 $77.76 



















cluded in the decision 
models for prevention of CINV.  It was assumed that the effectiveness, toxicity and cost of 
 
. Lindley and colleagues have reported the level of compliance with three-single drug 
ethasone 
(85%) and ondansetron (80%).  Currently, there is a lack of information on the level of 
t 
 
3. of delayed emesis is known to be dependent on the level of control in the acute 
emesis and the prophylactic antiemetic regimens prescribed (IGAR, 1994; Schnell, 2003).  
 of prophylactic 
atient 
 
4. sis and nausea) should be 
metic episodes per patient per treatment.  Since all 
clinical trials do not provide the average number of emetic episodes experienced per patient 
exp
 hours 
del Assumptions and Rationale 
In clinical practice, agents such as lorazepam, prochlorperazine or promethazine are 
prescribed in combination with the prophylactic antiemetic regimens in
these additional drugs will be consistent across the alternative treatment strategies and thus 
have not been included in the model.   
2
antiemetic regimens in patients receiving moderately high to highly emetogenic 
chemotherapy (Lindley et al., 2005).  The study results showed no significant differences in 
the level of compliance among patients receiving prochlorperazine (83%), dexam
compliance with combination antiemetic regimens and whether it differs based on the type of 
chemotherapy received by the patients.  For this study, it was assumed that patients have 
100% compliance with the antiemetic regimens in the acute and delayed phase.  Thus, any 
incidence of emesis in the acute or delayed phase was not due to non-compliance but a resul
of lack of efficacy by the prophylactic antiemetic regimen.  
The incidence 
The incidence of delayed emesis was assumed to be independent of the receipt of rescue 
medications or additional outpatient care in the acute phase.  The receipt of rescue 
medications or outpatient care in the delayed phase is assumed to be dependent only on the 
incidence of emesis in the delayed phase and independent of the type
antiemetic regimen received.  The probability of receipt of rescue medications and outp
care for each regimen is varied in sensitivity analyses to test the robustness of the study 
results.   
Ideally, failures (patients who experience emesis/nausea/eme
assessed by the average number of e
licitly, it is assumed that patients experience two emetic episodes on average in each 24 
hours.  It was also assumed that two doses of rescue medications will be required in 24
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for all the treatment arms (Johnson & Bosanquet, 1995; Kwong & Parasuraman, 1999).  For 
uncontrolled delayed emesis, it was assumed that patients receive rescue medications for two
days.  The estimates of number of doses of rescue medication and number of days wer
varied in sensitivity analyses to test the robustness of the CEA results. 
 
5. It was assumed t
 
e 
hat patients will either receive or not receive rescue medications for control 





de cleaning costs, laundering soiled clothes were not included in 
 costs will be based on the number of emetic episodes experienced by the 







sis and nausea if subsequent outpatient care is not required.   
 
6. Only costs due to lost productivity during the delayed phase were included in the model as
the indirect costs.  The workday lost during the acute phase is not included in the ind
estimates as it is incurred by all patients irrespective of the treatment received.   
 
7. The costs incurred by patients in hiring additional help for child care, home care or caregiver
costs were not included in the model.  The out-of-pocket costs for managing nausea and 
vomiting which may inclu
the model.  These
easing the costs by the same amounts in all the treatment arms would not affect the ICER 
calculations.  
 
8. Patients may use over the counter medications for treating nausea and vomiting and it is 
assumed that the usage will be similar in all the treatment arms.  Since the costs and benefits 
associated with these medications are assumed to be the same in all arms, their inclusion 
not affect the ICER calculations and are not included in the m
9. For the HE model, only the side effects due to metoclopramide were modeled.  It was 
assumed that the adverse events in the other regimens due to the individual antiemetics
be similar.  Thus incorporating the costs for treating adverse events by the same amounts in 
all the treatment arms will not affect the ICER calculations.  
 
Base-case Cost Effectiveness Analysis 
 
Decision models can be evaluated using either cohort simulation or first-order simulation
model.  In the first-order Monte Carlo simulation, a large number of patients are followed 
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through the model individually.  A single patient is randomly selected and will randomly select 
path at each change node in the decision model based on the probability of each outcome.  
path followed by different patients will differ based on chance.  Due to the process bei




ulation models can be used to 





ulti-way, threshold analysis and 
study, one way sensitivity analyses 







arm of the model.   
 
The base case analysis represents the average costs and effectiveness for a hypothetical 
cohort of 10,000 patients. The baseline model was analyzed using a first-order Monte Carlo 
simulation and this helps in determining the uncertainty associated with the derived costs and 
outcomes. The average costs and effectiveness obtained were then used to calculate the 
incremental cost-effectiveness ratio (ICER) for each treatment strategy. The ICER for a trea
strategy is calculated as the additional cost per completely controlled patient relative to t
most costly option.  These analyses were performed for both HE and ME models from the payer 




Sensitivity analysis is a means of assessing the extent to which the incremental costs a
incremental effectiveness of the alternative regimens are affected by parameter uncertainty and 
model assumptions (Briggs, Sculpher, & Buxton, 1994).  There are multiple methods which can
be used to conduct sensitivity analysis: one-way, two-way, m
probabilistic sensitivity analyses (Briggs et al., 1994).  In this 
e key assumptions and test the robustness of the model.  
Although, one-way sensitivity analyses are easy to understand, incremental costs a
effectiveness do not depend on single parameters.  Probabilistic sensitivity analysis is a method 
by which all parameters can be varied simultaneously to understand the overall impact on 
incremental costs and effectiveness (Agro et al., 1997; Briggs, Goeree, Blackhouse, & O'Brien,
2002).  Probabilistic sensitivity analysis (second-order Monte Carlo simulation) was conducte
assess the impact of simultaneous variations in the distribution of important variables around 
their point estimates.  In second-order Monte Carlo simulation each parameter with a specified 
range is associated with a distribution function and repeated samples are drawn at random from
these distributions to determine empirical distribution of cost-effectiveness ratio for each 
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treatment strategy (Shaw & Zachry, 2002).  The simulation can be run to generate hundreds
scenarios of different combinations of input variables and generate the output values for a
strategy.  Probabilistic sensitivity analysis provides superior infor
 of 
 
mation since it uses 
distributions of input values instead of just a single mean value.  
 
3.2: Phase II: Willingness-to-Pay and Cost-Benefit Analyses 
 
The objectives of phase II are 2.1) to determine the monetary value placed on improved 
emesis control due to addition of aprepitant to the standard regimen following administration of 
HE chemotherapy using WTP method, 2.2) to determine the monetary value placed on improv
emesis control with the introduction of palonosetron instead of the standard regimen following 
administration of ME chemotherapy using WTP method, 2.3) to determine the association 
between maximum WTP for improved emesis control following HE chemotherapy a
respondents’ demographic and clinical characteristics, 2.4) to determine the association betw
maximum WTP for improved emesis control following ME chemotherapy and respondents’ 
demographic and clinical characteristics, 2.5) to determine the net benefit of addition of 
aprepitant to the standard antiemetic regimen for prevention of CINV due to HE chemotherapy 





 ME chemotherapy.  In order to achieve the Phase II objectives, primary data will be 
ollected using a survey.  The study population, survey instrument, data collection process and 
sing Contingent Valuation (CV) Method 
onetary (in 
this case, dollar) values by presenting hypothetical scenarios about the healthcare intervention 
under e
 
 1 and 
c




WTP is based on the premise that the maximum amount of money an individual is 
willing to pay for a commodity is an indicator of the utility or satisfaction to them of that 
commodity.  The contingent valuation (CV) method was used to assess consumers’ WTP for a 
program.  It is a direct measurement of WTP using a survey-based approach to elicit m
valuation.  The following section describes the methodology employed for measuring 
patients’ WTP for 1) improved emesis control due to addition of aprepitant (new drug) to the
antiemetic regimen (5HT3 RA + dexamethasone) following HE chemotherapy – Scenario
2) improved emesis control due to the new drug palonosetron compared to the antiemetic 
regimen (5HT3 RA + dexamethasone) following ME chemotherapy – Scenario 2.  The main 
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purpose of determining the WTP is to use the monetary valuation of benefits of antiemetic 
regimen for conducting CBA of the emerging antiemetic regimens for preventing CINV 




vided by the 
ealth interventions.  For the purpose of this study, out-of-pocket payment was chosen as the 




tudy Population, Sample selection and Sample Size Estimation  
fo
 
The CV method was used to value the benefits offered by the two antiemetic agent
the purpose of this study, WTP was determined from the ex-post/user-based perspective. The 
multiple uncertainties and use of compound probabilities involved in the ex-ante perspective can
pose a substantial cognitive burden for the respondents.   Also, patients who are experiencing
condition are considered to be the best candidates to provide the value of benefits pro
h
payment vehicle, as it is a
r-based perspective.  A payment card format was employed to determine the maximum 
WTP for improved emesis control for the two scenarios, HE chemotherapy and ME 
chemotherapy. WTP can be asked in the various formats (explained in chapter 2) but each 
method is susceptible to a number of potential biases.  Range bias in payment scale format has 
been assessed but it was not found to be a significant factor (Ryan et al., 2004).  Since the 
payment card method provides a format where the consumer can “shop around” for a value th
they would most likely pay which is close to a realistic scenario, it was the format of choice i





Population is an aggregation of study elements.  In most cases, it is practically impossi
to survey the entire population. The survey sample is a subset of the population that is used to 
gain information about the entire population.  For the user-based perspective, the survey samp
can be drawn either from cancer patients or from the general population who are provided with 




he population for Phase II of this study was cancer patients recruited from the Mary 
Babb R
T
andolph Cancer Center (MBRCC) in Morgantown, WV. Patient preferences may be 
preferred when an analysis is designed to evaluate alternative interventions for the same 
condition and is not primarily intended for resource allocation decisions over a wide range of 
illness.  A patient population is appropriate for this study, since the purpose of our study is to 
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assess the most efficient way to create health given a defined condition, i.e. CINV and a selec





Patients with cancer who were 18 years or older in age and receiving their first or 
subsequent cycle of chemotherapy, or who have received chemotherapy in the past three months 
in an outpatient setting were eligible to participate in the study.  Eligible participants should be 
ble to understand and speak English.  Also, based on the discretion of the oncologist or the 




oncology nurses, patients with cog
 Size Estimation  
The sample size for the study was based on the number of patients required to detect a 
minimum mean difference in willingness to pay of $30 for both the scenarios.  The popula
standard deviation required for sample size calculation was obtained from a pilot study conducted 
among 20 patients.  The details of the pilot study are discussed later.  The sample size required 
for the study was determined using the PASS 6.0 software.  By accepting α = 0.05 (i.e., the 
probability of type I error is 5%), 
tion 
β = 0.15 (i.e., 85% detection power), standard deviation = 
$100.00, and a minimum difference in maximum WTP between the alternative regimens for 
Scenari d be 100 
 
pproached eligible participants and explained the purpose of the study. The 
primary esearcher described the study in detail and verbal consent was obtained, if patients were 
interest ts for 
e 
o 1 and Scenario 2 = $30, the estimated sample size required for the study woul
patients.  
 
Recruitment Procedures and Data Collection 
 
Approval for the survey instrument and the script for recruitment of participants were
sought from the Institutional Review Board of West Virginia University. The oncologist or the 
oncology nurse a
 r
ed in participating in the study.  The script for approaching and recruitment of patien
the study is attached as Appendix II.   
 
Data collection can be done by face-to-face interviews, self-administered surveys, mail 
surveys or telephone interviews.  In this study, data were collected by conducting face-to-face 
interviews with the patients when they come to the cancer center for regular check-ups, or for 
receiving chemotherapy.  There is agreement in the literature that face-to-face interviewing is th
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most preferred and reliable method for WTP elicitation (National Oceanic and Atmostpheric 
Administration, 1993);(Mitchell & Carson, 1989).  Face-to-face interviewing allows for 
presenting the maximum amount of information, provides an opportunity for respondents to 
consider their response and for reducing the potential for hypothetical bias (Smith et al, 1999b; 
(Olsen & Smith, 2001).  On completion of the interview, the participants were presented with a 
West Virginia University souvenir mug as a token of appreciation for their time and effort.
was collected over a period of f
  Data 





uch as type of 





to imagine that they are receiving HE chemotherapy which causes acute emesis in greater than 
nstrument Development 
 
The WTP survey was developed by obtaining information from the published literature 
and a multidisciplinary team of oncologists, a clinical pharmacist, health services researchers and
a health economist.  Two versions of the survey were used, differing only in the order of 
presentation of the two hypothetical scenarios.  In Version A, the HE chemotherapy scenario was 
presented first, followed by the ME chemotherapy scenario, whereas in Version B, the order was 
reversed.  Participants were alternately assigned to the two versions of the survey.  The survey 
has five sections and is presented as Appendix III.  The global approach was used to construct 
scenarios for WTP elicitation.  
 
The first section of the survey attempted to standardize the knowledge base of 
participants by presenting information on chemotherapy, description of nausea and vomiting, risk 
of emesis following chemotherapy, and standard treatment used to prevent emesis. Section two of 
the survey was designed to collect information about clinical characteristics, s
herapy, severity of nausea experienced and number of emetic episodes during acute and 
delayed phases. 
 
Patients were told at the beginning of the session that the scenarios presented were 
hypothetical and did not relate to their own personal situation.  Sections three and four of the 
survey include the description of the two clinical scenarios and all the relevant information ab
the antiemetic regimens.  The two scenarios differ in the type of chemotherapy received by the 
patients, and prophylactic antiemetic regimens compared.  The actual names of the new d
the standard treatment were not used for scenario descriptions.  In scenario 1, patients w
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99% of
y.  In Scenario 2, patients were 
sked to imagine that they are receiving ME chemotherapy which causes acute emesis in 30-90% 
esis in 55% of patients.  This was followed by the description of the 





 by their drug insurance plans.  They were asked 
 indicate the maximum amount that they would be willing to pay out-of-pocket for improved 
ol (reduction in acute emesis from 30% to 17% and delayed emesis from 55% to 
37%) d io 1.  
as 
at 
any people are not willing to forgo any money for health gains because either they are 
pposed to paying for health or they oppose the suggestion of paying out of pocket or increase in 
test is typically expressed as zero responses but sometimes 
may be , it is 
 or a 
 patients and delayed emesis in greater than 75% of patients.  This was followed by the 
description of the standard antiemetic regimen and the new regimen (standard regimen with 
aprepitant) for prevention of CINV following HE chemotherap
a
of patients and delayed em
standard antiemetic regi
ng ME chemotherapy.  
 
After information about each scenario was presented, respondents were asked whether 
they prefer the new regimen compared to the standard regimen for each scenario and the reasons
for their preferred choice.  This was followed by eliciting information about how important
considered the acute and delayed risk reduction due to the new regimens on a scale of 0 to 10, 
where 0 is not at all important and 10 is very important.  Respondents were asked to imagine
the new antiemetic regimens will not be covered
to
emesis contr
ue to addition of a three-day regimen of aprepitant to the standard regimen in scenar
Similarly, respondents were asked to indicate the maximum amount that they would be WTP out 
of pocket for improved emesis control (reduction in delayed emesis from 45% to 33%) for a 
single day treatment with palonosetron instead of the standard regimen.  The maximum WTP w
determined using the payment card method.  The payment card had a range of WTP amounts th




taxes or insurance premiums.  The pro
 excessively high amounts.  For respondents who provided $0 as the maximum WTP
important to determine whether it is “genuine” valuation of the benefits of the intervention
“protest” zero.  A follow-up question was asked to respondents who provided $0 as WTP to 
determine if it was a protest zero or a genuine zero.  Respondents were also asked to record the 
level of difficulty they had in understanding the hypothetical scenarios and to provide a 
maximum WTP amount.  The time taken to complete the interview was also recorded.  
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Section 5, the last section of the survey was designed to obtain demographic information 
such as age, gender, education, marital status, employment status, number of members in the 





The survey was reviewed by a multidisciplinary team of an oncologist, a clinical 




 among 20 cancer patients who were receiving chemotherapy or had received in the 






k obtained from the team regarding the relevance of questions, clarity of questions and 
response options were was used to modify the survey.  Based on the feedback, the efficacies of 
the regimens described in the hypothetical scenarios were presented using pie charts.  The 
modified survey was then used to conduct a pilot study.  The construct validity of the final surve
was assessed by testing the positive relationship between income levels and WTP amounts, 
which is discussed in the data analysis section.  
 
Pilot Study 
A pilot study was used to determine the range for the payment card method and to 
establish the time taken to complete the survey.  The other goals of the pilot study were to asses
the respondents’ level of understanding of the scenarios and WTP questions.  The study was 
conducted
eir maximum WTP for the improved emesis control due to the new antiemetic regimen.  
A range for the payment card for the final survey was created from the responses of the pilot 
survey.  
 
Data Handling and Data Analysis  
 
The principal investigator was responsible for obtaining, organizing, analyzing and 
maintaining the data.  The first two objectives (2.1 and 2.2) of Phase II of the study are to 
determine the maximum amount that patients with cancer are WTP for improved emesis contro
for both scenarios.  The actual amount marked on the payment card range was considered as th
maximum WTP amount.  Summary WTP is usually presented as the mean and/or median.
Though, the mean is sensitive to the shape of the distribution and less robust than the median, it 
is theoretically the correct measure of benefits for conducting a CBA.  It is rec
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mean WTP along with the range of values should be presented as a summary welfare measure in 
WTP st
the entire 
resented as means, medians or 
nducted to determine the differences in mean 
TP amount based on demographic and clinical characteristics.  
d 
 Based 
 in which the WTP data is treated, different regression models can be employed to 
tudy the association between WTP and respondent characteristics.  Some researchers consider 





eir maximum WTP amount.  In this 
case, th ed regression 
odels should be used for analyses.  However, in this study, the respondents were instructed to 
P amount if the amount they wish to circle was not shown in the payment 
card ran
e 
LS regression model for the purpose of determining the association 
between WTP and annual household income level (Davey et al., 1998; Dranitsaris, 1997; 
Dranitsaris et al., 2001a; O'Brien, Novosel, Torrance, & Streiner, 1995).  Also, in practice, OLS 
may provide a robust estimator of the mean WTP (Donaldson et al., 1998).    
udies (Smith, Olsen, & Harris, 1999c).  In this study, WTP estimates for scenario 1 and 
scenario 2 have been presented as means and medians.  The average WTP estimates for 
sample, sample excluding all zeroes and sample excluding only the protest zeroes are reported.  
Demographic and clinical characteristics of the sample are p
proportions.  Appropriate statistical tests were co
W
 
Objectives 2.3 and 2.4 involve determining the association between WTP for improve
emetic control and patients’ demographic and clinical characteristics for both scenarios. 
on the manner
s
the WTP data obtained from
ored dependent variable violates the assumption that the error term is normally 
distributed (Cameron & Huppert, 1989; Donaldson, Jones, Mapp, & Olsen, 1998).  To overcome
the problems with OLS models, researchers have explored the use of grouped data regression 
models to determine association of WTP with respondent characteristics (Donaldson et al., 1998). 
Another method is to consider the maximum WTP amount indicated on the payment scale as a 
continuous variable and use it as a dependent variable for ordinary least squares (OLS) regression 
models.   
 
Usually, studies employing payment card for WTP elicitation instructs the respondent 
circle an amount in the range provided that is closet to th
e maximum WTP amounts are restricted by the ranges provided and group
m
specify the exact WT
ge.  Thus, the maximum WTP amounts are not restricted by the limited range provided 
and can be considered as continuous variable and OLS models can be used to determine th
association of WTP and respondent characteristics.  A number of studies employing payment 
card method have used O
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If the observed WTP amount indicated on the payment scale has a skewed distribution, 
gression analyses with logarithmic of WTP as dependent variable will be performed. 
Multivariable regression models were perf  sample with positive WTP values. All 








Cost-Benefit Analyses of 
The last two objectives (2.5 and 2.6) of Phase II involve conducting CBA for determ
the net benefit of using the new regimens instead of the standard regimens for prevention of 
CINV following HE and ME chemotherapy.  The CBA were conducted from the payer 
perspective.  
 
Calculation of Net Benefit 
 
Cost benefit analysis is an economic evaluation method where the costs and benefits of 
od of the CBA 
model is one chemotherapy cycle and a payer perspective will be undertaken. WTP amounts 
. incremental benefits of the new 
antieme d ME 
l 
the health care intervention are valued in monetary terms.  The analytic time peri
were used as monetary measures of improved emesis control, i.e
tic regimens over the standard regimens for prevention of CINV following HE an
chemotherapy.  The cost parameters for the cost-benefit model were calculated as the incrementa
cost of the new antiemetic regimen compared to the standard regimen.  Costs from a payer 
perspective will include the acquisition cost of prophylactic antiemetic regimens.  The net benefit 
of the intervention is calculated as the difference of incremental costs and benefits of the new 
antiemetic regimen compared to the standard regimen.  




One-way sensitivity analyses were conducted to test the robustness of the study results.  
The average WTP amounts were varied between the ±95% confidence limits of the WTP 
estimates.  The impact of changes in the incremental costs of the antiemetic regimens on the net 
benefit was also studied.
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Phase I of the study involved constructing decision m
ciated with prophylactic an etic ime emotherapy-
ced n a and vomiting (CINV) following highly  moderately 
y.  This section presents the results on total costs, total 
ens incorporated in odel.   
sion 
 
naly su  
odels to outline the costs and 











ns for prevention of ch




ental cost-effectiveness ratios (ICER) of the different antiemetic 
the decision m
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ing
n C is zero.  The 
e co
 
A decision m s d benefits of four 
lactic antiem  f re ion  HE chemotherapy (Refer Table 
pothetical coh o ,0 a  pa t v  HE chemotherapy was evaluated 
rder Monte C u s was conducted based on the 
tion that the probability effects due t  regime analysis was also 
ed for th io odel where the probability en C was 
 the results are reported later in the p h sts from the payer’s perspective 
 the direct c whereas both direct 
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100 
 Carlo
Highly Emetogenic Chemotherapy – Side Effects Not Modeled  
 
Treatment Strategy Si
Table 4-1: Base Case Results from Payer Perspective using Monte  Simulation of 10,000 Patients with Cancer Receiving 
de Effects Not Modeled 
Payer Perspective Direct Costs Mean (SD) 
Effectiveness 
Mean (SD) 
Cost of achieving one 
patient with complete 
control of emesis 
Incremental cost effectiveness 
ratio/patient with complete control 
of emesis 
Regimen C (Metoclopramide) $187.18 ($33.37) 0.555 (0.497) $337.26 - 
Regimen B (Standard) $300.53 ($36.69) 0.478 (0.499) 
Regimen D (Ondansetron) $389.97 ($32.29) 0.539 (0.498) 
Regimen A (Aprepitant) $593.45 ($27.02) 0.676 (0.468) 
$628.72 Dominateda
$723.51 Dominateda
$877.88 $3,363.181/patient with complete 
control of emesis 
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 m
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg
QID (Days 2-4)  
Regimen D:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg
(Days 2-4) 
 
aDominated by regimen C
g (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
8 mg BID (Days 2-4) 
 BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
 BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID 
RESULTS   Reema Mody 
Regimen C, which includes metoclopramide as one of the antiemetic agents in the 
delayed phase, was the least expensive ($187.18 per patient for a period of 5 days) and regimen 
 (regimen with aprepitant) was the most expensive antiemetic treatment ($593.45) from the 
payer perspective.  The direct costs of achieving one patient with complete protection from 
emesis with regimen A was found to be $877.88 which was approximately 1.2 times the direct 
cost of regimen D ($723.51) and approximately 2.6 times the total cost of regimen C ($337.26).  
The ICER for each treatment strategy was calculated to determine the additional cost per patient 
with complete control of emesis relative to the next costly option.  Under the base-case 
assumptions using the direct costs, regimen A provided more health benefits and was more costly 
than regimen C, with a resulting ICER of $3,363.181 per patient with complete control of emesis.  
Regimens B and D were less effective and more costly than the base comparator, regimen C, i.e. 
regimens B and D are dominated by regimen C.  The direct costs and effectiveness for the 
antiemetic regimens are represented graphically in figure 4-1 where the X-axis represents the 
effectiveness with respect to the probability of achieving patients with complete control of 
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Figure 4-1: Direct Costs and Effectiveness of Different Antiemetic Regimens for Patients 
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The base case results for the total costs, effectiveness, total cost for achieving one patient 
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om Societal Perspective using Monte Carlo Simulation of 10,000 Patients with Cancer Re
Highly Emetogenic Chemotherapy – Side Effects Not Modeled  
 
Treatment Strategy Side Effects Not Modeled 
Table 4-2: Base Case Results fr ceiving 




Cost of achieving one 
patient with complete 
control of emesis 
Incremental cost effectivene




Regimen C (Metoclopramide) $295.89 ($149.29) 0.558 (0.497) $530.27 - 
Regimen B (Standard) $431.56 ($153.69) 0.478 (0.499) $902.85 Dominateda
Regimen D (Ondansetron) $494.84 ($148.27) 0.543 (0.498) $911.31 Dominateda
Regimen A (Aprepitant) $658.97 ($129.75) 0.684 (0.465) $963.41 $2,881.605/patient with complete 
control of emesis 
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4)  
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 
QID (Days 2-4) 
Regimen D:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 m
(Days 2-4) 
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Figure 4-2: Total Costs and Effectiveness of Different Antiemetic Regimens for Patients 
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Table 4-3: Base Case Results from Payer Perspective using Monte Carlo Simulation of 10,000 ei
Highly Emetogenic Chemotherapy – Side Effects Modeled  
 
Treatment Strategy Side Effects Modeled 
Patients with Cancer Rec ving 




Cost of achieving one 
patient with complete 
control of emesis 
Incremental cost effectiveness 
ratio/patient with complete 
control of emesis 
Regimen C (Metoclopramide) $187.65 ($34.90) 0.542 (0.498) $346.22 - 
Regimen B (Standard) $300.68 ($37.12) 0.478 (0.499) $629.04 Dominated*
Regimen D (Ondansetron) $390.50 ($34.36) 0.547 (0.498) $713.89 Extended Dominance**
Regimen A (Aprepitant) $593.66 ($28.11) 0.684 (0.465) $867.92 $2,857.20 per patient with 
complete control of emesis 
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 
(Days 2-4)  
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 
QID (Days 2-4) 
Regimen D:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 m
(Days 2-4) 
 
*    Regimen B dominated by regimen C  
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Figure 4-3: Direct Costs, Effectiveness of Different Antiemetic Regimens for Patients 
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Table 4-4: Base Case Results from Societal Perspective using Monte Carlo Simulation of 10,000 Patients with Cancer Re
Highly Emetogenic Chemotherapy – Side Effects Modeled  
 
Treatment Strategy Side Effects Modeled 
ceiving 




Cost of achieving one 
patient with complete 
control of emesis 
Incremental cost effectiveness 
ratio/patient with complete 
control of emesis 
Regimen C (Metoclopramide) $293.34 ($149.34) 0.548 (0.497) $535.29 - 
Regimen B (Standard) $429.87 ($154.56) 0.482 (0.499) $891.85 Dominated*
Regimen D (Ondansetron) $493.43 ($148.25) 0.548 (0.498) $900.42 Extended Dominance**
Regimen A (Aprepitant) $659.30 ($129.91) 0.682 (0.465) $966.72 $2,731.09 per patient with 
complete control of emesis  
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 
QID (Days 2-4) 
Regimen D:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 m
(Days 2-4) 
 
*    Regimen B dominated by regimen C  
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Figure 4-4: Total Costs, Effectiveness of Different Antiemetic Regimens for Patients 
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Sensitivity Analyses for Highly Emetogenic Chemotherapy Model 
 
The estimates for the input parameters, both costs and effectiveness were derived a
integrated from multiple sources.  Thus, like any other economic model, the present model 
contains some degree of uncertainty.  Sensitivity analysis is a commonly used tool to deal w
uncertainty in the model input parameters.  In one-way sensitivity analyses, one parameter at a 
time is varied over a certain range and the ICERs are recalculated.  A comparison between the 
original ICER and those obtained from sensitivity analyses provide an indication of the stab
of the model to changes in the values of the parameter.   
 






The efficacy parameters, probability of no acute emesis, probability of no delayed emesis 
given no acute emesis and probability of no delayed emesis given acute emesis were varied over 
a plausible range obtained from published literature.  Table 4-5 presents the range for sensitivi




lts for the model from the societal perspective. The ICER for each regimen obtained 
from sensitivity analyses are reported in Table 4-7.  
impact 
 
ty of no 
ty 
rom 0.870 to 0.900 decreased the ICER to $2,521.81 per patient with 
omplete control of emesis.  Similar impact on ICER of regimen A was obtained for analysis 
conducted from payer perspective.  
 
For the payer perspective, the changes in the probability of no delayed emesis given no 
acute emesis had a significant impact on the effectiveness of the considered treatment regimens 
but not on the costs.  However, the same changes had a significant impact on both the 
effectiveness and cost estimates of each regimen for the analysis conducted from the societal 
 
The change in the proportion of patients having no acute emesis has a significant 
on the effectiveness estimates for each regimen but a minor impact on the direct costs of each 
regimen.  Although the dominance status of each regimen remained the same as in the base case
analysis, the ICER of regimen A was extremely sensitive to the changes in the probabili
acute emesis for regimen A.  For example, for the societal perspective, lowering the probabili
of no acute emesis of regimen A from 0.870 to 0.742 increased the ICER to $19,536.81 per 
patient with complete control of emesis and conversely, increasing the probability of no acute 
emesis of regimen A f
c
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Table 4-5: One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from Payer 
Perspective – Efficacy Parameters 
 
    DIRECT COSTS EFFECTIVENESS
 Regimen A Regimen B Regimen C Regimen D Regimen A Regimen B Regimen C Regimen D 
Parameter: Probability of No Acute Emesis 
Base Case  $593.45 $300.53 $187.18 $389.97 0.676 0.478 0.555 0.539 
Regimens  Range         
Regimen A  0.742         $594.94 $300.71 $187.29 $390.26 0.578 0.477 0.558 0.542
 0.900         
         
         
         
         
         
         
$593.11 $300.71 $187.29 $390.26 0.701 0.477 0.558 0.542
Regimen B 0.690 $593.46 $301.31 $187.29 $390.26 0.678 0.444 0.558 0.542
 0.793 $593.46 $300.12 $187.29 $390.26 0.678 0.510 0.558 0.542
Regimen C 0.742 $593.46 $300.71 $188.02 $390.84 0.678 0.477 0.518 0.504
 0.832 $593.46 $300.71 $186.86 $390.84 0.678 0.477 0.581 0.565
Regimen D 0.742 $593.46 $300.71 $188.02 $390.84 0.678 0.477 0.518 0.504
 0.832 $593.46 $300.71 $186.86 $390.84 0.678 0.477 0.581 0.565
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
QID (Days 2-4) 
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Table 4-5 (Continued): One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from 
Payer Perspective– Efficacy Parameters 
 
    DIRECT COSTS EFFECTIVENESS
 Regimen A Regimen B Regimen C Regimen D Regimen A Regimen B Regimen C Regimen D 
Parameter: Probability of No Delayed Emesis Given No Acute Emesis 
Base Case  $593.45 $300.53 $187.18 $389.97 0.676 0.478 0.555 0.539 
Regimens         Range  
Regimen A  0.793         $593.99 $300.71 $187.29 $390.26 0.647 0.477 0.558 0.542
 0.866         
         
         
         
         
         
      
$592.95 $300.71 $187.29 $390.26 0.707 0.477 0.558 0.542
Regimen B 0.646 $593.46 $300.99 $187.29 $390.26 0.678 0.460 0.558 0.542
 0.694 $593.46 $300.42 $187.29 $390.26 0.678 0.484 0.558 0.542
Regimen C 0.733 $593.46 $300.71 $187.33 $390.26 0.678 0.478 0.556 0.542
 0.738 $593.46 $300.71 $187.26 $390.26 0.678 0.478 0.560 0.542
Regimen D 0.572 $593.46 $300.71 $187.29 $392.10 0.678 0.477 0.558 0.434
0.858 $593.46 $300.71 $187.29 $388.41 0.678 0.477 0.558 0.651
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
mg BID (Day 4) + Oral Metoclopramide 20 mg 
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4
QID (Days 2-4) 
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Table 4-5 (Continued): One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from 
Payer Perspective – Efficacy Parameters 
 
    DIRECT COSTS EFFECTIVENESS
 Regimen A Regimen B Regimen C Regimen D Regimen A Regimen B Regimen C Regimen D 
Parameter: Probability of No Delayed Emesis Given Acute Emesis 
Base Case  $593.45 $300.53 $187.18 $389.97 0.676 0.478 0.555 0.539 
Regimen  Range         
Regimen A  0.308         $593.48 $300.71 $187.29 $390.26 0.678 0.477 0.558 0.542
 0.326         
         
         
         
         
         
      
$593.44 $300.71 $187.29 $390.26 0.678 0.477 0.558 0.542
Regimen B 0.122 $593.46 $300.84 $187.29 $390.26 0.678 0.477 0.558 0.542
 0.185 $593.46 $300.58 $187.29 $390.26 0.678 0.477 0.558 0.542
Regimen C 0.088 $593.46 $300.71 $187.47 $390.26 0.678 0.477 0.558 0.542
 0.200 $593.46 $300.71 $187.12 $390.26 0.678 0.477 0.558 0.542
Regimen D 0.228 $593.46 $300.71 $187.29 $390.45 0.678 0.477 0.558 0.542
0.343 $593.46 $300.71 $187.29 $390.07 0.678 0.477 0.558 0.542
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
QID (Days 2-4) 
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Table 4-6: One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from Societa
Perspective – Efficacy Parameters 
l 
    
 
TOTAL COSTS EFFECTIVENESS
 Regimen A Regimen B Regimen C Regimen D Regimen A Regimen B Regimen C Regimen D 
Parameter: Probability of No Acute Emesis 
Base Case          $658.97 $431.56 $295.89 $494.84 0.684 0.478 0.558 0.543
Regimens         Range  
Regimen A  0.742         $680.49 $431.74 $295.64 $495.29 0.578 0.478 0.558 0.542
 0.900         
         
         
         
         
         
     
$655.72 $431.74 $295.64 $495.29 0.701 0.478 0.558 0.542
Regimen B 0.690 $660.43 $439.93 $295.64 $495.29 0.678 0.444 0.558 0.542
 0.793 $660.43 $423.71 $295.64 $495.29 0.678 0.510 0.558 0.542
Regimen C 0.742 $660.43 $431.74 $305.92 $502.79 0.678 0.478 0.519 0.504
 0.832 $660.43 $431.74 $289.69 $490.94 0.678 0.478 0.581 0.565
Regimen D 0.742 $660.43 $431.74 $305.92 $502.79 0.678 0.478 0.519 0.504
0.832 $660.43 $431.74 $289.69 $490.94 0.678 0.478 0.581 0.565
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
g BID (Day 4) + Oral Metoclopramide 20 mg 
:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID 
(Days 2-4) 
Regimen B
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4m
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Table 4-6 (Continued): One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from 
Societal Perspective – Efficacy Parameters 
 
    TOTAL COSTS EFFECTIVENESS
 Regimen A Regimen B Regimen C Regimen D Regimen A Regimen B Regimen C Regimen D 
Probability of No Delayed Emesis Given No Acute Emesis 
Base Case  $658.97        $431.56 $295.89 $494.84 0.684 0.478 0.558 0.543
Regimens         Range 
Regimen A  0.793         $670.06 $431.74 $295.64 $495.29 0.648 0.478 0.558 0.542
 0.866         
         
         
       
       
       
       
$651.05 $431.74 $295.64 $495.29 0.707 0.478 0.558 0.542
Regimen B 0.646 $660.43 $437.06 $295.64 $495.27 0.678 0.460 0.558 0.542
 0.694 $660.43 $426.41 $295.64 $495.27 0.678 0.494 0.558 0.542
Regimen C 0.733 $660.43 $431.74 $296.36 $495.29 0.678 0.478 0.556 0.542
 0.738 $660.43 $431.74 $295.17 $495.29 0.678 0.478 0.560 0.542
Regimen D 0.572 $660.43 $431.74 $295.64 $529.46 0.678 0.478 0.558 0.434
0.858 $660.43 $431.74 $295.64 $461.11 0.678 0.478 0.558 0.651
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
QID (Days 2-4) 
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Table 4-6 (Continued): One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from 
Societal Perspective – Efficacy Parameters 
 
   TOTAL COSTS EFFECTIVENESS
 Regimen A Reg Regimen D Regimen A men C Regimen D imen B Regimen C Regimen B Regi
Probability of No Delayed Emesis G ute Emesiiven Ac s 
Base Cas $431.56 $295.89 $494.84 0.684 0.478 0.558 0.543 e  $658.97 
Regi ng   mens Ra e       
Regi 60.78 $431.74 95.64 $495.29 0.678 0.477 0.558 0.542 men A  0.308 $6 $2
 60. 64 29 0.4 0.5 42 
Regi 0.1 60. 64 29 0.4 0.5 42 
 60. 64 29 0.4 0.5 42 
Regi 0.0 60. 01 29 0.4 0.5 42 
 60. 28 29 0.4 0.5 42 
Regi 0.2 60. 64 77 0.4 0.5 42 
 60. 64 86 0.4 0.5 42 
0.326 $6 08 $431.74 $295. $495. 0.678 77 58 0.5
men B 22 $6 43 $434.20 $295. $495. 0.678 77 58 0.5
0.185 $6 43 $429.35 $295. $495. 0.678 77 58 0.5
men C 88 $6 43 $431.74 $299. $495. 0.678 77 58 0.5
0.200 $6 43 $431.74 $292. $495. 0.678 77 58 0.5
men D 28 $6 43 $431.74 $295. $498. 0.678 77 58 0.5
0.343 $6 43 $431.74 $295. $491. 0.678 77 58 0.5
 
Regimen A
g BID (Day 4) + Oral Metoclopramide 20 mg 
methasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID 
:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4m
QID (Days 2-4) 
Regimen D:  IV Dexa
(Days 2-4) 
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Table 4-7: One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from Payer 
and Societal Perspective – ICERs for Efficacy Parameters 
 
 ICER per patient with complete control of ICER per patient with complete control of emesis – 
emesis  – Payer Perspective Societal Perspective 
 Regimen A imen D Regimen A Regimen D Regimen B Reg Regimen B 
Probability of No Acute Emesis  
Base Case  $3, 1 a 5 D a363.18 Dominated Dominateda $2,881.60 ominated Dominateda
Regimens Range       
Regimen A  0.742 $  a  a20,694.99 Dominated Dominateda $19,536.81 Dominated Dominateda
 0.900 $  a  a
 $  a  a
 $  a  a
 $  a  a
 $  a  a
 $  a  a
32 $4, 81 D a 59 D a
2,842.19 Dominated Dominateda $2,521.81 Dominated Dominateda
Regimen B 0.690 3,401.35 Dominated Dominateda $3,054.73 Dominated Dominateda
 0.793 3,401.35 Dominated Dominateda $3,054.73 Dominated Dominateda
Regimen C 0.742 2,545.98 Dominated Dominateda $2,226.10 Dominated Dominateda
 0.832 4,219.81 Dominated Dominateda $3,847.59 Dominated Dominateda
Regimen D 0.742 2,545.98 Dominated Dominateda $2,226.10 Dominated Dominateda
 0.8 219. ominated Dominateda $3,847. ominated Dominateda
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID 
 to Regimen C 
(Days 2-4);  
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4);  
Regimen C:  IV 
QID (Days 2-4);  
Regimen D
(Days 2-4) 
All treatments are compared
Dominated by regimen C a  
120 
RESULTS   Reema Mody 
Table 4-7 (Continued): One Way Sensitivity Analyses Results For Highly Emetogenic Chemotherapy Model with No Side Effects from 
Payer and Societal Perspective – ICERs for Efficacy Parameters 
 
Parameters/Range ICER per patient with complete control of 
emesis – Payer Perspective 
ICER per patient with complete control of emesis – 
Societal Perspective 
 Regimen A Regimen B Regimen D Regimen A Regimen B Regimen D 
Base Case $3,363.181  Dominateda Dominateda $2,881.605 Dominateda Dominateda
Probability of No Delayed Emesis Given No Acute Emesis  
Regimen A  0.793   $4,559.31 Dominateda Dominateda $4,197.39 Dominateda Dominateda
 0.866   
   
   
   
   
   
   
$2,726.00 Dominateda Dominateda $2,388.31 Dominateda Dominateda
Regimen B 0.646 $3,401.35 Dominateda Dominateda $3,054.73 Dominateda Dominateda
 0.694 $3,401.35 Dominateda Dominateda $3,054.73 Dominateda Dominateda
Regimen C 0.733 $3,337.42 Dominateda Dominateda $2,991.71 Dominateda Dominateda
 0.738 $3,445.34 Dominateda Dominateda $3,098.10 Dominateda Dominateda
Regimen D 0.572 $3,401.35 Dominateda Dominateda $3,054.73 Dominateda Dominateda
0.858 $7,633.18 Dominateda $2,173.08 $7,419.57 Dominateda $1,787.86 
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
QID (Days 2-4) 
Regimen D:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID 
(Days 2-4) 
All treatments are compared to Regimen C 
 a  Dominated by regimen C
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Table 4-7 (Continued): One Way Sensitivity Analyses 
Payer and Societal Perspective – ICERs for Efficacy Pa
 
Parameters/Range ICER per patient with c
emesis – Payer P
for Highly Emetogenic Chemotherapy
rs 
plete control of 
pective 
ICER per patient w
Soc
odel with No Side Effects
 complete control of emesis – 
al Perspective 
 Regimen A Regimen B RRegimen D Regimen A egimen B Regimen D 
Base Case $3,363.181 Dominateda DDominated $2,881.605 ominateda Dominateda
Probability of No Delayed Emesis Given Acute Emesis  
Regimen A  0.308 $3,401.51 Dominateda DDominateda $3,057.66 ominateda Dominateda
 0.326 $3,401.19 Dominated
Regimen B 0.122 $3,401.35 Dominated
 0.185 $3,401.35 Dominated
Regimen C 0.088 $3,399.83 Dominated
 0.200 $3,402.87 Dominated
Regimen D 0.228 $3,401.35 Dominated


























a $3,054.73 ateda Dominateda
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + I
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1)
QID (Days 2-4) 
Regimen D:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1)
(Days 2-4) 
All treatments are compared to Regimen C 
V O mg (Day 8 mg 
, I g BID ( 20 mg 
, I g BID ( g BID 
imen 
ndansetron 32 mg (Day 1), Oral Aprepitant 80 
 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
M Dexamethasone 8mg BID (Days 2-3) and 4m
M Dexamethasone 8mg BID (Days 2-3) and 4m
s 2-3) + Oral Dexamethasone 
Day 4) + Oral Metoclopramide 
Day 4) + Oral Ondansetron 8 m
a  Dominated by reg C
RESULTS   Reema Mody 
Effect of Changes in the Receipt of Rescue Medications  
The parameters, probability of receiving rescue medications in the acute phase given no 
acute e
s evident from Tables 4-8 and 4-9, the changes in the probability of receiving rescue 
medica ns in the acute phase given no acute emesis for each regimen had an impact on the 
ffectiveness results for that regimen but no significant impact on the costs.  The dominance 
tatus of each considered treatment remained the same as in base case but resulted in changes in 
the ICERs of regimen A.  Decreasing the proportion of patients receiving rescue medications for 
no acute emesis for regimen A to zero resulted in an ICER of $3,181.86 per patient with 
complete control of emesis from payer’s perspective and $2,857.60 from the societal perspective. 
Conversely, for other regimens, decreasing the proportion of patients receiving rescue 
medications for no acute emesis to zero resulted in an increased ICER for regimen A.   
 
The costs, effectiveness and ICER results were not sensitive to changes in the 
probabilities of receipt of rescue medications in the acute phase given acute emesis and receipt of 
rescue medications in the delayed phase given delayed emesis.  From the payer and societal 
perspectives, the costs, effectiveness and ICER results for the alternative regimens were sensitive 
to the changes in the probability of receipt of rescue medications in the delayed phase given no 
delayed emesis.  Decreasing the probability of receipt of rescue medications in the delayed phase 
given no delayed emesis for regimen A resulted in decreasing the ICER to $2,615.75 and 
$2,348.85, for the payer and societal perspective respectively.  Increasing the probability of 
receipt of rescue medications in the delayed phase given no delayed emesis for regimen A 
resulted in increasing the ICER to $3,506.52 and $3,149.23 for the payer and societal 
perspective, respectively.  The changes in this probability for regimen D resulted in a change in 
the dominance status of the antiemetic regimens.  When the probability of receiving rescue 
medications for regimen D was set at zero, the ICER from societal perspective for regimen A 
increased to $3,054.73 and regimen D was ruled out by extended dominance status (Table 4-10).  
 
mesis and given acute emesis and probability of receiving rescue medications in the 
delayed phase given no delayed emesis and given delayed emesis were varied over a plausible 
range shown in Chapter 3, Table 3-6.  Table 4-8 presents the range for each parameter for each 
regimen and the direct costs and effectiveness estimates from the payer’s perspective.  Table 4-9 
presents the results from the societal perspective. The ICER for each regimen obtained from 
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eceipt of Outpatient Care Effect of Changes in the R  
The im f ges i e he acute 
layed phase, either with no rescue medications or with rescue m  direct 
s, total co ffectiveness and ICERs are presented in Tables 4- -9 a e results 
atien ring either the acute or delayed phase. The dominance status of the antiemetic 
ens rem ame, from the payer and societal perspectives, as in the base-case 












pact o chan n th  probability of receiving outpatient care during t
edications, on
nd 4-10.  Thsts, e
e du
8, 4
ates were not sensitive to the changes in the probability of receipt of 
t car
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Table 4-8: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Receipt of Rescue
Medications 
 
    
 
DIRECT COSTS EFFECTIVENESS
 Regimen A Regimen B Regimen C Regimen D Regimen A Regimen B Regimen C Regimen D 
Parameter: Probability of Receiving Rescue Medications In the Acute Phase Given No Acute Emesis 
Base Case  $593.45 $300.53 $187.18 $389.97 0.676 0.478 0.555 0.539 
Regimens         Range  
Regimen A  0.000         $593.44 $300.71 $187.29 $390.26 0.686 0.477 0.558 0.542
 0.015         
         
         
         
         
         
         
$593.47 $300.71 $187.29 $390.26 0.676 0.477 0.558 0.542
Regimen B 0.000 $593.46 $300.69 $187.29 $390.26 0.678 0.483 0.558 0.542
 0.015 $593.46 $300.71 $187.29 $390.26 0.678 0.476 0.558 0.542
Regimen C 0.000 $593.46 $300.71 $187.27 $390.24 0.678 0.477 0.565 0.549
 0.015 $593.46 $300.71 $187.29 $390.26 0.678 0.477 0.557 0.541
Regimen D 0.000 $593.46 $300.71 $187.27 $390.24 0.678 0.477 0.565 0.549
 0.015 $593.46 $300.71 $187.29 $390.26 0.678 0.477 0.557 0.541
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
QID (Days 2-4) 
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Table 4-8 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Receipt of 
Rescue Medications 
 
    DIRECT COSTS EFFECTIVENESS
 Regimen A Regimen B Regimen C Regimen D Regimen A Regimen B Regimen C Regimen D 
Parameter: Probability of Receipt of Rescue Medications in the Acute Phase Given Acute Emesis 
Base Case  $593.45 $300.53 $187.18 $389.97 0.676 0.478 0.555 0.539 
Regimens         Range  
Regimen A  0.175         $593.43 $300.71 $187.29 $390.26 0.678 0.477 0.558 0.542
 1.000         
         
         
         
         
         
      
$593.60 $300.71 $187.29 $390.26 0.678 0.477 0.558 0.542
Regimen B 0.304 $593.46 $300.67 $187.29 $390.26 0.678 0.477 0.558 0.542
 1.000 $593.46 $300.96 $187.29 $390.26 0.678 0.477 0.558 0.542
Regimen C 0.304 $593.46 $300.71 $187.26 $390.23 0.678 0.477 0.558 0.542
 1.000 $593.46 $300.71 $187.49 $390.46 0.678 0.477 0.558 0.542
Regimen D 0.304 $593.46 $300.71 $187.29 $390.26 0.678 0.477 0.558 0.542
1.000 $593.46 $300.71 $187.29 $390.26 0.678 0.477 0.558 0.542
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
mg BID (Day 4) + Oral Metoclopramide 20 mg 
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4
QID (Days 2-4) 
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Table 4-8 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Receipt of 
Rescue Medications 
 
Parameters/Range    DIRECT COSTS EFFECTIVENESS
 Regimen A Regimen B Regimen C Regimen D Regimen A Regimen B Regimen C Regimen D 
Parameter: Probability of Receipt of Rescue Medications in the Delayed Phase Given No Delayed Emesis 
Base Case  $593.45 $300.53 $187.18 $389.97 0.676 0.478 0.555 0.539 
Regimens          Range
Regimen A  0.000         $592.96 $300.71 $187.29 $390.26 0.713 0.477 0.558 0.542
 0.055         
         
         
         
         
         
      
$593.51 $300.71 $187.29 $390.26 0.674 0.477 0.558 0.542
Regimen B 0.000 $594.46 $300.51 $187.29 $390.26 0.678 0.491 0.558 0.542
 0.035 $594.46 $300.76 $187.29 $390.26 0.678 0.474 0.558 0.542
Regimen C 0.000 $593.46 $300.71 $186.97 $390.26 0.678 0.477 0.581 0.542
 0.045 $593.46 $300.71 $187.34 $390.26 0.678 0.477 0.555 0.542
Regimen D 0.000 $593.46 $300.71 $187.29 $389.93 0.678 0.477 0.558 0.564
0.045 $593.46 $300.71 $187.29 $390.31 0.678 0.477 0.558 0.539
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
QID (Days 2-4) 
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Table 4-8 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Receipt of 
Rescue Medications 
 
    DIRECT COSTS EFFECTIVENESS
 Regimen A Regimen B Regimen C Regimen D Regimen A Regimen B Regimen C Regimen D 
Parameter: Probability of of Re atio elaye iven  Emesis Receipt scue Medic ns in the D d Phase G Delayed  
Base Case  $593.45 $300.53 $187.18 $389.97 0.676 0.478 0.555 0.539 
Regimens Range         
Regimen A  0.454 $593.08 $300.71 $1 29 26 78 77 58 42 87. $390. 0.6 0.4 0.5 0.5
 1.000 $594.79 $300.71 $1 29 26 78 77 58 42 
        
         
Regimen C 0.465 $593.46 $300.71 $186.84 $390.26 0.678 0.477 0.558 0.542 
 1.000 $593.46 $300.71 $189.55 $390.26 0.678 0.477 0.558 0.542 
65 $5 46 71 29 78 0.477 58 42 
        
87. $390. 0.6 0.4 0.5 0.5
Regimen B 0.477 $593.46 $300.38 $187.29 $390.26 0.678 0.477 0.558 0.542
 1.000 $593.46 $303.58 $187.29 $390.26 0.678 0.477 0.558 0.542
Regimen D 0.4 93. $300. $187. $389.83 0.6 0.5 0.5
 1.000 $593.46 $300.71 $187.29 $392.45 0.678 0.477 0.558 0.542
 
Regimen A:  Oral Aprepitant 125 mg + Oral D ne 12 a  (Day prepitant 80  (Days 2-3) + O al Dexametha mg 
Days 2-4) 
Regimen B:  Or metha g + IV m Oral Dexa asone 8 m D (Days 2-4) 
 
g BID (Day 4) + Oral Ondansetron 8 mg BID 
examethaso mg + IV Ond nsetron 32 mg  1), Oral A mg r sone 8 
(
al Dexa sone 20 m  Ondansetron 32 g (Day 1) , meth g BI
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg
QID (Days 2-4) 
Regimen D:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4m
(Days 2-4) 
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Table 4-8 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Receipt of 
Outpatient Care 
 
    DIRECT COSTS EFFECTIVENESS
    Regimen A Regimen B Regimen C Regimen D Regimen A Regimen B Regimen C Regimen D 
Base Case $593.45 $300.53 $187.18 $389.97 0.676 0.478 0.555 0.539 
Parameter: Pr bability of f Outpatient Care During Acute Ph n: o Receipt o ase Give
No Rescue 
Medications 0.000 $593 23 $30 29 $18 96 $38 93 0.6 8 0.4 7 0.5 8 0.542 . 0. 6. 9. 7 7 5
 0.030 92 $3 54 $1 94 91 78 77 58 42 
Rescue 
  $  $        
 $      
Pr ity of f Out are D ayed ven: 
$593. 01. 87. $390. 0.6 0.4 0.5 0.5
Medications 0.000 593.34 300.44 $187.08 $390.05 0.678 0.477 0.558 0.542
0.030 $593.70 $301.25 $187.71 $390.68 0.678 0.477 0.558 0.542
Parameter: obabil Receipt o patient C uring Del Phase Gi
No Rescue 
Medications  06 $2 84 $1 60 59 78 77 58 42 0.02 $593. 99. 86. $389. 0.6 0.4 0.5 0.5
 0.05 $  $        
escue 0.02 $592.91 $$299.72 $186.44 $389.43 0.678 0.477 0.558 0.542 
0.477 0.558 0.542 
593.86 301.58 $187.97 $390.92 0.678 0.477 0.558 0.542
R
Medications 
 0.05 $594.00 $301.69 $188.14 $391.08 0.678 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4);  
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4); 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
ID (Days 2-4);  
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Table 4-9: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Receipt of Rescue 
Medications 
 
    TOTAL COSTS EFFECTIVENESS
 Regimen A Regimen B Regimen C Regimen D Regimen A Regimen B Regimen C Regimen D 
Parameter: Probability of Receiving Rescue Medications In the Acute Phase Given No Acute Emesis 
Base Case          $658.97 $431.56 $295.89 $494.84 0.684 0.478 0.558 0.543
Regimens          Range
Regimen A  0.000         $660.41 $431.74 $295.64 $495.29 0.686 0.477 0.558 0.542
 0.015         
         
         
         
         
         
         
$660.41 $431.74 $295.64 $495.29 0.676 0.477 0.558 0.542
Regimen B 0.000 $660.43 $431.72 $295.64 $495.29 0.678 0.483 0.558 0.542
 0.015 $660.43 $431.74 $295.64 $495.29 0.678 0.476 0.558 0.542
Regimen C 0.000 $660.43 $431.74 $295.63 $495.27 0.678 0.477 0.565 0.549
 0.015 $660.43 $431.74 $295.65 $495.29 0.678 0.477 0.557 0.541
Regimen D 0.000 $660.43 $431.74 $295.63 $495.27 0.678 0.477 0.565 0.549
 0.015 $660.43 $431.74 $295.65 $495.29 0.678 0.477 0.557 0.541
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
QID (Days 2-4) 
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Table 4-9 (Continued):  One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Receipt of 
Rescue Medications 
 
    TOTAL COSTS EFFECTIVENESS
 Regimen A Regimen B Regimen C Regimen D Regimen A Regimen B Regimen C Regimen D 
Parameter: Probability of Receipt of Rescue Medications in the Acute Phase Given Acute Emesis 
Base Case          $658.97 $431.56 $295.89 $494.84 0.684 0.478 0.558 0.543
Regimens          Range
Regimen A  0.175         $660.39 $431.74 $295.64 $495.29 0.678 0.477 0.558 0.542
 1.000         
         
         
         
         
         
         
$660.57 $431.74 $295.64 $495.29 0.678 0.477 0.558 0.542
Regimen B 0.304 $660.43 $431.70 $295.64 $495.29 0.678 0.477 0.558 0.542
 1.000 $660.43 $431.99 $295.64 $495.29 0.678 0.477 0.558 0.542
Regimen C 0.304 $660.43 $431.74 $295.61 $495.26 0.678 0.477 0.558 0.542
 1.000 $660.43 $431.74 $295.84 $495.49 0.678 0.477 0.558 0.542
Regimen D 0.304 $660.43 $431.74 $295.64 $495.29 0.678 0.477 0.558 0.542
 1.000 $660.43 $431.74 $295.64 $495.29 0.678 0.477 0.558 0.542
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
QID (Days 2-4) 
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Table 4-9 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Receipt of 
Rescue Medications 
 
    TOTAL COSTS EFFECTIVENESS
 Regimen A Regimen B Regimen C Regimen D Regimen A Regimen B Regimen C Regimen D 
Parameter: Probability of Receipt of Rescue Medications in the Delayed Phase Given No Delayed Emesis 
Base Case          $658.97 $431.56 $295.89 $494.84 0.684 0.478 0.558 0.543
Regimens          Range
Regimen A  0.000         $659.92 $431.74 $295.64 $495.29 0.713 0.477 0.558 0.542
 0.055         
         
         
         
         
         
         
$660.48 $431.74 $295.64 $495.29 0.674 0.477 0.558 0.542
Regimen B 0.000 $660.43 $431.54 $295.64 $495.29 0.678 0.491 0.558 0.542
 0.035 $660.43 $431.79 $295.64 $495.29 0.678 0.474 0.558 0.542
Regimen C 0.000 $660.43 $431.74 $295.33 $495.29 0.678 0.477 0.581 0.542
 0.045 $660.43 $431.74 $295.69 $495.29 0.678 0.477 0.555 0.542
Regimen D 0.000 $660.43 $431.74 $295.64 $494.96 0.678 0.477 0.558 0.564
 0.045 $660.43 $431.74 $295.64 $495.34 0.678 0.477 0.558 0.539
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
QID (Days 2-4) 
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Table 4-9 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Receipt of 
Rescue Medications 
 
    TOTAL COSTS EFFECTIVENESS
 Regimen A Regimen B Regimen C Regimen D Regimen A Regimen B Regimen C Regimen D 
Parameter: Probability of Receipt of Rescue Medications in the Delayed Phase Given  Emesis Delayed
Base Case  $658.97 $431.56 $295.89 $494.84 0.684 0.478 0.558 0.543 
Regimens Range         
Regimen A  0.454 $660.04 74 $295.64 29 78 0.477 58 42 $431. $495. 0.6 0.5 0.5
 1.000 $661.75 74 64 29 78 77 0.558 42 
  $431.41      0.542 
   $295.64 $495.29     
Regimen C 0.465 $660.43 $431.74 $295.20 $495.29 0.678 0.477 0.558 0.542 
 1.000 $660.43 $431.74 $297.91 $495.29 0.678 0.477 0.558 0.542 
Regimen D 0.465 $660.43 $431.74 $295.64 $494.85 0.678 0.477 0.558 0.542 
 1.000 $660.43 $431.74 $295.64  0.678  0.558  
$431. $295. $495. 0.6 0.4 0.5
Regimen B 0.477 $660.43 $295.64 $495.29 0.678 0.477 0.558
 1.000 $660.43 $434.61 0.678 0.477 0.558 0.542
$497.48 0.477 0.542
 
Regimen A:  Oral itant Oral D one 12 ndanse  (Day 1), Oral Aprepitant Days 2-3) Dexameth  mg 
(Days 2-4) 
egimen B:  Oral Dexametha g + IV m  Oral D one 8 m Days 2-4) 
Regimen C:  IV Dexamethaso  + IV Ondan g  1), IM Dexa mg s 2-3) and 4mg BID (Day 4) + Oral Metoclopra mg 
:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID 
 
 Aprep  125 mg + examethas mg + IV O tron 32 mg  80 mg (  + Oral asone 8









BID (Day mide 20 
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Table 4-9 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Receipt of 
Outpatient Care 
 
 TOTAL COSTS EFFECTIVENESS 
 Regimen A Regi imen D Regimen A Regimen B Regimen C Regimen D men B Regimen C Reg
Base Case $658. 89 84 0.684 0.4 0.5 43 97 $431.56 $295. $494. 78 58 0.5
Parameter: Probability of Receipt of Outpatient Care During Acute Phase Given: 
No Rescue 
Medications 0.000 $660. 32 $295.32 96 0.678 0.4 0.558 0.542 20 $431. $494. 77 
 0.030 $660.89 .57 0 $495.94 0.678 0.4 0.558 42 
Rescue 
Medications 0.000 0.31 .46 3  0.678 0.4 0.558 0.542 
 0.0 60. 07 71 0.4 0.5 42 
Probability of Receipt g Delayed Phase Given: 
 $432  $296.3 77  0.5
 $66  $431  $295.4 $495.06 77 
30 $6 66 $432.28 $296. $495. 0.678 77 58 0.5
of Outpatient Care Durin
No Rescue 
Medications 0.02 0.02 .87 6 $494.62 0.678 0.4 0.558 42  $66  $430  $294.9 77  0.5
 0.83 .61 3  0.477 0.558 42 
Rescue 
Medications 0.02 59. 79 46 0.4 0.5 42 
0.05 $66  $432  $296.3 $495.95 0.678  0.5
 $6 88 $430.75 $294. $494. 0.678 77 58 0.5
 0.05 $660.97 $432.72 $296.49 $496.11 0.678 0.477 0.558 0.542 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
asone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID 
(Days 2-4);  
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4);  
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
QID (Days 2-4);  
Regimen D:  IV Dexameth
(Days 2-4) 
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Table 4-10: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer and Societal Perspective – ICERs
for Receipt of Rescue Medications 
 
 ICER per patient with complete control of 
emesis – Payer Perspective 
ICER per patient with complete control of emesis – 
 
Societal Perspective 
 Regimen A Regimen B Regimen D Regimen A Regimen D Regimen B 
Parameter: Probability of tions In th  EmesisReceiving Rescue Medica e Acute Phase Given No Acute  
Base Case  $3,363.181 Dominateda Dominateda $2,881.605 Dominateda Dominateda
Regimens Range       
Regimen A   $3,181.86 Dominateda Domi ateda $2,857.60 Dominateda Domi ateda0.000 n n
 0.015 $3,461.03 Dominateda  
Regimen B 00 $3,  $3,054.73 
0.015 $3,401.35  
Regimen C    
 $3,353.70 Dominateda  
Regimen D  28 Dominateda 79 D Dominateda
  $3,353.70 Dominateda Dominateda $3,011.94 Dominateda
Dominateda $3,108.34 Dominateda Dominateda
0.0 401.35 Dominateda Dominateda Dominateda Dominateda
Dominateda Dominateda $3,054.73 Dominateda Dominateda
0.000 $3,606.28 Dominateda Dominateda $3,238.79 Dominateda Dominateda
 
0.015 Dominateda $3,011.94 Dominateda Dominateda




Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4) 
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
QID (Days 2-4) 
Regimen D:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID 
(Days 2-4) 
a Dominated by regimen C 
All treatments are compared to Regimen C 
135 
RESULTS   Reema Mody 
Table 4-10 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer and Societal Perspective – 
ICERs for Receipt of Rescue Medications 
 
 ICER per patient with complete control o
emesis – Payer Perspective 
f  ICER per patient with complete control of emesis –
Societal Perspective 
 Regimen A Regimen B Regimen D  A en B  D Regimen Regim Regimen
Parameter: Probability of Receiving Rescue Medications In the Acute Phase Given Acute Emesis 
Base Case  a 605 nateda teda$3,363.181 Dominateda Dominated $2,881.  Domi Domina
Regimens Range       
Regimen A  0.175 $3,401.06 Dominateda Dominateda 4.44 nateda teda$3,05  Domi Domina
 a $3,055.92 nateda teda
 a 4.73 nateda Dominateda
 a 4.73 nateda teda
Regimen C 0.304  a 4.98 Dominateda Dominateda
 1.000 Dominateda $3,053.05 nateda teda
 a $3,054.73 nateda Dominateda
 a 4.73 nateda teda
1.000 $3,402.54 Dominateda Dominated  Domi Domina
Regimen B 0.304 $3,401.35 Dominateda Dominated $3,05  Domi
1.000 $3,401.35 Dominateda Dominated $3,05  Domi Domina
$3,401.60 Dominateda Dominated $3,05
 $3,399.68 Dominateda  Domi Domina
Regimen D 0.304 $3,401.35 Dominateda Dominated  Domi
1.000 $3,401.35 Dominateda Dominated $3,05  Domi Domina
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4);  
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1) , Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
QID (Days 2-4);  
Regimen D:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID 
(Days 2-4) 
a Dominated by regimen C 
All treatments are compared to Regimen C 
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Table 4-10 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer and Societal Perspective – 
ICERs for Receipt of Rescue Medications 
 
 I ICER per patient with complete control of 
emesis – Payer Perspective 
CER per patient with complete control of emesis – 
Societal Perspective 
   R  Reg Regim RegRegimen A Regimen B egimen D imen A en B imen D 
Parameter: Probability of Receiving Rescue Medications In the Delayed Phase Given No Delayed Emesis 
Base Case  D $2, Domi Do$3,363.181 Dominateda ominateda 881.605 nateda minateda
Regimens       Range  
Regimen A  0.000  D $2, Domi Do$2,615.75 Dominateda ominateda 348.85 nateda minateda
 0.055  D $3, Domi Do
  D $3, Domi Do
 0.035  D $3, Domi Do
 $4,201.21 D $3, Domi Do
  Dominateda $2, Domi Do
  D $3, Dominateda Extended Dominanceb
  Dominateda D $3,054.73 Domi Dominateda
$3,506.52 Dominateda ominateda 149.23 nateda minateda
Regimen B 0.000 $3.401.35 Dominateda ominateda 054.73 nateda minateda
$3.401.35 Dominateda ominateda 054.73 nateda minateda
Regimen C 0.000 Dominateda ominateda 733.41 nateda minateda
 0.045 $3,304.48 Dominateda 967.69 nateda minateda
Regimen D 0.000 $3,401.35 Dominateda ominateda 054.73 
0.045 $3,401.35 ominateda nateda
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4); Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4);  
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4
QID (Days 2-4); Regimen D:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg 
mg BID (Day 4) + Oral Metoclopramide 20 mg 
BID (Days 2-3) and 4mg BID (Day 4) + Oral 
Ondansetron 8 mg BID (Days 2-4) 
gimens C and A 
All treatments are compared to Regimen C 
a Dominated by regimen C 
b Regimen D is dominated by a blend of re
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Table 4-10 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer and Societal Perspective – 
ICERs for Receipt of Rescue Medications 
 
 ICER per 
emesis – P
pepatient with complete control of 
ayer Perspective 
ICER r patient with complete control of emesis – 
Societal Perspective 
 Regimen A B Regimen me egRegimen D Regi n A R imen B Regimen D 
Parameter: Probability of Receiving Res ion ye en D sis cue Medicat s In the Dela d Phase Giv elayed Eme
Base Case  $3,363.181 Dominateda Dominateda $2,881.605 Dominateda Dominateda
Regimens Range      Dominateda
Regimen A  0.454 $ 5 eda ted 051. om3,398.1  Dominat Domina a $3, 53 D inateda Dominateda
 1.000 $ 7 eda ted 065. om
egimen B 0.477 $ 5 eda ted 054. om
4.73 Dominateda Dominateda
 $3,405.09 Dominateda ted 058. om
1.000 $ 39 eda ted 035. om
 $ 35 eda ted 054. om
 1.000 $ eda ted 054. om Dominateda
3,412.4  Dominat Domina a $3, 85 D inateda Dominateda
R 3,401.3  Dominat Domina a $3, 73 D inateda Dominateda
 1.000 $3,401.35 Dominateda Dominateda $3,05
Regimen C 0.465 Domina a $3, 46 D inateda Dominateda
 3,382.  Dominat Domina a $3, 77 D inateda Dominateda
Regimen D 0.465 3,401.  Dominat Domina a $3, 73 D inateda Dominateda
3,401.35 Dominat Domina a $3, 73 D inateda
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
g BID (Day 4) + Oral Metoclopramide 20 mg 
methasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID 
re compared to Regimen C 
(Days 2-4) 
Regimen B
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4m
QID (Days 2-4) 
Regimen D:  IV Dexa
(Days 2-4) 
All treatments a
a Dominated by regimen C 
138 
RESULTS   Reema Mody 
139 
Table 4-10 (Continued): One Way rom Payer and Societal Perspect
ICERs for Receipt of Outpatient Care 
 
 ICER per p
eme
ent with complete control of 
– Societal Perspective 
 Sensitivity Analyses Results for HE Model with No Side Effects f
atient with complete control of 




 Regimen A Regimen B Regimen D  Regimen B Regimen D Regimen A 
Base Case $3,363.181 Dominateda Dominateda Dominateda Dominateda $2,881.605 
Parameter: Probability of Receipt of Outpatient Care During Acute Phase Given: 
No Rescue Medications 0.000 $3,402.15 Dominateda Dominateda Dominateda Dominateda $3,055.53 
 0.030 $3,399.75 Dominateda Dominateda
Rescue Medications 0.000 $3,402.14 Dominateda Dominateda
 0.030 $3,399.77 Dominateda Dominateda
Parameter: Probability of Receipt of Outpatient Car
 Dominateda Dominateda $3,053.13 
 Dominateda Dominateda $3,055.52 
 Dominateda Dominateda $3,053.15 
e During Delayed Phase Given: 
No Rescue Medications 0.02 $3,403.73 Dominateda Dominateda Dominateda Dominateda $3,057.11 
 0.05 $3,398.97 Dominateda Dominateda
Rescue Medications 0.02 $3,403.89 Dominateda Dominateda
 0.05 $3,398.82 Dominateda Dominateda
Dominateda Dominateda $3,052.35 
Dominateda Dominateda $3,057.27 
Dominateda Dominateda $3,052.20 
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV O Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4);  
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), I D (Day 4) + Oral Metoclopramide 20 mg 
QID (Days 2-4);  
Regimen D:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), I D (Day 4) + Oral Ondansetron 8 mg BID 
(Days 2-4).   
All treatments are compared to Regimen C  
ndansetron 32 mg (Day 1), Oral Aprepitant 80 mg (
 1), Oral Dexamethasone 8 mg BID (Days 2-4);  
M Dexamethasone 8mg BID (Days 2-3) and 4mg BI
M Dexamethasone 8mg BID (Days 2-3) and 4mg BI
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140 
Effect of Changes in Cost and Utilization Parameters 
The impact of changes in n m ens, infusion 
ber of days for which rescue medications were received, on cost d 
ctiveness are reported in Tables 4-11 and 4-12.  The impacts of changes in the parameters on 
nt r r n
y etic regim  and minus 20% of the base-case 
a
nge the dom
etic mens.  Increasing the total cost of regimen A by 20% increases the ICER for 
en A to $4,386.99 per patient with complete control of emesis from a pay ive, 
r patient n i m a perspective.  For 
sis co c from pay
men A by approximately $555 per patient with complete control of em
e regim  approximately by 
ch considered 
en re ed the same as in the base-case analysis.  The results were not s ve to the 
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in Table 4-13.  The total costs of the 
en plus 20% lactic antiem
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ctive, a 20% increase in the cost of aprepitant increased the 
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Table 4-11: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Cost Param
 
eters 
CT COSTS EFFECTIVENESS  DIRE
 Regimen A Regi C Regimen D Regimen A Regi Regimen D men B Regimen men B Regimen C 
Base Case  0.676 0.555 0.539 $593.45 $300.53 $187.18 $389.97 0.478 
Parameter: Total Prophylactic Antiemetic Regimen Costs  
Regimen  Range         
Regimen A  $  $475.76 $300.71 $  $  0  0  0  0  470.80 187.29 390.26 .678 .477 .558 .542
 $  $652.31 $  $  $  0  0  0  0  
$593.46 $242.30 $187.29 $390.26 0.678 0.477 0.558 0.542 
$350.46  $  $  $  0  0  0  0  
Regimen C $   $  $  $  0  0  0  0  
 $215.88  $  $  $  0  0  0  0  
Regimen D $   $  $  $  0  0  0  0  
 $459.67 $593.46 $300.71 $187.29 $466.87 0.678 0.477 0.558 0.542 
Cost repita
760.20 300.71 187.29 390.26 .678 .477 .558 .542
Regimen B $233.64 
 $593.46 359.12 187.29 390.26 .678 .477 .558 .542
143.92 $593.46 300.71 151.31 390.26 .678 .477 .558 .542
$593.46 300.71 223.27 390.26 .678 .477 .558 .542
306.45 $593.46 300.71 187.29 313.65 .678 .477 .558 .542
Parameter:  of Ap nt  
Aprepitant  $   $  $  $390.26 0.678 0  0  0.542 247.22 $531.70 300.71 187.29 .477 .558
 $370.80 $655.30 $300.71 $187.29 $390.26 0.678 0.477 0.558 0.542 
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
methasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
n 8 mg BID (Days 2-4) 
 
(Days 2-4); Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexa
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Table 4-11 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Cost 
Parameters 
  
S   DIRECT COST EFFECTIVENESS
 Regimen A     Regimen B  Regimen D Regimen B Regimen C Regimen D Regimen A Regimen C
Base Case $593.45 $300.53       $187.18 $389.97 0.676 0.478 0.555 0.539
Parameter: Cost of IV Ondansetron 
Ondansetron  13 $552.08 $259.23 $1 6.87 $3 9.84 78 77 0.558 42 $165. 7 7 0.6 0.4 0.5
 $247.69 $634.84 8    0.477   
arameter: In
$342.1 $197.71 $400.67 0.678 0.558 0.542
P fusion Costs  
First Drug $47.16 $581.56 $288.70       $175.32 $378.29 0.678 0.477 0.558 0.542
 $70.74 6 2      0.542 
g  6 1    0.477 0.558  
  6 1  $395.80    0.542 
Nu Day ivin edica ing D ase 
$605.3 $312.7 $199.26 $402.22 0.678 0.477 0.558
Second Dru $22.18 $593.4 $300.7 $181.75 $384.72 0.678 0.542
$33.26 $593.4 $300.7 $192.83 0.678 0.477 0.558
Parameter: mber of s of Rece g Rescue M tions Dur elayed Ph
No. of Days  9 $299.85  $389.50     1 day $592.8 $186.51 0.678 0.477 0.558 0.542
 3 days $594.03 $301.57 $188.06 $391.01 0.678 0.477 0.558 0.542 
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexa e 12 m a (Day repitant 80  (Days 2-3) + O xame mg 
Days 2-4);  
Regimen B:  Or thas  + IV mg  1), Oral Dexa one 8 mg ays 2-4) 
egimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
ay 4) + Oral Ondansetron 8 mg BID 
methason g + IV Ond nsetron 32 mg  1), Oral Ap mg ral De thasone 8 
(
al Dexame one 20 mg  Ondansetron 32  (Day methas  BID (D
R
QID (Days 2-4);  
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Table 4-12: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Cost Parame
 
ters 
 TOTAL COSTS EFFECTIVENESS 
 Regimen A Regi Regimen D Regimen A Regi Regimen D men B Regimen C men B Regimen C 
Base Case $494.84 $658.97 $431.56 $295.89 0.684 0.478 0.558 0.543 
Parameter: Total Prophylact et osts ic Antiem ic Regimen C  
Regimen Range         
Regimen A  $470.80 73 74 64 29 78 77 0.558 0.542 $542. $431. $295. $495. 0.6 0.4
 $7 20 13 74 64 29 78 77 0.558 0.542 
$660.43 $373.33 $295.64 $495.29 0.678 0.477 0.558 0.542 
$  $  $  $  $  0  0  0  0  
egimen C $  $  $  $  $  0  0  0  0  
$  $  $  $  $495.29 0  0  0  0  
egimen D $  $660.43 $  $  $  0  0  0  0  
 $459.67 $660.43 $431.74 $295.64 $571.90 0.678 0.477 0.558 0.542 
Cost repita
60. $778. $431. $295. $495. 0.6 0.4
Regimen B $233.64 
 350.46 660.43 490.15 295.64 495.29 .678 .477 .558 .542
R 143.92 660.43 431.74 259.66 495.29 .678 .477 .558 .542
 215.88 660.43 431.74 331.62 .678 .477 .558 .542
R 306.45 431.74 295.64 418.68 .678 .477 .558 .542
Parameter:  of Ap nt  
Aprepitant  $  $  $  $  $495.29 0  0  0  0  247.22 598.60 431.74 295.64 .678 .477 .558 .542
 $370.80 $722.20 $431.74 $295.64 $495.29 0.678 0.477 0.558 0.542 
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
methasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
n 8 mg BID (Days 2-4) 
(Days 2-4); Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexa
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Table 4-12 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Cost 
Parameters 
  
  TOTAL COSTS EFFECTIVENESS
 Regimen A Regimen D Regimen A men C Regimen D Regimen B Regimen C Regimen B Regi
Base Case $658. 31. 84 0.5 43 97 $4 56 $295.89 $494. 0.684 0.478 58 0.5
Parameter: Cost of IV Ondansetron 
Ondansetron  $165.13 $619.05 $390.26 $285.23 $484.87 0.678 0.477 0.558 0.542 
 $247.69 $701.80 $473.21 $306.06 $505.70 0.678 0.4 0.558 0.542 
Parameter: I fusion Costs
77 
n  
First Drug $47.1 48. 19. 83. 32 78 0.5 0.542 6 $6 52 $4 72 $2 67 $483. 0.6 0.477 58 
 0.7 72.33 $443. 07.62 $507.25 0.678 0.477 0.5 0.542 
Second Drug $22.1 60. 31. 90.10 75 0.678 0.5 0.542 
 $33.2 60.43 $431. 01.18 $500.83 78 0.477 0.5 0.542 
Parameter: Number of Days of Rece g Rescue M ons During Del Phase 
$7 4 $6 75 $3 58 
8 $6 43 $4 74 $2 $489. 0.477 58 
6 $6 74 $3 0.6 58 
ivin edicati ayed 
No. of  day 59. 30. 94. 53 78 0.5 0.542  Days 1 $6 85 $4 88 $2 87 $494. 0.6 0.477 58 
 3 61. 32.59 $296. 04 78 0.5 0.542  days $6 00 $4 42 $496. 0.6 0.477 58 
 
Regime epit g + O thason  Ondansetron 32 mg (Day 1) pitant 80  + Oral e 8 mg 
(Day
Regimen B:  Oral Dexame 0 mg nsetron ), Ora one 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamet mg etron 8 m  1), IM Dexa e 8mg BID (Days 2-3) and 4m ide 20 mg 
n A:  Oral Apr
s 2-4);  




 + IV Ondans
 32mg (Day 1
g (Day
l Dexamethas
methason g BID (Day 4) + Oral Metoclopram
QID (Days 2-4);  
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Table 4-13: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer and Societal Perspective – ICERs 
or Cost Parameters f
 
 ICER p ntrol of 
esis spect
ICER per p of emesis – 
Socie ive 
er patient with complete co
em  – Payer Per ive 
atient with complete control 
tal Perspect
 Regimen A Regimen B Regimen D Regimen A Regimen B Regimen D 
Base Case $3,363.181 Dominateda Dominateda $2,881.605 Dominateda Dominated 
Parameter: Tot ylact etic R sts al Proph ic Antiem egimen Co
Regimen        Range 
Regimen A  $470.80 $2,415.71 Dominateda Dominateda $2,069.09 Dominateda Dominateda
 $760.20  Dominateda  Dominateda
Regimen B    
  Dominateda  
Regimen C    Dominateda
a a 3.43 Dominateda Dominateda
Regimen D 5 $3,401.35 a a  a a
7  a a $3,054,73 a a
Parameter: Cost of Aprepitant 
$4,386.99 Dominateda $4,040.37 Dominateda
$233.64 $3,401.35 Dominateda Dominateda $3,054,73 Dominateda Dominateda
 $350.46 $3,401.35 Dominateda $3,054,73 Dominateda Dominateda
$143.92 $,3702.65 Dominateda Dominateda $3,356.03 Dominateda
 $215.88 $3,100.05 Dominated Dominated $2,75
$306.4 Dominated Dominated $3,054,73 Dominated Dominated
 $459.6 $3,401.35 Dominated Dominated Dominated Dominated
Aprepitant $247.22 $2,883.91 Dominateda Dominateda $2,537.29 Dominateda Dominateda
 $370.80 $3,918.79 Dominateda Dominateda $3,572.17 Dominateda Dominateda
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
Days 2-4); Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4);  
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
QID (Days 2-4); Regimen D:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral 
Ondansetron 8 mg BID (Days 2-4) 
(
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Table 4-13 (C E ith from Pa pective
ICERs for Cost Parameter
 
Parameters/Range iet
ontinued): One Way Sensitivity Analyses Results For H
s 
 ICER – Payer Perspective 
Model w  No Side Effects 
ICER – Soc
yer and Societal Pers
al Perspective 
 – 
 n D gimRegimen A Regimen B Regime  Regimen A Re en B Regimen D 
Base Case ted mi$3,363.181 Dominated Domina  $2,881.605 Do nated Dominated 
Parameter: Cost of IV Ondansetron 
Ondansetron  $165.13 ted mi $3,142.09 Dominated Domina  $2,795.47 Do nated Dominated 
 $247.69 ted mi
Parameter: Infusion Co
 $3,660.62 Dominated Domina
sts 
 $3,314.00 Do nated Dominated 
First Drug $47.16 ted mi   $3,401.93 Dominated Domina  $3,055.31 Do nated Dominated
 $70.74 ted mi  
Second Drug $22.18 ted mi  
 $33.26 ted mi
Parameter: Number of Days g D ed 
 $3,400.78 Dominated Domina
 $3,447.74 Dominated Domina
 $3,354.96 Dominated Domina











No. of Days 1 day ted mi$3,403.04 Dominated Domina  $3,056.42 Do nated Dominated 
 3 days ted minated    $3,399.66 Dominated Domina  $3,053.04 Do  Dominated
 
Regimen A:  Oral Aprepitant 125 mg  m y 1 Day 8 mg 
(Days 2-4); Regimen B:  Oral Dexam Dexame -4) 
Regimen C:  IV Dexamethasone 20 one 8mg BI D (Day 4 20 mg 
QID (Days 2-4); Regimen D:  IV De , IM Dexam 2-3) and
Ondansetron 8 mg BID (Days 2-4) 
 
 + Oral Dexamethasone 12 mg + IV Ondansetron 32
ethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral 
mg + IV Ondansetron 8 mg (Day 1), IM Dexamethas
xamethasone 20 mg + IV Ondansetron 8 mg (Day 1)
g (Da ), Oral Aprepitant 80 mg (
thasone 8 mg BID (Days 2
D (Days 2-3) and 4mg BI
ethasone 8mg BID (Days 
s 2-3) + Oral Dexamethasone 
) + Oral Metoclopramide 
 4mg BID (Day 4) + Oral 
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Effect of Changes in Rescue Medications for Breakthrough Emesis 
 
The delayed phase antiemetic drugs for regimens B and C did not include a 5-HT3RA for 
the base-case sis.  In the event of breakthrough emesis during the delay  phase, the base 
 receipt of agents other than 5-HT3RAs as rescue medications.  A 
s con cue m en C 
edications.  
d for ario .  
 add n of 5-HT3RA to rescue m regimen B increased the direct and 
en B t did not have any impact on the dom
er a i g dications for 
en C in se a  regime    le o a







en B and regim
inance status or 
 me

















g for two 
 are reported in Table 4-14
, bu






















thuswith n C and ad t
 
 in Table 4-15.  
rk-da
pat




















r patient with com
f variation in the average hourly wages on total costs, effectiveness and 
etic n from
rage hourly wage men A to 
plete co esis, while increasing the average wage by 
pact on the ICER of regimen A.  There are uncertainties regarding the amount 
e e IN  b
 hours to 2 study its 
act on th ER of the antiemetic regim s.  The results reported in Table 4-15 show that a 
 hours to 2.75 inc es the ICER to $3,314.70 per i w complete 
m , w r e los rk h
  




sulted in an increase in the ICER of regi
ctivity











ivalent to 3 wo





esis hile inc easing th  hours to 24 ours decrease
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Table 4-14: Change in the Antiemetic Regimen for Breakthrough Emesis for Highly Emetogenic Chemotherapy Model 
 
  P hange in Rescue Medicatioarameter: C ns in Delayed Phase for Regimen B  
Regimen Eff  D ICER per pa
complete control 
 per  
 co esis
ectiveness irect Costs tient with 
of emesis 
Total Costs ICER 
complete
 patient with
ntrol of em  
Regimen C 05 - 0.564 $187. - $294.19 
Regimen B 0.484 $336.20 Dominateda $465.93 Dominateda
Regi 0.549 $389.99 Dominateda $494.93 Dominated
i 25 368. $2,995.73 
meter: ange in Re a aye Regimen C 
men D a
Reg men A 0.684 $593. $3, 16 $659.37 
  Para Ch scue Medic tions in Del d Phase for 
Regimen Effectiveness Direct Costs ICER per patient with 
complete control of emesis 
Total Costs ICER per patient with 
complete control f emesis o
Regim 0 $  -  -  en C .564 222.00  $328.78
Regim 0 $  minate ominateda
Regimen D 0.549 $390.67 Dominateda $494.89 Dominateda
0.684 $593.63 $3,043.64 $659.08 $2,689.79 
en B .484 300.95 Do da $431.20 D
Regimen A 
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4);  
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
asone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID 
Days 2-4) 
ll treatment regimens compared to regimen C 
 Dominated by regimen C 
QID (Days 2-4);  
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Table 4-15: Change in the Indirect Costs Associated with CINV and its Treatment 
 
 Total Costs ICER per patient wi sis 
for Highly Emetogenic Chemotherapy Model 
th complete control of eme
 Regimen A Regimen B Regimen C Regimen D Regimen A Reg menimen B Regimen C Regi  D 
Base Case $658.97 $431.56 $295.89 $494.84 $2,881.605 Dom natinateda - Domi eda
Parameter: Average Wage Per Hour 
 Range         
Average Wage $14.96 $632.41 $376.92 $250.31 $451.35 $3,199.74 Dominat nateda - Domi eda
 $30.48 $672.82 $455.99 $315.70 $514.72 $2,990.58 Dominat nat
Number of Hours of Lost Productivity  
eda - Domi eda
 Range         
No. of Hours 2.75 hrs $610.20 $333.47 $214.38 $416.51 $3,314.70 Dominat nateda - Domi eda
 24 hrs $739.56 $586.59 $423.70 $619.41 $2,645.09 Dominat nateda - Domi eda
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Day 8 m
(Days 2-4);  
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID ( 20 
QID (Days 2-4);  
Regimen D:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID ( g B
(Days 2-4) 
All treatment regimens compared to regimen C 




s 2-3) + Oral Dexamethasone 
Day 4) + Oral Metoclopramide 
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Highly Emetogenic Che t py Model 
 
Although, one-wa  analyses are eas ental costs and 
effectiveness do not depend on single parameters and the overall variability in the decision model 
cannot be captured com Prob y Monte Carlo 
simulation provides a m  simu y  all the para estigate the overall 
impact on ICERs.  All costs and probabilities were given ranges 
specified for each of the variable.  Triangular distribution uses t ghest and the most 
likely value of any pa
 
The results of the probabilistic sensitivity analy fr er and societal 
perspectives are presented n Tab -  Although the dom he antiemetic 
regimens rema e as in the base-cas s en A increased to 
$3,923.51 per patient with complete protection from em er perspective and 








sis using second-order 
m
and a triangular distribution was 
he lowest, hi
 the pay









y to understand, increm
 anal
sis 







per patient with com
om
inanle 4 16. 
ined the s e analy
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Table 4-16: Probabilistic Sensitivity Analysis for Costs, Effectiveness and Incremental Cost Effectiveness Ratios for Antiemetic 
Regimens for Prevention of CINV in Patients Receiving Highly Emetogenic Chemotherapy from a Payer Perspective 
 






Cost of achieveing one patient 
with complete control of emesis 
Incremental cost 
effectiveness ratio/patient 
with complete control of 
emesis 
Regimen C (Metoclopramide) $187.65 ($10.38) 0.561 (0.015) $334.64 - 




Regimen D (Ondansetron) $386.74 ($18.83) 0.545 (0.047 $709.67 Dominated
a
Regimen A (Aprepitant) $594.28 ($25.91) 0.664 (0.031) $894.47 $3,923.51 
 
Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 mg + IV Ondansetron 32 mg (Day 1), Oral Aprepitant 80 mg (Days 2-3) + Oral Dexamethasone 8 mg 
(Days 2-4);  
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Metoclopramide 20 mg 
QID (Days 2-4);  
Regimen D:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day 1), IM Dexamethasone 8mg BID (Days 2-3) and 4mg BID (Day 4) + Oral Ondansetron 8 mg BID 
(Days 2-4) 
All treatment regimens compared to regimen C 
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Table 4-17: Probabilistic Sensitivity Analysis for Co c e s d c m ost Effe v s a s  Antiem c 
Regimens for Prevention of CINV in Pa py fro  
 
Treatment Strategy d 
sts, Effe tiv nes  an  In re ental C
tients Receiving Highly Emetogenic Chemothera
Side Effects Not Modele
cti ene s R tio  for











Cost of achieveing one 









Regimen C (Metoclopramide) $303.68 ($44.67) 0.560 (0.015) $541.89 - 
Regimen B (Standard) $439.64 ($54.8
Regimen D (Ondansetron) $499.28 ($48.7
Regimen A (Aprepitant) $669.57 ($38.9
9) 0.482 (0.016) $912.00 
3) 0.544 (0.046) $917.67 





Regimen A:  Oral Aprepitant 125 mg + Oral Dexamethasone 12 m  80 thasone 8 m
(Days 2-4);  
Regimen B:  Oral Dexamethasone 20 mg + IV Ondansetron 32mg
Regimen C:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (D  4m pramide 20 
QID (Days 2-4);  
Regimen D:  IV Dexamethasone 20 mg + IV Ondansetron 8 mg (Day  4m tron 8 mg B
(Days 2-4) 
All treatment regimens compared to regimen C 
a Dominated by regimen C 
g + IV Ondansetron 32 mg (Day 1), Oral Aprepitant
 (Day 1), Oral Dexamethasone 8 mg BID (Days 2-4) 
ay 1), IM Dexamethasone 8mg BID (Days 2-3) and
 1), IM Dexamethasone 8mg BID (Days 2-3) and
 mg (Days 2-3) + Oral Dexame
g BID (Day 4) + Oral Metoclo
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For Moderately Emetogenic Chemotherapy Decision Model – Base Case Analysis 
 
tsBase Case Analysis Resul  
 
A decision mode as s d benefits of four 
ylactic antiem  ME chemotherapy (Refer to 
o  hemotherapy was 
 simulation.  The base case results for the costs, 
eving one patient with complete protection from emesis and the ICER 
he four antiemetic regimens from the payer perspective are reported in Table 4-18.  
 
The results showed that regimen 3 was the least expensive while regimen 4 was the most 
 proph e ic imen for prevent following ME chemotherapy.  It 
ates were equivalent for regimens 1 
en which includes palonosetron) and 4 (ASC guidelines). The direct cost of 
eving tient with complete control of regimen including palonosetron 
ately e e t egimen 3.  Under the base case assumptions, from the 
er perspe n 1 over reg en 3 was $3,582.48 per patient with 
plete co esis.  Regim costs was 
inated b  regim 3 e e sts and the antiemetic regimens from the 





ens for prevention of 
hort
tructed to evaluate the total costs an
of 10,000 cance
proph
Table 3-2).  
evaluated using first-order Monte Carlo
effectiveness, cost of achi










etic regim CINV due to
r patients receiving ME c
ion of CINV 
O 1999 

























en 2, with lower effectiveness and higher 
ct co
c re re rese ted raphically
RESULTS  Reema Mody 
154 
o i c eceiv
Moderately Emetogen
 
Treatment Strateg D) 
Cost of achieveing one 
patient with complete 
control of emesis 
Inc  effectiveness 
complete 
emesis 
Table 4-18: Base Case Results from Payer Perspective using M
ic Chemotherapy  
y 

















er R ing 
Regimen 3 (NCCN 84) $253.74 ) $159.12 ($23.91) 0.627 (0.4 - 
Regimen 2 (Only O 00) $544.09 ted*
Regimen 1 (Palono 60) $580.25 .48 
Regimen 4 (ASCO) 59) $646.09 4,953.27 
ndansetron) $273.08 ($34.63) 0.502 (0.5
setron) $403.45 ($24.55) 0.695 (0.4









Regimen 1: IV Palonosetron 0.25
Regimen 2: IV Ondansetron
Regimen 3: IV Ondansetron mg BID (Days 2-5);  
Regimen 4: IV Ondansetron mg BID (Days 2-5) + Oral Ondansetron 4mg BI s 2-5) 
* Regimen 2 was dominated by R
mg;  
 32mg;  
 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4
 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4
egimen 3 
D (Day
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Figure 4-5: Direct Costs, Effectiveness of Different Antiemetic Regimens for Patients 





Regim ;  
Regim etron 32
imen 3: IV Ondan etron 8m IV xamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
men 4: IV Ondan etr 8m  IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral 













n 1: IV Palonosetron 0.25
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The base case results for the costs, effectiveness, cost of achieving one patient with 
complete protection from emesis and the ICER for each of the four antiemetic regimens from the 
societal perspective are reported in Table 4-19.  The total costs and effectiveness for the 
antiemetic regimens from the societal perspective are represented graphically in Figure 4-6.  
Similar to the results from the payer perspective, regimen 2 was dominated by regimen 3. The 
mean costs for achieving one patient with complete control of emesis for each antiemetic 
regimen were higher compared to those obtained from the payer’s perspective.  The mean costs 
for achieving one patient with complete antiemetic protection for regimen 2 was higher ($752.03) 
as compared to regimen 1 ($655.65).  From the societal perspective, the ICER for regimen 1 
compared to regimen 3 was $3,549.02 per patient with complete control of emesis and for 
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Table 4-19: Base Case Results from Payer Perspective using Monte Carlo Simulation of 10,000 Patients with Cancer Receiving 























Regimen 3 (NCCN) .24) $216.31 ($122 0.630 (0.483) $343.35 - 
Regimen 2 (Only Ondan .06) 
Regimen 1 (Palonosetro .53) 




0.507 (0.500) $752.03 
0.698 (0.459) $655.65 





Regimen 1: IV Palonosetron 0.25
Regimen 2: IV Ondansetron 32m
Regimen 3: IV Ondansetron 8m l De
Regimen 4: IV Ondansetron 8m l De setr





g + IV Dexamethasone 8mg, Ora
g + IV Dexamethasone 8mg, Ora
egimen 3 
xamethasone 4mg BID (Days 2-5);  
xamethasone 4mg BID (Days 2-5) + Oral Ondan on 4mg BID (Days 2-5) 
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Figure 4-6: Total Costs, Effectiveness of Different Antiemetic Regimens for Patients 




Regi setron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8 g + IV Dexameth e 8mg a x t ne 4mg BID (Days 2-5);  
Regimen 4: IV Ondansetron 8 meth mg t e 4mg BID (Days 2-5) + Oral 























g BID  
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Sensitivity Analyses for Moderately Emetogenic Chemotherapy Model 
 
Effect of Changes in Control of Acute and Delayed Emesis  
 
The efficacy parameters, probability of no acute emesis, probability of no delayed emesis 
esis and probability of no delayed emesis given acute em varied over 
 published literature.  
sis and  the payer’s perspective.  Table 4-21 presents 
e r the model from societal perspective. The ICER for each regimen obtained 
 sensitivity ys re rep  
 
The change in the probability of no acute emesis for regimen 1 had a significant impact 
e tiven and I er and societal 
he pr b 8 t 6 r en with 
inated by regimen 3.  Additionally, the ICER for regimen 4 was 
c parison to regim h n tion.  This result was similar to 
regimen 4 over regim ates (value not shown in the 
, increasing the probability of no acute emesis for regime  0.850 to 
s the dominance status, with regimen 4 being dominated by regimen 3.  The results 
esis for regimens 3 and 4.  
 
T hang  of no delayed emesis given no acute em ilar 
t on ults. c roba ty for en 1 results in it being 
inated b ns and increasing the probability, results in regim
inated.  Si  decreasing the probability for regimens 3 and 4 translates into higher costs 
 higher eff v ss of regimen 1, while incre ng the obability of regi ens 3 and 4 
n 1 from d on dom
inance.  
given no acute em




on the costs, 
perspectives.  Decreasing 
palonosetron being dom
calculated in 
the ICER of 
table).  Conversely
0.900 change












esis have a sim
en 4 being 
m
 Table 4-20 presents the 
the direct costs and effectiveness from
results fo


















esulted in the regim
om en
en 3, calculated for base-case 
 3, t e o ly non-dominated op
estim

















e  ICER calculations base inance and extended 
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Table 4-20: One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Efficacy 
Parameters 
 
    DIRECT COSTS EFFECTIVENESS
 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 3 Regimen 4 
Parameter: Probability of No Acute Emesis 
Base Case  $403.45 $273.08       $159.12 $451.30 0.695 0.502 0.627 0.699
Regimen Range         
Regimen 1  0.680 $406.13 $273.10 $159.33 $451.39 0.554 0.625 0.503 0.696 
 0.9  $273.10      
$275.00 
      
$161.37 
  $273.10      
$161.37 
  $273.10      
00 $402.84  $159.33 $451.39 0.734 0.503 0.625 0.696
Regimen 2 0.576 $403.59 $159.33 $451.39 0.693 0.402 0.625 0.696 
0.864 $403.59 $271.20 $159.33 $451.39 0.693 0.604 0.625 0.696
Regimen 3 0.714 $403.59 $273.10 $452.99 0.693 0.503 0.500 0.557 
0.900 $403.59  $159.23 $451.32 0.693 0.503 0.631 0.702
Regimen 4 0.714 $403.59 $273.10 $452.99 0.693 0.503 0.500 0.557 
0.900 $403.59  $159.23 $451.32 0.693 0.503 0.631 0.702
 
Regimen 1: IV Palonosetron 0.25mg;  
 Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
Oral Ondansetron 4mg BID (Days 2-5) 
 
Regimen 2: IV Ondansetron 32mg,  
VRegimen 3: IV Ondansetron 8mg + I
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + 
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Table 4-20 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Effic
Parameters 
acy 
arameters/Range   
 
P  DIRECT COSTS EFFECTIVENESS
 Regimen 1 Regimen 2 Regimen 3 Regimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 4 
Parameter: Probability of No Delayed Emesis Given No Acute Emesis 
Base Case   $273.08       $403.45 $159.12 $451.30 0.695 0.502 0.627 0.699
Regimen         Range  
Regimen 1  0.739 $405.95 $273.10 $159.33 $451.39 0.554 0.503 0.625 0.696 
 0.9     
  $271.69     
$273.10 $161.56 
  $273.10     
$159.33 
     
50 $403.26 $273.10 $159.33 $451.39 0.713 0.503 0.625 0.696
Regimen 2 0.649 $403.59 $274.78 $159.33 $451.39 0.693 0.402 0.625 0.696 
0.950 $403.59  $159.33 $451.39 0.693 0.589 0.625 0.696
Regimen 3 0.684 $403.59 $451.39 0.693 0.503 0.500 0.696 
0.950 $403.59  $158.09 $451.39 0.693 0.503 0.694 0.696
Regimen 4 0.762 $403.59 $273.10 $453.88 0.693 0.503 0.625 0.557 
1.000 $403.59 $273.10 $159.33 $450.77 0.693 0.503 0.625 0.731
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5) 
161 
RESULTS  Reema Mody 
Table 4-20 (Continued): One Way Sensitivity Analyses Results For ME Model with No Side Effects from Payer Perspective– Efficacy 
Parameters 
 
Parameters/Range    DIRECT COSTS EFFECTIVENESS
 Regimen 1 Regimen 3 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 4 
Probability of No Delayed Emesis Given Acute Emesis 
Base Case  $403.45       0.699 $273.08 $159.12 $451.30 0.695 0.502 0.627
Regimen Range         
Regimen 1  $403.89 $273.10 $159.33 0.693 0.696 0.000 $451.39 0.503 0.625 
  $159.33      
$451.39 
  0.693 0.503   
0.000 $159.80 $451.39 0.693 0.503 0.625 0.696 
 0.568 $403.59 $273.10 $158.90 $451.39 0.693 0.503 0.625  
0.300 $159.33 
  $451.21     
0.300 $403.21 $273.10  $451.39 0.693 0.503 0.625 0.696
Regimen 2 0.000 $403.59 $273.53 $159.33 0.693 0.503 0.625 0.696 
0.300 $403.59 $272.33 $159.33 $451.39 0.625 0.696
Regimen 3 $403.59 $273.10 
0.696
Regimen 4 $403.59 $273.10 $451.82 0.693 0.503 0.625 0.696 




Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5) 
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Table 4-21: One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Efficacy 
Parameters 
    
 
TOTAL COSTS EFFECTIVENESS
 Regimen 1 Regimen 2 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 3 Regimen 4 
Parameter: Probability of No Acute Emesis 
Base Case   $381.05  $475.84  0.500  0.701 $457.64 $216.31 0.698 0.630
Regimen          Range
Regimen 1  0.680 $499.24 $382.14 $217.31 $476.71 0.554 0.503 0.625 0.696 
 0.9  $382.14     
0.576 $217.31 $476.71 0.693 0.402 0.625 0.696 
 0.8     
0.714 $458.66 
 0.9     
0.714 $458.66 
 0.9     
00 $446.72  $217.31 $476.71 0.734 0.503 0.625 0.696
Regimen 2 $458.66 $412.76 
64 $458.66 $351.52 $217.31 $476.71 0.693 0.604 0.625 0.696
Regimen 3 $382.14 $247.31 $497.65 0.693 0.503 0.500 0.557 
00 $458.66 $382.14 $215.96 $475.77 0.693 0.503 0.631 0.702
Regimen 4 $382.14 $247.31 $497.65 0.693 0.503 0.500 0.557 
00 $458.66 $382.14 $215.96 $475.77 0.693 0.503 0.631 0.702
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
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Table 4-21 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Efficacy 
Parameters 
 
  TOTAL COSTS EFFECTIVENESS 
 Regimen 1 Re gimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 4 gimen 2 Re Regimen 3 
Parameter: Probabil elaity of No D yed Emesis Given No Acute Emesis 
Base Case  $457.64 $381.05 $216.31 $475.84 0.698 0.500 0.630 0.701 
Regimen Rang   e       
Regimen 1  0.739 $505.51 $3 14 $217. $476. 0.554 0.503 0.625 0.696 82. 31 71 
 0.9 14 $217.31 $4 71 0.7 0.5 0.625 0.6
Regimen 2 49 58.66 $217. 0.6 0.4 0.625 0.6
 0.950 $458. 61 $217.31 $476.71 0.693 0.589 0.625 0.6
Regimen 3 84 58.66 $262. $4 0.6 0.5 0.500 0.696 
 950 8.6  $192.0  $  0.6 0.5 .694 0.6
Regimen 4 0.762 $458.66 $382.14 $217.31 $527.14 0.6 0.503 0.625 0.557 
 1.0 58. 14 $217.31 $4  0. 0.5 0.625 0.7
50 $452.08 $382. 76. 13 03 96 
0.6 $4 $417.02 31 $476.71 93 02 96 
66 $352. 96 
0.6 $4 $382.14 70 76.71 93 03 
0.  $45 6 $382.14 9 476.71 93 03 0 96 
93 
693 00 $4 66 $382. 63.97 03 31 
 
Regimen 1: onos g;  
Regimen 2 s ,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
 Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5) 
 IV Pal etron 0.25m
: IV Ondan etron 32mg
Regimen 4: IV Ondansetron 8mg + IV
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Table 4-21 (Continued): One Way Sensitivity Analyses Results For ME Model with No Side Effects from Societal Perspective– Efficacy 
Parameters 
 
 TOTAL COSTS EFFECTIVENESS 
 Regimen 1 Re gimen 3 Regimen 4 Regimen 1 Regimen 2 gimen 3 Regimen 4 gimen 2 Re Re
Parameter: Probabil  ity of No Delayed Emesis Given Acute Emesis
Base Case  $457.64 $381.05 $216.31 $475.84 0.698 0.500 0.630 0.701 
Regimen Rang     e     
Regimen 1  0.000 $464.60 82.14 $217.31 $476.71 0.6 0.503 0.625 0.696 $3 93 
 0.300 $451.20 $382.14 17. 93 0.503 0.625 0.696 
Regimen 2 00 66 04 $217.31 0.5 0.625 0.6
08 17. 71 93 0.5 0.625 0.6
Regimen 3 00 66 14 26.95 0.5 0.625 0.6
4 08.  0.5 0.625 0.6
Regimen 4 00 6 4 217.31 2 0.5 0.625 0.
4 217. 4  0.5 0.625 0.
$2 31 $476.71 0.6
0.0 $458. $391. $476.71 0.693 03 96 
 0.300 $458.66 $366. $2 31 $476. 0.6 03 96 
0.0 $458. $382. $2 $476.71 0.693 03 96 
 0.568 $458.66 $382.1  $2 70 $476.71 0.693 03 96 
0.3 $458.6 $382.1 $ $485.3 0.693 03 696 






Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  




on 0.25mg;  
tron 32mg,  
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Table 4-22: One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer and Societal Perspective – ICER
for Efficacy Parameters 
 
s 
 ICER per patient with complete control of emesis – Payer ICER per patient with complete control of emesis – Societal 
Perspective Perspective 
 R  2 me men 4 n 1 Regimen 2 3 4 egimen 1 Regimen Regi n 3 Regi Regime Regimen Regimen 
Parameter: Probability of No Acute Emesis 
B  $14,953.27 $3,549.02 Dominateda - $6,499.87 ase Case  $3,582.48 Dominateda -
R Range       egimen   
R 0 Domi a D minateda - $4,118.70 minateda Do inateda - $3 58.01 egimen 1  .680 nated o Do m ,6
 0.900 2,237.88$ eda - nateda 8.29 da - da
en 2 0.5 $ eda - 55.68 $3,546.97 da - 8 
$ eda - 65.68 6.97 da - 8 
Regimen 3 0.7 minanceb nateda 6.38  Dominan eb - Do
a
 0.9 $ eda - 39.52 Extended nancec d
a - 9 
0.7 minanceb nateda 4.32 D a - $4, 16 
 0.900 a 9. 7.29 a - $8, 67 
 Dominat  Domi $2,10 Dominate Dominate
Regim 76 3,589.75 Dominat  $16,6  Dominate $6,292.0
 0.864 3,589.75 Dominat  $16,6  $3,54  Dominate $6,292.0
14 $1,256.47 Extended Do - Domi $1,09 Extendedc minated
00 3,913.53 Dominat  $5,2  Domi Dominate $3,631.1
Regimen 4 14 $1,256.47 Extended Do - Domi $3,63 ominated 220.
$3,913.53 Dominated - $5,23 52 $3,43 Dominated 893.
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5) 
b Dominated by a blend of regimen 3 and regimen 1; c Dominated by a blend of regimen 3 and 4
All regimens compared to regimen 3 
a Dominated by regimen 3; 
166 
RESULTS  Reema Mody 
167 
Table 4-22 (Continued): One Way Sensiti Fo del with No Side Effects from Payer and Societal Perspect
ICERs for Efficacy Parameters 
 
 ICER per patient with com s – er ICER per patient with complete control of emesis – Soci
Perspective 
vity Analyses Results 






 Regimen 1 Regime Regimen 1 Regimen 2 Regimen 3 Ren 2 Regimen 3 Regimen 4 gimen 4 
Probability of No Delayed Emesis Given No Acute Emesis 
Base Case  $3,582.48 Domina 4,9  $3,549.02 Dominateda - $6,49  teda - $1 53.27 9.87
Regimen Range         
Regimen 1 0.739 Dominateda Dominateda 11  Dominateda Dominateda - $3,65  - $4, 8.70 8.01
 0.950 $2,786.28 Dominateda mi a $2,681.61 Dominateda - Domin
Regimen 2 0.649 $3,589.75 Dominateda 6,6  $3,546.97 Dominateda - $6,29  
 0.950 $3,589.75 Dominateda 6,6  $3,546.97 Dominateda - $6,29  
Regimen 3 0.684 $1,253.66 Extended Dominanceb 6,665.68 $1,015.05 
Extended 
Dominanceb - $6,29  
 0.950 Dominateda Dominateda 0,606.36 Dominateda Dominateda - $194,660.47 
Regimen 4 0.762 $3,589.75 Dominateda minateda $3,546.97 Dominateda - Dominateda
 1.000 Extended Dominancec Dominated
a 749.35 Extended Dominancec Dominated
















Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8 e 4mg BID (Days 2-5);  
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8 e 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5) 
All regimens compared to regimen 3 
a Dominated by regimen 3; b Dominated by a blend of re Dominated by a blend of regimen 3 and 4 
mg, Oral Dexamethason
mg, Oral Dexamethason
gimen 3 and regimen 1; c 
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Table 4-22 (Continued): One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer and Societal Perspective – 
ICERs for Efficacy Parameters 
 
 ICER e IC ctive – Payer Perspectiv ER – Societal Perspe
 Re Reg eg Re  en en en 4 gimen 1 imen 2 R imen 3 gimen 4 Regimen 1 Regim  2 Regim  3 Regim
         
P robability of N d Eme  Acutarameter: P o Delaye sis Given e Emesis 
B  $3,582.48 Dominate - $14,953. 7 $3, 9.02 ominateda - $6,499.87 ase Case da 2 54 D
R R   egimen ange       
Regimen 1  0 $3, Domi 6,  32 minateda - 220.16 .000 594.15 nateda - $1 561.40 $3,634. Do $4,
 0  $3,  Domi 6,  29 minateda - 893.67 
Regimen 2 0.000 $3, Domi 6,  97 minateda - 292.08 
0  $3,589.75 Domi 6,  97 minateda - 292.08 
Regimen 3 0 $,3 Domi 6,  27 minateda - 292.08 
68 $3,  Domi 6,  55 minateda - 292.08 
Regimen 4 0 $3, Domi 6,  97 minateda - 294.71 
 0.682 $3,589.75 Dominateda - $16,602.76 $3,546.97 Dominateda - $5,014.84 
.300 584.23 nateda - $1 796.61 $3,437. Do $8,
589.75 nateda - $1 665.68 $3,546. Do $6,
 .300 nateda - $1 665.68 $3,546. Do $6,
.000 582.77 nateda - $1 665.68 $3,405. Do $6,
 0.5 595.99 nateda - $1 665.68 $3,673. Do $6,
.300 589.75 nateda - $1 813.59 $3,546. Do $9,
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5) 
ll regimens are compared to regimen 3 
a Dominated by regimen 3 
A
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Effect of Changes in the Receipt of Rescue Medications 
The results of sensitivity analy s edications 
ed phase are reported in Table 4-23 from the payer perspective and in 
 the societal perspective.  The ICER results are presented in Table 4-25. The 
to changes in the probability
 and edic
ed phase given delayed emesis.  The probabilities of receiving rescue m
te emesis and in the delayed phase given no delayed emesis have a 
pact on the  of receiving 
edications in the acute phase given no acute emesis, and for regime , 
e probability resulted in a change in the dominance status of the various 
etic regim ns (Refer to Table 4-25).  Sim l h
d t s th e e ed emesis 
ens 1, 3 and 4.  
 













Effect of Changes in the R




 of receiving rescue medications in the 
ations in the 
edications in the 
ns 3 and 4
due to the variations 
esis,  the probability of receiving rescue m
 model results.  For regimen 1, increasing the probability
e










d phase given no delayme ica







The results of sensitivity analysis on the probability of receipt of outpatient care during 
acute and yed phase m th y 4.  
 of receiving outpatient care either in the acute phase or ed phase.  The 
inanc a of the anti e re  a d e  the 
er and
dela  fro e pa er perspective are reported in Tables 4-23 and 4-2
sults are presented in Table 4-25. The base-case results were not sensitive to changes 
e st
 societal perspectives.   
the delay
tus em tic gimens rem ine  th  same as the base case results; from
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Table 4-23: One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Receipt of Rescue 
Medications 
 
    DIRECT COSTS EFFECTIVENESS
 Regimen 1 Regimen 2 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 3 Regimen 4 
Probability of Receiving Rescue Medications In the Acute Phase Given No Acute Emesis 
Base Case   $273.08  $451.30     $403.45 $159.12 0.695 0.502 0.627 0.699
Regimen          Range
Regimen 1  0.000 $403.42 $273.10 $159.33 $451.39 0.727 0.503 0.625 0.696 
  0.652    
$451.39 
  $403.59      
Regimen 3 0.000 
   0.503 0.610  
$451.24 0.693 
  $273.10   0.503   
0.104 $403.69 $273.10 $159.33 $451.39 0.503 0.625 0.696
Regimen 2 0.000 $403.59 $273.05 $159.33 0.693 0.528 0.625 0.696 
0.104  $273.17 $159.33 $451.39 0.693 0.473 0.625 0.696
$403.59 $273.10 $159.17 $451.24 0.693 0.503 0.698 0.777 
0.125 $403.59 $273.10 $159.36 $451.43 0.693 0.679
Regimen 4 0.000 $403.59 $273.10 $159.17 0.503 0.698 0.777 
0.125 $403.59  $159.36 $451.43 0.693 0.610 0.679
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
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Table 4-23 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Receipt of 
Rescue Medications 
 
 DIRECT COSTS EFFECTIVENESS 
 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 3 Regimen 4 
Parameter: Probability of Receiving Rescue Medications In the Acute Phase Given Acute Emesis 
Base Case          
Regimen  $403.45 $2 08 $1 12 $4 30 0. 95 0.502 0. 27 0.699 Range 73. 59. 51. 6 6
Regimen 1  0.696 0.240 $403.57 $273.10 $159.33 $451.39 0.693 0.503 0.625 
     
0.693 
     
0.693 
     
 1.0    0.696 
1.000 $403.76 $273.10 $159.33 $451.39 0.693 0.503 0.625 0.696
Regimen 2 0.240 $403.59 $273.01 $159.33 $451.39 0.503 0.625 0.696 
1.000 $403.59 $273.42 $159.33 $451.39 0.693 0.503 0.625 0.696
Regimen 3 0.300 $403.59 $273.10 $159.29 $451.39 0.503 0.625 0.696 
1.000 $403.59 $273.10 $159.41 $451.39 0.693 0.503 0.625 0.696
Regimen 4 0.300 $403.59 $273.10 $159.33 $451.39 0.693 0.503 0.625 0.696 
00 $403.59 $273.10 $159.33 $451.39 0.693 0.503 0.625
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
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Table 4-23 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Receipt of 
Rescue Medications 
 
    DIRECT COSTS EFFECTIVENESS
 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 3 Regimen 4 
Parameter: Probability of g Re ation elaye iven N yed Em Receivin scue Medic s In the D d Phase G o Dela esis 
Base Case  $403.45 $273.08 $159.12 $451.30 0.695 0.502 0.627 0.699 
Parameter Range         
Regimen 1  0.000 $402.80 $273.10 $159.33 $451.39 0.749 0.503 0.625 0.696 
 0.1 10 $159.33 39 74 03 25 96 
$403.59 $159.33 0.693 0.625 
      
Regimen 3 0.000 $403.59 $273.10 $158.43 $451.39 0.693 0.503 0.683 0.696 
 0.120 $403.59 $273.10 $159.69 $451.39 0.693 0.503 0.601 0.696 
0.625 
 0.1     
00 $403.87 $273. $451. 0.6 0.5 0.6 0.6
Regimen 2 0.000 $272.32 $451.39 0.557 0.696 
0.120 $403.59 $273.29 $159.33 $451.39 0.693 0.490 0.625 0.696
Regimen 4 0.000 $403.59 $273.10 $159.33 $450.37 0.693 0.503 0.761 




 P etron 0.25mg;  
: IV Ondansetron 32mg,  
egimen 3: IV O etron 8 exame mg, Ora hasone Days 2






mg + IV D





 4mg BID (
e 4mg BI
-5);  
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Table 4-23 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Receipt of 
Rescue Medications 
 
   EFFECTIVENESS DIRECT COSTS
 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 3 Regimen 4 
Parameter: Probability of Receiving Rescue Medications In the Delayed Phase Given Delayed Emesis 
Base Case        0.627  $403.45 $273.08 $159.12 $451.30 0.695 0.502 0.699
Regimen          Range
Regimen 1  0.400 $403.33 $273.10 $159.33 $451.39 0.693 0.503 0.625 0.696 
      
0.625 
   0.503   
0.696 
  $403.59      
$273.10 $451.28 0.503 0.625 
      
1.000 $404.88 $273.10 $159.33 $451.39 0.693 0.503 0.625 0.696
Regimen 2 0.378 $403.59 $272.62 $159.33 $451.39 0.693 0.503 0.696 
1.000 $403.59 $275.79 $159.33 $451.39 0.693 0.625 0.696
Regimen 3 0.389 $403.59 $273.10 $159.06 $451.39 0.693 0.503 0.625 
1.000  $273.10 $160.72 $451.39 0.693 0.503 0.625 0.696
Regimen 4 0.389 $403.59 $159.33 0.693 0.696 




Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
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Table 4-23 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Receipt of 
Outpatient Care 
 
    DIRECT COSTS EFFECTIVENESS
 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 3 Regimen 4 
Base Case $403.45 $273.08 $159.12 $451.30 0.695 0.502 0.627 0.699 




ons  $40 31 $27 58 $15 19 $4 26 0.6 3 0.5 3 0.6 5 0.696 0.000 3. 2. 9. 51. 9 0 2
 0.030 15 $2 15 $1 60 67 93 03 25 96 
Rescue 
        0.625  
   $273.55       
 Pr ity of f Outpatient Care During Delayed ven: 
$404. 74. 59. $451. 0.6 0.5 0.6 0.6
Medications 0.000 $403.47 $272.88 $159.18 $451.24 0.693 0.503 0.696
0.030 $403.83 $159.63 $451.70 0.693 0.503 0.625 0.696
Parameter: obabil Receipt o Phase Gi
No Rescue 
s 0.02 20 $2 28 $1 90 21 93 03 25 96 Medication $403. 72. 58. $451. 0.6 0.5 0.6 0.6
          
Rescue 0.02 $403.20 $272.37 $158.93 $451.22 0.693 0.503 0.625 0.696 
93 0.503 0.625 0.696 
0.05 $403.98 $273.92 $159.75 $451.58 0.693 0.503 0.625 0.696
Medications 
 98 $273.83 $159.73 $451.57 0.60.05 $403.
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
egimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
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Table 4-24: One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Receipt of Rescue
Medications 
 
    
 
TOTAL COSTS EFFECTIVENESS
 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 3 Regimen 4 
Parameter: Probability of Receiving Rescue Medications In the Acute Phase Given No Acute Emesis 
Base Case          $457.64 $381.05 $216.31 $475.84 0.698 0.500 0.630 0.701
Regimen          Range
Regimen 1  0.000 $458.59 $382.14 $217.31 $476.71 0.727 0.503 0.625 0.696 
  $476.71     
 0.104    0.625  
      
Regimen 4 $458.66 $382.14 $217.16 $476.56 0.693 
      
0.104 $458.74 $382.14 $217.31 0.652 0.503 0.625 0.696
Regimen 2 0.000 $458.66 $382.08 $217.31 $476.71 0.693 0.528 0.625 0.696 
 $458.66 $382.21 $217.31 $476.71 0.693 0.473 0.696
Regimen 3 0.000 $458.66 $382.14 $217.16 $476.56 0.693 0.503 0.698 0.777 
0.125 $458.66 $382.14 $217.34 $476.74 0.693 0.503 0.610 0.679
0.000 0.503 0.698 0.777 
0.125 $458.66 $382.14 $217.34 $476.74 0.693 0.503 0.610 0.679
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
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Table 4-24 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Receipt of 
Rescue Medications 
 
    TOTAL COSTS EFFECTIVENESS
 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 3 Regimen 4 
Parameter: Probability of Receiving Rescue Medications In the Acute Phase Given Acute Emesis 
Base Case          $457.64 $381.05 $216.31 $475.84 0.698 0.500 0.630 0.701
Regimen          Range
Regimen 1  0.240 $458.64 $382.14 $217.31 $476.71 0.693 0.503 0.625 0.696 
      
  $458.66      
0.300 
      
  $458.66      
1.000 $458.83 $382.14 $217.31 $476.71 0.693 0.503 0.625 0.696
Regimen 2 0.240 $458.66 $382.11 $217.31 $476.71 0.693 0.503 0.625 0.696 
1.000  $382.46 $217.31 $476.71 0.693 0.503 0.625 0.696
Regimen 3 $458.66 $382.14 $217.27 $476.67 0.693 0.503 0.625 0.696 
1.000 $458.66 $382.14 $217.39 $476.79 0.693 0.503 0.625 0.696
Regimen 4 0.300 $458.66 $382.14 $217.39 $476.79 0.693 0.503 0.625 0.696 
1.000  $382.14 $217.39 $476.79 0.693 0.503 0.625 0.696
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
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Table 4-24 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Receipt of 
Rescue Medications 
 
    TOTAL COSTS EFFECTIVENESS
 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 3 Regimen 4 
Parameter: Probability of g Re ation elayed Phase Given N yed Em Receivin scue Medic s In the D o Dela esis 
Base Case  $457.64 $381.05 $216.31 $475.84 0.698 0.500 0.630 0.701 
Regimen Range         
Regimen 1  0.000 $457.87 $382.14 $217.31 $476.71 0.749 0.503 0.625 0.696 
 0.100 $458.94 $382. 31 71 74 03 25 96 
 0.1      
Regimen 3 0.000 $458.66 $382.14 $216.41 $476.71 0.693 0.503 0.683 0.696 
 0.120 $458.66 $382.14 $217.67 $476.71 0.693 0.503 0.601 0.696 
  $477.13  0.503  0.669 
14 $217. $476. 0.6 0.5 0.6 0.6
Regimen 2 0.000 $458.66 $381.35 $217.31 $476.71 0.693 0.557 0.625 0.696 
20 $458.66 $382.33 $217.31 $476.71 0.693 0.490 0.625 0.696
Regimen 4 0.000 $458.66 $382.14 $217.31 $475.68 0.693 0.503 0.625 0.761 
0.120 $458.66 $382.14 $217.31 0.693 0.625
 
Regimen 1: IV P etron 
Regimen 2: IV Ondansetron 32mg,  
egimen 3: IV Ondansetron 8 exame mg, Ora hasone Days 2
Regimen 4: IV Ondansetron 8 me mg, hason D (Day Oral Ondans mg BID (Day  
 
alonos 0.25mg;  
R mg + IV D





 4mg BID (
e 4mg BI
-5);  
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Table 4-24 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Receipt of 
Rescue Medications 
 
 TOTAL COSTS EFFECTIVENESS 
 Regimen 1 Re Regimen 3 Regimen 4 Regimen 1 Regimen 2 gimen 3 Regimen 4 gimen 2 Re
Probability of Receiving R scue Medic ayed Emesise ations In the Delayed Phase Given Del  
Base Case $216. 84 98 0.5 0.6 0.7 $457.64 $381.05 31 $475. 0.6 00 30 01 
Regimen Range         
Regimen 1  00 40 82.14 $217.31 76.71 0.5 0.625 0.60.4 $458. $3 $4 0.693 03 96 
 1.00 . $217. 6.71 0.5 0.625 0.696 
 2 78 8.66 .66 $217.31 .71 0.5 0.625 0.69
 1.000 8. .83 $217. .71  0.5 0.625 0.6
 3 0.38 66 .14 $217.05 6.71 0.5 0.625 0.69
 1.000 8. .14 $218. .71  0.5 0.625 0.6
 4 0.38 66 .14 $217.31 6.59 0.503 0.625 0.69
 1.000 8. .14 $217. .32  0.5 0.625 0.6
0 $459.95 $382 14 31 $47  0.693 03 
Regimen 0.3 $45  $381 $476 0.693 03 6 
 $45 66 $384 31 $476  0.693 03 96 
Regimen 9 $458.  $382 $47 0.693 03 6 
 $45 66 $382 70 $476  0.693 03 96 
Regimen 9 $458.  $382 $47 0.693 6 
 $45 66 $382 31 $477  0.693 03 96 
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
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Table 4-24 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Receipt of 
Outpatient Care 
 
 TOTAL COSTS   EFFECTIVENESS
 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 2 gimen 3 Regimen 4 Re
Base Case 84 0.5 0.6 0.7$457.64 $381.05 $216.31 $475. 0.698 00 30 01 
Parameter: Probability of Receipt of Outpatient Care During Acute Phase Given: 
No Rescue 
ons 0.000 $458.38 $381.62 $217.17 $476.57 0.693 0.503 0.625 0.696 Medicati
 0.030 2 9 217.58 98  0.503 0.6 0.6
Rescue 
Medications 00 4 91 $217.16 56  0.5 0.625 0.6
59 $217. 01 93 0.5 0.6 0.6
Probability of g
 $459.2  $383.1 $  $476. 0.693 25 96 
0.0  $458.5  $381.  $476. 0.693 03 96 
 0.030 $458.90 $382. 61 $477. 0.6 03 25 96 
Receipt of Outpatient Care Durin  Delayed Phase Given: 
No Rescue 
Medications 0.02 $458.27 $381. 2 $216.89 $476.52 0.693 0.503 0.625 0.696 3
 0.05 $459.05 6 $217.73 89 0.693 0.5 0.625 0.6
Rescue 
Medications 2 7 41 $216.91 53  0.5 0.6 0.6
 $382.87 $217.71 $476.88 0.693 0.503 0.625 0.696 
 $382.9  $476. 03 96 
0.0  $458.2  $381.  $476. 0.693 03 25 96 
 0.05 $459.05
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
on 8mg + IV DexaRegimen 3: IV Ondansetr
Regimen 4: IV Ondans
methasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
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Table 4-25: One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer and Societal Perspective – ICERs
for Receipt of Rescue Medications  
 
 IC er  
 
ER per patient with complete control of emesis – Pay
Perspective 
ICER per patient with complete control of emesis – Societal
Perspective 
 R R Regimen 1 egimen 2 egimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 3 Regimen 4 
Base Case $3,582.48 Dominateda - $14,953.27 $3,549.02 Dominateda - $6,499.87 
Parameter: Probability o g R ations In the Acu en No sis f Receivin escue Medic te Phase Giv Acute Eme
Regimen 1  $2,388 78 Domi a - Domi teda $2, 0.30 Dom nateda - Dominated 0.000 . nated na 36 i
 E
Do D -  Exte nance
b -  
Regimen 2 D -  $6,292.08 
$ D -    $6,292.08 
Regimen 3 D Dominateda -  da Dominateda   
 $  Dominateda - Dominateda $2,918.23 Dominateda - Dominated 
Regimen 4 0.000 D Do - $3, 35 a - $3, 58 
 0.125 $2,953. D - Do 23 D - D nated 
0.104 xtended minanceb ominated
a $4,118.69 nded Domi Dominateda $3,658.01
0.000 $3,589.75 ominateda $16,665.68 $3,546.97 Dominateda -
 0.104 3,589.75 ominateda $16,665.68 $3,546.97 Dominateda
0.000 ominateda $3,690.35 Dominate - $3,277.58
0.125 2,953.43
ominateda minateda 690. Dominateda Dominated 277.
43 ominateda minateda $2,918. ominateda omi
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2 setr
egimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5) 
n 3 
: IV Ondan on 32mg,  
R
Regimen 4: IV Ondansetron 8mg + IV 
eAll regimens were compared to regim
a Dominated by regimen 3 
 b Dominated by a blend of regimen 3 and regimen 4
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Table 4-25 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer and Societal Perspective – 
ICERs for Receipt of Rescue Medications  
 
 ICER per patient with complete control of emesis – 
Payer Perspective 
ICER per patient with complete control of emesis – Societal 
Perspective 
 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 4 Regimen 1 Regimen 2 Regimen 3 
Probability of Receiving Rescue Medications In the Acute Phase Given Acute Emesis 
Base Case  a   $  Dominateda -  $3,582.48 Dominated - $14,953.27 3,549.02 $6,499.87
Regimen          Range
Regimen 1  0.240 a   $  -  $3,589.54 Dominated - $16,670.84 3,546.75 Dominateda $6,297.24
 a   $  Dominateda -  
 a   $  -  
  Dominateda  $16,665.68 $3,546.97 - $6,292.08 
   $3,547.55 Dominateda - $6,278.28 
 1.000 $3,588.51 -  $3,545.72 -  
Regimen 4 0.300 Dominateda   $3,546.97 -  
 1.000   $  Dominateda -  
1.000 $3,592.29 Dominated - $16,605.50 3,549.51 $6,231.90
Regimen 2 0.240 $3,589.75 Dominated - $16,665.68 3,546.97 Dominateda $6,292.08
1.000 $3,589.75 - Dominateda
Regimen 3 0.300 $3,590.34 Dominateda - $16,651.87
 Dominateda $16,695.20 Dominateda $6,321.61
$3,589.75 - $16,665.68 Dominateda $6,292.08
 $3,589.75 Dominateda - $16,665.68 3,546.97 $6,292.08
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
xamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5)
ed to regimen 3 
 Dominated by regimen 3
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
 Regimen 4: IV Ondansetron 8mg + IV De
All regimens were compar
a
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Table 4-25 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer and Societal Perspective – 
ICERs for Receipt of Rescue Medications  
 
 ICER per patient with complete control of emesis – 
Payer Perspective 
ICER per patient with complete control of emesis – Societal 
Perspective 
 Regimen 1 Regimen 4 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 2 Regimen 3 
Probability of Receiving Rescue Medications In the Delayed Phase Given No Delayed Emesis 
Base Case  $3,582.48 Dominateda - $14,953.27 $3,549.02 Dominateda - $6,499.87 
Regimen Range         
Regimen A  0.000 Dominateda - Dominateda 94 D - Do$1,972.53 $1,948. ominateda minateda
 0.1 ed 
Dominanceb Dominated
a - $4, 70 Extend nanceb - $3,658.01 
- $1  97 - $6, 08 
 0.1 - $16,665.68 $3,546.97 - $6, 08 
Regimen C 0.000 Extended 
Dominanceb Dominated
a - $23,208.07 Extended Dominanceb Dominateda - $20,620.16 
0.120 $2,658.10 Dominateda - $16,665.68 37 Dominateda - $6,292.08 
Regimen D Dominateda -  Extended Dominanceb - $1,902.38 
 0.120 - Dominateda   
00 Extend 118. ed Domi Dominateda
Regimen B 0.000 $3,589.75 Dominateda 6,665.68 $3,546. Dominateda 292.
20 $3,589.75 Dominateda Dominateda 292.
 $2,626.
0.000 Dominateda $2,412.92 Dominateda
 $3,589.75 Dominateda $,3546.97 Dominateda - Dominateda
 
Regimen 1: I setr  
Regimen 2 s
: IV Ondansetron 8m asone 8mg, Oral Dexam g BID (Days 2-5);  




etron 32mg,  
Regimen 3 g + IV Dexameth ethasone 4m
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5) 
All regimens were compared to regimen 3 
a Dominated by regimen 3 
182 
RESULTS  Reema Mody 
183 
Table 4-25 (Continued): One Way Sensitivity Analyses Results for ME Model with No Si  Payer and Societal Perspective
ICERs for Receipt of Rescue Medications  
 
 ICER per patient with complete control of emesis – 
Payer Perspective 
control of emesis – Socie
Perspective 
de Effects from
ICER per patient with complete 
 – 
tal 
 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 3 Regimen 4 
Probability of Receiving Rescue Medications In the Delayed Phase Given Delayed Emesis 
Base Case  $3,582.48 Dominated - $14,953.27 $3,549. Dominated - $6,49  02 9.87
Regimen Range         
Regimen A  0.400 $3,585.97  Dominated - $16,755.44 $3,543.19 Dominated - $6,38  1.85
 1.000 $3,608.68 Dominated - $16,216.85 $3,565. Dominated - $5,84  
Regimen B 0.378 $3,589.75 Dominated - $16,665.68 $3,546.97 Dominated - $6,29  
 1.000 $3,589.75 Dominated - $16,665.68 $3,546. Dominated - $6,29  
Regimen C 0.389 $3,593.62 Dominated - $16,665.68 $3,550.83 Dominated - $6,29  
 1.000 $3,569.27 Dominated - $16,665.68 $3,526. Dominated - $6,292.08 
Regimen D 0.389 $3,589.75 Dominated - $16,625.65 $3,546.97 Dominated - $6,252.06 








Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5) 
All regimens were compared to regimen 3 
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Table 4-25 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer and Societal Perspective – 
ICERs for Receipt of Outpatient Care  
 
 ICER per patient with complete control of emesis – 
ct
ICER per patient with complete of emesis – Societal 
pe
control 
Payer Perspe ive Pers ctive 
 Regi Regi Regim Regim Re 1 gimen 2 gimen 3 imen 4 men 1 men 2 en 3 en 4 gimen Re Re Reg
B  $14,953.27 $3,549.02 Dominateda - $6,499.87 ase Case $3,582.48 Dominateda -
Parameter: Prob of Receipt of Outpatient Care During Acute Phase Gi n: ability ve
No Rescue 
Medications 58 Domi 6,71 $3, 87 inated
a 341.93 nateda - $1 5.53 544. Dom - $6,0.000 $3, 7.65 
 0.030 $3,593.96 Dominateda - $16,565.97 $3,551.17 Dominateda - $6,192.38 
Rescue 
ications 0 3,59 Domi 6,65 $3  inated
a - $6,281.38 
$3,58 Domi 6,68 $3, 07 inateda - $6,313.49 
Parameter: Pr utpatient Care During Delayed Ph  
0.21 nateda - $1 4.97 ,547.42 Dom.000 $Med
 0.030 8.85 nateda - $1 7.09 546. Dom
obability of Receipt of O ase Given:
No
Medications  0.020 $3,590.23 Dominated - $16,737.45 $3,546.73 Dominated
a - $6,256.19  Rescue a
 0.050 $3,589.28 Dominateda - $16,593.90 $3,546.73 Dominateda - $6,220.31 
R 0.020 $3,58 Dominateda 6,740.96 $3,547.10 Dominateda - $6,367.36 
 0.0 $3,58 62 Domi 6,59 $3, 83 inateda - $6,216.80 
escue 
Medications 9.89 - $1
50 9. nateda - $1 0.40 546. Dom
 
; Regimen 1: IV Palonosetron 0.25mg Regimen 2: IV Ondansetron 32mg, Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID 
Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5) (Days 2-5); Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (
All regimens were compared to regimen 3; a Dominated by regimen 3
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Utilization Parameters 
The impact o  changes in ens, cost of 
palonosetron, cost of ondansetron, infusion costs, and the number of days of receiving rescue 
med ions durin e delayed phase from the payer and societal perspectives are reported in 
Tables 4-26 and 4-27, respectively nted in Table 4-28.  The ICER 
results showed that regimen 1 was dominated by regimen 3 for four conditions, 1) when the cost 
of regimen 1 was increased by 20%, 2) decreasing the cost of regimen 4 by 20%, 3) increasing 
the cost of pa  20%, an ond  by 20%.   
 
Effect of Changes in Rescue Medications for Breakthrough Emesis
f the total cost of prophylactic antiemetic regim
icat g th
.  The ICER results are prese
lonosetron by d 4) decreasing the cost of ansetron
 
 
The delay e ategi , 2 an  
HT e base-case a alysis.  In the eve f em ase, 
prochlorperazine was the rescue medication used for base-case a alysis.  The use of 5-HT3RA if 
not used prophylactically y some guidelines. A scenario analys
conducted in which rescu  medications for regimens 1, 2 and doses o
ondansetron 8 mg  days in addition to the other rescue m ications.  The im f 
changes in rescue m reakthrough emesis during ed phase on costs and ICERs 
are reported in Table 4-29.   
 
Addition of ondansetron as rescue medication in the delayed phase changed 
dom tiem ens
dom 3,658.01 pe patient 
with com e con  of emesis.  The change in the rescue me tions in the dela se for 
regim the do n e stat n he IC  e t etic regim
results were de for regim n 3.  Although the dominance status 
rem e, th t e en 3 of 
regim




es 1 d 3
esis in the delay
did not include a 5-
3RA in th
inance status of the a
inated b
en 2 did not change
ained sa














3 included two 
ed
 delay
men 3 was $
dica
of th








 from the societal perspective.  Regim
en 4 over regiy
plet
sensitive to the changes 
m
 regimen 4 and the ICE
trol
 











ER  an iem
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Table 4-26: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Payer Perspective – Cost Parameters 
 
    DIRECT COSTS EFFECTIVENESS
 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 3 Regimen 4 
Base Case $403.45        $273.08 $159.12 $451.30 0.695 0.502 0.627 0.699
Parameter: Total Prophylactic Antiemetic Regimen Costs  
Regimen          Range
Regimen 1  $319.31 $323.75 $273.10 $159.33 $451.39 0.693 0.503 0.625 0.696 
  $483.42        
  $403.59        
  $403.59 $326.17     0.625  
  $123.73    $451.39     
   $190.26  0.693    
     0.693    
  $403.59  $159.33      
$478.98 $273.10 $159.33 $451.39 0.693 0.503 0.625 0.696
Regimen 2 $212.29 $220.03 $159.33 $451.39 0.693 0.503 0.625 0.696
$318.43 $159.33 $451.39 0.693 0.503 0.696
Regimen 3  $403.59 $273.10 $128.40 0.693 0.503 0.625 0.696
$185.59 $403.59 $273.10 $451.39 0.503 0.625 0.696
Regimen 4 $358.74 $403.59 $273.10 $159.33 $361.71 0.503 0.625 0.696
$538.10 $273.10 $541.07 0.693 0.503 0.625 0.696
Cost of Palonosetron 
Palonosetron $272.16 $335.55   $451.39     $273.10 $159.33 0.693 0.503 0.625 0.696
         $408.24 $471.63 $273.10 $159.33 $451.39 0.693 0.503 0.625 0.696
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
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Table 4-26 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Payer Perspective – Cost 
Parameters 
  
    DIRECT COSTS EFFECTIVENESS
 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 3 Regimen 4 
Base Case $403.45        $273.08 $159.12 $451.30 0.695 0.502 0.627 0.699
Parameter: Cost of IV Ondansetron 
Ondansetron  $165.13         $403.59 $231.70 $149.00 $382.40 0.693 0.503 0.625 0.696
 $247.69 $403.70        $314.50 $169.70 $520.40 0.693 0.503 0.625 0.696
Parameter: Infusion Costs  
First Drug         0.696 $47.16 $391.70 $261.12 $147.44 $439.55 0.693 0.503 0.625
  $415.48        
Second Drug  $403.59        
          
$70.74 $285.08 $171.21 $463.23 0.693 0.503 0.625 0.696
$22.18 $273.10 $153.79 $445.85 0.693 0.503 0.625 0.696
$33.26 $403.59 $273.10 $273.10 $456.93 0.693 0.503 0.625 0.696
Parameter: Number of Days of Receiving Rescue Medications During Delayed Phase 
No. of Days 1 day $403.07 $272.31 $158.78 $450.99 0.693 0.503 0.625 0.696 
          3 days $404.10 $273.89 $159.88 $451.79 0.693 0.503 0.625 0.696
 
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
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Table 4-27: One Way Sensitivity Analyses Results for HE Model with No Side Effects from Societal Perspective – Cost Parameters 
 
 TOTAL COSTS EFFECTIVENESS 
 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 3 Regimen 4 
Base Case $457.64 $381.05 $216.31 $475.84 0.698 0.500 0.630 0.701 
Parameter: Total Prophylactic Antiemetic Regimen Costs  
Regimen Range         
Regimen 1  $319.31 $378.82 $382.14 $217.31 $476.71 0.693 0.503 0.625 0.696 
 $478.98 $538.49 $382.1  $217.31 $476.71 0.693 0.503 0.625 0.696 
Regimen 2 $212.29 $458.6  $329.0  $217.31 $476.71 0.693 0.503 0.625 0.696 
 43 6  $ 7.31 71 93 25 0.
3 3 6  $ 6.38  0.693 0.503 0.625 0.6
 9 6 4 $ 8.24   0.625 0.696 
Regimen 4 4 $458.66 4 $ 7. 03 93 25 0.6








21  $476.  0.6 0.503 0.6 696 
Regimen  $123.7  $458.6 4
 $382.1
18  $476.71 96 
$185.5  $458.6 24  $476.71 0.693 0.503 
  $358.7  $382.1 21 31 $387. 0.6 0.503 0.6 96 
$538.1  $458.6 21
Cost of Pal nosetron 
Palonosetron $272.16 $390.62 $382.14 $217.31 $476.71 0.693 0.503 0.625 0.696 
 $408.24 $526.70 $382.14 $217.31 $476.71 0.693 0.503 0.625 0.696 
 
Regimen 1: IV tro
Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
Oral Ondansetron 4mg BID (Days 2-5) 
 Palonose
: IV Ondans
n 0.25mg;  
mg,  Regimen 2 etron 32
Regimen 3: IV Ondansetron 8mg + IV 
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Table 4-27 (Continued): One Way Sensitivity Analyses Results for ME Model with No Side Effects from Societal Perspective – Cost 
Parameters 
  
  TOTAL COSTS EFFECTIVENESS
 Regimen 1 gimen 3 Regimen 4 Regimen 1 Regimen 2 gimen 3 Regimen 4 Regimen 2 Re Re
Base Case 84 0.5 0.6$457.64 $381.05 $216.31 $475. 0.698 00 30 0.701 
Parameter: Cost of IV Ondansetron 
Ondansetron  $165.13 $458.66 $340.70 $207.00 $407.70 0.693 0.503 0.625 0.696 
 $247.69 $458.66 $423.60 $227. 70 0.6 0.6
Parameter: I
70 $545. 0.693 0.503 25 96 
nfusion Costs  
First Drug $47.16 $446.77 $370.16 $205.42 $464.87 0.693 0.503 0.625 0.696 
 $70.74 12 $229.20 $488.55 0.503 0.6 0.696 
Second Dr 8 14 $211. 17 0.625 0.6
6 66 $382.14 $222.85 5  0 0.6 0.
Parameter: Number of Days of Receiv Medicati ns Durin hase 
 $470.55 $394. 0.693 25 
ug $22.1  $458.66 $382. 77 $471. 0.693 0.503 96 
 $33.2  $458.  $482.2 0.693 .503 25 696 
ing Rescue o g Delayed P
No. of Days 1 day $458.14 $381.35 $216.76 $476.31 0.693 0.503 0.625 0.696 
 3 d ays 17 93 $217.86 1  0.503 0.6 0. $459.  $382.  $477.1 0.693 25 696 
 
Regimen 1
g + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5) 
 
: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8m
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Table 4-28: One Way Sensitivity Analyses Results for ME Model with No 
or Cost and Utilization Parameters 
Side Effects from Payer and Societal Perspective – ICERs 
 ICER per patient with complete c
pe
control of emesis – Societal 
f
 
ontrol of emesis – ICER per patient with complete 
Payer Pers ctive Perspective 
 Regimen 1 Regimen 2 Regimen 3 Regimen 1 Re egimen 4 Regimen 4 gimen 2 Regimen 3 R
Parameter: Total Costs of Prophylactic egimens  Antiemetic R
Base Case $3 8 Dominated - $14,953.27 $3,549. Domin $6,499.87  ,582.4 02 ated a - 
Regimen       Range     
Regimen 1 31 $2,416.40 Do - $4 6 $2,373. Dominateda - $34,125.16 $319. minateda 4,498.7 61 
 $478.98 Dominateda Dominateda - $4,118.70 Dominated a Dominateda - $3,658.01 
Regimen 2 29 D 54 om 6,292.08 
 3 $3,589.75 Do - $16 65.68 $3,546. Dominateda - $6,292.08 
Regimen 3 3 $4,  Do - $4,001.53 Domi $6,292.08 
 9 $3, Do - 8 $3,092. Dominateda - $6,292.08 
Regimen 4 4 Do a Do -  Dominat Dominateda  $2,393.36 
 $538.10 $3,589.75 Dominateda - $37,555.49 
Paramete alo
$212. $3,589.75 ominateda - $16,665.68 $3, 6.97 D inateda - $
$318.4  minateda ,6 97 
$123.7 044.31 minateda  $16,665.68 nateda - 
$185.5  135.20 minateda $16,665.6 41 
$358.7 minated minateda $2,854.04 ed a -
- $47,929.09 $3,546.97 Dominateda
r: Cost of P nosetron 
Palonosetron $272.16 $2,589.81 Dominateda  $2,547.03 Dominateda - $30,011.56 - $40,385.15
 $4 Do a Do - $4, 8.70 Dominated Dominateda - $3,658.01 08.24 minated minateda 11  a
Regimen 1: IV Palonosetron 0.
Regimen etron 32
Regimen etron 8m Dexamet , Oral Dexamethas D (Days 2-5);  
Regimen etron 8m Dexamet , Oral Dexametha  (Days 2-5) + Or etron 4mg BID (Days 2-5) 
All regim pared to n 3; a Dom  regimen 3
25mg;  
2: IV Ondans
 3: IV Ondans
mg,  
g + IV hasone 8mg one 4mg BI
 4: IV Ondans
ens were com




sone 4mg BID al Ondans
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Table 4-28 (Continued): One Way Sensitivity Analyses Results for ME Model with No Sid pective
ICERs for Cost and Utilization Parameters 
 
Parameters/Range ICER per patient with complete control of emesis – 
Payer Perspective 
ICER per pa
e Effects from Payer and Societal Pers




 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 1 Regimen 2 Regimen 3 Regimen 4 
Base Case $3,582.48 Dominateda - $14,953.27 $3,549. 6,49  02 Dominated a - $ 9.87
Parameter: Cost of IV Ondansetron 
Ondansetron  $165.13 Dominated Dominateda - $3,291.22 Dominated 2,83   Dominateda - $ 0.54
 $247.69 $3,438.98 Dominateda - $40,698.18 $3,396. 0,3 8 
Infusion Costs 
19 Dominateda - $3 24.5
First Drug $47.16 $,3589.74 Dominateda - $16,682.53 $3,546. 6,30  96 Dominateda - $ 8.94
 $70.74 $3,589.76 Dominateda - $16,648.82 $3,546. 6,27  
Second Drug $22.18 $3,671.17 Dominateda - $14,734.37 $3,628. 4,36  
 $33.26 $3,508.33 Dominateda - $18,596.98 $3,465. 8,23  
Parameter: Number of Days of Receiving Rescue Medications During Delayed Phase 






55 Dominateda - $
No. of Days 1 day $3,590.26 Dominateda - $16,706.68 $3,547. 6,33  48 Dominateda - $ 3.08
 3 days $3,589.25 Dominateda - $16,624.68 $3,546. 6,25  46 Dominateda - $ 1.08
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ond
All regimens were compared to regimen 3 
a Dominated by regimen 3 
 
ansetron 4mg BID (Days 2-5) 
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Table 4-29: Change in the Antiemetic Regimen for Breakthrough Emesis 
 
  Change in Rescue Meds in Delayed Phase for Regimen 1  
Regimen Effectiveness Direct C  patient with complete 
 of te c es
 osts ICER per
control emesis 
Total Costs ICER per patient with 
comple ontrol of em is 
Regimen 3 0.6 $1 - 31 - 27 59.33 $217.
Regimen 2 0.502 $273.10 Dominated by regimen 3 $382.14 Dominated by regimen 3 
en 0.6 $4 ,913. 68 nated by regimen 4 
Regimen 0.6 $4 $8,990. 71 $3,658.  
Change in Rescue Meds in Delayed Phase for Regimen 2 
Regim 1 93 25.60 $3 32 $480. Domi
4 96 51.39 44 $476. 01
  
Regimen ctiv Direc  ICE tient lete 
control of emesis 
ost  per patient with 
complete control of emesis 
 Effe eness t Costs R per pa with comp Total C s ICER
Regimen 3 0.627 $159.33 - $182.80 - 
Regimen 2 0.502 $306.96 Dominated by regimen 3 $273.10 Dominated by regimen 3 
$403.50 $3,244.54 
$451.39 $16,665.68 $451.39 $16,665.68 
  Change in Rescue Meds in Delayed Phase for Regimen 3 
Regimen 1 0.693 $403.50 $3,589.75 
Regimen 4 0.696 
Regimen Effectiveness Direct Costs ICER per patient with complete 
control of emesis 
Total Costs ICER per patient with 
complete control of emesis 
Regimen 3 0.627 $182.80 - $240.80 - 
Regimen 2 0.502 $273.10 Dominated by regimen 3 $382.14 Dominated by regimen 3 
Regimen 1 0.693 $403.50 $3,244.54 $458.56 $3,201.76 
Regimen 4 0.696 $451.39 $16,665.68 $476.71 $6,292.08 
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Effect of Changes in Indirect Costs Associated with CINV and its Treatment 
 
 
The impact of variation in the average hourly wages on total costs, effectiveness, and 
ICER for each antiemetic regimen from the societal perspective is presented in Table 4-30. 
Decreasing the hourly wage by 20% resulted in an increase in the ICER of regimen 4 from
$6,499.87 to $10,631.89 per patient with complete control of emesis.  Due to lack of sufficient 
and reliable data regarding the amount of lost productivity associated with delayed CINV, it was 
varied in sensitivity analysis to understand its impact on costs and ICERs.  Decreasing the 
number of hours of lost productivity to 2.75 hours increased the ICER of regimen 4 to 
$14,072.28 per patient with complete control of emesis, while increasing the number of hours of 
lost productivity to 24 hours (equivalent to 3 work-days) decreased the ICER of regimen 4 to 
$3,113.57.    
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Table 4-30: Change in the Indirect Costs Associated with CINV and its Treatment  
 
 TOTAL COSTS ICER per patient with complete control of emesis 
 Regimen 1 Regimen 2 Regimen 3 men 1 Regimen 2 Regimen 3 Regimen 4 Regimen 4 Regi
Base Case $4 381.05  2 ,499.87 57.64 $  $216.31 $475.84 $3,549.0 Dominated a - $6
Parameter: Average Wage Per Hour 
Average 14.96 $4 36.52  $466. 3,564.87 Dominated a - $10,631.89  Wage $ 35.62 $3 $193.05 12 $
 $30.48 $468.85 $402.32 $228.04 $481.39 $3,539.05 Dominated a - $4,372.24 
Parameter: Number of Hours of Lost Productivity  
No. of Hours 2.75 hrs 00.36 $173.82 $457. $3,579.06 Dom 14,072.28 $417.36 $3 72 inated a - $
 24 hrs 11. 83 $506.62 ominateda Dominated - $3,113.57 $523.74 $5 00 $285. D  a
 
Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5);  
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethasone 4mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5) 
All regimens were compared to regimen 3 
a Dominated by regimen 3 
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Moderately Emetogenic Chemotherapy Model  
 
The results o obabilistic sensitivity analysis from the payer perspectives are shown in 
Table 4-31.  The results  sensitive to the simultaneous variation in all the parameters.  
From the payer perspectiv en 2 was dominated by regimen 3 while regimen 1 was 
excluded from the ICER inance.  The ICER of regimen 4 
compared to regimen 1 was $3,091. p control of emesis and compared 
to regimen 3 was calculated to be $5,370.87 per patient with complete control of emesis.  The 
results of probabilistic sensitivity analysis om the societal perspectives are shown in Table 4-
32.  The results for the societal perspective were similar to those for the payer perspective. From 
the societal perspective, the ICER of regimen 4 compared to regimen 1 was $1,446.30 per patient 
with complete control of e esis and compared to regimen 3 was $4,831.22 per patient with 













calculations due to extended dom
58 per patient with com lete 
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Table 4-31: Probabilistic Sensitivity Analysis for Costs, Effectiveness and Incremental eness metic 
Regimens for Prevention of CINV in Patients Re ic Che her Payer 
 
Treatment Strategy rspe e 
Cost Effectiv
apy from a 
Ratios for Antie
























l cost effectiveness 
with complete control 
f emesis 
Regimen 3 $179.21 (8.24) 0.59 0.66 (0.056) $30 5 - 
Regimen 2 $279.86 (17.72) 0.51 9.0 D
Regimen 1 $411.05 (28.33) 0.63 1.4 nde











Regimen 1: IV Palonosetron 0.25mg;  
Regimen 2: IV Ondansetron 32mg,  
Regimen 3: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral D 2-5);  
Regimen 4: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral D 2-5) + Oral D (Days
All regimens were compared to regimen 3 
 
* Regimen 2 was dominated by regimen 3 
** Regimen 1 is dominated by a blend of regimen 3 and regimen 4 w ween 0.206 







examethasone 4mg BID (Days 
examethasone 4mg BID (Days 
ith a coefficient of inequity bet
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Probabilistic Sensitivity Analysis for Costs, Effectiveness and Incremental Cost Effectiveness Ratios for Antiemetic 
Regimens for Prevention of CINV in Patients Receiving Highly Emetogenic Chemotherapy from a Societal Perspective 
 














ost o  one
con
 








Regime . 1 56) - n 3 $256 49 (35.3 ) 0.596 (0.0 $430.01 
Regimen 2 .30 ( 2) 61) Dominated*
Regimen 1 .85 (44 4)  (0.054) Extended Dominancea





















: IV Palonosetron 0.25mg;  
: IV Ondansetron 32mg,  
: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethas mg BID (Days 2-5);  
: IV Ondansetron 8mg + IV Dexamethasone 8mg, Oral Dexamethas mg BID (Days 2-5) + Oral Ondansetron 4mg BID (Days 2-5) 
 
All r ens were compared to regimen 3 
* Re n 2 was dominated by regimen 3 
¶ men 4 compared to regimen 3 without excluding the extended dominance strategy 







 ICER for regi
one 4
one 4
 a bl nd o men 3 an regi  between 0.106 and 0.355
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4.2: Results for Phase II 
 
Phase II of this study involved face-to-face interviews of cancer patients to determine 
their willingness-to-pay for improved emesis control due to two new antiemetic regimens for 
prevention of CINV.  The WTP amounts were then used as a measure of benefits to conduct cost-
benefit analyses of new antiemetic agents for prevention of CINV due to highly emetogenic and 
moderately emetogenic chemotherapy agents. 
 
A total of 124 patients with cancer were approached by nurses or oncologists for 
participation in the study.  Out of 124 patients, four patients refused to participate in the study.  A 
total of 120 patients agreed to participate in the study yielding a response rate of 96.8%.  Of the 
120 respondents, 59 respondents received version A and 61 received version B of the survey.  
 
Demographic Characteristics of Study Participants 
 
As shown in Table 4-33, the mean age of the study population was 56.5 years (SD = 12.0 
years, range = 22 – 85 years).  Sixty percent of the study population was female. More than 44% 
of the study population had annual household income level below $30,000.  Approximately 58% 
f the respondents had one more member in their household and 13% of the respondents lived 
alone.  Approximately 39% of respondents had primary health care coverage through their or 
their spouse’s employer. Almost 36% of the respondents had Medicare as their primary health 
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Table 4-33: Demographic Characteristics of Respondents 
haracteristics N ) 
 
Demographic C (Valid %
Total N = 120 
Age -  Mean (SD) 56.5 (12.0) 
Gender
      Male 
      Fem
Race 










-time or Full-time) 
Annual Household Income Level 
53 (4 2%) 
Type of
Medicaid 15  
47 ) 




ale 72 (60.0%) 
 
17 (97.5%
 Americ 2 (1.7%) 
(0.8%) 
Education Level  
Less than high school ed 22 (18.3%) 
Completed high school edu 3 (44.2%)
More than high school edu 45 (37.5%) 
l Status  
Married 
Not Married/Single/D 27 (22.5%) 
ment  
Not working 88 (73.3%) 
Working (Part 32 (26.7%) 
 
≤$30,000 4.
$30,001 - $60,000 37 (30.8%) 
>$60,000 30 (25.0%) 
 Primary Insurance  





a Other type of insurance coverage included self coverage, VA, MAMSI 
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Clinical Characteristics of Study Participants 
 
Table 4-34 shows the clinical characteristics of all the respon ith 28% of patients 
diagnosed with breast can pe of cancer among the study 
population followed by lung cancer (23.3% of respondents).  Based on the  for 
classifying ion chemotherapy regimens as defined in Table  in Chapter 2, 
almost 57% of the respondents received highly emetogenic chemotherapy.  Only 10% of all 
respondents otherapy  participants 
had received prophy otherapy ntion of CINV 
during the acute phase.  A majority of the study respondents (54.2%) received a combination of a 
5-HT3RA and corticosteroid before chemotherapy.  With 16.7% of respon bination 
of Aloxi an  was the next most common antiemetic rescribed.  The 
three-drug r tant (Emend®), 5-HT3RA and corticoste rescribed to 
approximately he patients received a single drug regimen of 
3RA.  The study results also showed that various other antiemetic combination regimens 
Aloxi+Emend, Aloxi+Emend+corticosteroid, 5-HT3RA+Emend, Emend+corticosteroid 
ere prescribed during the acute phase for prevention of CINV.  
Experience of Study Participants   
 
The past experiences of CINV of study respondents are reported in Table 4-35.  
ompared to 44.2% of patients experiencing nausea, only 23.3% of respondents experienced 
emesis following chemotherapy.  Among patients experiencing nausea, the mean severity as 
ported using a 100mm VAS was found to be 50.3 (SD=25.1).  Of the respondents who 
xperienced emesis, almost 82.1% of them reported experiencing 1-2 emetic episodes following 
hemotherapy.  
dents.  W
cer, it was the most prevalent ty
 algorithm
combinat s 2-3 and 2-4
received cisplatin-based highly emetogenic chem .  All study
lactic antiemetic regimens before chem  for preve
dents, the com
d a corticosteroid regimen p
egimen of aprepi roid was p
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Table 4-34: Clinical Characteristics of Respondents 
 
Clinical Characteristics N (%) 
Total N = 120 
Type of Cancer  
Breast 34 (28.3%) 
Lung 28 (23.3%) 
Colorectal 16 (13.3%) 
Urogenital 19 (15.8%) 
Respiratory 2 (1.7%) 
Other 19 (15.8%) 
Unknown 2 (1.7%) 
Cycle of Chemotherapy  
Chemotherapy-naïve  22 (18.3%) 
Received in last 3 months 6 (5.0%) 
1st cycle of new regimen 11 (9.2%) 
> 1 cycle of chemotherapy 81 (67.5%) 
Type of Chemotherapy Regimen  
Aloxi + Corticosteroid 20 (16.7%) 
HE (Cisplatin-based) 13 (10.8%) 
HE (Non-cisplatin) 55 (45.8%) 
ME (30-90%) 27 (22.5%) 
LE (10-30%) 23 (19.2%) 
Unable to classify 2 (1.7%) 
Antiemetic Regimen – Acute Phase  
5-HT3RA + Corticosteroid 65 (54.2%) 
Emend + 5-HT3RA + Corticosteroid 10 (8.3%) 
Only 5-HT3RA 13 (10.8%) 
Other single agent regimena 5 (4.2%) 
Other combination regimensb 6 (5%) 
 
a Includes either corticosteroid or Aloxi or Emend or compazine  
b Includes either Aloxi+Emend, Aloxi+Emend+corticosteroid, 5-HT3RA+Emend, Emend+Corticosteroid 
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Table 4-35: Past Experience of Chemotherapy-Induced Nausea and Vomiting (CINV) 
 
Past Experience of CINV N (%) 
Experience of nausea during last cycle  
      Yes  53 (44.2%)  
      No  37 (30.8%) 
      Not Applicable 30 (25.0%) 
Severity of Nausea (N = 53), Mean (SD) 50.3 (25.1) 
Experience of emesis during last cycle  
      No 62 (51.7%) 
     1-2 episodes 23 (19.2%) 
     3-5 episodes 4 (3.3%) 
     > 5 episodes 1 (0.8%) 
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Results for Objectives 2.1 and 2.2  
 
Scenario 1 l Following A  of et em – Emetic Contro dministration  Highly Em ogenic Ch otherapy 
  
Scenario 1 of the survey described the improveme t in the probability of acute and 
ant) to the standard regimen of 5-
xamethasone for prevention of CINV due to highly emetogenic chemotherapy. 
e leve ce th ondents place on improved 
 the acute and delayed phase. The mean perceived level of importance for 
duction in the probability of acute emesis from 30% to 17% due to the addition of new drug 
was 8.8 (SD=1.7) and reduction in the probability of delayed emesis from 55% to 37% was 9.2 
(SD=1.5).  Due to ordinal nature of the dependent variable, Wilcoxon signed rank test was used 
to test for significant differences in the perceived level of importance of improvements in acute 
emesis and delayed emesis. The null hypothesis tested was that there are no significant 
differences in the perceived importance of the acute emesis control and delayed emesis control. It 
is evident from the results shown in Table 4-36 that the respondents perceived delayed emesis 
control to be of greater importance as compared to the acute emesis control.  
 
The WTP results for scenario 1 are shown in Table 4-37. Though all respondents 
preferred the addition of the new drug to the standard regimen compared to receiving only the 
standard regimen, approximately 91% (N =109) gave positive WTP value for receiving the new 
drug for a 3-day regimen.  Out of 11 respondents who reported that they would not pay anything 
out-of-pocket to receive the new drug, two gave zero values reflective of “protest zeroes”.  The 
remaining nine respondents genuinely placed zeroes as they were unable to afford out-of-pocket 
payments for the new drug. Thus, among 109 respondents who gave a positive WTP value for the 
3-day regimen of the new drug, the mean WTP was $89.90 (SD=101.90) and median was $60.00.  
 
Due to the non-normal distribution of the WTP amounts, Mann-Whitney U test was used 
to test whether the maximum WTP differed based on the order of scenarios presented.  The 
results in Table 4-38 indicate that the WTP amounts for scenario 1 did not differ significantly 
based on the order of scenarios presented. The results are presented for the sample without 
protest zeroes and for the sample with only positive WTP values.   
 
Respondents were also asked to state the reasons for preferring the addition of the new 
drug to the standard regimen. About 60.0% of the respondents provided a reason for preferring 
n




The results in Table 4-36 show th
emesis control in
l of importan at resp
re
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the new regimen for prevention of CINV due to highly emetogenic chemotherapy.  A majority of 
spondents (N = 18) reported that they would take anything that would prevent them from 
getting “sick”, and n iting were unpleasant and Sixteen respondents 
he new drug as it will increase th t m aintain their 
work and get on with their daily activities.  One sixth of the respondents 
preferred the new drug in addition to the standard regimen due to its ability to better control 
ting. The impact of nausea and vomiting on life was mentioned as one 





ausea and vom painful. 
reported that they prefer t eir ability to ea ore, m
weight, sleep well, go to 
nausea and vomi quality of 
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Table 4-36: Perceived level of importance of improved emesis control (Scenario 1) 
 
Item (N = 120) Mean (SD) Median Z value Significance 
   - 4.712 0.000* 
Perceived leve nce – 
Acute emesis 
8.8 (±1.72) 10.0   l of importa
Perceived level of importance – 
Delayed emesis 
9.2 (±1.51) 10.0    
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Table 4-37: Willingness-to-Pay Results for Scenario 1 
 
WTP Values N (%)  
Non-zero values  109 (90.8%)  
Protest zeroes  2 (1.7%)  
Genuine zeroes 9 (7.5%)  
 Mean (SD) Median 
Maxim  WTP amount for 3 days of aprepitant for 
overall 
$83.1 (100.8) $50.0 um
control of emesis (N = 118) 
Maximum WTP amount for 3 days of aprepitant for 
overall control of emesis (N = 109) 
$89.9 (101.9) $60.0 
 
206 
RESULTS  Reema Mody 
Table 4-38: Differences in Willingness-to-Pay Based on the Order of Scenarios Prese
For Scenario 1.  
 
Item Mean (SD) Median (Range) Z value P va
nted – 
lue 
For sample without protest zeroes 
(N = 118) 
  -0.008 0.994 
Maximum WTP amount for 3 d
aprepitant – Version A (N = 59
ays of 
) 
87.1 (±117.22) 45.00 
(0.00-600.00) 
  
Maximum WTP amount for 3 days of 
aprepitant – Version B (N = 59) 
79.1 (±81.96) 60.00  
(0.00 – 300.00) 
  
For sample without all zeroes 
(N = 109) 
    
Maximum WTP amount for 3 days of 
aprepitant – Version A (N = 55) 
93.4 (±118.97) 50.00 
(3.00-600.00) 
-0.189 0.850 
Maximum WTP amount for 3 days of 
aprepitant – Version B (N = 54) 
86.4 (±81.89) 60.00  
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Scenario 2 – Emetic Control Following Administration of Moderately Emetogenic Chemotherapy 
The scenario  improved emesis control due to single injection of 
palonosetron instead of the standard regimen of 5-HT3RA and dexamethasone for prevention of 
dministration of moderately emetogenic chemotherapy.  The acute control of 
med to be equivalent between the two regimen n perceived level of 
ducing the chance of delayed emesis from 45% .6 (SD=1.6).  Out 
f 120 respondents, only one did not prefer the new drug and the reasons reported were “dislike 
of injection” and “12% risk reduction of emesis is not much”
able 4-39.  Of those respondents who 
 who reported that they would not pay 
anything out-of-pocket to receive the new drug, two gave zero values reflective as “protest 
 
ut-of-pocket payments for the new drug.  Thus, among 108 respondents who gave a positive 
TP value for the single injection of the new drug, the mean WTP was $83.5 (SD=94.5) and 
edian was $55.0.  The results of the Mann-Whitney U test reported in Table 4-40 indicate that 
e WTP amounts for scenario 2 did not differ significantly based on the order of scenarios 
resented.  The results are presented for the sample without protest zeroes and for the sample 
ith only positive WTP values.   
 
Respondents were also asked to state the reasons for preferring the new drug to the 
tandard regimen in scenario 2.  About 61.0% of the respondents provided a reason for preferring 
e new regimen for prevention of CINV due to moderately emetogenic chemotherapy.  
pproximately one fourth of respondents (N = 18) reported that they prefer the new drug as it is 
 be taken as a one-time injection instead of a multi-day regimen.  The other reasons for 
referring the new drug included better control of emesis, ability of get back to work, do daily 
activities, ability to eat and maintain weight.  The impact of nausea and vomiting on quality of 
life was mentioned as one of reasons for preference of the new drug by three respondents.  
 
Wilcoxon signed rank test was used to test if there were significant differences in the 
maximum WTP based on the scenario.  As shown in Table 4-41, scenario 1 the median WTP for 
scenario 1 was significantly higher than that for scenario 2 for the sample without protest zeroes 
 
 2 described the
CINV following a
emesis was assu s. The mea
importance of re  to 33% was 8
o
.    
 
The WTP results for scenario 2 are shown in T
preferred the new drug, approximately 91% (N =109) gave posit
new drug for a 3-day regimen.  Out of 11 respondents
ive WTP value for receiving the 
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and sample without any zeroes.  The level of difficulty in understanding the hypothetical 
cenarios ands  in answering the WTP questions was assessed using a 11-point Likert type scale.  
The mean level of difficulty in understandin s w n erin
the WTP questions was 2.5 (SD=2.5). About 4% of the study population reported a score of 
g  in nderstanding the pothetical scenarios  oth




g the scenario as 1.5 (SD=1.74) a d in answ g 
reater than 5 for the level of difficulty  u hy .  On the er 
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Table 4-39: WTP Results for Scenario 2 
 
WTP Values* N (%)  
Non-zero values  108 (90.8%)  
Protest zeroes  2 (1.7%)  
Genuine zeroes 9 (7.6%)  
Median  Mean (SD) 
Maximum WTP amount for a single
palonosetron for overall control of emesis (N = 117) 
$77.1 (93.45) 45.0 injection of $  
Maximum WTP amount for a single injection of 
palonosetron for overall control of emesis (N = 108) 
$55.0 $83.5 (94.5) 
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Table 4-40: Differences in WTP results based on the order of scenarios presented – For 
 
Item Mean (SD) Median (Range) Z value P value 
Scenario 2. 
 
For sample 0.720 without protest zeroes 
(N = 117) 
  -0.359 
Maximum WTP amount for single 
injection of palonosetron –           
Version A (N = 59) 
80.1 (±106.04) 45.00  
(0.00-600.00) 
  
Maximum WTP amount for single 
injection of palonosetron –          
Version B (N = 58) 
74.0 (±79.45) 47.5  
(0.00-300.00) 
  
For sample without all zeroes   -0.210 0.834 
(N = 108) 
Maximum WTP amount for single 
injection of palonosetron –          
Version A (N = 55) 
85.9 (±107.55) 50.00  
(3.00 – 600.00) 
  
Maximum WTP amount for single 
injection of palonosetron –           
Version B (N = 53) 
81.0 (±79.64) 60.00  
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Table 4-41: Differences in maximum WTP amounts between scenarios 
 
alue Item Mean (SD) Median (range) Z value P v
Sample without protest zeroes   -2.879 0.004* 
Maximum WTP for scenario 1 83.4 (±101.15) 50.00 
(0.00 – 600.00) 
  
Maximum WTP for scenario 2 77.1 (±93.45) 45.00 
(0.00 – 600.00) 
  
Sample without zeroes   -2.879 0.004* 
Maximum WTP for scenario 1 90.4 (±102.27) 60.00 
(3.00 – 600.00) 
  
Maximum WTP for scenario 2 83.5 (±94.48) 55.00 
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Results for Objectives 2.3 and 2.4 
  
Differences in WTP for scenario 1 based on demographic and clinical characteristics 
 
The differences in maximum WTP amount for scenario 1 based on de hic 
c teristics are presented in Table 4-42.  Due to l nature of the WTP 
data, non parametric statistics were emplo hitney sed to test for 
differences in WTP for factors with two groups while Kruskal-Wallis test was used for factors 
w  two groups. To determin  ar ifferent from each 
other following a significant Kruskal-Wallis test result, post hoc tests using Mann Whitne st 
were conducted.  The results displayed a le with only positive WTP values.  
 
WTP for scenario 1 differed significantly based on education level comp ted, 
employment status and annual household incom  level.  There were no significant differences in 
WTP for  on age, gender, number of members in the househol arital 
status.  Post hoc tests showed that respondents who comple e = -2.357, p value = 
0 than H  (Z value 14, p value = 0.000) 
reported significantly higher WTP as compared to respondents who did not com
was no  WTP nd chool education and 
those with greater than high school education (Z value = -1.717, p value = 0.086).  Post h s 
s espondents who reported annual household income in the range $30,000-$60,000 (Z 
value = -5.207, p value = 0.000) and respondents with higher than 
v ly higher WTP as compared to respondents who with annual 
h me ≤ $30,000.  There was no sig ificant difference n the WT nt b  
r annual household incom  range $ -$60,000 and those with ≥ 
60,000 (Z value = -0.512, p value = 0.609).  Mann-Whitney d that e ployed 
respondents her WTP as ared  were unemployed or 
r s that there e no significant differences  for scenario 
1 ical characteristics such as mothera erience, pr ious 
experience of CINV, and level of emetogenicity of the chem imen.  
 
Differences in WTP for scenario 2 based on demographic and cl
mograp and 
linical charac  the non-norma
yed. Mann W U test was u
ith more than e which groups e significantly d
y U te
re for the samp
le
e
scenario 1 based d and m
ted HS (Z valu
.018) and respondents with higher S education  = -3.5
plete HS.  There 
significant difference in the  between respo ents with high s
oc test
howed that r
≥ 60,000 (Z value = -5.464, p 
alue = 0.000) reported significant
ousehold inco n  i P amou etween
espondents with e level in the 30,000
 U test showe m
reported significantly hig comp  to those who
etired.  Results in Table 4-43 show ar in WTP
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The differences in maximum WTP amount for scenario 2 based on demographic and 
linical characteristics are presented in Table 4-44. WTP for scenario 2 differed significantly 
based on highest level of education comp ual e er o 
s P for scenario 2 based on age, gender, number o ers 
household, employment status and marita
 
ests showed that respondents who completed HS (Z value = -1.990, p value = 
0.047) and respondents with more than HS education (Z value = -3.053, p value = 0.002) 
r com nde ot complete HS.  There 
was no significant difference in the WTP between respondents with high school education and 
those with greater than high school education (Z value = -1.193, p value = 0.233).  Post hoc tests 
showed that respondents who reported annual household income in the range $30,000-$60,000 (Z 
value = -5.111, p value = 0.000) and respondents with higher than ≥ 60,000 (Z value = -4.909, p 
value = 0.000) reported significantly higher WTP as compared to respondents who with annual 
household income ≤ $30,000.  There was no significant difference in the WTP amount between 
respondents with annual household income level in the range $30,000-$60,000 and those with ≥ 
60,000 (Z value = -0.315, p value = 0.752).  
  
Results in Table 4-45 shows that there are no significant differences in WTP for scenario 
2 based on clinical characteristics such as previous chemotherapy experience, previous 








leted and ann  household incom  level. Th e were n
ignificant differences in WT f memb in the 
l status.   
Post hoc t
eported significantly higher WTP as pared to respo nts who did n
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Table 4-42: Differences in maximum WTP amount based on demographic characterist
Scenario 1 
ics – 
D  P )  
 
emographic Characteristics Mean WT Median (range Z value p value 
Age   0.439 0.803   
     78.2 (53.47) 75.00 
(1 00) 
     45-64 years 86.6 (101.71) 
(3 0.00) 
  
     ≥65 years 102.4 (122.72) 
(1 00) 
  
Gender   -0.813 0.416 
105.8 4.52) 60.00 
(5.00-600.00) 
      Fem 60.00 
(3.00-500.00) 
  
Education Level 12.678 0.002*
 education 35.3 (24.75) 00 
(10.00-100.00) 
  
      C l education   
) 
  
      M ucation )  
) 
  
Mar -0.686 0.492 
      Married 95.8 (110.5) 60.00 
(3.00-600.00) 
  
      Not 
Married/Single/Divorced/Widowed 
67.8 (55.8) 45.00 
(5.00-200.00) 
  
Employment   -2.484 0.013*
      Not working 77.3 (90.97) 45.00 
(3.00-600.00) 
  
      Working (Part-time or Full-time) 122.7 (121.74) 75.00 
(5.00-500.00) 
  
Annual Household Income Levela   40.595 0.000*
      ≤$30,000 37.5 (32.79) 30.00 
(3.00-150.00) 
  
      $30,001 - $60,000 114.0 (85.50) 100.00 
(15.00-300.00) 
  










      Male  (12   
ale 80.0 (84.22) 
a   
      Less than high school 30.
ompleted high schoo 77.8 (72.10) 60.00
(3.00-300.00
ore than high school ed 121.3 (132.00 75.00
(10.00-600.00
ital Status   
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Table 4-42 (Continued): Differences in maximum WTP amount based on demographic 
characteristics – Scenario 1 
 Z p
 
Demographic Characteristics Mean WTP Median (range)  value  value 
Number of Members in the 5.746 0.057 
Household 
  
      Zero 63.3 (52.84) 
(20.00-200.00) 
  
      One member 78.1 (93.16) 
(5.0 0) 
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Table 4-43: Differences in maximum WTP amount based on clinical characteristics – 
Scenario 1 
 
Clinical Characteristics M M Z pean (SD) edian (range)  value  value 
Presence of nausea and vomiting   5.060 0.080 
Neither nausea nor vomiting 86
(
  






Past chemotherapy experience   -0.971 0.331 
Chemotherapy naïve  59.5 (39.57) 50.00 
(10.00-150.00) 
  
Current or past experience 96.8 (110.20) 60.00 
(3.00-600.00) 
  
Level of emetogenicity   1.269 0.530 
Highly emetogenic  85.9 (104.90) 50.00 
(5.00-600.00) 
  
Moderately emetogenic 102.0 (92.52) 75.00 
(3.00-300.00) 
  






Either naus 9.2 (118.30) 
.00-600.00) 
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Table 4-44: Differences in maximum WTP amount based on demographic characteristics – 
Scenario 2 
 
D ics ) e) e  emographic Characterist Mean (SD Median (rang Z valu p value
Age   0.503a 0.777  
     75. 3.94) 00 
0.00) 
     4 years 79.4 (88.46) 
0) 
  
 94.9 (120.67) 50.00 
0) 
  











ducation )   
0) 
  
More than high school education 105.6 (120.04) 75.00 
(8.00-600.00) 
  
arital Status   -0.770 0.442 





59.6 (45.07) 35.00 
(5.00-200.00) 
  
mployment   -1.857 0.063 
Not working 75.9 (91.50) 40.00 
(3.00-600.00) 
  
Working (Part-time or Full-time) 102.3 (100.58) 75.00 
(5.00-500.00) 
  
Annual Household Income Levela   35.884 0.000*
≤$30,000 36.6 (32.68) 30.00 
(3.00-150.00) 
  
$30, 1 - $60,000 106.5 (80.00) 100.00 
(15.00-300.00) 
  
>$60 00 129.5 (136.11) 100.00 
(10.00-600.00) 
  
<45 years 8 (5 75.
(5.00-20
  
45-6 37.50  
(3.00-500.0
    ≥65 years 
(8.00-600.0
 -0.754 0.451 
Male 94.2 (110.7 60.00 
0.0(5.00-60
47.50 
ducation Level   8.7
Less than high school educ 35.7 (23.6 30.00 
(5.00-100.0
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Table 4-44 (Continued): Differences in maximum WTP amount based on demographic 
characteristics – Scenario 2 
 
   Demographic Characteristics Mean (SD) Median (range) Z value p value
Number of Members in the Household   4.684 0.096 
      Zero 53.8 (34.45) 35.00 
(20.00-100.00) 
  
 One member 79.2 (93.85) 45.00 
(5.00-600.00) 
  
      More than one member 106.5 (105.88) 75.00 
(3.00-500.00) 
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Table 4-45: Differences in maximum WTP amount based on demographic characteristics – 
Scenario 2 
 
Clinical Characteristics Mean (SD) Median (range) Z value p value 
Presence of nausea and vomiting   5.532 0.063 
     Neither nausea nor vomiting 77.1 (85.76) 35.00 (3.00-300.00)   
     Either nausea or emesis or both 103.3 (116.34) 75.00 (5.00-600.00)   
     Not applicable 56.5 (41.75) 42.50 (8.00-150.00)   
Past chemotherapy experience   -0.974 0.330 
      Chemotherapy naïve  56.9 (39.28) 42.50 
(8.00-150.00) 
  
      Current or past experience 89.6 (102.18) 60.00 
(3.00-600.00) 
  
Level of emetogenicity   1.405 0.495 
      Highly emetogenic  79.1 (91.67) 50.00 
(5.00-600.00) 
  
      Moderately emetogenic 93.8 (86.89) 75.00 
(3.00-300.00) 
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Results of Multivariate Analyses 
Multivariate analyses conducted to determine the association between WTP and 
demographic and clinical characteristics.  The r or inclusion in the regression 
models were identified based on the results of the bivariate analyses whi ented in the 
previous section.  This is a recommended approach for removing unimportant covariates so that a 
m eable set of variables can be submitted to multivariate techniques (George, 1988).  
T s for inclusion in the model was set at 0.15.  Based on 
the criteria, the variables included in the regression models were age, employment status, level of 
education completed, annual household income, number of m
experience with CINV. sis was conducted to test for multicollinearity  
the independent variables.  Although significant positive correlations of 1) an
i , 2) income with employment, and 3) e on with oyment were 
found the magnitude of correlation was low.  Thus, all three variables were included in the 
regression models.   
 





he preset α value for screening variable
embers in the household and past 
  Correlation analy among
nual household 
ncome with education ducati  empl
 
s of ordinary least squares (OLS) and semi-logarithmic regression 
m ed to determine the association between WTP and various respondent 
characteristics for scenario 1.  The use of semi-logarithm odel did not lead to any 
changes in the significance of the variables but lead to changes in the sign of the regression 
oefficients, when compared to OLS results.  The results of the OLS model showed no 
ignificant association of WTP with employment status, highest level of education completed, 
umber of members in the household and past experience of CINV.   There was a significant 
association between WTP and annual household income level.  Respondents with annual 
ousehold income level between $30,001 and $60,000 were willing to pay $62.85 more and those 
ith >$60,000 were willing to pay $76.35 more compared to those with income ≤$30,000.   
 
Results of the semi-log model showed significant differences in WTP amount based on 
the annual household income level.  Respondents with annual household income level between 
30,001 and $60,000 were willing to pay approximately 179% more as compared to those 
spondents with income ≤$30,000.  Similarly, respondents with annual household income 
>$60,000 were willing to pay approximately 198% more compared to those respondents with 
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income ≤$30,000.  Although not significant, patients who had received chemotherapy bu
xperience nausea or vomiting rep
t did not 
orted lower WTP amounts compared to those who never had 
chemotherapy. On the other hand, patients who usea/vo e 
past reported higher WTP amounts as compared to those who never had chemotherapy.  
 
Results for Scenario 2
e
 had experienced na miting or both in th
 
results of ordinary least squares (O d semi-logarithmic regression 
models employed to determine the association between WTP and various respondent 
characteristics for scenario 2.  The use of semi-logarithmic regression mode ot lead  
c f the variables but change e sign o egression 
coefficients, when compared to OLS results.  The results of the OLS model showed no 
significant association of WTP with employme , high l of ed  comp
n bers in the household and past exp  There was a significant 
association between WTP and annual household income level.  Respondents with annual 
household income level between $30,001 and $60,000 were willing to pay $62.50 more and those 
with >$60,000 were willing to pay $81.27 more compared to th e with incom  ≤$30,000. 
d significant differences in WT
the annual household income level.  Respondents with annual household income level between 
$ $60,000 were willing to pay approximat % more as compared to those 
spondents with income ≤$30,000.  Similarly, respondents with annual household income 
>$60,000 were willing to pay approximately 209% more compared to those respondents with 
income ≤$30,000.   
 
 
Table 4-47 shows LS) an
l did n  to any
hanges in the significance o  lead to s in th f the r
nt status est leve ucation leted, 
umber of mem erience of CINV.  
os e   
 
Results of the semi-log model showe P amount based on 
30,001 and ely 182
re
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Table 4-46: Multivariate analysis to test the association between WTP and annual 
household income – Scenario 1 
Demographic Characteristics Linear Regression Semi-logarithmic 
 
 β coefficient P value β coefficient P value 
Age  2.078 0.043* 0.008 0.407 
Employed 30.145 0.225 0.144 0.527 
Highest Level of Education Completed      
      Completed High School  30.714 0.269 0.388 0.129 
      More than High School  43.980 0.148 0.437 0.117 
Annual Household Income      
      $30,001 - $60,000 62.845 0.005* 1.045 0.000*
      >$60,000 76.349 0.004* 1.122 0.000*
Number of Members in the Household 14.408 0.145 -0.004 0.962 
INV     
      Neit
Past Experience of C
her nausea nor emesis 15.121 0.537 -0.071 0.750 
      Either Nausea and/or emesis 22.805 0.344 0.203 0.358 
F-statistic 3.894 6.854 
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Table 4-47: Multivariate analysis to test the association between WTP and annual 
household 
 
income – Scenario 2 
Demographic Characteristics Linear Regression Semi-logarithmic 
 β coefficient P value β coefficient P value 
Age  1.516 0.117 0.004 0.670 
Employed 6.664 0.777 0.013 0.954 
Highest Level of Education Completed      
      Completed High School  34.826 0.186 0.396 0.126 
      More than High School  35.434 0.218 0.360 0.202 
Annual Household Income      
      $30,001 - $60,000 62.499 0.003 1.058 0.000 
      >$60,000 81.271 0.001 1.158 0.000 
Number of Members in the Household 9.085 0.331 -0.056 0.544 
Past Experience of CINV     
      Neither nausea nor emesis 8.502 0.713 -0.111 0.627 
      Either Nausea and/or emesis 21.578 0.345 0.226 0.314 
F-statistic 3.297 6.173 
Adjusted R2 16.2% 30.3% 
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Results for Objective 2.5  
 
Net Benefit o  Adding Aprepitant to the Standard Regimen f  
 regimen and the new regi en for prevention of CINV considered in 
able 4-48.  The co f the regimens per patient per cycle were 
prices presented in Table 3-7.  The base case results for the cost benefit 
si f CINV following HE chemotherapy are presented in Table 4-48.  The 
ding aprepitant t tandard regimen of a 5-HT3RA and corticosteroid 
ue to HE chemotherapy was $89.90 (SD=$101.9, 95% CI = $70.77-
gimen and the standard regimen was $529.29 and $233.10, 
 resulting in the incremental cost for the new regimen to be $296.11.  Since the 
greater than the be ts, the cost of the new regimen was calculated 
l costs.  The net costs for the new 




sts oscenario 1 are shown in T











s for prevention o
ental benefit of ad
n of CINV d
 The total cost of the new re
o the s







 analy s conducted to test the robustness of the  varying the total 
ew and the standard regimens.  The variations in costs were based on variations in 
inistration of t ntiemetic drugs in the two regimens.  Table 4-49 
sults of fo scenarios to stud  im ylactic antiemetic 
ens on the net benefit of the new ens.  
 
Scenario A i acing IV ond mg with oral ondansetron 8mg as prior 
 of the two dose menta gimen 
d from $356.77-
e increm ta i ere higher com e incremental costs in Scenario B 
bination of a 5-HT and corticosteroid were used in the delayed phase.  The 
ses conducted t f ates revealed that the net benefits ranged 
tion of cost neutrality.  For scenario C, the 
ed phase 
en.  Scenario D inv g the dose of ondansetron in the new regimen and this 
h et t i n is highly costs of 
 
Sensitivity sis wa results by
l costs of the new re
en.  Overall, the results 
 sensitive to the total 
cost of the n
dosage and route of adm
shows the re
regim
evidence suggest equivalent efficacy




between -$30.09 and $8.17 and this suggests a 
net costs were insensitive to the changes in the dose 
regim




















s.  The incre
pared to th
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the new and standard regimen based on the drug dose and route of administration employed in 
the stud    
 
y.
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Table 4-48: Incremental costs, mental Bene tieme Reg rapy 
 
Regi e  
 (
 Be   
 – 














NEW REGIMEN     
Acute phase - Aprepitant 125 mg 
Dexamethasone 12 mg 
Delayed phase – Aprepitant 80 m
Dexamethasone 8mg (Days 2-4)   
 
+ IV Ondansetron 32 mg + Oral 
g (Days 2-3) Oral 
$529.29   
STANDARD REGIMEN – Ba   seline   
Acute phase - IV Ondansetron 32 
mg 
Delayed phase – Oral Dexamethasone 
.11 06.8-$ 34) 
mg + Oral Dexamethasone 20 
8 mg BID (Days 2-4)   













of the prophylactic antiemetic drugs and the administration cos
  
 drugs  
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Table 4-49: Sensitivity Analysis Results Based on Changes in the Drug Dosage and Route of Administration  
 
Regimen Total Incremental Incremental 
B
Net Benefit  
Costs Costs (IC) enefits (IB) (IC – IB) 
NEW REGIMEN     
Acute phase - Aprepitant 125 mg + IV Ondansetron 32 mg + Oral 
Delayed phase – Aprepitant 80 mg (Days 2-3) Oral Dexamethasone 8mg 
29   Dexamethasone 12 mg 
(Days 2-4)   
$529.  
STANDARD REGIMEN – Scenario A     
Acute phase - Oral Ondansetron 8 mg + Oral Dexamethasone 20 mg 
Delayed phase – Oral Dexamethasone 8 mg BID (Days 2-4)   




STANDARD REGIMEN – Scenario B     
Acute phase - IV Ondansetron 32 mg + Oral Dexamethasone 12 mg 
Delayed phase – Oral Dexamethasone 8 mg BID (Days 2-3)  and 8mg on 
Day 4 + Oral Ondansetron 8mg BID (Days 2-4) 




STANDARD REGIMEN – Scenario C     
Acute phase - Oral Ondansetron 8 mg + Oral Dexamethasone 20 mg 
Delayed phase – Oral Dexamethasone 8 mg BID (Days 2-3)  and 8mg on 
Day 4 + Oral Ondansetron 8mg BID (Days 2-4) 




NEW REGIMEN – Scenario D     
Acute phase - Aprepitant 125 mg + Oral Ondansetron 8 mg + Oral 
Dexamethasone 12 mg 
Delayed phase – Aprepitant 80 mg (Days 2-3) Oral Dexamethasone 8mg 
(Days 2-4)   






 Calculated by subtracting total cost of the regimen from the total cost of the new regimen 
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r Objective 2.6 
f  Palonosetron in f the Stand  Regimen  Using stead o ard  
 
Scenario 2 of the WTP survey involved substituting palonosetron for preventing CINV 
following ME chemotherapy instead of the standard regimen of a 5-HT3RA and corticosteroid.  
The incremental costs, incremental bene and net costs associated with the use of palonosetron 
are reported in Table 4-50.  The net cost of palonosetron for prevention of CINV following ME 
chemotherapy ycle is $160.99  new regimen of palonosetron 
were recalcul ing the 95% CI of the maximum WTP which resulted in the net costs within 










Sensitivity nalysis was conducted to test the robustness of the results by varying the total 
cost of the new and the standard regimens.  The sensitivity analyses were conducted by varying 
the total cost of the regimens. The cost d on the cha elayed phase 
regimen empl g ME chem .  Table 4-51 shows the 
results of two scenarios designed to study the impact of variations in the prophylactic antiemetic 
regimens on the net benefit of the new antiemetic regimens.  Scenario A involved calculating the 
net costs of the palonosetron regimen compared to a  IV d dansetron 32 mg.  The 
net costs decreased as compared to the base case results but were still indicative that the 
incremental costs of the palonosetron regimen exceeded the incremental benefits.  Scenario B 
involved calculating the net costs associated with em bination regimen of a 5-
HT3RA and dexamethasone in the delayed phase of en.  Due to the high total 
costs of the standard regim com to men, the former 
regimen was dominated b w reg n.  




oyed for prevention of CINV followin
 sin
ploy




ared en under scenario B, as 
y the ne ime
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Table 4 ntal Be ts a New f M motherapy 
 
Net Benefit  
(IC – IB) 
-50: Incremental costs, Increme
Regimen 
nefi nd Net Benefit of  Antiemetic Regimen or E Che




NEW   REGIMEN    
Acute  
STAN  
Acute eth e 8
Delay  (D s 2-5) 
0.99 
($14 -$178.81) 
 phase - IV Palonosetron 0.25mg 
DARD REGIMEN 
phase – IV Ondansetron 8mg + IV Dexam
ed Phase – Oral Dexamethasone 4mg BID
$340.20   





























st of the regimen includes the cost of the proph metic drugs and the administration cost of the IV drugs  
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 Sensitivity in the o r o E h otherap




Analysis Results Based on Changes 
Regimen 
Drug Dosage and Route f Administ ati n for H  C em





(IC – IB) 
y 
NEW REGIMEN     
Acute phase – IV Palonosetron 0.25mg   $340.20    
Standard Regimen – Scenario A     





Standard Regimen – Scenario B     







ndansetron 8mg + IV Dexamethasone 8 mg 
ral Dexamethasone 4 mg BID (Days 2-5)  + 
4mg BID (Days 2-5) 









rio  and proB is dominated by the new regimen as the latter costs less vides increased emesis protection 








 for prevention of CINV due to HE and ME 
chemotherapy.  A contingent valuation survey was developed in Phase II to estimate the 
monetary
DISCUSSION AND RECOMMENDATIONS 
 
 
The primary goal of this study was to conduct a comprehensive economic evaluation of 
prophylactic antiemetic regimens for prevention of chemotherapy-induced nausea and vomiting
(CINV) following administration of highly emetogenic (HE) and moderately emetogenic (M
chemotherapy.  The introduction of more efficacious but more costly new antiemetic agents for 
prevention of CINV may pose a significant economic burden on payers, hospital formularies
society.  In Phase I of the study, two decision models were developed to quantify the costs and 
benefits of the various antiemetic regimens
 value of improved emesis control due to the new antiemetic regimens among cancer 
patients.  The detailed methodology for determination of cost-effectiveness of the alternative 
antiemetic regimens and estimating the maximum willingness-to-pay (WTP) for improved 
emesis control is reported in Chapter 3.  The results of the decision models and the survey are 
presented in Chapter 4.  This chapter discusses the major study findings and their implications.  It 
also includes the major limitations of the study and presents the significance of the study results.  
Finally some recommendations for future research are also included in this chapter.  
 
5.1: Review of Phase I Findings 
 
The introduction of more efficacious but more costly new antiemetic agents for 





  Cost-effectiveness analysis is an economic evaluation method used to compare new 
treatments to standard of care to make informed decision-making.  The incremental cost-
effectiveness (ICER) was calculated as the additional cost of the new treatment divided by th
increased benefit of the new treatment.  Two decision models were developed to determine the
costs, effectiveness and incremental cost-effectiveness ratios of prophylactic antiemetic regimen
for prevention of CINV due to HE and ME chemotherapy.  The cost-effectiveness analyses were 
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For Highly Emetogenic Chemotherapy Model 
 
Results from the payer and societal perspectives showed that the cost for complete
control of emesis in one patient is the lowest for regim
 
en C and the highest for regimen A.  When 





l cost-effectiveness ratio (ICER) of $3,363.181 per patient with complete 






The cost effectiveness results were sensitive to the model including the side effects 
associa
en C 
 A was approximately three times more expensive than regimen C from the payer 
perspective.  The lower acquisition cost of regimen C was the principal driving force that resulted 
in a lower overall cost of the primary therapy.  The ratio decreased to 2.5 times when the 
effectiveness of the regimens were used in the calculations.  However, the differential in the tot
cost of the aprepitant regimen was not compensated for fully by the superior efficacy and lower
resource utilization during the delayed phase.  From the payer perspective, the base-case an
yielded an incrementa
amethasone) compared to regimen C (included metoclopramide in the delayed phase).  
Regimens B and D were dominated by regimen C and were excluded from the ICER 
calculations.  The ICER for regimen A was found to be $2,881.605 per patient with complete 
control of emesis from the societal perspective.   
 
One-way sensitivity analysis was conducted to identify key variables that may have an 
impact on the ICERs of the treatment regimens.  The ICER of the regimens were sensitive to the
probability of no acute emesis, the probability of no delayed emesis given no acute emesis, 
the probability of receiving rescue medications in the delayed phase given no delayed emesis.  
Increasing the probability of no delayed emesis given no acute emesis for regimen D resulted in 
changes in the dominance status of the regimens.  Regimen D was no longer dominated by 
regimen C and had an ICER of $2,173 per patient with complete control of emesis from the p
perspective and $1,787 from the societal perspective.  The results were not very sensitive to 
changes in the total cost of prophylactic antiemetic regimens, infusion costs, costs of IV 
ondansetron and cost of aprepitant.  The total costs and ICER for each regimen were not sensitiv
to variations in the number of hours of lost productivity and the average wages per hour.  
 
ted with regimen C (includes metoclopramide in the delayed phase).  The ICER for 
regimen A decreased from both payer and societal perspectives and regimen D was excluded 
from the calculations due to extended dominance.  Across all the sensitivity analyses, regim
233 
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remained the least expensive treatment, though the cost-effectiveness of the regimen varied wit
changes in the parameter estimates.   
 
Although simple sensitivity analysis can be helpful in identifying factors that affect C
ratios, single value analysis can be extremely misleading. In reality, within the possible ran
each variable, thousands of possible combinations of values can exist. In this study, probabilistic







t all parameter variations simultaneously.  Results from the probabilistic sensitivity 
analyse he HE model showed that the expected mean costs and effectiveness were similar to 
n dominance status of the 
regimens, though the ICERs for regimen A were higher as compared to the base case analysis, 
from the payer and societal perspectives.  
 
This study is among the first to evaluate the cost-effectiveness of four antiemetic 
regimens, new regimen A (addition of aprepitant to the standard regimen), regimen B (standard 
used in aprepitant clinical trials), regimen C (recommended by ASCO 1999 guidelines) and 
regimen D (most common clinical practice) for prevention of CINV following HE chemotherapy.  
Currently, three studies evaluating the cost-effectiveness of adding aprepitant to the standard 
regimen have been published in abstract format (Deuson, 2004; Ehlken et al., 2004; Moore et al., 
2005).  These studies have evaluated the cost effectiveness of addition of aprepitant to the 
standard regimen but have not compared it to regimens used commonly in clinical practice.  The 
results of the study may not be directly comparable to the three published economic evaluations 
due to the differences in the treatment comparators, perspective, time horizons and methodology 
employed.  
es 
five cycles of chemotherapy and the ICER was calculated to be $172,789 per QALY for strategy 
s for t
those obtained in the base case analysis. There were no changes i
 
Ehlken and colleagues (2004) conducted a study in office-based settings in Germany to 
determine the incremental costs and effects associated with addition of aprepitant to the standard 
regimen from the payer perspective.  The ICER for aprepitant regimen was calculated to be 
€21,764 per quality-adjusted life years (QALY).  The published abstract does not provide any 
information regarding the source of utilities for calculations of QALYs.  Moore and colleagu
(2005) constructed a Markov model to compare the cost-effectiveness of three regimens: 
standard therapy, addition of aprepitant to the standard regimen (strategy 1) and addition of 
aprepitant to the standard regimen if CINV (strategy 2) occurs. The analysis was conducted for 
234 
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1 and $160,236 per QALY for strategy 2.  The authors concluded that use of aprepitant was not 
cost effective and should only be used in high-risk populations.  Zbrozek and colleagues 
(Zbrozek et al., 1994) also reported high cost/QALY values for ondansetron compared to 
metoclopramide for prevention of acute CINV.   
 
The high ICER for aprepitant in the previous two studies may be a function of employing 
the concept of QALYs for CINV, an acute condition with short term impact on quality of life and 




bility to return to work and results in lost 





reported the use of 5-HT3RAs in the delayed phase even though there is insufficient evidence 
regarding its superiority compared to more traditional agents such as metoclopramide and 
on from emesis, may prove to be better indicators to compare the cost-effectiveness of 
various antiemetic regimens. This is especially true until more robust methods are available to 
determine the utilities for acute conditions which are not shown to have a direct impac
survival of patients.   
 
The previous economic evaluations (Ehlken et al., 2004; Moore et al., 2005) of the new 
antiemetic regimen were conducted from the payer perspective and thus did not include the 
indirect costs arising due to lost work productivity.  The survey results from phase II of 
showed that uncontrolled emesis affects patients’ a
ivity among patients and their caregivers (O'Brien et al., 1993).  The addition of indirect
costs led to an increase in the total costs associated with each of the four antiemetic regimens.  
However, the increase in the costs of regimen C was greater than that of regimen A which 
resulted in a decrease in the ICER of regimen A from 3,363.181 to $2,881.605 per patient with 
complete control of emesis.  The study findings underscore the importance of controlling delaye
emesis as it results in added costs.  Regimen A provides better protection during delayed phase 
compared to regimen C, leading to reduced health care resource utilization which ultimately 
translates into better cost-effectiveness for regimen A.  Additionally, the base case results show 
that compared to regimen D, the regimen A with aprepitant costs only an additional $154 to 
achieve complete control of emesis in one patient but provides better overall control of emesis. 
When the indirect costs are added to the direct costs, the difference in the total costs of achi
one patient with complete protection from emesis between the two regimens decreases to $52. 
 
Previous antiemetic drug utilization studies (DURTO, 2003; Fabi et al., 2003) have 
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dexamethasone (IGAR, 1997; Latreille et al., 1998a).  The effectiveness of regimen C (which 
includes metoclopramide in the delayed phase) had better efficacy in controlling emesis as 







alysis, regimen 2 was dominated by regimen 3 from both perspectives. From 
the pay perspective, the ICER for regimen 1 compared to regimen 3 was $3,582.48 and the 




tients with severe nausea and two or 
 became similar when the side effects of the regimen C are taken into consideration.  
However, the cost of achieving one patient with complete control of emesis is lower with
regimen C. Thus, the model results provide additional evidence that use of 5-HT3RA during t
delayed phase does not result in a sufficient increase in effectiveness to offset the increase in 
costs.   
 
For Moderately Emetogenic Chemotherapy Model 
 
The decision model for prevention of CINV following administration of moderately 
emetogenic chemotherapy compared four antiemetic regimens, regimen 1 (only palonosetron
regimen 2 (only ondansetron), regimen 3 (combination of ondansetron and dexamethasone in the
acute phase and dexamethasone in the delayed phase) and regimen 4 (combination of 
ondansetron and dexamethasone in acute and delayed phase).  The base case results from the 
payer and societal perspectives showed that without considering the effectiveness, the cost 
associated with CINV and its treatment is highest for regimen 4 and lowest for regimen 3.  In th
cost-effectiveness an
er 
  The ICER for regimen 1 compared to regimen 4 was $3,549.02 and the ICER for 
regimen 4 compared to regimen 1 was $6,499.87, from the societal perspective.  
 
To our knowledge, only one study has conducted an economic evaluation of palonosetron 
compared to the older 5-HT3RAs with and without the addition of dexamethasone (Vanscoy
al., 2004).  There have been no published cost-effectiveness evaluations comparing palonosetron 
to other combination antiemetic regimens recommended for prevention of CINV following M
chemotherapy.  Vanscoy and colleagues (Vanscoy et al., 2004) conducted a pharmacoeconomic 
evaluation of palonosetron in patients receiving moderately emetogenic chemotherapy. The 
outcomes and resource utilization for extreme events were compared for two groups of patients, 
one group receiving palonosetron and the other receiving either ondansetron, dolasetron or 
granisetron. The extreme event of CINV was defined as pa
236 
DISCUSSION  Reema Mody 








s because of differences in the treatment 






f regimen 4 was decreased by 20%, the cost of palonosetron was 
increased by 20% and the cost of ondansetron was decreased by 20%.   A probabilistic sensitivity 
analysis
 
episodes on any day and moderate to severe nausea the following day.  The study was 
conducted from the payer perspective and found that use of palonosetron resulted in a reduction
in extreme events, which translates into significant savings for payers. However, the study did 
not examine the impact of CINV on emergency room visits, hospitalization costs or patient 
productivity. The current study results cannot be directly compared to results of this study as the 
latter does not report any cost-effectiveness ratios for the antiemetic regimens.   
 
Previous economic evaluations have compared 5-HT3RAs to the traditional antiemetic
agents such as metoclopramide, or compared 5-HT3RAs against one another for prevention of
CINV due to moderately emetogenic chemotherapy (Cox & Hirsch, 1993; Kwong & 
Parasuraman, 1999; Lachaine & Laurier, 2002; Lachaine et al., 1999).  Kwong and Parasuraman 
(Kwong & Parasuraman, 1999) reported that the cost of one additional effectively treated pati
(no emesis and no adverse event for a three-day period) with ondansetron was $258 as compar
to metoclopramide from a third-party payer perspective.  However, as stated earlier, these resul
cannot be compared to the current study result
 
One-way sensitivity analysis was conducted to identify key variables that may have an 
impact on the ICERs of the treatment regimens.  The results very sensitive to changes in 1) 
probability of no acute emesis, 2) the probability of no delayed emesis given no acute emesis
the probability of receiving rescue medications in the acute phase given no acute emesis and 4) 
the probability of receiving rescue medications in the delayed phase given no delayed e
The variations in these parameters changed the dominance status and the ICERs of the individu
antiemetic regimens.  The ICER results were also sensitive to changes in the cost param
The ICER results showed that regimen 1 was dominated by regimen 3 when the cost of regimen 
1 was increased by 20%, cost o
 was conducted to take into account all parameter variations simultaneously.  This 
resulted in removal of regimen 1 from the ICER calculations due to extended dominance by a
blend of regimen 3 and regimen 4.  Compared to the base case estimates, the ICER of regimen 4 
compared to regimen 3 decreased from $3,655.35 to $1,446.30 per patient with complete control 
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of emesis from the societal perspective. Thus, overall sensitivity analysis results show that t
model estimates were very sensitive to variations in cost and efficacy parameters.   
 
The sensitivity of the ICER results to changes in the parameter may be explained in part 
by the following.  The calculation of the ICER for regimen 4 over regimen 3 resulted in 
$3,593.01 from payer perspective and $3,655.35 from the societal perspective.  These ICER 
estimates for regimen 4 are very similar to the ICER estimates for regimen 1.  Also, as mentioned 
earlier, regimens 1 and 4 have very similar effectiveness (0.695 and 0.699, respectivel
differ in costs associated with CI
he 
y) and only 
NV and its treatment.  Thus, the economic evaluation of regimen 
1 and 3 can be conducted using the cost-minimization method.  However, due to the inclusion of 
le differences in their effectiveness, the ICER results for the 









both regimens in the model, and litt
s were conducted by removing regimen 4 from the decision model and the ICER for 
regimen 1 compared to regimen 3 was $3,682 per patient with complete control of emesis from
the payer perspective and $3,233 per patient with complete control of emesis from the societal 
perspective.  Probabilistic sensitivity analysis was also conducted for the new model with the 
three regimens. The ICER for regimen 1 compared to regimen 2 was approximately twice that 
obtained from the base case of the new model, however, the dominance status of the regimens 
remained the same.  
 
Summary of Results for Phase I  
 
When making treatment decisions, supportive care providers should select the most cost
effective treatm
e managed care environment, the treatment with the lowest CE ratio may not always b
the first choice.  The definition of a cost-effective therapy should be based on the compariso
the CE ratios of treatments for various diseases.  In this case, it could be compared to other 
supportive care treatments for cancer.  Although the threshold for determining whether an
intervention is cost-effective is hard to define and generalize, less than $50,000 per life-year
gained is generally considered acceptable for therapeutic interventions and more than $100,000 
per life-year gained is generally considered excessive (Mark et al. 1995).  Nevertheless, many 
interventions that cost as much as $100,000 per year of life saved have been accepted (Hillman 
and Kim, 1995).  The interpretation of acceptable cost-effectiveness ratios usually depend on the 
individual decision makers and their budget constraints.   
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The available data do not allow direct comparisons of the CE ratios obtained in this 
to those using life-years gained as effectiveness measures in the literature.  Some studies have
used life years gained while others have used quality adjusted life years gained.  Even amon




 per QALY, utilities from different sources have been 






other studies lack of antiemetic side effects were also 
a criteria for efficacy (Kwong & Parasuraman, 1999).  In the current study, for the HE 
chemotherapy model the base case analysis considered the control of emesis as the effectiveness 
metic regimens employing utilities have reported very high cost per QALY estimates 
which fall above the acceptable cutoff of $100,000/QALY.  Although, regimen C which inclu
metoclopramide in the delayed phase has the lowest cost per patient with complete control of 
emesis in patients receiving HE chemotherapy, it may not be the first choice of treatm
providers due to its side effects profile and multi dosing regimen per day.  The ICER for the 
aprepitant regimen from payer perspective was calculated to be $3,363 per patient with 
control of emesis, which lies within the acceptable cutoff mentioned earlier.  The sensitivity 
analysis results show that the ICER for regimen A remains below the acceptable threshold of 
$50,000 per QALY.  Thus, it can be considered cost effective in preventing CINV for patients 
receiving highly emetogenic chemotherapy.   
 
In addition to the economic factors, another factor that plays a role in selecting an 
intervention is patient preference.  As indicated by the qualitative data from our survey results, 
almost 25% of patients preferred a single IV dose of palonosetron for prevention of CINV 
compared to the multi dosing regimen of other antiemetic drugs.  Clinicians and health care 
providers will most likely take patient preference into consideration when choosing the optimal 
antiemetic intervention.  However, patient preferences have not been incorporated in a 
quantifiable manner in the decision models.  If patients show preference for single IV dose of 
palonosetron compared to a three-day regimen for prevention of CINV following ME 
chemotherapy, the ICER of the palonosetron regimen will be more cost-effective compared to 
other combination regimens.   
 
The criteria for the effectiveness measure in clinical trials and economic evaluations for 
antiemetic agents are not explicitly established (Lachaine & Crott, 2003).  In some previous 
economic evaluations the efficacy criteria adopted was complete control of emesis or both 
and emesis (Ballatori et al., 1994) while in 
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measur
le 
e.  However, scenario analysis was also conducted where the lack of side effects of 
regimen 4 was a criterion for effectiveness.  Most of the previous economic evaluations were 
limited to the acute phase of CINV and underestimates the costs associated with CINV and its 
treatment.  The previous evaluations were conducted to determine the cost-effectiveness of sing
drug antiemetic regimens with multi-dosing regimens which is no longer relevant.  With the 
current guidelines and recommendations, combination regimens are the standard of practice and 
multi-dosing regimens are replaced by single dose administration. Thus, the current study 
provides economic results about the commonly employed antiemetic regimens in the 
recommended dosing schedule.  
 
5.2: Review of Phase II Findings 
 
Cost effectiveness analysis (CEA) and cost-utility analysis (CUA) are the most popula
techniques used to conduct economic evaluation of healthcare interventions.  These
commonly employed to determine
r 
 are most 
 the incremental costs for receiving the incremental benefits, 
measured as clinical outcomes or life-years saved or QALYs gained.  Although these methods 
provide helpful ways to determine cost-effective health care interventions, it is not feasible to 
employ them for acute conditions such as CINV where individuals experience the condition for a 
very short time period and may not be willing to forego future life years.  In such scenarios, 
monetary valuation of benefits of the health care intervention may be more appropriate and can 
be used to determine the net benefit of the intervention.  The net benefit values can be used to 
create a monetary rank order of disparate healthcare interventions for resource allocation using 
fixed budgets.  
 
The primary goal of phase II was to determine the monetary value that patients with 
cancer place on improved emesis control.  A contingent valuation survey was developed to 
measure patients’ valuation of emesis control and data were collected by conducting face-to-face 
interviews with the study participants.  This monetary value of benefits was then used to 
calculate the net benefit of the new antiemetic regimens compared to the standard regimen 
employed for prevention of CINV following HE and ME chemotherapy.  The global perspective 
was used to develop the hypothetical scenarios for WTP estimation.  The clinical, economic and 
quality to 
delayed emesis offered by the new antiemetic regimens.  All 120 study participants preferred the 
of life outcomes associated with the antiemetic prophylaxis were explicitly presented 
the respondents.  Patients with cancer placed high importance on the risk reduction of acute and 
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addition of aprepitant to the standard regimen compared to only the standard regimen.  In the 
case of palonosetron, only one respondent preferred to receive the standard regimen due to 
dislike of injection and not enough emesis risk reduction for the palonosetron regimen
WTP estimate was determined for the entire time period for which nausea and vomiting is 
associated with HE chemotherapy.   
 
.  The 











 reported by Dranitsaris and colleagues.  However, if the estimates from the 
previous study are used to estimate the maximum WTP for a period of three days, the results 
would be $8 for Greece, $70 for Italy, $114 for Canada, and $144 for Spain.  The results of our 
study and the previous study (Dranitsaris et al., 2001b) show that patients’ monetary valuation of 
benefit and quality of life are probably related to cultural differences and variations in the 
healthcare systems among the countries.   
 
T
 palonosetron instead of the standard regimen for prevention of CINV following ME 
chemotherapy.  Our results showed that respondents were willing to pay on average $83.50 for a 
single dose regimen of palonosetron to receive a 12% reduction in delayed emesis.  
Approximately 91% of the study respondents were willing to pay for improved emesis contr
obtained due to the addition of aprepitant to the standard regimen for CINV due to HE 
chemotherapy.  The WTP for improved emesis control due to the addition of aprepitant to a 
three-day regimen of a 5-HT3RA and dexamethasone for each cycle of chemotherapy was found
to be $89.90.  This amount was for a 13% reduction in the incidence of acute emesis and 18% 
reduction in the incidence of delayed emesis following administration of HE chemotherapy.   
 
The present study is the first to determine the monetary value of improved emesis contro
in the United States.  A previous study conducted in Spain, Greece, Italy and Canada reported the
monetary value that patients with cancer place on improved emesis control following cisplatin
chemotherapy (Dranitsaris et al., 2001b).  The study determined the maximum WTP separately 
for the acute and delayed phases of emesis.  For a 10% improvement in acute emesis, a WTP in 
the range of $6-$54 per day was reported.  Similarly for a 20% improvement in delayed emesi
WTP in the range of $6-$45 per day for 4 days was reported.  The study was conducted based on
hypothetical benefits and not actual benefits of aprepitant as obtained from randomized clinic
trials.  Due to the differences in the methodology employed, our results could not be compare
directly to those
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The qualitative data from the study participants showed that patients prefer the modest 
benefits offered by the new antiemetic regimens because nausea and vomiting affect their ability 
to return to work, ability to enjoy food, and their overall quality of life.  Additionally, about one-
fourth of the patients prefer palonosetron due to its single IV dosing regimen compared to the 
multi-day dosing pattern of the standard antiemetic regimen.  However, in spite of what cancer 
patients reported about the importance of avoiding CINV, only about 6% of patients interviewed 
were willing to make out-of-pocket payments to cover the additional costs of the new drugs.  It is 
suggested that this may be due to the fact that cancer patients face a number of chemotherapy-
related complications such as hair loss, neutropenia, anemia mucositis etc, in which nausea and 
vomiting is only a part of the problem (Ortega, Dranitsaris, & Puodziunas, 1998).  Ortega and 
colleagues reported similar results based on a WTP study which was conducted to estimate the 
monetary value of epoetin alfa for chemotherapy-induced anemia (Ortega et al., 1998).  Only 
about 4% of cancer patients were willing to pay the actual costs of epoetin alfa for 
chemotherapy-induced anemia.   
 
In the present study, WTP was measured using the ex-post or user based perspective.  
Neumann and Johannesson (1994) explored WTP for in vitro fertilization using both ex-post and 
ex-ante scenarios (Neumann & Johannesson, 1994).  The study results showed that the implied 
WTP per baby is much higher for the insurance-based approach than the user-based approach.  
Hypothetically, user-based and insurance-based approaches should provide equivalent WTP but 
in general, since individuals are more risk averse about health care issues, the two methods 
results in different WTP.  The method selected for determining WTP is important, since the 
insurance-based approach is expected to provide a higher mean WTP than the user-based 
approach (Gafni, 1996).  In another study, the WTP estimates for benefits of epoetin alfa therapy 
obtained from the general population were higher compared to those obtained from cancer 
patients receiving chemotherapy (Ortega et al., 1998).  Our study, which was conducted using 
user-based perspective among cancer patients, may have resulted in underestimation of the 
monetary value of the benefits of the new antiemetic regimens.  The study, if conducted in the 
general population using the insurance-based perspective would be able to capture the non-user 
values or externalities associated with the use of antiemetic regimens.   
 
The WTP survey included two scenarios: one for HE chemotherapy and one for ME 
chemotherapy.  It is suggested that the WTP values offered for a question are partly determined 
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by the value provided for previous questions (Smith et al., 1999a). Thus, in this case it may result 
in order bias whereby the respondents may give WTP amounts for the second scenario based on 
those provided for the first scenario (Stewart, O'Shea, Donaldson, & Shackley, 2002; 
Venkatachalam, 2004).  To avoid order bias, two versions of the survey were offered alternately 
to the respondents. Also, results of the bivariate statistical analyses showed that order in which 
the scenarios were presented did not bias the WTP values.   
 
Many people are not willing to provide a monetary valuation for health gains because 
either they are opposed to paying for health or they oppose the suggestion of paying out of pocket 
(Smith, Olsen, & Harris, 1999d). The protest is usually expressed as zeroes or high WTP 
amounts.  Smith and colleagues (Smith et al., 1999d) have recommended that WTP studies 
should report the proportion of zero responses and the protest bids.  Individuals who oppose the 
valuation of health in monetary terms or think that they should not have to pay for health care 
intervention give a very high valuation or zeros for maximum WTP. These are called as protest 





 to be 
employed to determine the validity of the WTP results.  One method suggested to assess the 
n assessment should be conducted to separate the genuine zeroes from the protest zer
in the WTP study.  In the current study, approximately 10% of the population reported zero bids 
as their WTP amounts.  Out of these respondents, only about 2% were categorized as pro
zeroes.  A review of WTP literature showed that based on the format of the WTP question u
in the study, the proportion of protestors ranged from 9.3% for the payment card method, 18.1% 
for the open ended format to 23.7% for the dichotomous choice method (Reaves, Kramer, & 
Holmes, 1999).  The proportion of zero bids and protest zeroes in our study which employed the 
payment card method was either lower or comparable to the proportions reported in the literature 
(Donaldson, Thomas et al., 1997; Smith et al., 1999d).  The lower proportion of zero bids for 
studies employing the payment card method may be because the payment card format may ease 
the valuation task faced by the survey respondents. Additionally, since the present data were 
collected using face-to-face interviews, participants had an opportunity to ask questions and 
clarify doubts.  
 
Due to the hypothetical nature of contingent valuation studies, it is difficult to assess th
validity of the WTP responses (O'Brien et al., 1998; Smith et al., 1999c).  Ideally to establish
criterion validity, one would compare the hypothetical values with actual observed market 
purchases.  However, such a market does not exist for comparison and other methods need
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construct validity of WTP responses is based on the premise that most goods and services have a
positive income elasticity, i.e. higher inco
 
mes should be associated with higher WTP (Smith et 
al., 1999c).  This theoretical construct can be tested by assessing the association of WTP amounts 
with respondents’ income level (Neumann & Johannesson, 1994; Smith et al., 1999c).  The 
theoreti
 The 
WTP amounts to the annual household income level of the respondents. The positive effect of 
 the results of other WTP studies in the literature and establishes the 
construct validity of the survey results (Davey et al., 1998; Dranitsaris et al., 2001a).   
e 
nd emesis are significant predictor 
of CINV (Molassiotis et al., 2002; Montgomery et al., 1998; Roscoe et al., 2000).  The patients 
may ha formation 
ch 
NV.   
In the present study, all respondents received a prophylactic antiemetic regimen for 
prevention of acute emesis following chemotherapy.  Consistent with the results of a previous 
antiemetic drug utilization study (DURTO, 2003), the current study results showed that more 
than half of the respondents received the combination regimen of a 5-HT3RA and dexamethasone 
for prevention of acute CINV.  This regimen is consistent with the ASCO, NCCN and MASCC 
cal validity of the study can also be assessed by regressing the WTP on a group of 
independent variables believed to be predictors of WTP (Neumann & Johannesson, 1994). 
results of the semilogarithmic models for scenarios 1 and 2 showed the positive association of 
income is consistent with
 
Consistent with findings of a previous study (Dranitsaris et al., 2001a), clinical 
characteristics of the respondents, such as past experience of nausea and emesis did not have a 
significant influence on the WTP estimates for scenarios 1 and 2 .  Though the multivariat
results were not significant, it was found that patients who were chemotherapy naïve reported 
higher WTP compared to those who had received chemotherapy in the past but had not 
experienced CINV.  The higher WTP amounts reported by chemotherapy naïve patients can be 
explained in part based on the patients’ pre-treatment expectation of CINV.  Previous research 
has shown that patients’ pre-treatment expectation of nausea a
ve pre-conceived expectancy regarding side effects of chemotherapy based on in
either obtained from oncologists or nurses, or from their past experience with nausea and 
vomiting (may be due to pregnancy or motion sickness) or from other information sources su
as television, friends and family (Roscoe et al., 2000).  Thus chemotherapy naïve cancer patients 
may have pre-treatment expectations of experiencing side effects of chemotherapy which could 
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recommended guidelines for prevention of CINV (R. J. Gralla et al., 1999; MASCC, 2004; 
NCCN, 2005).  Since the respondents in our study were unable to provide complete information 
about the antiemetic regimens prescribed for prevention of delayed CINV, we could not 
determine its consistency with the recommended guidelines.  The existing antiemetic regimens 
provide reasonably good protection against emesis but past studies have reported their 
inadequacy in controlling nausea (IGAR, 1995a, 2004; Molassiotis et al., 2002).  This is reflected 
in the current study with approximately 44% of respondents experiencing nausea in spite of 
rophy
, 1996).  It 
e 
e 
ayer’s perspective by subtracting the incremental benefits of the new 
ental costs due to the new regimen. If the value obtained is positive, it is 
rmed as net costs and if the value obtained is negative, it is termed as net benefits.  The addition 
of aprep cle.  On 
onal costs 
f $1,237.26.  Similarly, the incremental costs of using a single IV dose of palonosetron were 





use e interventions, such as 
epoetin alfa for prevention of chemotherapy-induced anemia, amifostine for chemotherapy-
p lactic antiemetic regimens.  Past studies have shown that nausea is ranked as the most 
incapacitating side effects by cancer patients (Boer-Dennert et al., 1997; Griffin et al.
has been shown that nausea has a greater impact than vomiting on patient outcomes, overall 
functioning, emotional status, enjoyment of eating and quality of life (Foubert & Vaessen, 2005).  
Thus, there is need for more effective control of acute and delayed nausea following 
chemotherapy.  
 
The WTP estimates obtained from the contingent valuation survey were used as th
monetary valuation of benefits of the new antiemetic regimens for prevention of CINV and wer
used in cost-benefit analysis (CBA).  The net cost of the new antiemetic regimens were 
calculated from the p
regimen from the increm
te
itant to the standard regimen results in a net cost of $206.21 per chemotherapy cy
an average, patients with cancer received six cycles of chemotherapy resulting in additi
o
higher than the incremen
The sensitivity analyses results showed that the incremental costs remained higher compared to 
emental benefits when the cost of standard regimen for scenario 1 was increased. The high 
ts of the new antiemetic regimens were not justified by the benefits of the regimen as valued 
he cancer patients receiving chemotherapy.  This study is among the first to use CBA to 
duct economic evaluation of antiemetic regimens for prevention of CINV.  CBA has been 
d to determine the economic value of other supportive cancer car
induced toxicity (Dranitsaris, 1997; Ortega et al., 1998), comparing antineoplastic agents 
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.3: Implications of Study Findings
anitsaris, Elia-Pacitti, & Cottrell, 2004), and in the area of diabetes care (Davey et al., 1998;
nitsaris, Longo, & Grossman, 2000).   
5  
sup
add linicians.  
Imp
 
The study results will be a valuable addition to the scientific literature in the field of 
portive cancer care, pharmacoeconomics, and economic evaluation methodologies.  In 
ition to its academic importance, the study results have implications for payers and c
 
lications for Payers 
 
The cost-effectiveness estimates for the prophylactic antiemetic regimens for preventio
INV following HE and ME chemotherapy, obtained from the phase I of the study, has 





pub elines, common regimens used in clinical practice and the addition of new 
ntiemetic agents to the standard regimens.  The dosage schedule and duration of therapy was 
also based on recommendations and clinical practice.  Thus, the study attempted to provide cost 
effectiveness estimates for real-life use of antiemetic agents. The drug formulary administrators 
of managed care organizations can use the parameter estimates and the structure of the decision 
odel to create budget impact models for their populations.  
 
The costs associated with using 5-HT3RA in the delayed phase (regimen 4) for 
prevention of CINV due to moderately emetogenic chemotherapy was higher as compared to the 
palonosetron regimen without any comparable increase in antiemetic effectiveness.  This is 
consistent with previous results which report use of costly 5-HT3RAs for delayed phase with no 
added benefits.  Hospital and managed care organizations can promote the dissemination of the 
commendations for appropriate antiemetic use so as to decrease costs without any impact on 
the benefits.  
 
The monetary valuation of the improved emesis control provided by the two new 
antiemetic regimens allowed us to quantify the clinical, economic and humanistic outcomes 
ssociated with CINV and its treatment.  This comprehensive evaluation of benefits using WTP 
stimates can be used to calculate the net benefits of prophylactic antiemetic regimens compared 
 other interventions, either other antiemetic regimens or other competing healthcare 
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and drug formulary committees for resource allocation decisions.  In a fixed budget scenario, a 





plications for Clinical Practice
ra
compared with the net benefit of the new antiemetic regimen. This will help in reallocation of
urces as interventions with smaller net benefits can be replaced with those regimens with 




pha  results obtained from Phase II also have implications for the 
ncologists and nurses.  Patients place high importance on receiving even a modest improvement 







The results from Phase II of the study suggest that control of nausea is not ad
ieved with the current antiemetic regimens and is an area for further research for 
rmaceutical companies.  The
o
in the control of CINV.  Nausea and vomiting is perceived by cancer patients to affect their 
lity of life, ability to eat and return to work.  Oncologists and nurses should be cogniz
level of importance that control of CINV has for patients so that they provide the best 
phylactic treatment for prevention of CINV.  In addition, there is a scope for improvement 
ng clinicians with respect to adhering to the recommendations for utilization of the 





Limitations of Phase I 
te 
such 
tainty in the parameter estimates 
ensitivity analysis. 
 
2. The ed for 
 
 
Both phases of the study have limitations and these are discussed below.  These 
itations need to be considered when deriving inferences from the reported results.   
 
1. A decision model for economic evaluation is only as good as the data that is used to popula
the model.  An ideal data source would be a randomized, double-blind study examining the 
efficacy and the resource utilization associated with all the treatment alternatives.  Since 
a study is not available, cost and efficacy parameters were synthesized from a number of 
published studies and expert opinion.  The impact of uncer
on the results was evaluated by conducting s
 base case analysis assumes that the study populations in the source studies us
parameter estimates are comparable in their demographic and clinical characteristics.  In
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reality, this is possible only through randomization of the cohort to each treatment strategy 
included in the model. However, it is doubtful that such a randomized controlled clinical trial 
would be conducted in the near future.   
 
3. In an attempt to balance a valid representation of the clinical path of CINV and its trea
and to keep the model transparent enough for the end-user to understand, a simple de
model was constructed.  It was assumed in the base case that rescue medications were given
for two days.  It was also assumed that patients who receive rescue medications for 




eive outpatient care were able to control 
their nausea and emesis and do not require any more medications.  However, in clinical 
prac
r 
   
n high-risk populations based on age and gender classification. However, the 
current decision model did not consider patient differences and their impact on ICER.  This is 
due to lack of sufficient data regarding the efficacy and cost parameters in the different 
gender and age groups.  
 
6. The indirect costs due to caregiver burden, requiring home help etc. due to uncontrolled 
delayed emesis were not included in the model.  Also, the estimates for lost work 
productivity were based on one published study and future studies should collect primary 





tice, patients may be switched to another rescue medication if the first agent does not 
work. Thus, the rescue medications may differ for each day during the delayed phase.  It is 
difficult to decide on the sequence of the rescue medications and the level of control achieved 
by them.  
 
4. The cost-effectiveness estimates of the antiemetic regimens are for a single cycle of 
chemotherapy and for chemotherapy naïve patients.  The results cannot be generalizable fo
multiple cycles of chemotherapy or for patients who have previous chemotherapy experience.
 
5. It is reported widely that patient characteristics such as age and gender are associated with 
incidence of CINV.  It would be useful to determine the ICER of the new antiemetic 
regimens i
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ion itself.  
tudy, we 
tried to minimize range bias by conducting a pilot study to determine the range for the final 
pay
e 
 WTP survey was conducted among cancer patients receiving care at the Mary Babb 
Randolph Cancer Center in Morgantown, WV.  The study population may not be 
representative of the general United States population and thus it limits the generalizab
the study results.  
 
8. WTP estimates were obtained from the user-based perspective because the users are most 
familiar with the health outcomes being described. However, this may result in 
underestimation of the WTP for improved emesis control as it does not include the dollar 
valuation by the nonusers.  
 
9. The contingent valuatio
eral biases, such as hypothetical bias and strategic bias.  The validity of the WTP 
responses were established by determining the positive association of respondents’ inco
their WTP amounts.  Strategic bias is said to exist when respondents deliberately give WTP 
amounts that differs from their true WTP.  Although, respondents were instructed to imagine
that their insurance does not pay for the drug, respondents know that in reality their insuranc
will pay for it and may thus provide higher WTP values.   
 
10. Hypothetical bias is said to occur due to the hypothetical nature of the WTP quest
In addition, the WTP amounts are based on stated preferences rather than observation of 
actual behavior.  Thus, it difficult to validate the WTP results obtained using surveys by 
actual observation of the behavior in the market.  
 
11. The payment card format of WTP elicitation is susceptible to range bias.  In this s
ment card and also instructed the respondents to give the exact WTP amount, if it is 
greater than the highest amount on the payment card.  However, respondents may still b
restricted in their responses based on the range provided.  
 
5.5: Recommendations for Future Research 
 
The economic evaluations in this study were conducted for a single cycle of 
chemotherapy.  However, chemotherapy is administered for an average of 6 cycles and it is 
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important to demonstrate the cost-effectiveness of the antiemetic regimens over multiple cycles 
of chemotherapy.  As mentioned earlier, the model is only as good as the data used to develop the 
odel.  The model should be populated with estimates of effectiveness and costs for each 
ntiemetic regimen obtained from their use in clinical practice.  Future economic evaluations 
hould be conducted to determine the cost-effectiveness of the addition of aprepitant to a 
ombination of palonosetron and dexamethasone for prevention of CINV due to highly 
emetogenic chemotherapy.  Future research should be targeted at developing a decision model 
that incorporates compliance with antiemetic regimens, and patient preference for antiemetic 
agents to make it more relevant to clinical practice.  
 
The contingent valuation study for determining WTP amounts for the aprepitant-based 
regimen and palonosetron should be conducted among the general population using the ex-ante 
perspective.  This will provide the actual societal value of the new antiemetic regimens including 
the user, non-user and externality values.  The externality values are obtained from a section of 
the general population who are not currently non-diseased and not at future risk but will be 
willing-to-pay for making the intervention available to the others. The WTP estimates thus 
obtained can be then utilized in CBA conducted form a societal perspective.  In the US health 
care system, people make co-payments to receive health care services.  Thus, WTP estimates for 
improved emesis control using increased co-payments as payment vehicle should be conducted in 
the United States general population.  Such a study would allow us to compare the differences in 
WTP amounts for supportive cancer care such as prevention of CINV, based on the payment 
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5.6: Conclusions 
V following highly emetogenic chemotherapy.  The lowest cost for 
ation 
nd metoclopramide in the delayed phase.  When the side effects of regimen C were included in 
e 
ighest effectiveness, i.e. patients with complete control of emesis. The combination regimen of 
sone in the acute and the 
 
acute and only dexamethasone in the delayed phase.  The palonosetron regimen had similar 
inimization analysis.  The results could not be compared to any cutoff values to determine 
r achieving one patient with complete control of emesis.  If the current threshold for acceptable 
revention of CINV following chemotherapy would be considered as cost-effective.  
a high 
vel of importance in achieving better control of nausea and emesis.  It also reiterates that 
).  
 based on the $50,000 per QALY threshold, the new regimens were considered cost-
y the 
ocietal benefits of the intervention.  Future research should determine the willingness-to-pay for 
 
The three-drug combination (regimen A) of aprepitant, a 5-HT3RA and dexamethasone in 
the acute phase and aprepitant and dexamethasone in the delayed phase incurred the highest cost 
or prevention of CINf
prevention of CINV following highly emetogenic chemotherapy was incurred by the combin
regimen (regimen C) of a 5-HT3RA and dexamethasone in the acute phase, and dexamethasone 
a
the model, it increased the costs incurred.  The results showed that regimen A provided th
h
5-HT3RA and dexamethasone in the acute and the delayed phase was dominated and not 
considered cost-effective.   
 
For prevention of CINV due to moderately emetogenic chemotherapy, the costs were 
highest for the combination regimen of 5-HT3RA and dexametha
delayed phase (regimen 4), followed by the regimen with single dose of palonosetron (regimen 
1), and followed by the regimen with a single dose of ondansetron (regimen 2). The least costs
were incurred by the combination regimen (regimen 3) of 5-HT3RA and dexamethasone in the 
effectiveness as regimen 4 and thus, the two regimens could be compared using cost-
m
whether the regimens were cost-effective because there is no established criterion regarding cost 
fo
ICER values of intervention, i.e. below $50,000 per QALY is employed, the new regimens for 
p
 
The study results emphasizes that cancer patients receiving chemotherapy place 
le
uncontrolled CINV has a significant impact on patients’ health-related quality of life (HRQOL
Although,
effective, the cost-benefit analysis results showed that the incremental costs of the new regimen 
exceeded the incremental benefits of the new regimens.  However, in the present stud
incremental benefits were from the patients’ perspective and may be an underestimation of the 
s
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improved emesis control from the general population so as to capture both the user and non-user 
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APPENDIX I – Expert Panel Survey 
 
 
1. In your practice, among 50 patients receivi  single-day chemotherapy and prophylactic 
 medications, on an average, how many patients require intravenous infusion of 





mon rescue medications that you prescribe for breakthrough 
 during the acute and delayed phase? 
. On an average, how much time do you spend on the phone with the patient to enquire 
 CINV? 
 
emotherapy Out , on an 













2. Do you give prescriptions for rescue medications for delayed phase breakthrough emesis 









4. Now please consider the 5 days following single-drug chemotherapy administration.  In 
your practice, among 50 patients receiving chemotherapy, on an average, how many 









. In your practice, among 50 patients receiving single-drug ch6
average how many patients have to come back to the outpatient clinic for additional 
medical care (such as saline infusion and rescue antiemetic agents) for uncontrolled 
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APPENDIX II – Oncolo r Patient Recruitment 
 
Hello Ms/Mr _____________, I would like to talk to you about a study that a pharmacy 
student is doing as part of her Ph.D dissertation.  She is conducting a study among patients at 
the cancer center to determine what it the value they place on certain new drug treatments 





ailable to prevent some s
me.  If you are interested in knowing more about the study and being a part of it I can 
troduce her to you.  
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APPENDIX III – Version A of the Willingness-To-Pay Survey 
 
r: 
his is the information sheet that explains the study in detail. The interview has five sections 
 
{After the participant finishes reading the cover letter} 
Will you participate in the study? 
{If No},  
Thank you for your time.  
{If Yes},  
I would like to assure you that the information you provide would be kept strictly 
confidential. You are not required to give your name or any contact information. Your 
participation in the study is voluntary and you can withdraw from the study at any time. You 
do not have to answer any questions that may make you uncomfortable. The scenarios that I 
will describe in this study are entirely imaginary and have nothing to do with your condition. 
Your responses are valuable for this research and will increase the understanding of how 
patients with cancer value the benefits provided by different drugs to prevent nausea and 
vomiting due to chemotherapy.  




“Before I ask you any questions, here is some information about cancer, chemotherapy and 
its related side effects. We can go over the material together”. 
 













CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING QUESTIONNAIRE 
 
Interviewe
Hello, I am Reema Mody, a PhD student in the School of Pharmacy at West Virginia 
University. Dr. __________________ (name of the attending oncologist) should have 
explained briefly about the research study that I am conducting.  
{Hand over the cover letter attached in the Section C of the protocol}  
T
and will take about 25-30 minutes to complete. We can go over the information letter
together or you may read it and let me know if you have any questions regarding the study.   




Nausea and Vomiting due to Chemotherapy  
W
C n spread 
a e  it. As you know, 
cancer can be treated with surgery, radiat
two specific side effects of chemoth
 
C
e of drugs to kill cancer cells. Chemotherapy is usually given in 
onths. But chemotherapy drugs may sometimes cause 
si
v led Ch g 
(C e that 
 
N
Nausea is having a sick feeling in the stomach, and vomiting is throwing up. Patients 
r each by itself. Nausea and vomiting can 
o
 
miti g are n t prev ontro  to loss of 
of nutrients and electrolytes. 
may n ble to equent 
vomiting can sometimes be dangerous because it can lead to loss of fluids from the 
 
There are some drugs available to prevent nausea and vomiting due to chemotherapy. 
These drugs are to be taken before chemotherapy and for 3-4 days after chemotherapy.  
 
 
  SECTION 1:Cancer, Chemotherapy and 
 
HAT IS CANCER? 
ancer is a disease that affects various body tissues. If not treated, cancer ca
nd can be fatal. But not everyone who gets canc r will die from
otherapy. Our study focuses on ion and chem
erapy.  
HEMOTHERAPY AND ITS SIDE EFFECTS  
Chemotherapy is the us
4-6 cycles over a period of 4-6 m
de effects. Nausea and vomiting are two side effects of chemotherapy. Nausea and 
omiting due to chemotherapy is cal emotherapy-induced Nausea and Vomitin
INV). While these two side effects are not fatal, they can sometimes be so sever
some patients refuse further treatment for their cancer.  
AUSEA AND VOMITING DUE TO CHEMOTHERAPY  
can experience both nausea and vomiting o
ccur within 24 hours of chemotherapy and can last for 1 to 5 days after chemotherapy.  
If nausea and vo n o ented or c lled, it can sometimes lead
appetite, loss Patients may not feel like doing anything, 
ot be able to cook and clean, and may not be a  go to work. Fr
body.  
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 any questions about this information?” 
w. 
ant has questions, answer their questions before moving to Section 2.  
“Do you have
 
{If No},  
“Since you have no questions about this section, we will go to the section 2 of this intervie
Here I will be asking some questions about your past experiences with chemotherapy and 
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KGROUNDSECTION 2 - BAC  INFORMATION 
terviewer will ask the following questions: 
1. What type of cancer have you been diagnosed
emotherapy
□   1st cy
□    1  cycle of new chemotherapy   □ 2nd cyc      




4. Antiemetic regimen:  
Prechemotherapy antiemetics    Postchemotherapy antiemetics 
____________________________  ________________________________ 
____________________________  ________________________________ 
 
5. Did you experience nausea in the 4-5 days following your last chemotherapy cycle?  
□     Yes  □     No □     Don’t know 
If ‘Yes’, continue with Q6. If ‘No’ or ‘Don’t know’, go to Q7.  
 
6. {Show the scale below to the participant}  
Can you please mark X on this line to describe the severity of nausea that you experienced in 
the 4-5 days following your last chemotherapy cycle? 
50 
Nau
. Did you experience vomiting episodes in the 4-5 days following your last chemotherapy 
cycle? 
□     Yes  □    No  □    Don’t know 
If ‘Yes’, continue with Q8. If ‘No’ or ‘Don’t know’, go to the next section. 
 
8. Can you tell me on an average, how many episodes of vomiting you experienced per day 
during your last chemotherapy cycle? {Explain the meaning of episodes of vomiting as two 
bouts separated from each other by at least 1 minute}.  
 






 with?   ________________ 
2. Can you tell me which cycle of ch
□ Received in the last 3 months      
st
 are you receiving today?  
cle (never had chemotherapy)     
le   □ 3rd cycle    □     4th cycle
cycle 






  0           
  
 No Nausea                           Moderate 
 
          100 
     
sea  Severe nausea 
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{After completion of section 2} 
o 
ut are developed only for the purpose 
ely imaginary”.  









“Now, let’s move on to the Section 3 of this interview. Here, I will be describing to you tw
scenarios about chemotherapy, nausea and vomiting, and its treatment. The scenarios are 
completely imaginary and does not relate to your condition. Dr. ______________ (attending 
oncologist) may have discussed the course of treatment for your condition and the possible side 
ffects with you. The scenarios that I am going to talk aboe
of this study”.  
 
Interviewer:  
“Imagine a scenario where the doctor has told you that you will be receiving certain 
chemotherapy drugs to treat cancer. As I mentioned earlier, the scenario is entir
“The doctor says that if drugs are not given to p
patients will experience nausea and vomiting within the first 24 hours of chemotherapy, and 7
of 100 patients will experience nausea and vomiting for 3-4 days after chemotherapy. 
ever, there are treatments available that can prevent nausea and vomiting due to 
motherapy”.    
“
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Treatment A Treatment B 




Treatment A should be taken before 
chemotherapy and for 3 days after 
chemotherapy. 
atment A should be taken before 
motherapy and for 3 days after 
motherapy.   chemotherapy. In addition,  
NEW DRUG is to be taken before 
chemotherapy and for 2 days after 
30 out of 100 patients will experience nausea 
and vomiting within 24 hours of 
chemotherapy  
 
 within 24 hours of chemotherapy 
17 out of 100 patients will experience nausea 
and vomiting













With Treatment A, 55 out of 100 patients 
will experience nausea and vomiting for 3-4 
days after chemotherapy 
 







With Treatment B, 37 out of 100 patients will 
experience nausea and vomiting for 3-4 days 
after chemotherapy 
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{Show the Insert B and explain to the participan
 
“Imagine that you are currently taking treatment A to prevent nausea and vomiting due to 
chemotherapy. This treatment has to be taken before chemotherapy and for three days after 
chemotherapy. Based on studies, out of 100 patients receiving Treatment A, 30 patients will have 
nausea and vomiting during 24 hours of chemoth
 
“Now, imagine that there is another treatment B available, which is the addition of the new drug 
to the old treatment A. This new drug is to be tak dition to the old treatment before 
chemotherapy and for two days after chemothera  of 100 patients receiving treatment B, 
17 patients will have nausea and vomiting within 24 hours of chemotherapy. Thus, with the new 
treatment B, the chance of nausea and vomiting is reduced from 30% to 17%.  
 
9. {Show the scale below to the respondent}  
Indicate on this scale how important would i uce your chance of having 
vomiting and nausea within the first 24 hour otherapy from 30 in 100 to 17 in 
100.  
{Point out the appropriate pie charts on Insert B}  
 
0 1 2 3 4 5 6 7 8 9 10 
 
      Not at all       Somewh              Very  





“Now, with the old Treatment A, out of 100 patients who receive it, 55 patients will have nausea 
and vomiting for 3-4 days after chemotherapy. With the new treatment B, out of 100 patients 
who receive it, 37 patients will have nausea and r 3-4 days after chemotherapy. Thus, 
with the new treatment B, the chance of nausea and educed from 55% to 37%.  
 
10. {Show the scale below to the respondent}  
Indicate on the scale below how important would it be for you to reduce your chance of 
vomiting and nausea for 3-4 days after che y from 55 in 100 to 37 in 100.  
{Point out the appropriate pie charts on Inse
 
0 1 2 3 4 5 6 7 8 9 10 
 
      Not at all       Somewhat               Very  






t be for you to red
s after chem
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Interviewer: “Assume that the two treatments cause similar side effects.  
 
11. Will you be willing to take the new drug along with treatment A if the new drug was available 
______________________________________________________ 
tments cause similar side effects. But the new treatment B costs more 
an the old treatment A due to the addition of the new drug.  
One way of measuring the value of the new drug is to ask you how much money you would be 
willing to pay to receive the new drug.  
at no extra cost in preference to only treatment A?  
 
□     Yes   □     No □    Don’t know 




ssume that the two treaA
th
 
Now imagine that your drug insurance plan will not cover the cost of the new drug. This means 
that you will have pay extra out-of-pocket for 3-day treatment, before chemotherapy and 2 days 
after chemotherapy, with the new drug for every cycle of chemotherapy. Now, this is simply a 
method of measuring the value you placed on the new drug and there is no right or wrong 
answer to this question. 
 
Keeping in mind your own income level, thinking realistically about how much you can afford to 
pay, please look at this scale and indicate the maximum amount that you would be willing to 
pay for new drug to be taken for 3 days? Also please keep in mind that you have to pay this 
amount every month for 4 cycles in equal installments”.  
 
12. Please state the maximum amount that you would be willing to pay for new drug to be 
taken for 3 days?   
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If more than $1,000, 



























$2.50 Put a O around the maximum amount that you are sure you 
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If the maximum WTP is $0, go to Q13. If the maximum WTP is any other value, go to the next 
section.  
 
13. If the ma 0, please check one of the following options: 
me to prevent nausea and vomiting due to chemotherapy  
d not have to pay out of poc iting 
or medications to prevent nausea and vomiting due to 
 
ximum WTP in Q12 is $
 
□ $0 is what it would be worth to 
 People shoul□ ket for medication to prevent nausea and vom
due to chemotherapy 
□ I cannot afford to pay out of pocket f
chemotherapy  
□   I object the question 
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Now, lets move on to Section 4 of this interview. Similar to the first scenario,“  the second 
eiving certain 
otherapy drugs to treat the cancer. These drugs are different from the one described in the 
earlier scenario. The doctor says that if drugs are not given to prevent nausea and vomiting, 
approximately 60 patients will experience nausea and vomiting within the first 24 hours of 
chemotherapy, and 55 out of 100 patients will experience nausea and vomiting for 3-4 days after 




scenario is also completely imaginary. The scenario that I am going to talk about is developed 
only for the purpose of this study.  
 
“Imagine a scenario where the doctor has told you that you will be rec
chem
c
to chemotherapy.   
 
this study we are considering two treatments that can prevent nausea and vomiting due to
motherapy”.  
 
and explain Insert C to the participant}. {
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INSERT C 
Treatment X Treatment Y 
Treatment X should be taken before 
motherapy and for 3 days aft








Tr  as an injection before 
chemotherapy 
c
eatment Y is given
Treatment X is given as an injection 
before chemotherapy and is to be taken 
orally (by mouth) for the remaining 3 
days after chemotherapy  
Treatment X and Treatment Y have similar chances of reducing nausea and vomiting withi
hours of chemotherapy.  
n 24 
42 out of 100 patients will experience 




42 out of 100 patients will experience nau














45 out of 100 patients will experience 
nausea and vomiting for 3-4 days after 
chemotherapy 







33 out of 100 patients will experience nausea and 
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“Imagine that you are currently taking treatment X to prevent na d miting due to 
chemotherapy. This treatment has to be taken as an injection before chemotherapy and by mouth 
for three days after chemotherapy. Based on studies, out of 100 patients receiving Treatment A, 
42 patients will have nausea and vomiting during 24 hours of chemotherapy.  
 
“Now, imagine that there is a new treatment Y available, which is to be taken as an injection only 
before chemotherapy. Out of 100 patients receiving treatment B, 42 patients will have nausea and 
vomiting within 24 hours of chemotherapy. Thus, treatments X and Y have similar chances of 
preventing nausea and vomiting within 24 hours of chemotherap
 
“Now, with the old treatment X, out of 100 patients who receive at nts will have nausea 
and vomiting for 3-4 days after chemotherapy. With the new treatment Y, out of 100 patients 
who receive it, 33 patients will have nausea and vomiting for 3-4 fte  Thus, 
with the new treatment Y, the chance of nausea and vomiting is r  fr .  
 
14. {Show the scale below to the respondent}  
Indicate on the scale below how important would it be for y duce your hance of 
vomiting and nausea for 3-4 days after chemotherapy fr  100 to 3 .  
{Point out the appropriate pie charts on Insert C} 
 
0 1 2 3 4 5 6 7 8 9 10 
 
      Not at all       Somewhat               Very  
      important        important           important 
usea an vo
y”.  




om 45% to 33%
ou to re  c
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{Keep the Insert C in front of the respondents} 
 
Interviewer: Assume that the two treatments cause similar side effects.  
 
15 Will you be willing to take the new drug Y if it is available at no extra cost in . 
□     No □     Don’t know 
___ _____________________________________________________ 
_________________________________________ 
ow imagine that the cost of the new drug is not covered by your drug insurance plan. 
his me
emotherapy cy  meth d of m
you placed on the treatment Y. The r g answer to this question. 
eeping in mind your own income level, thinking realistically about how much you can 
amo
preference to treatment X?  
 
□     Yes   
Please state reasons for your answer 
_____________
____________________________
       
Interviewer:  
Assume that the two treatments cause similar side effects. But the new treatment Y costs “
more than the old treatment X. One way of measuring the value of the treatment Y is to 
ask you how much money you would be willing to pay to receive treatment Y.  
N
ans that you will have to pay extra out-of-pocket to receive treatment Y for one T
day for every ch cle. Now, this is simply a o easuring the value 
re is no right o  wron
K
afford to pay, please look at the scale and indicate the maximum amount that you would 
be willing to pay to for treatment Y for one day? Remember that you have to pay this 
unt for 4 chemotherapy cycles in equal installments”.  
 
 
16. Please state t x  amount that you would be willing to pay ew drug to be 
r 1
he ma imum  for n
? taken fo  day
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Put a O around the maximum 
 
 $8.00
amount that you are sure you 
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If the maximum WTP is $0, go to Q17. ny other value, go to Q18. 
 




□    I object the question 
 
Interviewer:  
oing the interview” 
 
18. {Show the scale below to the participant} On the scale shown, please indicate the level of 
difficulty you had in understanding the scenarios and the questions along with it.  
 
      Not at all    emely 
      difficult  ficult                difficult 
19. {Show the scale be e the level of 
difficulty you had i d Q. 16) on the maximum amount that 
 
0 1 2 3 4 5 6 7 8 9 10 
 
y 
 If the maximum WTP is a
 
□ $0 is what it would be worth to me to prevent nausea and vomiting due to chemoth
□ People should not have to pay out of pocket for medication to prevent nausea and vomiting 
due to chemotherapy 
□ I cannot afford to pay out of pocket for medications to prevent nausea and vomiting d
“Now I will be asking some questions about the level of difficulty you had in d
0 1 2 3 4 5 6 7 8 9 10 
 
                  Somewhat                Extr
       dif 
 
low to the participant} On the scale
n answe ing the questions (Q.12 an
 shown, please indicat
r
you are willing to pay for the new drug and Treatment Y? 
      Not at all                      Somewhat                Extremel
      difficult          difficult                difficult 
 
 
Interviewer: This is the e 
questionnaire) your ba










 last section of the interview and it related to (present the Section 5 of th
ckground, such as age, race, education, employment, etc.  









SECTION 5: DEMOGRAPHIC INFORMATION 
 
{Interviewer will read t
 
e? 
21. What is your gender? ale 
22. What is your race? 
___ 
3. {Show the question} Please mark the highest level of education completed? 
□   Never attended school       □ E gh school  
  
□ College graduate 
What is you
   Married       
□    Widowed    
□   Full time worker (≥
□   Working at home 
26. {Show the question
 
   ≤ $15,000       □    $ ,001 - $60,000 
0  
7. Please state  your household (Excluding yourself) 
________________
28. {Show the question
□    Private  er’s compensation 
 
{After com let taken to complete the interview: ________ 
 “Thank you so much f  
information you have p
ccept this gift”.  
he questions}  
20. What is your ag  _______ (years) 
□     Male □    Fem
 
□   Caucasians □   African American     □   Asian □  Other (Please specify) ______
2
lementary school □  Some hi
□   High school graduate or GED        □ Some college or technical school 
 □  Other (Please specify) _____________ 
24. r marital status? 
□ □   Single (Never married)      □  Divorced     
□   Living together (not married)     
25. {Show the question} Which category best describes your employment status? 
30 hours per week) □   Part time worker (< 30 hours per week)  
      □    Student □   Not working      
} Please indicate your approximate total annual household income.  
15,001 - $30,000 □   $30,001 - $45,000      □  $45□
□   $60,001 - $75,00          □   $75,001 - $100,000    □   > $100,000 
2  the number of members living in
 
} What type of insurance do you have?  
□   Medicare           □  Medicaid     □  Work
□   HMO  □   None           □ Other (Please specify) __________________ 
p ion of Section 5} Record the time 
or the time and effort you have taken to complete this interview. The
rovided is valuable to this study. As a token of my appreciation, please 
a
CURRICULUM VITAE  Reema Mody
  
Curriculum Vitae  
OFFICE
 
REEMA MODY, MBA, Ph.D. 
         RESIDENCE 
675, North Field Drive       1310, S. White Oak Drive 
E-mail: reema.mody@tap.com
Lake Forest, IL 60045                       Apt 726  
Tel: 847-582-6740       Waukegan, IL 60085 
Fax: 847-582-6610        Tel: 304-685-0519 
 
PRESENT POSITION 
12/2005 – Present  Manager, Health Economics and Outcomes Research 
TAP Pharmaceutical Products Inc. Lake Forest, IL 60045 
 
EDUCATIONAL BACKGROUND 
08/2000 – 12/2005 Doctoral Candidate, Department of Pharmaceutical Systems and Polic




06/1997 – 05/1999 Post Graduate Diploma in Pharmaceutical Management (MBA),  
rmacy, University of Mumbai, Mumbai, India 
01/2005 – 12/2005 Research Fellow, Department of Pharmaceutical Systems and Policy, 






n model to evaluate the clinical and economic 
implications of noncompliance in patients with hypertension and conduct 
SIES College of Management Studies, Mumbai, India.  
Major: Pharmaceutical Marketing 
 
06/1992 – 05/1996 B.S. in Pha
PROFESSIONAL EXPERIENCE 
West Virginia University. Funded by a research gra
Ltd.   
Dissertation: Economic evaluation of emerging antiemetic regimens
prevent chemotherapy-induced nausea and vomiting (CINV) following 
cancer chemotherapy. Major Advisor: Lesley-Ann Miller, Ph.D.  
 
07/2001 – 12/2004  Research Fellow, Office of Drug Abuse Intervention Studies (ODAIS) 
affiliated with CDC-funded Prevention Research Center, West Virginia 
University.  
 Developed evaluation measures, performed data analysis, assisted in 
writing grants and manuscripts for evaluation of a school-based 
adolescent smoking cessation program sponsored by the American Lung
05/2003 – 08/2003 Outcomes Research Intern, Abbott Laboratories, Center for 
Pharmaceutical Appraisal & Outcomes Research, GPRD divisio 
 Development of a simulatio
288 
CURRICULUM VITAE  Reema Mody
  
sensitivity analysis to estimate the cost savings associated with increased 
compliance to antihypertensive regimen, and   
Designed a Phase IV study for one of Abbott’s marketed products 
/2001 Graduate Teaching Assistant, School of Pharmacy,  
West Virginia University 
 
07/1999 – 10/1999 Management Trainee, Product Management Team, Unichem Laboratories 
Ltd., Mumbai, India   
cer 
chemotherapy. Funded by a research grant from MGI Pharma Ltd.  
Role: Principal  




Role: Research Assistant  
Resp tion of project report and 
publication of stud s 
 
d prescription utilization and 
 
Role:  
rement, conducted descriptive analyses 
 
charact ng WV Medicaid population 
 12/2003 ibitors versus Tamoxifen in the 
 
Role:  
nt, developed decision tree 
ness of 
treatment strategies for advanced breast cancer  
 
08/2002 – 09/2003 Developing a tool for assessing physicians’ readiness to adhere with 
clinical practice guidelines for treatment of myocardial infarction patients. 
Funded by West Virginia University Senate Research Grant 
incorporating health care resource utilization and general health status 
outcome measures  
 
08/2000 – 06
06/1996 – 04/1997 Medical Sales Representative, Wockhardt Ltd., Mumbai, India 
 
RESEARCH EXPERIENCE 
09/2003 – 12/2005 Economic evaluation of emerging antiemetic regimens to prevent 
chemotherapy-induced nausea and vomiting (CINV) following can
Investigator 
ently working on dissertation project to det
and cost-effectiveness of newly emerging antiemetic regimens to p
 
02/2004 – 09/2004 Impact of cardiovascular comorb n overall and diabetes-related 
health care utilization and costs in type-2 diabetes patients. Funded by 
Takeda Pharmaceuticals North America, Inc. 
onsibilities included data analysis, genera
y results in peer-reviewed journal
08/2003 – 12/2003 Rates of hypertension-related medical an
costs in Medicaid population 
Principal Investigator 
As part of course curriculum requi
to determine the prevalence of hypertension and hypertension-related
rates of healthcare utilization and costs based on demographic 
eristics amo
 
8/2003 – Economic evaluation of Aromatase inh0
first-line treatment of advanced breast cancer 
Principal Investigator 
As part of course curriculum requireme
incorporating Markov model for determining cost-effective
289 
CURRICULUM VITAE  Reema Mody
  
 
Role: Research Assistant  
Responsibilities included conducting phone interviews for survey item 
generation, developing survey instrument, and data analysis 
Mody R, Smith M. Smoking status and health-related quality of life (HRQOL): Findings from the 
romotion (In press) 
o on teen 
l of Adolescent 
ypertensive medications 
eveloping profiles of postmenopausal women being prescribed estrogen 
therapy to prevent osteoporosis. Journal of Community Health. 2002 Oct;27(5):335-350 
 
Hassan M, Kalsekar I, Madhavan S, Mod . Determinants of readiness to quit 
n of childbearing age. Journal of the American Medical Women’s 
A view) 
Mody R, Kalsekar I, Kavookjian J, Iyer S, Rajagopalan R, Pawar V. Economic impact of 
cardiovascular co-morbidity in patients with type 2 diabetes. Journal of Diabetes and Its 
Complications (Under review)  
Kalsekar I, Iyer S, Mody R, Rajagopalan R, Kavookjian J. Economic consequences of choice of 
diabetes therapy in a Medicaid population. Journal of Managed Care Pharmacy (Under review) 
 
SELECTED RESEARCH PRESENTATIONS 
Mody R, Miller LAN. Willingness-to pay for antiemetic regimens for prevention of 
chemotherapy-induced nausea and vomiting. Accepted as a poster presentation at the 27th 
Annual Meeting of the Society for Medical Decision Making, San Francisco, CA, October 2005 
 
Mody R, Kalsekar I, Kavookjian J, Iyer S, Rajagopalan R, Pawar V. Economic impact of 
cardiovascular co-morbidity in patients with type 2 diabetes. Presented as a poster at the ISPOR 
10th Annual International Meeting, Washington DC, May 2005 
 
Kavookjian J, Mody R, Kalsekar I, Iyer S, Rajagopalan R, Pawar V. Prevalence of co-morbid 
conditions and concomitant medication use among type 2 diabetes patients in a state Medicaid 
population. Presented as a poster at the ISPOR 10th Annual International Meeting, Washington 
DC, May 2005 
 
Kalsekar I, Iyer S, Mody R, Rajagopalan R, Kavookjian J. Economic consequences of choice of 
diabetes therapy in a Medicaid population. Oral presentation at the ISPOR 10th Annual 
International Meeting, Washington DC, May 2005 
 
RESEARCH PUBLICATIONS 
Behavioral Risk Factor Surveillance System (BRFSS) Data. American Journal of Health 
P
 
Horn K, Dino G, Goldcamp J, Kalsekar I, Mody R. The Impact of Not On Tobacc
smoking cessation: End-of-program evaluation results, 1998 to 2003. Journa
R
 
esearch.  2005 Nov; 20(6): 640-661 
Mody R, Miller LAN. Confounding factors affecting association of antih
and pulse pressure (Letter), American Journal of Medicine. 2004 Nov 1;117(9):709-10 
 
Amonkar M, Mody R. D




CURRICULUM VITAE  Reema Mody
  
291 
Mody R, Smith M. Rates of hypertension-related medical and prescription utilization and costs in 
a state Medicaid population. Presented at the Drug Information Association (DIA) Meeting, 
Washington D.C., June 2004  
 
Miller LAN, Mody R, Singer ME. Understanding the characteristics of non-traders in TTO utility 
elicitation. Oral presentation at the ISPOR 9PthP Annual International Meeting, Arlington, VA, May 
2004 
 
Miller LAN, Mody R (Presenting Author). A descriptive analysis to investigate the differences 
between traders and non-traders in time trade off. Presented as a poster at the ISPOR 9PthP Annual 
International Meeting, Arlington, VA, May 2004 
 
Mody R, Smith M. Smoking Status and health-related quality of life (HRQOL): Findings from 
the Behavioral Risk Factor Surveillance System (BRFSS) Data. Oral presentation at the ISPOR 
8PthP Annual International Meeting, Arlington, VA, May 2003  
 
Mody R, Kavookjian J, Kamat S, Coffindaffer J. Assessing physician’s barriers to adherence with 
clinical practice guidelines for prescribing beta-blockers in post myocardial infarction patients. 
Presented as a poster at the Annual American Pharmaceutical Association Meeting, New 
Orleans, March 2003 
RELEVANT GRADUATE COURSES 
Basic Econometrics      Research Methods 
Pharmacoeconomics      Survey Research 
Decision Analysis in Healthcare    Data Management and Analyses 
Outcomes Research and Quality of Life Assessment  Social and Behavioral Theory 
Epidemiology       Principles of Marketing 




10/2005 SMDM Annual Meeting   
Courses:Probabilistic Cost-Effectiveness Modeling 
  
07/2004 Graduate Summer Institute of Epidemiology and Biostatistics, Johns 
Hopkins School of Public Health  
Courses: Multilevel Models, Statistical Analysis for Cohort Study   
   Designs 
 
05/2004  ISPOR International Annual Meeting  
Courses: Old and new utility measures in health economics and  
               outcomes research, Reed Johnson & Brett Hauber 
 
05/2003  ISPOR International Annual Meeting  








Statistical packages: SPSS, STATA, FoxPro, SAS 
   
Decision Analysis software: DATA TreeAge, @RISK, Precision Tree 
    
HONORS AND AFFILIATIONS 
2004: Student Poster Award – 1Pst P place, Drug Information Association (DIA) 40Pth P Annual  
 Meeting   
2004: Graduate Research Award, School of Pharmacy, West Virginia University  
2003: Best Student Podium Award, ISPOR 8PthP Annual International Meeting  
2003-2004: Vice-President of the West Virginia ISPOR Student Chapter  
2005-Present: Member, Society of Medical Decision Making (SMDM)  
2001-Present: Member, International Society for Pharmacoeconomics & Outcomes Research  
                       (ISPOR) 
REVIEWER 
Preventive Medicine  
Contributed Research Abstract Review Committee for 8PthP Annual meeting of ISPOR 
 
 
